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  Fat	  free	  mass	  
FPG:	  Fasting	  plasma	  glucose	  
FoxO:	  Forkhead	  box	  O	  
G6P:	  Glucose-­‐6-­‐phosphate	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GAP-­‐43:	  Growth	  Associated	  Protein	  43	  
GI:	  Gastrointestinal	  
h2:	  Heritability	  
HAHDB:	  Hydroxyacyl-­‐CoA	  dehydrogenase	  
HAT:	  Histone	  acetyltransferase	  	  
HCR	  rat:	  High	  capacity	  running	  rat	  
HDAC:	  Histone	  deacetylase	  
HDL:	  High	  density	  lipoprotein	  
HF:	  Heart	  failure	  
HFD:	  High-­‐fat	  diet	  
HILIC:	  Hydrophilic	  interaction	  chromatography	  
HOMA-­‐IR:	  Homeostatic	  Model	  Assessment	  of	  Insulin	  Resistance	  
HSL:	  Hormone-­‐sensitive	  lipase	  
hTERT:	  Human	  telomerase	  reverse	  transcriptase	  
IFG:	  Impaired	  fasting	  glucose	  
IGF-­‐1:	  Insulin-­‐like	  Growth	  Factor	  1	  
I𝜅B𝛼:	  Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor,	  alpha	  
IKK𝛽:	  I𝜅B	  kinase,	  beta	  
IL-­‐6:	  Interleukin	  6	  
IWMC:	  Investigational	  Weight	  Management	  Clinic	  
LCAD:	  Long-­‐chain	  acyl-­‐CoA	  dehydrogenase	  
LC-­‐MS:	  Liquid	  chromatography-­‐mass	  spectrometry	  
LCR	  rat:	  Low	  capacity	  running	  rat	  
LDL:	  Low	  density	  lipoprotein	  
LPL:	  Lipoprotein	  lipase	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MANOVA:	  Multivariate	  analysis	  of	  variance	  
MDA:	  Malondialdehyde	  
MDRTC:	  Michigan	  Diabetes	  Research	  and	  Training	  Center	  
METs:	  Metabolic	  equivalents	  
MFN:	  Mitofusin	  
MMTT:	  Mixed	  meal	  tolerance	  test	  
MPTP:	  1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine	  
MRM:	  Multiple	  reaction	  monitoring	  
MS:	  Mass	  spectrometry	  
mtDNA:	  Mitochondrial	  DNA	  
MTE:	  Mitochondrial	  thioesterase	  
MZ:	  Monozygotic	  twins	  
NAD+:	  Nicotinamide	  adenine	  dinucleotide	  
NADH:	  Nicotinamide	  adenine	  dinucleotide	  hydride	  
nDNA:	  Nuclear	  DNA	  
NDUFS:	  NADH-­‐ubiquinone	  oxireductase	  Fe-­‐S	  
NMDA:	  N-­‐methyl-­‐d-­‐aspartate	  
Nor:	  Neuron-­‐derived	  orphan	  receptor	  
NRF:	  Nuclear	  respiratory	  factor	  	  
Nur77:	  Nerve	  growth	  factor	  IB	  
OXPHOS:	  Oxidative	  phosphorylation	  
p16INK4a:	  Cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (inhibitor	  of	  CDK4)	  
PA:	  Phosphatidic	  acid	  
PAD:	  Peripheral	  artery	  disease	  
PAI-­‐1:	  Plasminogen	  activator	  inhibitor-­‐1	  	  
PC:	  Phosphatidylcholine	  
PCR:	  Polymerase	  chain	  reaction	  
PE:	  Phosphatidylethanolamine	  
PEG:	  Polyethylene	  glycol	  
PEPCK-­‐C:	  Phosphoenolpyruvate	  carboxykinase-­‐C	  
PFK:	  Phosphofructokinase	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PG:	  Phosphatidylglycerol	  
PGC-­‐1𝛼:	  Peroxisome	  proliferator-­‐activated	  receptor	  gamma	  coactivator	  1,	  alpha	  
PKB:	  Protein	  kinase	  B	  
PKC:	  Protein	  kinase	  C	  
PI:	  Phosphatidylinositol	  
PI3K:	  Phosphatidylinositide	  3-­‐kinase	  
PPAR:	  Peroxisome	  proliferator-­‐activated	  receptor	  
PS:	  Phosphatidylserine	  
PUFA:	  Polyunsaturated	  fatty	  acid	  
QC:	  Quality	  control	  
qPCR:	  Quantitative	  polymerase	  chain	  reaction	  
QUAD:	  Quadratic	  
REE:	  Resting	  energy	  expenditure	  
RMR:	  Resting	  metabolic	  rate	  
ROS:	  Reactive	  oxygen	  species	  
RPLC:	  Reversed-­‐phase	  liquid	  chromatography	  
RQ:	  Respiratory	  quotient	  
RQE:	  Respiratory	  quotient	  at	  VO2max	  
RQR:	  Respiratory	  quotient	  at	  rest	  
RSD:	  Relative	  standard	  deviation	  
RT:	  Retention	  time	  
RUNX:	  Runt-­‐related	  transcription	  factor	  
SBP:	  Systolic	  blood	  pressure	  
SD:	  Standard	  deviation	  
SEM:	  Standard	  error	  of	  mean	  
SIM:	  Selected	  ion	  monitoring	  
SIRT:	  Sirtuin	  
SOD:	  Superoxide	  dismutase	  
SPH:	  Synaptophysin	  
SREBP-­‐1c:	  Sterol	  regulatory	  element-­‐binding	  protein-­‐1c	  
TCA:	  Tricarboxylic	  acid	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TEM:	  Transmission	  electron	  microscopy	  
TFAM:	  Mitochondrial	  transcription	  factor	  A	  
TG:	  Triglyceride	  
TGF-­‐𝛽1:	  Transforming	  growth	  factor-­‐beta	  1	  
TIG:	  Tazarotene-­‐induced	  gene	  
TNF-­‐𝛼:	  Tumor	  necrosis	  factor-­‐alpha	  
UCP:	  Uncoupling	  protein	  
UDP:	  Uridine	  diphosphate	  
UQCRC:	  Ubiquinol-­‐cytochrome	  c	  reductase	  core	  
VLDLR:	  Very	  low	  density	  lipoprotein	  receptor	  
WC:	  Waist	  circumference	  




































Individuals	   with	   higher	   cardiorespiratory	   fitness	   (CRF),	   most	   often	   assessed	   by	  
measuring	  maximal	   oxygen	   consumption	  while	   performing	   incremental	   exercise,	   have	   a	  
decreased	  risk	  of	  a	  wide	  variety	  of	  metabolic	  diseases	  and	  a	  reduced	  mortality	  rate.	  Rats	  
selected	   for	   increased	   CRF	   show	   improved	  metabolic	   status	   and	   longevity	   and	   a	   higher	  
mitochondrial	   capacity	   for	   fatty	   acid	   (FA)	   and	   branched-­‐chain	   amino	   acid	   (BCAA)	  
catabolism	   as	   they	   age.	   To	   determine	   whether	   these	   findings	   are	   associated	   with	   CRF-­‐
induced	   delayed	   metabolic	   aging	   in	   humans,	   we	   assessed	   CRF	   reported	   as	   VO2max	  
(ml/min/kg	   fat	   free	  mass),	   fasting	   plasma	  metabolites	   that	   are	   related	   to	   FA	   and	   amino	  
acids	   (AA)	  metabolism,	  as	  well	  as	  2	  hr-­‐postprandial	   skeletal	  muscle	  metabolites	   levels	   in	  
lean	  (n	  =	  28	  plasma,	  n	  =	  15	  muscle)	  and	  obese	  (n	  =	  124	  plasma,	  n	  =	  99	  muscle)	  individuals,	  
the	  latter	  before	  and	  after	  4-­‐6	  months	  of	  caloric	  restriction	  (CR)	  by	  800	  kcal/day	  of	  high-­‐
protein	   liquid	  diet.	   	  VO2max	   fell	  with	  age,	  but	  was	  higher	  at	  any	  age	   in	   lean	  compared	  to	  
obese.	   Multiple	   linear	   regression	   analysis	   of	   plasma	   metabolites	   demonstrated	   that	   FA-­‐
derived	   acylcarnitines	   and	   the	   ratio	   of	   BCAA	   intermediates	   to	   their	   substrates	   increased	  
with	  age,	   suggesting	   that	  aging	  reduces	  capacity	   for	   fatty	  acid	  oxidation	  (FAO)	  and	  BCAA	  
catabolism.	  Regardless	  of	  age,	  higher	  CRF	  was	  associated	  with	   lower	   levels	  of	  FA-­‐derived	  
acylcarnitines.	   In	   addition,	   CRF	   counteracted	   the	   age-­‐associated	   increase	   in	   FA-­‐derived	  
acylcarnitines,	   suggesting	   that	   higher	   CRF	   directly	   mitigates	   age-­‐associated	   incomplete	  
FAO.	   	  CR	  also	  decreased	  FA-­‐derived	  acylcarnitine	   levels	  and	  decreased	   the	  ratio	  of	  BCAA	  
intermediates	  to	  their	  substrates,	  suggesting	  that	  CR	  decreases	  metabolic	  markers	  of	  aging.	  
Multiple	   linear	   regression	   analysis	   of	   skeletal	   muscle	   metabolites	   showed	   that	   most	  
phospholipids	  decreased	  with	  age	  and	  polyunsaturated	  phospholipids	  increased	  with	  age,	  
consistent	  with	  the	  age-­‐induced	   increase	   in	  susceptibility	   to	   lipid	  peroxidative	  damage	  of	  
mitochondria.	  AAs	  and	  a	  ratio	  of	  valine	   intermediate	  to	  valine	  were	  negatively	  correlated	  
with	   VO2max,	   but	   FA-­‐derived	   acylcarnitines	   were	   positively	   correlated	   with	   VO2max,	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suggesting	   that	   higher	   CRF	   is	   associated	   with	   improved	   mitochondrial	   capacity	   for	   AA	  
catabolism	   and	   FAO.	   VO2max	   was	   also	   positively	   correlated	   with	   glutathione	   (the	   most	  
abundant	   endogenous	   antioxidant),	   DHEAS	   and	   UDP-­‐n-­‐acetyl	   glucosamine,	   all	   of	   which	  
decrease	  with	  age,	  suggesting	  that	  higher	  CRF	  is	  associated	  with	  lessened	  oxidative	  stress	  
which	   may	   play	   a	   role	   in	   slowing	   aging.	   	   Unlike	   plasma	   metabolites,	   CRF	   was	   not	  
statistically	   associated	   with	   age-­‐related	   changes	   in	   skeletal	   muscle	   metabolite	   levels.	  
Rather,	   CRF	   was	   directly	   associated	   with	   changes	   in	   skeletal	   muscle	   metabolites	  
independent	   of	   age	   and	   its	   effect	  was	   in	   part	  mediated	   by	  mitochondrial	   DNA	   (mtDNA)	  
count	   number,	   suggesting	   an	   expansion	   of	   mitochondria	   with	   CRF.	   CR	   decreased	  
isoleucine+leucine-­‐to-­‐their-­‐substrates	   ratio	   and	   increased	   FA-­‐derived	   acylcarnitines,	  
suggesting	  that	  CR	  improves	  mitochondrial	  capacity	  for	  AA	  catabolism	  and	  FAO	  as	  well.	  CR	  
also	   decreased	   the	   levels	   of	   polyunsaturated	   FAs	   (PUFAs),	   and	   increased	   levels	   of	  
glycocholic	  acid,	  a	  metabolite	  inversely	  related	  to	  lifespan	  in	  humans,	  again	  supporting	  the	  
notion	   that	   CR	   delays	   metabolic	   aging.	   Because	   both	   high	   CRF	   and	   CR	   can	   improve	  
substrate	   utilization	   of	  mitochondria	   and	   show	   evidence	   of	   delayed	  metabolic	   aging,	   the	  
effects	   of	   high	   CRF	   and	   CR	   are	   comparable.	   Both	   appear	   to	   induce	   metabolite	   profiles	  
consistent	  with	  a	  ‘younger’	  metabolic	  state,	  offering	  insight	  into	  the	  mechanisms	  by	  which	  



















Living	   longer,	   healthier	   lives	   has	   long	   been	   a	   goal.	  Modern	   society	   has	   brought	   a	  
tremendous	  number	  of	  advances,	  including	  better	  sanitation,	  assured	  food	  supply	  and	  safer	  
working	   conditions	   and	   medical	   advances	   have	   reduced	   infant	   mortality	   and	   enhanced	  
infectious	  disease	  control.	  Collectively,	  these	  developments	  allow	  us	  to	  live	  longer	  than	  our	  
ancestors;	   however,	   we	   are	   now	   at	   an	   increased	   risk	   of	   developing	   multiple	   chronic	  
diseases,	   including	   cardiometabolic	  diseases,	   cancer	   and	  neurodegeneration	  due	   to	   aging	  
and	   increasingly,	   unhealthy	   diets.	   Essentially,	   we	   live	   longer	   but	   are	   sicker.	   	   Improving	  
conditions	  such	  that	  we	  remain	  healthy	  throughout	  our	  lives	  (healthspan)	  is	  an	  important	  
goal.	  	  	  
It	  is	  generally	  accepted	  that	  cardiorespiratory	  fitness	  (CRF)	  is	  positively	  associated	  
with	   improved	  health	  and	   longevity.	  Though	  CRF	   is	   largely	  genetically	  determined,	   it	  can	  
be	   increased	  by	   regular	   aerobic	   training.	   To	  maintain	  peak	  CRF,	   regular	   aerobic	   training	  
must	  continue	  throughout	  the	  lifespan.	  This	  is	  nearly	  impossible,	  as	  older	  individuals	  may	  
lack	   the	  endurance	   to	   train.	   	  Additionally,	   aerobic	   training	  can	  be	   time-­‐consuming	  and	   is	  
often	   not	   ideal	   for	   people	   in	  modern	   society.	   Caloric	   restriction	   (CR)	   is	   another	   strategy	  
that	  promotes	  health	  and	  extends	  lifespan	  in	  most	  animals.	  However,	  CR	  is	  also	  difficult	  to	  
maintain	   long-­‐term	   as	   our	   brains	   provide	   a	   ‘food	   reward’,	   encouraging	   continued	  
consumption,	   particularly	   high-­‐fat	   and	   high-­‐sugar	   diets	   prevalent	   in	   modern	   society.	  
Moreover,	   eating	   together	   is	   a	   common	   social	   interaction,	   thus	   the	   potential	   anti-­‐social	  
nature	  CR	  may	  decrease	  adherence.	  
Because	  lifelong	  aerobic	  training	  and	  CR	  are	  nearly	  impossible	  to	  achieve,	  the	  creation	  
of	   comparable	   drug	  mimetics	   offers	   a	   potentially	   viable	   alternative	   to	  maximize	   lifespan	  
healthspan.	  Before	  mimetics	  can	  be	  developed,	  the	  mechanisms	  by	  which	  aerobic	  training	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and	   CR	   benefit	   health	   and	   increase	   lifespan	   must	   be	   determined.	   Mitochondria	   are	  
intricately	  involved	  in	  both	  metabolism	  and	  aging,	  providing	  a	  key	  nexus	  that	  links	  health	  
and	  longevity	  while	  offering	  a	  potential	  drug	  target	  worthy	  of	  additional	  exploration.	  	  	  
	  
1.1 Aims	  and	  scope	  
This	  thesis	  involves	  the	  intrinsic	  (genetic,	  non-­‐trained)	  component	  of	  CRF	  and	  how	  
it	  may	  relate	  to	  caloric	  restriction.	  The	  aim	  is	  to	  better	  understand	  how	  high	  intrinsic	  CRF	  
and	  CR	  are	  associated	  with	  good	  health	  and	  longevity.	  I	  focus	  on	  the	  effects	  of	  CRF	  and	  CR	  
on	  mitochondrial	  metabolism	  as	  these	  organelles	  are	  innately	  involved	  in	  metabolism	  and	  
whose	  function	  decreases	  with	  age.	  	  
My	  research	  was	  conducted	  with	  samples	  and	  data	  obtained	  from	  obese	  adults	  who	  
participated	   in	  the	  University	  of	  Michigan	  Investigational	  Weight	  Management	  Clinic	  who	  
have	  undergone	  a	  program	  of	  clinically-­‐monitored	  weight	  loss	  using	  caloric	  restriction	  and	  
the	   systematic	   collection	  of	   clinical	   data	   and	   samples.	   	   This	   clinic	   is	   directed	  by	  Dr.	  Amy	  
Rothberg	  and	   the	   research	  arm	  of	   the	  program	   is	  directed	  by	  Dr.	  Charles	  Burant.	   	  These	  
data	  were	   derived	   from	   samples	   collected	   at	   baseline	   and	   again	   after	   3-­‐4	  months	   of	   CR.	  
Non-­‐obese	  individuals	  were	  recruited	  and	  serve	  as	  controls	  both	  for	  the	  IWMC	  cohort.	  	  We	  
performed	   analysis	   of	   both	   plasma,	   and	   skeletal	  muscle,	   the	   latter	   a	   primary	   organ	   that	  
determines	  CRF	  and	  is	  responsible	  for	  nutrient	  metabolism.	  	  For	  my	  studies	  of	  metabolism,	  
I	  employed	  a	   targeted	  metabolomic	  approach	  to	   identify	  metabolites	   involved	   in	  nutrient	  
(amino	  acids,	  glucose	  and	  fat)	  metabolism,	  as	  well	  as	  an	  untargeted	  metabolomic	  approach	  
to	   identify	   additional	   metabolites	   that	   are	   affected	   by	   age,	   CRF	   or	   CR.	   	   I	   also	   assessed	  
mitochondrial	  DNA	  (mtDNA)	  and	  examined	  how	  the	   levels	  of	  mtDNA	  and	  mutations	  may	  
be	  associated	  with	  age-­‐dependent	  changes	  in	  metabolism.	  	  
	  
1.2 Study	  overview	  
My	   thesis	   has	   7	   Chapters	   including	   an	   introduction.	   The	   additional	   6	   Chapters	  
consist	  of	  background	  knowledge	  about	   the	  effects	  of	  CRF	  and	  CR	  on	  health	  and	   lifespan	  
(Chapters	   2	   and	   3),	   biological	   research	   to	   identify	   how	   CRF	   and	   CR	   are	   associated	  with	  
health	  and	  longevity	  (Chapters	  4	  and	  5),	  methodological	  research	  to	  clarify	  the	  importance	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of	  metabolomic	  data	  normalization	  (Chapter	  6),	  as	  well	  as	  implications	  of	  the	  current	  study	  
and	  future	  directions	  (Chapter	  7).	  
In	  Chapter	  2,	   I	  review	  the	  evidence	  that	   intrinsic	  CRF	   is	  genetically	  determined.	   In	  
addition,	   I	  describe	  the	  benefits	  of	  high	  CRF	  as	   improved	  health	  and	  decreased	  mortality,	  
based	  upon	  several	  longitudinal	  studies	  in	  humans.	   	   	  I	   include	  in-­‐depth	  studies	  from	  a	  rat	  
genetic	  model	  of	  aerobic	  treadmill	  running	  capacity	  that	  serves	  as	  the	  basis	  for	  my	  clinical	  
studies.	  I	  also	  review	  additional	  human	  studies	  to	  identify	  potential	  mechanisms	  by	  which	  
high	  CRF	  is	  associated	  with	  good	  health	  and	  extended	  lifespan.	  The	  review	  will	  show	  that	  
despite	   an	   extensive	   number	   of	   studies,	   how	   CRF	   effects	   nutrient	   metabolism	   and	  
modulates	  aging	  remain	  unknown.	  	  	  
In	   Chapter	   3,	   I	   review	   the	   anti-­‐aging	   effects	   of	   CR,	   i.e.	   CR	   attenuates	   age-­‐related	  
diseases	   in	  animals	  and	  humans.	   	   In	  addition,	   I	  review	  the	  mitochondrial	   theory	  of	  aging,	  
the	  modulating	   effects	   of	   CR	  on	   age-­‐related	  decline	   in	  mitochondrial	   function,	   as	  well	   as	  
epigenetic	   regulations	   linked	   to	   the	   anti-­‐aging	   effects	   of	   CR.	   Although	   my	   review	  
demonstrates	  that	  the	  modulating	  effects	  of	  CR	  on	  the	  age-­‐related	  decline	  in	  mitochondrial	  
function	  have	  been	  extensively	  documented,	  the	  influence	  of	  mtDNA	  on	  this	  relationship	  is	  
uncertain	  and	  was	  therefore	  included	  in	  my	  project.	  	  	  
Chapter	  4	  contains	  the	  first	  part	  of	  my	  original	  research,	  in	  which	  I	  study	  the	  effects	  
of	  CRF	  and	  CR	  on	  age-­‐related	  changes	  in	  plasma	  metabolite	  levels.	  In	  this	  study,	  I	  employed	  
a	  targeted	  metabolomic	  approach	  to	  quantitate	  the	  levels	  of	  amino	  acids	  (AAs),	  branched-­‐
chain	  ketoacids	  (BCKAs),	  free	  fatty	  acids	  (FFAs)	  and	  acylcarnitines	  in	  fasting	  plasma	  of	  non-­‐
obese	  and	  obese	  subjects,	  the	  latter	  at	  both	  before	  and	  after	  12-­‐16	  weeks	  of	  CR.	  The	  results	  
demonstrate	   that	   aging	   is	   associated	   with	   incomplete	   whole	   body	   fatty	   acid	   oxidation	  
(FAO)	   and	   decreased	   mitochondrial	   capacity	   of	   branched-­‐chain	   amino	   acid	   (BCAA)	  
catabolism.	  High	  CRF	   and	  CR	   are	  directly	   associated	  with	  more	   complete	   FAO.	  High	  CRF	  
also	  counteracts	  age-­‐related	  incomplete	  FAO,	  and	  CR	  improves	  the	  mitochondrial	  capacity	  
of	   BCAA	   catabolism.	   Both	   high	   CRF	   and	   CR	   delay	   metabolic	   aging,	   consistent	   with	   a	  
‘younger’	  metabolic	  state.	  
The	  results	  described	   in	  Chapter	  4	   inspired	  me	   to	  extend	  my	  work	   to	  mtDNA	  and	  
metabolomic	   analysis	   of	   human	   skeletal	   muscle,	   described	   in	   Chapter	   5.	   In	   this	   study,	   I	  
sought	   to	   identify	  mechanisms	  by	  which	  high	  CRF	  and	  CR	  delay	  metabolic	   aging.	   I	   chose	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skeletal	  muscle	   because	   it	   is	   a	  major	   organ	   that	   is	   accessible,	   contributes	   to	   CRF	   and	   is	  
responsible	   for	   nutrient	   metabolism.	   I	   utilized	   a	   targeted	   metabolomic	   approach	   to	  
quantitate	   the	   levels	   of	   AAs,	   oleic	   acid,	   acylcarnitines,	   glycolysis	   metabolites,	   TCA	   cycle	  
metabolites	   and	   nucleotides,	   as	  well	   as	   an	   untargeted	  metabolomic	   approach	   to	   identify	  
additional	  metabolites,	  especially	   lipids.	  Because	  mtDNA	  is	  affected	  by	  aging	  and	  differed	  
between	   high	   and	   low	   CRF	   rats	   as	   well	   as	   between	   ad	   libitum-­‐fed	   and	   CR	   rats,	   I	   also	  
analyzed	   mtDNA	   in	   these	   samples	   via	   real-­‐time	   PCR.	   	   I	   found	   that	   metabolite	   levels	   in	  
skeletal	  muscle	  change	  with	  age.	  High	  CRF	  and	  CR	  are	  associated	  with	  better	  mitochondrial	  
capacity	   of	   AA	   and	   fatty	   acid	   (FA)	   utilization,	   resulting	   in	   more	   TCA	   cycle	   metabolite	  
production.	   Unlike	   plasma	  metabolites,	   CRF	   does	   not	   modulate	   the	   effect	   of	   age-­‐related	  
changes	  in	  skeletal	  muscle	  metabolite	  levels.	  Rather,	  it	  is	  directly	  associated	  with	  changes	  
in	  metabolite	   levels	   in	   skeletal	   muscle,	   and	   this	   effect	   at	   baseline	   is	   partly	  mediated	   by	  
mtDNA	  count	  number.	  However,	  CR	  diminishes	  the	  effect	  of	  CRF	  on	  mtDNA	  count	  number.	  
High	  CRF	  is	  also	  associated	  with	  higher	  levels	  of	  UDP-­‐n-­‐acetyl	  glucosamine	  and	  DHEAS	  that	  
are	  observed	  to	  decrease	  with	  age,	  suggesting	  that	  high	  CRF	  delays	  metabolic	  aging.	  CR	  also	  
delays	  aging	  by	  decreasing	  the	  level	  of	  glycocholic	  acid,	  which	  is	  a	  marker	  of	  short	  lifespan,	  
and	   by	   decreasing	   the	   level	   of	   polyunsaturated	   FAs	   (PUFAs),	   which	   are	   associated	  with	  
susceptibility	  to	  lipid	  peroxidative	  damage	  to	  mitochondria	  that	  usually	  increases	  with	  age.	  
These	  benefits	  of	  high	  CRF	  and	  CR	  are	   again	   consistent	  with	  a	   ‘younger’	  metabolic	   state,	  
and	  may	  be	  associated	  with	  improved	  metabolic	  health	  and	  longevity.	  	  
Chapter	   6	   is	   methodological	   research	   that	   describes	   metabolomic	   data	  
normalization.	   Because	   liquid	   chromatography-­‐mass	   spectrometry	   (LC-­‐MS)	   used	   for	  
metabolomic	  research	  usually	  drifts	  over	  the	  course	  of	  a	  run	  and	  not	  all	  internal	  standard	  
are	   available	   to	   set	   a	   quality	   control	   for	   all	   metabolites,	   a	   drift	   correction	   method	   is	  
necessary	   for	   data	   normalization	   to	   ensure	   that	   data	   from	   samples	   analyzed	   in	   many	  
batches	  over	  an	  extended	  period	  of	   time	  can	  be	  compared	   in	  an	  accurate	  manner.	   In	   this	  
study,	  I	  demonstrate	  a	  quadratic	  drift	  correction	  method	  among	  14	  batches	  of	  analysis	  of	  
418	   plasma	   samples	   obtained	   during	   a	  mixed	  meal	   tolerance	   test	   (MMTT)	   in	   non-­‐obese	  
and	  obese	  subjects,	   the	   latter	  at	  both	  before	  and	  after	  12-­‐16	  weeks	  of	  CR.	  Corrected	  data	  
reveal	   differential	   meal	   tolerance	   in	   non-­‐obese	   and	   obese	   subjects,	   whereas	   greater	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variability	  in	  the	  uncorrected	  data	  resulted	  in	  the	  loss	  of	  statistical	  significance	  among	  most	  
of	  the	  comparisons.	  
In	  Chapter	  7,	  I	  describe	  the	  implications	  of	  my	  studies	  and	  future	  directions.	  In	  this	  
Chapter,	  I	  discuss	  how	  results	  from	  metabolomic	  studies	  in	  fasting	  plasma	  (Chapter	  4)	  and	  
postprandial	  skeletal	  muscle	  (Chapter	  5)	  are	  consistent	  with	  the	  benefits	  of	  high	  CRF	  and	  
CR	  on	  health	  and	  longevity	  as	  previously	  documented	  by	  others	  and	  reviewed	  in	  Chapter	  2	  
and	  3.	  My	  results	  fit	  within	  the	  established	  literature,	  suggesting	  they	  represent	  potential	  
mechanisms	  that	   link	  high	  CRF	  and	  CR	  to	  improved	  health	  and	  longevity.	  Based	  upon	  the	  
results	   of	   my	   research,	   I	   recommend	   that	   future	   research	   focus	   on	   the	   development	   of	  
effective	  targeted	  therapies	  to	  improve	  health	  and	  maximize	  lifespan.	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  of	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on	  health	  and	  longevity	  in	  humans	  
	  
2.1	  Introduction	  
Intrinsic	   cardiorespiratory	   fitness	   (CRF)	   is	   defined	   as	   the	   relative	   ability	   of	   the	  
circulatory,	  respiratory,	  and	  muscular	  systems	  to	  supply	  oxygen	  to	  skeletal	  muscle	  during	  
sustained	   physical	   activity	   (1).	   It	   is	   usually	   reported	   in	   metabolic	   equivalents	   (METs),	  
maximal	  oxygen	  uptake	  (VO2max)	  per	  body	  weight	  or	  VO2max	  per	  fat-­‐free	  mass	  (FFM)	  and	  
measured	   by	   specific	   tests	   on	   the	   treadmill	   or	   cycle	   ergometer	   (1).	   One	   metabolic	  
equivalent	  is	  defined	  as	  the	  amount	  of	  oxygen	  consumed	  while	  sitting	  at	  rest	  and	  is	  equal	  to	  
3.5	  ml	  O2	  per	  kg	  body	  weight	  x	  min.	  	  In	  testing	  CRF,	  in	  men	  of	  30-­‐40	  years,	  less	  than	  9	  METs	  
is	  considered	  poor	  CRF	  and	  greater	  than	  15	  METs	  is	  considered	  excellent	  (2)	  
This	  chapter	  contains	  details	  about	  the	  heritability	  of	  CRF,	  and	  the	  benefits	  of	  high	  
intrinsic	  (untrained)	  CRF	  as	  related	  to	  health	  and	  longevity	  in	  humans.	  These	  benefits	  have	  
been	   demonstrated	   in	   longitudinal	   studies	   in	   humans	   and	   remain	   after	   adjusting	   for	  
multiple	   variables	   such	   as	   age,	   sex,	   race,	   study	   year,	   obesity,	   hypertension,	   diabetes	  
mellitus	   (DM),	   hyperlipidemia,	   cardiovascular	   diseases	   (CVD),	   smoking,	   alcohol	   intake,	  
physical	  activity,	  fiber	  intake,	  body	  mass	  index	  (BMI),	  waist	  circumference	  (WC),	  percent	  of	  
body	   fat,	   fasting	   plasma	   glucose	   (FPG),	   systolic	   blood	   pressure	   (SBP),	   diastolic	   blood	  
pressure	   (DBP),	   lipid	  profiles,	  medication,	   electrocardiogram	   (ECG)	  and	   family	  history	  of	  
related	  diseases.	  To	  identify	  potential	  mechanisms	  responsible	  for	  the	  benefits	  of	  high	  CRF,	  
research	   in	   the	   rat	   genetic	   model	   of	   aerobic	   treadmill	   running	   capacity	   and	   humans	   as	  
related	  to	  CRF	  are	  also	  included.	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2.2	  CRF	  is	  highly	  genetically	  determined.	  	  	  
Although	   aerobic	   training	   can	   increase	  CRF	   (3-­‐24),	   there	   are	   large	   interindividual	  
differences	   in	  CRF	  at	  baseline	  and	   in	  response	   to	  similar	   training	  (25,	  26).	  Moreover,	   the	  
health	  benefits	  of	  CRF	  are	  independent	  of	  physical	  activity	  and	  even	  more	  dominant	  than	  
CRF	   increases	  by	  physical	  activity.	  Multiple	   studies	  have	  demonstrated	   that	  CRF	  predicts	  
health	   and	   age-­‐adjusted	  mortality,	   even	  when	   physical	   activity	   was	   included	   in	   analysis	  
(27-­‐41),	   and	   that	   the	   effects	  of	  physical	   activity	  on	  health	   and	  mortality	   lost	   significance	  
when	  CRF	  was	  included	  in	  the	  model	  (34,	  40,	  41).	  	  This	  suggests	  that	  intrinsic	  CRF	  is	  highly	  
genetically	  determined.	  	  This	  has	  been	  supported	  by	  studies	  using	  the	  intraclass	  correlation	  
coefficient	   (r)	   of	   body	   weight	   and/or	   FFM-­‐adjusted	   VO2max	   among	   monozygotic	   twins	  
(MZ)	   (42-­‐48),	   dizygotic	   twins	   (DZ)	   (42-­‐48),	   siblings	   (44,	   48-­‐52),	   and	   parents-­‐offsprings	  
(49-­‐51).	   After	   correction	   for	   body	   weight	   and	   FFM,	   r	   remained	   significant	   even	   after	  
adjustment	   by	   age	   (44,	   49-­‐52),	   sex	   (44,	   47,	   50-­‐52),	   fat	   mass	   (52),	   skinfolds	   (49,	   50),	  
physical	  activity	  (50),	  smoking	  (50)	  and	  socio-­‐economic	  status	  (50).	  Within	  MZ,	  DZ,	  siblings	  
and	  parent-­‐offspring,	  r	  values	  for	  weight-­‐adjusted	  VO2max	  were	  0.62-­‐0.95,	  0.04-­‐0.51,	  0.18-­‐
0.41	   and	   30.03-­‐0.34,	   and	   r	   values	   for	   FFM-­‐adjusted	   VO2max,	   were	   0.61-­‐0.70,	   0.28-­‐0.57,	  
0.29-­‐0.65	   and	   0.21-­‐0.29,	   respectively.	   The	   ratio	   of	   VO2max	   variance	   between	   and	  within	  
twin	  pairs,	   sibling	  pairs	   and	   families	   (F-­‐ratio)	  was	   evaluated	  within	   two	  of	   these	   studies	  
(44,	  52).	  After	  correcting	  for	  age	  and	  sex,	  F-­‐ratios	  of	  MZ,	  DZ,	  siblings	  and	  parent-­‐offspring	  
for	  body	  weight-­‐adjusted	  VO2max	  were	  5.79	  (44),	  3.09	  (44),	  2.56	  (44)	  and	  2.63	  (52),	  and	  
for	  FFM-­‐adjusted	  VO2max,	  were	  4.07	  (44),	  3.64	  (44),	  5.11	  (44)	  and	  2.72	  (52),	  respectively.	  
These	   studies	   demonstrate	   that	   VO2max	   variance	   between	   twin	   pairs,	   sibling	   pairs	   and	  
families	  was	  2.56-­‐5.79	  times	  higher	  than	  VO2max	  within	  each	  grouping.	  After	  correction	  for	  
age	  and	   sex,	   the	  F-­‐ratio	  of	  VO2max	  variance	  within	  MZ	  pairs	   to	  variance	  within	  DZ	  pairs	  
was	   1.90	   for	   body	   weight-­‐adjusted	   VO2max	   and	   1.21	   for	   FFM-­‐adjusted	   VO2max	   (44).	  
Without	  age	  and	  sex	  adjustment,	  this	  F-­‐ratio	  ranged	  between	  13.90-­‐16.45	  for	  body	  weight-­‐
adjusted	   VO2max	   (42,	   43).	   The	   heritability	   (h2)	   of	   body-­‐weight	   adjusted	   VO2max	   was	  
estimated	  to	  be	  between	  38.0-­‐93.4%	  (42,	  44-­‐47,	  52).	  A	  meta-­‐analysis	  found	  that	  the	  h2	  of	  
body-­‐weight	  adjusted	  VO2max	  was	  72%	  (48).	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2.3	  The	  relationship	  between	  CRF	  and	  health	  
Research	   has	   included	   both	   children	   and	   adults.	   In	   children,	   low	   CRF	   has	   been	  
associated	  with	  obesity,	  weight	  gain	  and	  increased	  adiposity.	   In	  adults,	   low	  CRF	  has	  been	  
associated	   with	   obesity,	   weight	   gain,	   impaired	   fasting	   glucose	   (IFG),	   DM,	   hypertension,	  
metabolic	   syndrome,	   cardiovascular	   disease	   (CVD)	   event,	   cancer	   and	   postoperative	  
hospital	  stay.	  	  
	  
2.3.1	  High	  CRF	  is	  protective	  against	  obesity,	  weight	  gain	  and	  increased	  adiposity.	  
CRF	   was	   negatively	   associated	   with	   BMI	   in	   boys	   and	   girls	   7-­‐13	   years	   of	   age,	   at	  
baseline	  and	  after	  12	  (53)	  and	  18	  months	  (33)	  of	  follow-­‐up.	  Boys	  and	  girls	  with	  high	  (above	  
median	   of	   each	   sex)	   baseline	   CRF	   were	   89%	   and	   85%	   less	   likely	   to	   remain	   or	   become	  
overweight,	  respectively	  (33).	  Each	  15%	  increase	  in	  baseline	  VO2max	  was	  associated	  with	  
1.38	  kg	  less	  fat	  mass	  gain	  in	  Hispanic	  boys	  (average	  baseline	  age	  of	  11.7	  years)	  4	  years	  later	  
after	  adjusting	  for	  age,	  Tanner	  stage,	  and	  lean	  mass	  (54).	  CRF	  is	  also	  inversely	  associated	  
with	   obesity	   and	   BMI	   in	   men	   and	   women.	   A	   separate	   study	   reported	   that	   every	   1-­‐
ml/kg/min	  (or	  about	  0.28	  MET)	  increase	  in	  baseline	  VO2max	  resulted	  in	  a	  13%	  decrease	  in	  
obesity	   incidence	   and	   a	   9%	   decreased	   incidence	   of	   a	   10	   kg	   weight	   gain	   20	   years	   later	  
among	  all	  subjects	  (55).	  This	  inverse	  relationship	  between	  high	  VO2max	  (ml/kg/min)	  and	  
rate	  of	  weight	  gain	  after	  a	  shorter	  period	  (1	  year)	  of	  follow-­‐up	  has	  also	  been	  documented	  in	  
women	  (56).	  
	  
2.3.2	  High	  CRF	  is	  protective	  against	  IFG.	  
Higher	  CRF	  was	   found	  to	  protect	  against	   incidence	  of	   IFG.	  A	  study	   in	  men	  showed	  
that	  those	  in	  the	  highest	  quintile	  for	  fitness	  were	  14%	  less	  likely	  to	  develop	  IFG	  than	  those	  
in	  the	  lowest	  fitness	  quintile	  in	  the	  5.1	  years	  since	  baseline	  (57).	  Similarly,	  a	  separate	  study	  
in	  men	   documented	   a	   47%	   lower	   incidence	   of	   IFG	   in	   the	   highest-­‐fitness	   group	   after	   an	  
average	  follow-­‐up	  of	  6	  years	  (58).	  	  	  	  	  
	  
2.3.3	  High	  CRF	  is	  protective	  against	  DM.	  
A	  protective	  effect	  of	  high	  CRF	  against	  DM	  was	  documented	  in	  men	  and	  women	  after	  
4-­‐26	  years	  of	  average	  or	  median	  follow-­‐up	  (29,	  31,	  37,	  41,	  57-­‐66).	  Within	  these	  studies,	  the	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highest-­‐fitness	  group	  experienced	  33-­‐85%	  lower	  incidence	  of	  DM	  when	  compared	  to	  their	  
lowest-­‐fit	  counterparts	  (29,	  31,	  37,	  57-­‐61,	  63-­‐65).	  The	  lower	  incidence	  of	  DM	  persisted	  in	  
all	   strata	   of	   BMI	   (29,	   57),	   WC	   (57),	   percent	   fat	   (57),	   baseline	   fasting	   glucose	   (31)	   and	  
parental	   DM	   (63)	   with	   a	   range	   of	   21-­‐75%.	   A	   few	   studies	   also	   evaluated	   the	   decreased	  
incidence	  of	  DM	  per	  1-­‐unit	   increase	   in	  CRF.	  One	  reported	  a	  21%	  and	  3%	  decrease	   in	  DM	  
incidence	   per	   1-­‐min	   increase	   in	   treadmill	   duration	   in	   non-­‐obese	   and	   obese	   subjects,	  
respectively	  (29).	  A	  separate	  study	  documented	  an	  8%	  decreased	  DM	  incidence	  per	  1-­‐MET	  
increase;	   this	  was	  preserved	   in	  all	  strata	  of	  age,	  sex,	  race,	  smoking,	  obesity,	  hypertension	  
and	  hyperlipidemia	  with	  a	  range	  of	  2-­‐13%	  (37).	  Another	  study	  documented	  that	  for	  each	  
standard	  deviate	  (SD	  =	  1.6)	  increase	  in	  maximal	  METs,	  and	  individual	  was	  70%	  less	  likely	  
to	   develop	   DM	   (41).	   A	   meta-­‐analysis	   (66)	   demonstrated	   that	   a	   1-­‐MET	   increase	   was	  
associated	  with	  5%	  decrease	  in	  DM	  incidence	  and	  assumed	  that	  this	  1-­‐MET	  increase	  would	  
prevent	  23	  cases	  of	  DM	  per	  100,000	  people	  per	  year	  with	  a	  DM	   incidence	  of	  5	  per	  1000	  
person-­‐year.	  	  	  	  	  
	  
2.3.4	  High	  CRF	  is	  protective	  against	  hypertension.	  
A	  negative	   relationship	   between	  CRF	   and	   incidence	   of	   hypertension	  was	   found	   in	  
both	  men	   and	  women	   after	   4-­‐18	   years	   of	   average	   or	  median	   follow-­‐up	   (29,	   36,	   67-­‐71).	  
Compared	   to	   the	   lowest-­‐fitness	   group,	   the	   highest-­‐fitness	   group	   had	   a	   27-­‐65%	   lower	  
incidence	  of	  hypertension	  (29,	  36,	  67-­‐71).	  The	  lower	  hypertension	  incidence	  remained	  in	  
all	  strata	  of	  age	  (67),	  BMI	  (29,	  67)	  and	  the	  presence	  of	  pre-­‐hypertension	  at	  baseline	  (67)	  
with	   a	   range	  of	   22-­‐76%.	  The	  decreased	   incidence	  of	   hypertension	  per	  1-­‐unit	   increase	   in	  
CRF	   has	   also	   been	   previously	   calculated.	   A	   1-­‐min	   increase	   in	   treadmill	   duration	   was	  
associated	  with	  17%	  and	  19%	  decreased	  incidence	  of	  hypertension	  in	  non-­‐obese	  and	  obese	  
subjects,	   respectively	   (29).	   A	   1-­‐MET	   increment	   was	   associated	   with	   10-­‐32%	   decreased	  
hypertension	  incidence	  (67,	  68,	  70).	  Interestingly,	  one	  study	  documented	  that	  the	  positive	  
association	  between	  BMI	  and	  hypertension	  incidence	  was	  weakened	  after	  adding	  CRF	  into	  
the	  model	  of	  analysis	  (68).	  
	  
2.3.5	  High	  CRF	  is	  protective	  against	  metabolic	  syndrome.	  
Metabolic	   syndrome	   is	   defined	   as	   the	   presence	   of	   ≥3	   of	   the	   following	   criteria	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according	   to	   the	   National	   Cholesterol	   Education	   Program/Adult	   Treatment	   Panel	   III	  
(NCEP/ATP	   III)	   (72):	   abdominal	   obesity	   (WC	   >102	   cm	   in	   men	   and	   >88	   cm	   in	   women),	  
triglycerides	   ≥150	  mg/dl,	   HDL	   <40	   mg/dl	   in	   men	   and	   <50	   mg/dl	   in	   women,	   SBP	   ≥130	  
mmHg	  or	  DBP	  ≥85	  mmHg,	   and	   glucose	   ≥110	  mg/dl.	   It	   has	   been	   shown	   that	   high	  CRF	   is	  
protective	  against	  incidence	  of	  metabolic	  syndrome	  in	  both	  men	  and	  women.	  Research	  in	  
young	  adults	  (18	  to	  30	  years	  or	  age)	  discovered	  that	  the	  highest-­‐fitness	  group	  were	  47%,	  
75%	   and	   21%	   less	   likely	   to	   develop	  metabolic	   syndrome	   among	   all	   subjects,	   non-­‐obese,	  
and	  obese	  subjects,	  respectively,	  compared	  to	  their	  lowest-­‐fit	  counterparts	  after	  15	  years	  of	  
follow-­‐up	   (29).	   Per	   every	   1-­‐min	   increase	   of	   treadmill	   duration	   in	   non-­‐obese	   and	   obese	  
group,	   metabolic	   syndrome	   incidence	   decreased	   by	   22%	   and	   7%,	   respectively	   (29).	  
Another	   study	   also	   found	   a	   negative	   association	   between	   CRF	   and	   incident	   metabolic	  
syndrome	  after	   the	   average	   follow-­‐up	  of	   5.7	   years	   (73).	  Men	   and	  women	   in	   the	  highest-­‐
fitness	  group	  had	  53%	  and	  63%	  lower	  metabolic	  syndrome	  incidence	  than	  those	  in	  lowest-­‐
fitness	  group	  of	  the	  same	  sex,	  respectively	  (73).	  This	  lower	  incidence	  remained	  in	  all	  strata	  
of	   BMI,	   age	   and	   number	   of	   baseline	   metabolic	   risk	   factors	   (according	   to	   the	   criteria	   of	  
metabolic	  syndrome)	  with	  a	  range	  of	  41-­‐85%	  (73).	  
	  
2.3.6	  High	  CRF	  is	  protective	  against	  CVD	  events.	  
A	  protective	  effect	  of	  high	  CRF	  against	  CVD	  (overall,	  coronary	  heart	  disease	  (CHD),	  
atrial	  fibrillation	  (AF)	  or	  stroke)	  events	  was	  observed	  in	  both	  men	  and	  women	  after	  3-­‐18.2	  
years	  of	  average	  or	  median	  follow-­‐up	  (40,	  74-­‐90).	  Participants	  in	  the	  highest-­‐fitness	  group	  
experienced	  22-­‐62%	  lower	  overall	  CVD	  event	  incidence	  as	  compared	  to	  their	  lowest-­‐fitness	  
counterparts	  (83,	  85-­‐87).	  The	  lower	  incidence	  persisted	  when	  subjects	  were	  dichotomized	  
as	  healthy	  (54%)	  and	  unhealthy	  (46%)	  (82)	  and	  when	  only	  participants	  with	  hypertension	  
were	   evaluated	   (30%	   in	   men	   and	   59%	   in	   women)	   (84).	   Subjects	   in	   the	   highest-­‐fitness	  
group	  had	  19-­‐67%	  lower	  incidence	  of	  CHD	  compared	  to	  those	  in	  the	  lowest-­‐fitness	  group	  
(40,	  77-­‐79,	  83,	  85,	  88).	  The	  lower	  CHD	  incidence	  persisted	  when	  people	  were	  dichotomized	  
by	  race	  (65%	  in	  white	  and	  73%	  in	  black)	  (90),	  when	  only	  participants	  with	  hypertension	  
were	  enrolled	  (29%	  in	  men	  and	  53%	  in	  women)	  (84)	  and	  when	  only	  people	  with	  one	  or	  
more	   risk	   factors	   (smoking,	   high	   cholesterol	   level	   and	   high	   SBP)	   were	   included	   with	   a	  
range	   of	   71-­‐85%	   (78).	   A	   meta-­‐analysis	   found	   that	   people	   in	   the	   highest-­‐fitness	   group	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(≥10.9	  METs)	  had	  36%	  lower	  incidence	  of	  overall	  CVD	  and/or	  CHD	  event	  than	  those	  in	  the	  
lowest-­‐fitness	  group	  (<7.9	  METs)	  (91).	  When	  compared	  with	  the	  lowest-­‐fitness	  group,	  the	  
highest-­‐fitness	  group	  had	  56%	  and	  57%	  lower	  incident	  AF	  among	  all	  subjects	  and	  subjects	  
with	   known	  CVD,	   respectively	   (89).	  Men	   and	  women	   in	   the	   highest-­‐fitness	   category	   had	  
29%	   and	   31%	   lower	   stroke	   incidence,	   respectively,	   as	   compared	   to	   the	   lowest-­‐fitness	  
group	  (85).	  The	  decrease	  in	  overall	  CVD,	  CHD	  and	  AF	  incidence	  per	  unit	  increase	  of	  CRF	  has	  
also	  been	  previously	  calculated.	  Each	  1-­‐MET	   increase	  was	  associated	  with	  10%	  and	  23%	  
decreased	   incidence	  of	  overall	  CVD	  event	   in	  men	  and	  women,	   respectively	   (87).	  A	  1-­‐min	  
increment	   of	   treadmill	   duration	   resulted	   in	   13%	   decrease	   in	   incidence	   of	   overall	   CVD	  
events	   (80).	   Additionally,	   each	   20-­‐W	   increase	   of	   workload	   during	   the	   exercise	   test	   was	  
associated	   with	   a	   9%	   decreased	   incidence	   of	   overall	   CVD	   events	   (86).	   The	   decreased	  
incidence	   of	   overall	   CVD	   event	   per	   each	   MET	   increase	   was	   preserved	   in	   all	   strata	   of	  
smoking,	  BMI,	  hypertension	  and	  LDL	  cholesterol	  level	  with	  a	  range	  of	  17-­‐29%	  (82).	  Each	  1-­‐
MET	  increase	  was	  also	  associated	  with	  a	  20%	  decrease	  in	  CHD	  incidence	  (88).	  Similarly,	  a	  
separate	  study	  found	  6%	  and	  3%	  decreased	  incident	  CHD	  per	  each	  MET	  increment	  in	  men	  
and	  women,	  respectively	  (81).	  The	  decreased	  incidence	  of	  CHD	  per	  1-­‐MET	  increment	  was	  
preserved	  in	  all	  strata	  of	  Framingham	  risk	  score	  (http://cvdrisk.nhlbi.nih.gov)	  with	  a	  range	  
of	  3-­‐13%	  (81).	  A	  meta-­‐analysis	  showed	  that	  a	  1-­‐MET	  increase	  was	  associated	  with	  a	  15%	  
decrease	  in	  incident	  overall	  CVD/CHD	  events,	  and	  the	  decreased	  incidence	  persisted	  in	  all	  
strata	   of	   age,	   sex,	   smoking,	   number	   of	   risk	   factors,	   exercise	   ECG,	   follow-­‐up	   duration,	  
ergometer	  used	  for	  testing,	  and	  maximal/submaximal	  workload	  testing	  with	  a	  range	  of	  10-­‐
23%	  (91).	  The	  decrease	  in	  AF	  incidence	  per	  1-­‐MET	  increment	  of	  CRF	  was	  also	  documented	  
(7%	   among	   all	   subjects	   and	   6%	   among	   subjects	   with	   known	   CVD),	   and	   the	   decreased	  
incidence	  per	  each	  MET	  increase	  remained	  in	  all	  strata	  of	  age,	  sex,	  race,	  smoking,	  obesity,	  
hypertension,	  DM	  and	  hyperlipidemia	  with	  a	  range	  of	  8-­‐16%	  (89).	  
	  
2.3.7	  High	  CRF	  is	  protective	  against	  cancer.	  
A	  study	  in	  men	  found	  that	  the	  highest-­‐fitness	  group	  had	  27%	  lower	  cancer	  incidence	  
(overall,	  lung	  and	  gastrointestinal	  (GI)	  tract)	  than	  their	  lowest-­‐group	  counterparts	  after	  an	  
average	  follow-­‐up	  of	  16.7	  years,	  and	  this	  was	  preserved	  when	  subjects	  were	  dichotomized	  
as	   physically	   active	   (26%)	   and	   physically	   inactive	   (33%)	   (92).	   The	   authors	   also	   noted	   a	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20%	   and	   12%	   decreased	   incidence	   of	   lung	   and	   GI	   tract	   cancer,	   respectively,	   per	   1-­‐MET	  
increase	  (92).	  	  
	  
2.3.8	  High	  CRF	  is	  protective	  against	  postoperative	  hospital	  stay.	  
CRF	   and	   postoperative	   (hepatobiliary	   surgery)	   hospital	   stay	   duration	   were	  
negatively	   associated	   (93).	   Furthermore,	   patients	   in	   the	   high	   CRF	   group	   (VO2max	   >10	  
ml/kg/min)	   spent	   shorter	   total	  period	   in	  a	  hospital	  and	   in	  a	   critical	   care	  unit	   than	   those	  
whose	   VO2max	   <10	   ml/kg/min,	   and	   the	   results	   were	   consistent	   when	   patients	   were	  
dichotomized	  into	  those	  younger	  or	  older	  than	  75	  years	  of	  age	  (93).	  Interestingly,	  high	  CRF	  
patients	  spent	  similar	  durations	  of	  both	   total	  and	  critical	   care	  unit	   stay	  regardless	  of	  age	  
group	  (93).	  
	  
2.4	  The	  relationship	  between	  CRF	  and	  mortality	  
The	   association	   between	   CRF	   and	   all-­‐cause	   mortality,	   CVD	   mortality,	   stroke	  
mortality,	   dementia	   mortality,	   cancer	   mortality	   and	   postoperative	   mortality	   to	   date	   has	  
only	  been	  documented	  in	  adults.	  	  
	  
2.4.1	  High	  CRF	  is	  protective	  against	  all-­‐cause	  mortality.	  
High	   CRF	  was	   found	   to	   be	   protective	   against	   all-­‐cause	  mortality	   in	   both	  men	   and	  
women	  after	  6.2-­‐28.7	  years	  of	  average	  or	  median	  follow-­‐up	  (27,	  28,	  30,	  34,	  35,	  38,	  39,	  82,	  
83,	   86,	   87,	   90,	   94-­‐131).	   Compared	   to	   subjects	   in	   the	   lowest-­‐fitness	   group,	   those	   in	   the	  
highest-­‐fitness	  group	  demonstrated	  a	  24-­‐74%	  lower	  all-­‐cause	  mortality	  (27,	  28,	  34,	  39,	  83,	  
86,	  87,	  94-­‐96,	  98-­‐100,	  102,	  105,	  107,	  108,	  110,	  114,	  118,	  120,	  121,	  123,	  125-­‐127,	  129).	  A	  
meta-­‐analysis	  found	  that	  people	  in	  the	  highest-­‐fitness	  group	  (≥10.9	  METs)	  had	  41%	  lower	  
all-­‐cause	  mortality	  than	  those	  in	  the	  lowest-­‐fitness	  group	  (<7.9	  METs)	  (91).	  The	  lower	  all-­‐
cause	   mortality	   was	   preserved	   when	   only	   people	   with	   diseases	   were	   enrolled.	   As	  
compared	  with	  their	   lowest-­‐fitness	  counterparts,	  subjects	  with	  peripheral	  artery	  diseases	  
(PAD)	  (128),	  hypertension	  (30),	  DM	  (104,	  111)	  and	  documented	  or	  suspected	  CHD	  (35)	  in	  
the	   highest-­‐fitness	   group	   had	   41%,	   57%,	   52-­‐78%	   and	   40%	   lower	   all-­‐cause	   mortality,	  
respectively.	  The	  lower	  all-­‐cause	  mortality	  also	  persisted	  in	  all	  strata	  of	  race	  (90,	  113,	  120),	  
BMI	  (35,	  38,	  103,	  106,	  107,	  111,	  121,	  123,	  125),	  WC	  (35,	  38,	  101,	  123),	  fat	  mass	  (101),	  FFM	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(101),	   percent	   fat	   (35,	   101,	   111,	   123),	  waist-­‐to-­‐hip	   ratio	   (123),	   DM	   or	   glucose	   (97,	   106,	  
122),	  hypertension	  or	  BP	  (98,	  106),	  cholesterol	  level	  (98,	  106),	  metabolic	  syndrome	  (112),	  
CVD	  (106,	  119,	  120,	  122),	  symptom	  of	  CHD	  (115),	  chronic	  obstructive	  pulmonary	  disease	  
(COPD)	   (106),	   smoking	   (28,	   98,	   101,	   106),	   alcohol	   intake	   (126),	   dietary	   intake	   (124),	  
physical	  activity	  (34),	   leisure	  time	  (39),	  health	  status	  (82,	  98)	  and	  number	  of	  risk	   factors	  
(82,	   122)	   with	   a	   range	   of	   6-­‐83%.	   Interestingly,	   the	   lower	  mortality	   persisted	   after	   sub-­‐
stratifying	   subjects	   in	   each	   lowest-­‐fitness	   (130)	   and	   highest-­‐fitness	   group	   (131)	   into	   3	  
groups.	  In	  the	  lowest-­‐fitness	  group,	  the	  highest-­‐lowest	  group	  at	  all	  age	  ranges	  had	  40-­‐47%	  
lower	  all-­‐cause	  mortality	  than	  the	  lowest-­‐lowest	  group	  counterparts	  (130).	  Among	  those	  in	  
the	   highest-­‐fitness	   group,	   the	   highest-­‐highest	   group	   had	   39%	   lower	   all-­‐cause	   mortality	  
than	   those	   in	   the	   lowest-­‐highest	   group	   (131).	  The	   results	   from	  sub-­‐stratification	   suggest	  
that	  there	  is	  no	  threshold	  of	  CRF	  as	  a	  predictor	  of	  all-­‐cause	  mortality.	  	  
The	   decrease	   in	   all-­‐cause	   mortality	   per	   unit	   increment	   of	   CRF	   was	   previously	  
calculated	   in	  several	   studies.	  A	  1-­‐MET	   increase	  was	  associated	  with	  a	  7-­‐19%	  decrease	   in	  
all-­‐cause	  mortality	  (106,	  108-­‐110,	  114,	  116,	  117,	  120,	  125,	  127).	  Additionally,	  each	  20-­‐W	  
workload	  increase	  during	  the	  exercise	  test	  was	  associated	  with	  a	  14%	  decreased	  all-­‐cause	  
mortality	   (86).	   A	  meta-­‐analysis	   showed	   that	   each	   1-­‐MET	   increase	  was	   associated	  with	   a	  
13%	  decrease	   in	   all-­‐cause	  mortality	   (91).	   The	  decrease	   in	   all-­‐cause	  mortality	  per	  1-­‐MET	  
increase	  was	  also	  observed	  when	  only	  subjects	  with	  PAD	  were	  enrolled	  (18%)	  (128)	  and	  
when	   subjects	  were	   stratified	   by	   race	   (120)	   and	   CVD	   (120)	  with	   a	   range	   of	   9-­‐24%.	   The	  
aforementioned	   meta-­‐analysis	   that	   reported	   decreased	   all-­‐cause	   mortality	   in	   the	   fittest	  
individuals	  also	  documented	  a	  decrease	  in	  all-­‐cause	  mortality	  per	  1-­‐MET	  increment	  in	  all	  
strata	   of	   age,	   sex,	   smoking,	   number	   of	   risk	   factors,	   exercise	   ECG,	   average	   of	   follow-­‐up	  
duration,	   ergometer	   used	   for	   testing,	   and	  maximal/submaximal	  workload	   testing	  with	   a	  
range	   of	   9-­‐16%	   (91).	   Interestingly,	   significant	   associations	   of	  metabolic	   syndrome	   (112,	  
116),	  WC	   (118),	  BMI	   (105,	  116,	  121),	  physical	   activity	   (34)	  and	   leisure	   time	   (39)	  vs.	   all-­‐
cause	  mortality	  disappeared	  after	  adding	  CRF	  into	  the	  model.	  Moreover,	  fit	  people	  with	  risk	  
factors	  such	  as	  obesity	  (30,	  35),	  high	  WC	  (30,	  35,	  123),	  high	  percent	  of	  fat	  (30,	  35,	  123)	  and	  
high	   waist-­‐to-­‐hip	   ratio	   (123)	   had	   no	   higher	   all-­‐cause	   mortality	   as	   compared	   with	   their	  
fit/normal	  counterparts	  even	   they	  were	  hypertensive	   (30).	  A	   few	  studies	   found	   that	  CRF	  
was	  a	  more	  dominant	  predictor	  of	  all-­‐cause	  mortality	  than	  several	  other	  risk	  factors.	  Even	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in	   the	   presence	   of	   risk	   factors,	   including	   overweight	   or	   obesity	   (82,	   111,	   125),	   high	  WC	  
(123),	  high	  percent	  of	   fat	  (123),	  high	  waist-­‐to-­‐hip	  ratio	  (123),	  DM	  (122),	  CVD	  (122),	  high	  
BP	  or	  hypertension	  (82,	  98),	  high	  cholesterol	  (98),	  smoking	  (28,	  82),	  poorer	  dietary	  intake	  
(124)	  and	  less	  physically	  active	  (34,	  39),	  fit	  people	  demonstrated	  lower	  all-­‐cause	  mortality	  
than	  unfit	  people	  without	  any	  risk	  factors.	  	  
	  
2.4.2	  High	  CRF	  is	  protective	  against	  CVD	  mortality.	  
A	   protective	   effect	   of	   high	   CRF	   against	   CVD	   (overall,	   CHD	   and	   heart	   failure	   (HF))	  
mortality	  was	  discovered	   in	  both	  men	  and	  women	  after	  7-­‐26	  years	  of	  average	  or	  median	  
follow-­‐up	  (27,	  28,	  30,	  35,	  82,	  86,	  87,	  94-­‐96,	  98,	  101,	  103,	  107,	  109,	  112-­‐117,	  126-­‐128,	  132-­‐
136).	  As	  compared	  with	  the	  lowest-­‐fitness	  group,	  subjects	  in	  the	  highest-­‐fitness	  group	  had	  
11-­‐82%	  lower	  overall	  CVD	  mortality	  (27,	  28,	  86,	  87,	  96,	  98,	  107,	  114,	  126,	  132).	  This	  lower	  
overall	   CVD	   mortality	   was	   preserved	   when	   only	   people	   with	   diseases	   were	   enrolled,	  
including	   hypertension	   (70%)	   (30),	   documented	   or	   suspected	  CHD	   (49%)	   (35)	   and	  PAD	  
(60%)	  (128).	  The	  lower	  overall	  CVD	  mortality	  also	  persisted	  in	  all	  strata	  of	  race	  (107),	  BMI	  
(35,	   103,	   107,	   127,	   132),	   percent	   fat	   (35,	   101),	   fat	   mass	   (101),	   FFM	   (101),	   WC	   (35),	  
hypertension	   or	   BP	   (96,	   98,	   127,	   132),	   DM	   or	   glucose	   (127,	   132),	   metabolic	   syndrome	  
(112),	  heart	  disease	  (96),	  symptom	  of	  CHD	  (115),	  stroke	  (96),	  health	  status	  (82,	  98,	  132),	  
cholesterol	   level	   (98,	   132),	   alcohol	   intake	   (126)	   and	   smoking	   (28,	   98,	   127,	   132)	   with	   a	  
range	  of	  2-­‐83%.	  For	  CHD	  and	  HF	  mortality,	   subjects	   in	   the	  highest-­‐fitness	  group	  had	  17-­‐
84%	   lower	   CHD	  mortality	   (95,	   134,	   135)	   and	   75%	   lower	   HF	  mortality	   (136)	   than	   their	  
lowest-­‐fitness	   counterparts.	   The	   lower	   HF	   mortality	   persisted	   in	   all	   strata	   of	   BMI	   and	  
number	  of	  risk	  factors	  (obesity,	  hypertension,	  DM,	  smoking	  and	  family	  history	  of	  CVD)	  with	  
a	   rage	   of	   27-­‐75%	   (136).	   For	   overall	   CVD	  mortality,	   each	   1-­‐MET	   increase	  was	   associated	  
with	  5-­‐26%	  decreased	  mortality	  (87,	  109,	  114,	  116,	  117).	  A	  separate	  study	  documented	  a	  
12%	  decrease	  in	  overall	  CVD	  mortality	  per	  20-­‐W	  workload	  increase	  during	  an	  exercise	  test	  
(86).	  The	  decrease	  in	  overall	  CVD	  mortality	  per	  unit	  increase	  of	  CRF	  was	  also	  observed	  in	  
all	  strata	  of	  BMI,	  BP,	  LDL	  cholesterol	   level,	  smoking	  and	  health	  status	  with	  a	  range	  of	  15-­‐
51%	   (82).	   For	   CHD	  mortality,	   1-­‐SD	   increase	   of	   cumulative	   work	   per	   body	   weight	   (0.57	  
kJ/kg)	   during	   the	   exercise	   test	  was	   associated	  with	  15%	  decreased	  mortality	   (133).	   The	  
decrease	   in	   CHD	   mortality	   per	   1-­‐MET	   increment	   was	   also	   found	   when	   subjects	   were	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dichotomized	   as	   healthy	   (18%)	   and	   unhealthy	   (28%)	   (82).	   Interestingly,	   the	   effects	   of	  
obesity	   (116)	   and	   metabolic	   syndrome	   (112,	   116)	   on	   overall	   CVD	   mortality	   were	  
weakened	  after	  adding	  CRF	  into	  the	  model	  of	  analysis.	  In	  addition,	  fit	  subjects	  who	  had	  high	  
BMI,	   high	   WC	   or	   high	   percent	   of	   fat	   had	   no	   higher	   overall	   CVD	   mortality	   than	   their	  
fit/normal	  counterparts	  (30,	  35)	  even	   if	   they	  had	  hypertension	  (30).	  A	   few	  studies	   found	  
that	  CRF	  was	  a	  more	  dominant	  predictor	  of	  overall	  CVD	  mortality	  than	  several	  other	  risk	  
factors.	   Fit	   smokers	   (28)	   as	   well	   as	   those	   with	   any	   combination	   of	   smoking,	   high	  
cholesterol,	   and	  high	  BP	   (98)	  had	   lower	  overall	   CVD	  mortality	   compared	   to	  unfit	   people	  
with	  no	  risk.	  Another	  study	  also	  documented	  that	   fit	  people	  with	  high	  BMI,	  high	  BP,	  high	  
glucose,	   high	   cholesterol,	   or	   who	   smoked	   had	   lower	   overall	   CVD	   mortality	   than	   unfit	  
subjects	  with	  no	  risk	  (132).	  Interestingly,	  after	  including	  CRF	  as	  a	  parameter,	  classification	  
of	   the	   risk	   of	   overall	   CVD	  mortality	   in	   asymptomatic	   individuals	  without	   known	   CVD	   at	  
both	   10	   and	   25	   years	   was	   improved	   (137),	   suggesting	   that	   CRF	   is	   a	   critical	   factor	   for	  
prediction	  of	  overall	  CVD	  mortality.	  	  
	  
2.4.3	  High	  CRF	  is	  protective	  against	  stroke	  mortality.	  
A	   study	   in	   men	   documented	   an	   inverse	   relationship	   between	   CRF	   and	   stroke	  
mortality	  (138).	  Men	  in	  the	  highest-­‐fitness	  group	  experienced	  68%	  lower	  stroke	  mortality	  
than	  their	  lowest-­‐fitness	  group	  counterparts	  after	  an	  average	  follow-­‐up	  of	  10	  years.	  
	  	  	  
2.4.4	  High	  CRF	  is	  protective	  against	  dementia	  mortality.	  
A	   negative	   relationship	   between	   CRF	   and	   dementia	   mortality	   in	   both	   sexes	   was	  
identified	   after	   an	   average	   follow-­‐up	   of	   17	   years	   (139).	   Compared	   to	   the	   lowest-­‐fitness	  
group,	  subjects	  in	  the	  highest-­‐fitness	  group	  had	  34%,	  69%	  and	  51%	  lower	  mortality	  from	  
Alzheimer’s	   disease,	   vascular	   dementia	   and	   overall	   dementia	   (Alzheimer’s	   disease	   plus	  
vascular	   dementia),	   respectively	   (139).	   Each	   MET	   increment	   was	   associated	   with	   13%,	  
18%	   and	   14%	   decreased	   mortality	   from	   Alzheimer’s	   disease,	   vascular	   dementia	   and	  
overall	  dementia,	  respectively,	  and	  the	  decrease	  in	  mortality	  from	  overall	  dementia	  per	  1-­‐
MET	  increment	  was	  preserved	  in	  all	  strata	  of	  age,	  sex,	  BMI	  and	  chronic	  medical	  conditions	  
with	  a	  range	  of	  7-­‐34%	  (139).	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2.4.5	  High	  CRF	  is	  protective	  against	  cancer	  mortality.	  
A	  negative	  association	  between	  CRF	  and	  cancer	  mortality	  was	  observed	  in	  both	  men	  
and	  women	  after	  7-­‐24.9	  years	  of	  average	  or	  median	  follow-­‐up	  (32,	  92,	  94,	  96,	  99,	  140-­‐147).	  
As	   compared	   with	   the	   lowest-­‐fitness	   group,	   people	   in	   the	   highest-­‐fitness	   group	  
demonstrated	  37-­‐64%	  lower	  overall-­‐cancer	  mortality	  (92,	  96,	  99,	  140-­‐143,	  147).	  A	  meta-­‐
analysis	   found	   45%	   lower	   overall-­‐cancer	   mortality	   in	   the	   highest-­‐fitness	   group	   as	  
compared	  with	   the	   lowest-­‐fitness	   group	  with	   or	  without	   adjustment	   for	   adiposity	   (148).	  
The	   lower	   cancer	  mortality	   in	   the	   highest-­‐fitness	   group	   compared	   to	   their	   lowest-­‐group	  
counterparts	  was	  also	  found	  in	  specific	  cancer	  mortality,	  including	  smoking-­‐related	  cancer	  
(66%)	   (140),	   nonsmoking-­‐related	   cancer	   (46%)	   (140),	   lung	   cancer	   (57%)	   (32,	   144),	  
overall	  GI	   tract	  cancer	   (44-­‐45%)	  (144,	  146),	   colon	  cancer	   (39%)	  (146),	   colorectal	  cancer	  
(42-­‐47%)	   (144,	   146),	   liver	   cancer	   (72-­‐78%)	   (144,	   146)	   and	   breast	   cancer	   (45%)	   (145)	  
regardless	  of	  pre-­‐DM	  and	  DM	  (144).	  The	  lower	  overall	  and	  specific	  cancer	  mortalities	  were	  
preserved	  in	  all	  strata	  of	  BMI	  (143,	  147),	  percent	  body	  fat	  (143,	  147),	  WC	  (143),	  DM	  (144)	  
and	  smoking	  (32,	  141)	  with	  a	  range	  of	  16-­‐67%.	  Moreover,	  people	  with	  high	  CRF	  who	  had	  
high	  BMI,	  high	  WC	  or	  high	  percent	  body	  fat	  had	  lower	  overall	  cancer	  mortality	  than	  those	  
with	  low	  CRF	  who	  had	  none	  of	  these	  risk	  factors	  (144).	  Interestingly,	  positive	  correlations	  
of	  BMI,	  percent	  of	   fat	  and	  WC	  with	  overall	   cancer	  mortality	  were	  weakened	  after	  adding	  
CRF	   into	   the	   model	   of	   analysis,	   suggesting	   that	   CRF	   attenuates	   obesity-­‐induced	   cancer	  
mortality	  (143).	  
	  
2.4.6	  High	  CRF	  is	  protective	  against	  postoperative	  mortality.	  
Patients	  in	  the	  high-­‐fitness	  category	  (≥5	  METs)	  had	  lower	  immediate	  postoperative	  
(Coronary	   Artery	   Bypass	   Graft)	   and	   30-­‐day	   postoperative	  mortalities	   as	   compared	  with	  
those	   in	   the	   low-­‐fitness	   group	   (<5	  METs)	   (149).	   Another	   study	   in	  men	   and	  women	   also	  
investigated	   the	  relationship	  between	  preoperative	  CRF	  and	  postoperative	  (hepatobiliary	  
surgery)	  mortality	  and	  found	  that	  patients	  in	  the	  high	  CRF	  group	  (VO2max	  >10	  ml/kg/min)	  
had	   48%	   lower	   postoperative	  mortality	   than	   those	  whose	   VO2max	   <10	  ml/kg/min	   (93).	  
When	  patients	  were	  dichotomized	  as	  <75	  years	  and	  >75	  years	  of	  age,	  those	  in	  the	  high	  CRF	  
group	  had	  a	  mortality	  rate	  of	  less	  than	  5%	  regardless	  of	  age	  group,	  but	  those	  in	  the	  low	  CRF	  
group	  who	  were	  younger	   than	  75	  years	  had	   an	  11%	  mortality	   rate	   and	   those	  who	  were	  
	   17	  
older	   than	  75	  years	  had	  a	  22%	  mortality	   rates	   (93).	   In	   summary,	  high	  CRF	   is	   associated	  
with	   lower	   postoperative	   mortality	   in	   all	   strata	   of	   age,	   and	   interestingly,	   high	   CRF	  
attenuates	  age-­‐related	  postoperative	  mortality.	  	  
	  
2.5	  The	  rat	  genetic	  model	  of	  aerobic	  treadmill	  running	  capacity	  
In-­‐depth	   studies	   that	   identify	   how	   CRF	   influences	   health	   and	   longevity	   are	  
necessary.	  However,	  completing	  such	  studies	  in	  humans	  is	  difficult.	  Therefore,	  a	  rat	  genetic	  
model	   of	   aerobic	   treadmill	   running	   capacity	   was	   established.	   The	   model	   was	   first	  
developed	   (150)	  by	   running	  18	  male	  and	  24	   female	  outbred	  Sprague-­‐Dawley	  rats	  on	   the	  
treadmill	  once	  a	  day	  for	  5	  days.	  The	  treadmill	  was	  set	  at	  a	  constant	  15°	  inclination	  and	  the	  
initial	  speed	  of	  10	  m/min	  was	  increased	  by	  1	  m/min	  every	  2	  min.	  The	  total	  distance	  run	  on	  
the	   single	   best	   day	  was	   taken	   as	   the	  measure	   of	   endurance	   performance.	   The	   2	   lowest-­‐
performing	   pairs	   and	   2	   highest-­‐performing	   pairs	   were	   selectively	   bred	   through	   3	  
generations.	   After	   3	   generations	   of	   selection,	   performance	   of	   the	   high-­‐selected	   line	  
averaged	   659±36	  m,	   whereas	   those	   of	   the	   low-­‐selected	   line	   averaged	   388±28	  m.	   After	  
that,	   a	   larger-­‐scale	   selection	  was	   completed	   in	  96	  male	   and	  96	   female	  non-­‐sibling	  N:NIH	  
rats	  (151)	  by	  Steve	  Britton	  and	  Lauran	  Koch	  in	  1996	  (152,	  153).	  Rats	  ran	  on	  the	  treadmill	  
as	  previously	  described.	  Based	  on	  maximal	  running	  capacity,	  the	  top	  13	  males	  and	  females	  
were	   bred	   together	   to	   initiate	   the	   high	   capacity	   running	   (HCR)	   line,	   and	   the	   bottom	   13	  
males	   and	   females	  were	  bred	   together	   to	   initiate	   the	   low	  capacity	   running	   (LCR)	   line.	   In	  
this	  breeding	  scheme,	  each	  of	  the	  13	  families	  contributed	  1	  male	  and	  1	  female	  to	  the	  next	  
generation,	   which	   were	   in-­‐turn	   rotationally	   bred	   with	   another	   pre-­‐arranged	   family.	   By	  
2011,	   they	   had	   bred	   for	   28	   generations	   and	   the	   HCR	   and	   LCR	   rats	   differed	   in	   maximal	  
running	  capacity	  about	  7-­‐fold	  (154).	  In	  additional	  to	  higher	  running	  capacity,	  HCR	  rats	  also	  
demonstrate	   better	   health,	   including	   lower	   body	   weight	   (153,	   155-­‐178)	   despite	   higher	  
food	  intake	  per	  body	  weight	  (167,	  176,	  178),	  higher	  resting	  metabolic	  rate	  (RMR)	  per	  body	  
weight	  (165,	  176,	  178,	  179),	  higher	  energy	  expenditure	  of	  activity	  (179),	   lower	  adiposity	  
(152,	  158,	  161,	  164,	  166,	  168,	  171,	  172,	  176,	  180,	  181),	  higher	  insulin	  sensitivity	  (152,	  158,	  
159,	  161,	  163-­‐166,	  168,	  169,	  172,	  178,	  180-­‐183),	  more	  favorable	  plasma	  lipid	  profiles	  (152,	  
158,	  159,	  161,	  163-­‐165,	  168,	  178,	  180,	  181),	  less	  hepatic	  lipid	  accumulation	  (164,	  176),	  less	  
age-­‐related	  hepatic	   fibrosis	  and	  apoptosis	  (164),	   lower	  BP	  (152,	  161,	  164,	  180,	  181),	   less	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cardiac	   arrhythmia	   (184),	   better	   cardiac	   function	   (152,	   155,	   161,	   180,	   181,	   185,	   186),	  
greater	  endothelial-­‐mediated	  vasodilatation	  (161,	  181),	  better	  pulmonary	   function	  (160),	  
higher	  tissue	  O2	  diffusive	  capacity	  (152,	  156,	  161),	  more	  O2	  uptake	  by	  skeletal	  muscle	  (155,	  
161,	  180),	  higher	  capillary	  density	   in	  muscle	  (152,	  157),	   less	  sleep	  problem	  (187),	  better	  
coping	  with	  stress	  (188)	  and	  more	  resistance	  to	  high-­‐fat	  diet	  (HFD),	  including	  less	  weight	  
gain	  (154,	  158,	  159,	  161,	  176,	  179,	  180),	  less	  or	  no	  increase	  in	  fat	  mass	  (154,	  158,	  159,	  161,	  
166,	  176,	  179,	  180),	  no	  reduced	  insulin	  sensitivity	  (154,	  158,	  159,	  161,	  166,	  180,	  182),	  less	  
increase	   in	   intramuscular	   lipid	   density	   (159),	   no	   increased	   hepatic	   lipid	   accumulation	  
(176)	   and	   more	   reduction	   in	   respiratory	   quotient	   (RQ)	   when	   compared	   to	   their	   LCR	  
counterparts	  (176).	  Moreover,	  female	  HCR	  rats	  are	  protected	  from	  ovariectomy-­‐associated	  
increases	  in	  adiposity	  and	  insulin	  resistance	  (178).	  	  
Survivability	  evaluation	  at	  generations	  14,	  15	  and	  17	  found	  that	  median	  lifespan	  of	  
HCR	  was	   28-­‐45%	   longer	   than	   LCR	   rats	   (154,	   185).	   Genetic	   analysis	   identified	   increased	  
variation	  between	  HCR	  and	  LCR	  lines	  but	  decreased	  difference	  within	  lines	  over	  breeding	  
generation	  with	  h2	  for	   the	  running	  capacity	  phenotype	  of	  47±2	  and	  43±2%	  for	  HCR	  and	  
LCR	   lines,	   respectively,	   over	   28	   generations	   (174).	   Interestingly,	   microarray-­‐based	   gene	  
analysis	  on	  skeletal	  muscle	  of	  HCR	  and	  LCR	  rats	  found	  the	  largest	  differentiation	  between	  
lines	   in	   old-­‐rest	   rats	   and	   smallest	   differentiation	   in	   young-­‐rest	   rats	   (189).	   The	   results	  
suggest	  that	  the	  differentiation	  in	  gene	  expression	  is	  age-­‐dependent.	  Up-­‐regulation	  of	  genes	  
related	  to	  mitochondrial	  pathways	  in	  skeletal	  muscle	  of	  HCR	  rats	  was	  documented,	  with	  an	  
overall	   difference	   of	   2,838	   genes	   between	   HCR	   and	   LCR	   lines	   (189).	   The	   data	   also	  
suggested	  that	  the	  changes	  in	  gene	  expression	  that	  was	  related	  to	  aging	  was	  smaller	  in	  HCR	  
than	   LCR,	   suggesting	   a	   slowing	   of	   aging	   in	   the	   muscle.	   	   A	   difference	   in	   cardiac	   gene	  
expression	   between	   HCR	   and	   LCR	   rats	   was	   also	   revealed	   (190).	   1,540	   out	   of	   28,000	  
screened	   cardiac	   genes	   differed	   between	   lines	   (190).	   Because	   the	   rat	  model	   exhibits	   the	  
difference	   in	   health,	   longevity	   and	   genetic	   phenotype	   between	   lines	   as	   well	   as	   high	   h2	  
within	  lines,	  the	  model	  is	  comparable	  with	  previous	  human	  data,	  and	  is	  therefore	  valuable	  
for	  further	  in-­‐depth	  studies	  of	  CRF.	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2.6	   In-­‐depth	   studies	   to	   identify	  mechanisms	   by	  which	   high	   CRF	   is	   associated	  with	  
good	  health	  and	  longevity	  	  
To	  understand	  how	  CRF	  determines	  health	  and	   longevity,	   the	  rat	  genetic	  model	  of	  
aerobic	  treadmill	  running	  capacity	  was	   initially	  used	  to	   identify	  differences	  between	  HCR	  
and	  LCR	  lines.	  A	  few	  studies	  in	  humans	  have	  also	  been	  completed.	  The	  differences	  between	  
high	   and	   low	   CRF	   include	   mitochondrial	   content,	   mitochondrial	   biogenesis,	   oxidative	  
phosphorylation	   (OXPHOS)	  and	  mitochondrial	   respiration,	   reactive	  oxygen	   species	   (ROS)	  
production,	   oxidative	   stress,	   anti-­‐oxidative	   stress,	   indicators	   of	   insulin	   sensitivity,	  
branched-­‐chain	   amino	   acid	   (BCAA)	   catabolism	   and	   lipid	  metabolism,	   as	  well	   as	   physical	  
activity	  and	  leanness.	  
	  
2.6.1	  High	  CRF	  is	  associated	  with	  higher	  mitochondrial	  content	  and	  related	  markers.	  
Mitochondrial	  content	  quantified	  by	  transmission	  electron	  microscopy	  (TEM)	  (169)	  
and	   by	   estimation	   from	   the	   yield	   of	   mitochondria	   from	   isolation	   procedure	   (171)	   was	  
found	  to	  be	  higher	  in	  skeletal	  muscle	  of	  HCR	  rats.	  Citrate	  synthase	  (CS)	  activity,	  a	  marker	  of	  
mitochondrial	   content,	   was	   higher	   in	   HCR	   rat	   skeletal	   muscle	   compared	   to	   their	   LCR	  
counterparts	  (152,	  157-­‐159,	  161,	  169-­‐172).	  Liver	  CS	  activity	  was	  also	  higher	  in	  HCR	  than	  
LCR	  rats	  (164).	  CPS1,	  another	  marker	  of	  hepatic	  mitochondrial	  content,	  was	  higher	  in	  HCR	  
rats	  as	  well	  (164).	  
	  
2.6.2	  High	  CRF	  is	  associated	  with	  more	  indicators	  of	  mitochondrial	  biogenesis.	  
PGC-­‐1𝛼	  plays	  a	  major	  role	  in	  controlling	  mitochondrial	  biogenesis	  and	  was	  higher	  in	  
skeletal	   muscle	   of	   HCR	   compared	   to	   LCR	   rats	   (152,	   161,	   172,	   178,	   181).	   MtDNA	   count	  
number,	  an	  indicator	  of	  mitochondrial	  biogenesis	  (191),	  was	  higher	  in	  HCR	  skeletal	  muscle	  
as	  well	  (172).	  Following	  HFD,	  a	  decrease	  in	  mRNA	  expression	  of	  PGC-­‐1𝛼	  in	  skeletal	  muscle	  
was	  observed	  only	  in	  LCR	  rats	  (166).	  A	  positive	  correlation	  between	  VO2max	  and	  mtDNA	  
count	  number	  has	  also	  been	  documented	  in	  human	  skeletal	  muscle	  (192).	  
	  
2.6.3	  High	  CRF	  is	  associated	  with	  more	  indicators	  of	  OXPHOS	  and	  higher	  mitochondrial	  
respiration.	  
Bioinformatic	   analysis	   of	   skeletal	  muscle	   gene	   expression	  data	   revealed	   that	   gene	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sets	   involving	   OXPHOS	   were	   more	   highly	   expressed	   in	   HCR	   vs.	   LCR	   rats	   (165).	   Several	  
enzymes	   involving	   mitochondrial	   OXPHOS	   were	   higher	   in	   skeletal	   muscle	   of	   HCR	   rats,	  
including	  Complex	  I	  (172,	  178),	  Complex	  II	  (172,	  178),	  Complex	  III	  (172),	  UQCRC2	  (a	  part	  
of	  Complex	  III)	  (152,	  158,	  161,	  181),	  COXI	  (a	  part	  of	  Complex	  IV)	  (152,	  158,	  159,	  161,	  171,	  
181),	  COXII	  (a	  part	  of	  Complex	  IV)	  (172),	  COXIV	  (a	  part	  of	  Complex	  IV)	  (172),	  Complex	  V	  
(152,	  158,	  161,	  172,	  178,	  181),	  UCP2	  (152,	  158,	  161,	  181),	  UCP3	  (154,	  159,	  163,	  172)	  and	  
PGC-­‐1𝛼	  (152,	  158,	  161,	  172,	  178,	  181).	  Following	  HFD,	  skeletal	  muscle	  mRNA	  expression	  of	  
PGC-­‐1𝛼	  decreased	   in	   LCR	   but	   not	   HCR	   rats	   (166),	   and	   COXI	   and	   UCP3	   skeletal	   muscle	  
mRNA	  expression	  increased	  more	  in	  HCR	  vs.	  LCR	  rats	  (159,	  161).	  Tweedie	  and	  colleagues	  
(170)	  discovered	  that	  the	  proportion	  of	  electron	  transport	  capacity	  that	  was	  attributable	  to	  
leak,	   an	   index	   of	   mitochondrial	   uncoupling	   that	   drives	   OXPHOS	   (193),	   was	   greater	   in	  
skeletal	   muscle	   of	   HCR	   rats.	   Mitochondrial	   protein	   deacetylation	   via	   SIRT3	   activation,	  
another	   indicator	  of	  OXPHOS	  (194-­‐201),	  was	  reduced	   in	  HCR	  skeletal	  muscle	  at	  rest,	  and	  
was	  rapid	  during	  exercise,	  suggesting	  that	  HCR	  rats	  have	  a	  greater	  ability	  to	  continuously	  
produce	  ATP	  through	  OXPHOS	  during	  exercise	  (202).	  Mitochondrial	  respiration	  in	  skeletal	  
muscle	   was	   also	   directly	   measured,	   and	   a	   higher	   respiration	   was	   found	   in	   HCR	   rats,	  
indicating	  a	  greater	  capacity	  of	  complex	  IV	   in	  the	  mitochondria	  (170-­‐172).	   In	  an	  exercise	  
mimicking	   condition,	   HCR	   rats	   also	   demonstrated	   higher	   mitochondrial	   respiration	   in	  
skeletal	  muscle,	  which	   possibly	   contributes	   to	   greater	   running	   capacity	   (203).	   HCR	   liver	  
mitochondria	  also	  demonstrated	  higher	  respiration	  regardless	  of	  diet	  (176).	  	  
	  	  	  	  	  	  	  	  
2.6.4	  High	  CRF	  is	  associated	  with	  lower	  markers	  of	  oxidative	  stress	  and	  oxidative	  DNA	  
damage	  likely	  due	  to	  a	  greater	  capacity	  for	  anti-­‐oxidative	  stress.	  
Surprisingly,	   skeletal	   muscle	   of	   HCR	   rats	   revealed	   higher	   mitochondrial	   ROS	  
production,	  as	  evidenced	  by	  since	  greater	  H2O2	  emission	  (170,	  171).	  However,	  markers	  of	  
mitochondrial	   oxidative	   stress	   (4-­‐HNE)	   (171)	   and	  mitochondrial	   oxidative	   DNA	   damage	  
(8dOHG)	   (170)	  were	   lower	   in	   skeletal	  muscle	   of	  HCRs.	  This	   can	  be	   explained	  by	   greater	  
ROS	   buffering	   capacity	   because	  markers	   of	   anti-­‐oxidative	   stress	   were	   higher	   in	   skeletal	  
muscle	   of	   HCR	   rats,	   including	   total	   SOD	   activity	   (170)	   and	   SOD2	   expression	   (171).	  
Following	  HFD,	  SOD	  activity	  in	  skeletal	  muscle	  were	  significantly	  reduced	  in	  LCRs,	  but	  non-­‐
significantly	   increased	   in	  HCR	  rats	   (166).	  Less	  oxidative	   stress	  was	  also	   revealed	   in	   liver	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mitochondria	  of	  HCR	  rats,	  as	  4-­‐HNE	  level	  was	  lower	  when	  compared	  to	  LCR	  rats	  (164).	  In	  
human	  plasma,	   higher	   CRF	  was	   associated	  with	   lower	  markers	   of	   oxidative	   stress	   (MDA	  
and	   8-­‐iso-­‐PGF2α)	   as	   well	   as	   markers	   of	   oxidative	   DNA	   damage	   (8-­‐OHdG),	   but	   was	  
associated	  with	  higher	  activity	  of	  an	  antioxidant	  enzyme	  glutathione	  peroxidase	  (204).	  
	  
2.6.5	  High	  CRF	  is	  associated	  with	  increased	  insulin	  sensitivity.	  	  
Real-­‐time	  PCR	  analysis	  of	  skeletal	  muscle	  found	  that	  Nur77,	  a	  gene	  associated	  with	  
insulin	   sensitivity,	   was	   up-­‐regulated	   in	   HCR	   rats	   (163).	   Additionally,	   a	   BCAA	   catabolism	  
associated	  gene	  set	  was	  more	  highly	  expressed	  in	  HCR	  vs.	  LCR	  rats	  (165).	  This	  is	  important	  
because	  BCAAs	  are	  markers	  of	  insulin	  resistance	  (205-­‐207).	  Many	  proteins	  associated	  with	  
insulin	  sensitivity	  have	  been	  documented	  to	  be	  higher	  in	  the	  skeletal	  muscle	  of	  HCR	  vs.	  LCR	  
rats,	   including	   I𝜅B𝛼	  (182),	   beta-­‐2	   adrenergic	   receptor	   (154,	   168),	  AMPK𝛾3	   (163),	  Nur77	  
(154,	  163,	  168,	  172),	  PPAR-­‐𝛾	  (152,	  158,	  161,	  181),	  Akt1	  (169),	  Akt2	  (169)	  and	  Nor1	  (172).	  
In	  addition,	  phosphorylation	  of	  Akt	  on	  threonine	  T308	  and	  serine	  S473,	  mechanisms	  that	  
drive	   insulin	   signaling,	   were	   higher	   in	   HCR	   rats	   as	   was	   phosphorylation	   of	   AS160,	   a	  
downstream	  substrate	  of	  Akt	  (169).	  Skeletal	  muscle	  glucose	  uptake	  and	  oxidation	  (169)	  as	  
well	  as	  insulin-­‐stimulated	  glucose	  transport	  and	  insulin	  signal	  transduction	  were	  higher	  in	  
skeletal	  muscle	  of	  HCRs	  (154,	  168,	  172).	  The	  increased	  insulin	  sensitivity	  in	  HCR	  rats	  was	  
associated	  with	   a	   greater	   response	   to	   beta-­‐adrenergic	   stimulation	   in	   skeletal	  muscle,	   as	  
indicated	   by	   increased	   isoproterenol-­‐induced	   lipolysis	   (glycerol	   release),	   which	   was	  
associated	  with	  higher	  basal	  triacylglycerol	  lipase	  activity,	  ser660	  phosphorylation	  of	  HSL	  
and	   beta-­‐2	   adrenergic	   receptor	   protein	   in	   skeletal	   muscle	   (163).	   Following	   HFD,	  
phosphorylation	   of	   IRS-­‐1	   on	   serine	   S407,	   a	  mediator	   of	   IKK𝛽-­‐induced	   insulin	   resistance,	  
was	   higher	   only	   in	   skeletal	   muscle	   of	   LCR	   rats	   (182).	   In	   metabolomic	   analysis,	  
mitochondria	  of	  HCR	  skeletal	  muscle	  demonstrated	  a	  greater	  capacity	  for	  BCAA	  catabolism	  
(202).	   Further	   supporting	   this	   finding,	   mitochondrial	   protein	   deacetylation	   via	   SIRT3	  
activation,	  a	  regulator	  of	  BCAA	  catabolism	  (208),	  was	  reduced	  in	  HCR	  at	  rest,	  and	  was	  rapid	  
during	   exercise	   (202).	   A	   study	   in	   human	   skeletal	   muscle	   also	   showed	   that	   high	   CRF	   is	  
associated	  with	   increased	   indicators	   of	   insulin	   signaling,	   including	   protein	   expression	   of	  
PI3K	  and	  PKB	  Ser473	  phosphorylation	  (209).	  	  A	  separate	  human	  study	  demonstrated	  that	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high	   CRF	   is	   associated	   with	   a	   higher	   insulin	   secretion	   and	   a	   higher	   shift	   in	   substrate	  
utilization	  toward	  primarily	  carbohydrate	  oxidation	  during	  exercise	  (210).	  
	  
2.6.6	  High	  CRF	   is	  associated	  with	   increased	   lipid	  metabolism	  as	  well	  as	   indicators	  of	  
lipid	  metabolism.	  	  
A	   study	   in	   skeletal	   muscle	   of	   HCR	   and	   LCR	   rats	   using	   real-­‐time	   PCR	   found	   that	  
Nur77	  and	  UCP3,	   two	  genes	  associated	  with	   fatty	  acid	  metabolism,	  were	  up-­‐regulated	   in	  
HCR	  rats	  (163).	  Bioinformatic	  analysis	  of	  gene	  expression	  revealed	  that	  a	  gene	  set	  involved	  
in	   fatty	   acid	   oxidation	   (FAO)	  was	  more	   highly	   expressed	   in	  HCR	   vs.	   LCR	   skeletal	  muscle	  
(165).	   Real-­‐time	   PCR	   analysis	   indicated	   up-­‐regulation	   of	   several	   FAO	   related	   genes	   in	  
skeletal	  muscle	   of	  HCR	   vs.	   LCR	   rats,	   including	   LPL,	   CPT1A,	   CPT1B,	   CPT2,	  HAHDB,	  UCP2,	  
UCP3,	   ACO1	   and	   ACO2	   (165).	   Additionally,	   several	   proteins	   responsible	   for	   lipid	  
metabolism	  were	  also	  higher	  in	  HCR	  skeletal	  muscle,	  including	  Nur77	  (154,	  163,	  168,	  172),	  
𝛽-­‐HAD	  (152,	  157,	  161,	  172),	  UCP2	  (152,	  158,	  161,	  181),	  UCP3	  (154,	  161,	  163,	  168,	  172),	  
FAT/CD36	  (154,	  163,	  168,	  172)	  and	  AMPK𝛾3	  (163).	  Following	  HFD,	  skeletal	  muscle	  UCP3	  
significantly	   increased	   in	   HCR	   but	   not	   LCR	   rats	   (159).	   Skeletal	   muscle	   of	   HCR	   rats	  
demonstrated	   higher	   rates	   of	   FAO	   (166,	   169,	   172)	   and	   palmitate	   oxidation	   (154,	   168)	  
compared	  to	  their	  LCR	  counterparts.	  	  
Metabolomic	  analysis	  indicated	  that	  skeletal	  muscle	  mitochondria	  of	  HCR	  rats	  have	  
a	  greater	  capacity	  for	  FAO	  (202).	  Mitochondrial	  protein	  deacetylation	  via	  SIRT3	  activation	  
is	   a	   regulator	   of	   FAO	   (211),	   and	   in	  HCR	   rats	  was	   found	   to	   be	   reduced	   at	   rest	   and	   rapid	  
during	  exercise	  (202).	  In	  liver,	  HCRs	  had	  lower	  SREBP-­‐1c,	  a	  regulator	  of	  fatty	  acid	  synthase	  
genes,	   and	   lower	   activity	   of	  ACC,	   an	   inhibitor	   of	   FAO,	   suggesting	   a	   less	   hepatic	   lipogenic	  
phenotype	   (164).	   Conversely,	   activity	   of	  𝛽-­‐HAD,	   the	   rate-­‐limiting	   enzyme	   for	   FAO,	   was	  
higher	   in	   HCR	   vs.	   LCR	   liver	   at	   rest	   (164).	   Isolated	   liver	   mitochondria	   of	   HCR	   rats	  
demonstrated	   higher	   complete	   fatty	   oxidation	   (176)	   and	   higher	   complete	   palmitate	  
oxidation	   (164)	   than	   their	   LCR	   counterparts.	   In	   addition,	   HCR	   liver	   displayed	   lower	  
peroxisomal	   enzyme	   activity	   for	   both	   acyl	   CoA	   oxidase	   and	   catalase,	   suggesting	   a	  
compensatory	  increase	  in	  peroxisomal	  activity	  to	  mitigate	  the	  reduced	  liver	  mitochondrial	  
oxidative	   capacity	   in	   LCRs	   (164).	   Following	   HFD,	   liver	   palmitate	   oxidation	   remained	  
unchanged	   in	   HCR	   but	   decreased	   significantly	   in	   LCR	   rats	   (159).	   The	   increase	   in	   whole	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body	  FAO	  after	  HFD	  exposure	  was	  also	  significantly	  greater	  in	  HCRs	  as	  demonstrated	  by	  a	  
greater	  reduction	  in	  respiratory	  quotient	  (RQ)	  following	  HFD	  (176).	  It	  has	  also	  found	  that	  
genes	  involved	  in	  lipid	  metabolism	  (ACADSB,	  VLDLR,	  CPT1A	  and	  MTE1)	  were	  more	  highly	  
expressed	  in	  the	  left	  ventricle	  of	  HCR	  vs.	  LCR	  rats	  (190).	  In	  humans,	  high	  CRF	  is	  associated	  
with	  higher	  fat	  oxidation	  during	  exercise	  (209,	  212,	  213).	  
	  
2.6.7	  High	  CRF	  is	  associated	  with	  increased	  markers	  of	  physical	  activity	  and	  leanness.	  
Orexin-­‐induced	   activity	   and	   PEPCK-­‐C,	   markers	   of	   high	   physical	   activity	   and	  
leanness,	   were	   higher	   in	   skeletal	   muscle	   of	   HCR	   vs.	   LCR	   rats	   (179).	   In	   addition,	   NAD-­‐
dependent	   deacetylase	   SIRT1,	   which	   is	   associated	   with	   high	   energy	   expenditure,	   was	  
higher	  HCR	  skeletal	  muscle	  (179).	  Furthermore,	  HCR	  rats	  were	  less	  sensitive	  to	  fatigue	  and	  
demonstrated	   faster	  metabolic	   recovery	  after	  maximal	  muscle	  contraction,	  both	  of	  which	  
possibly	   contribute	   to	   greater	   running	   capacity	   (173).	   Analysis	   of	   brain	   and	   plasma	  
revealed	  higher	  striatal	  dopaminergic	  activity,	  a	  neurotransmitter	  responsible	  for	  physical	  
performance,	   and	   lower	   plasma	   corticosterone	   level	   in	  HCR	   rats	   as	   compared	  with	   their	  
LCR	  counterparts	  after	  8	  weeks	  of	   running	   trial	   (162).	   	  The	   lower	  plasma	  corticosterone	  
level	  suggests	  that	  HCR	  rats	  are	  less	  stressed	  by	  training	  (162).	  	  
	  
2.7	  Summary	  
• CRF	   is	   defined	   as	   the	   ability	   of	   the	   circulatory,	   respiratory,	   and	  muscular	   systems	   to	  
supply	   oxygen	  during	   sustained	  physical	   activity.	   It	   is	   reported	   in	  METs,	  VO2max	  per	  
body	  weight	  or	  VO2max	  per	  FFM	  and	  measured	  by	  exercise	  tests	  on	  equipment	  such	  as	  
a	  treadmill	  or	  cycle	  ergometer.	  
• There	   are	   large	   interindividual	   differences	   of	   CRF	   in	   the	   absence	   of	   training	   and	   in	  
response	   to	   similar	   aerobic	   training.	   Moreover,	   the	   effects	   of	   CRF	   on	   health	   and	  
longevity	  are	   independent	  of	  physical	  activity	  and	  even	  more	  dominant	   than	  physical	  
activity.	   Heritability	   studies	   in	   twins	   and	   families	   demonstrate	   that	   CRF	   is	   highly	  
genetically	  determined	  .	  
• High	  CRF	  is	  protective	  against	  several	  diseases	  and	  pathologies,	  including	  obesity,	  DM,	  
hypertension,	  metabolic	  syndrome,	  coronary	  heart	  disease,	  cardiac	  arrhythmia,	  stroke,	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and	  cancer,	  as	  well	  as	  postoperative	  hospital	  stay	  and	  is	  independent	  of	  any	  other	  risk	  
factors.	  
• High	  CRF	  is	  also	  associated	  with	  lower	  all-­‐cause	  mortality	  and	  specific	  mortality	  such	  as	  
CVD	  mortality,	   stroke	  mortality,	   dementia	  mortality	   and	   cancer	  mortality,	   as	   well	   as	  
postoperative	  mortality	  regardless	  of	  any	  other	  risk	  factors.	  
• The	   rat	   genetic	   model	   of	   aerobic	   treadmill	   running	   capacity	   is	   useful	   for	   in-­‐depth	  
studies	   to	   identify	  mechanisms	  by	  which	  high	  CRF	   is	  associated	  with	  good	  health	  and	  
longevity.	  	  
• In-­‐depth	   studies	   in	   the	   rat	   genetic	   model	   of	   aerobic	   treadmill	   running	   capacity	   and	  
humans	  demonstrated	   that	  high	  CRF	   is	  associated	  with	  higher	  mitochondrial	   content,	  
higher	   mitochondrial	   biogenesis,	   higher	   OXPHOS	   and	   mitochondrial	   respiration,	  
greater	  ROS	  buffering	  capacity,	  higher	   indicators	  of	   insulin	  sensitivity,	  higher	  capacity	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Systematic	  literature	  review:	  Anti-­‐aging	  effects	  of	  caloric	  restriction	  
	  
3.1	  Introduction	  
Caloric	  restriction	  (CR)	   is	  defined	  as	  a	  reduction	   in	  caloric	   intake,	   typically	  by	  20–
40%	  of	  ad	  libitum	  consumption,	  whereas	  protein	  and	  micronutrients	  intake	  are	  adequate	  
to	   avoid	  malnutrition	   (1,	   2).	   CR	  without	  malnutrition	   is	   the	  most	   acceptable	   non-­‐genetic	  
paradigm	  to	  increase	  lifespan	  (2-­‐4).	  The	  effect	  of	  CR	  on	  longevity	  was	  first	  reported	  in	  a	  rat	  
study	   in	   1935	   (5).	   Because	   of	   this	   study,	   the	   anti-­‐aging	   effects	   of	   CR	   were	   widely	  
investigated	   and	   CR	   was	   shown	   to	   extend	   lifespan	   in	   various	   non-­‐primate	   animals,	  
including	   rats,	  mice,	  yeast,	  Drosophila,	   rotifers,	  bowl	  and	  doily	   spiders,	   and	  C.	  elegans	  (6-­‐
14),	  by	  20-­‐100%	  (15-­‐27).	  Several	   studies	   in	   these	  animals	   found	   that	   the	  effect	  of	  CR	  on	  
longevity	   was	   associated	   with	   attenuation	   of	   age-­‐related	   pathologies,	   including	  
cardiometabolic	   diseases	   (28-­‐37),	   cognitive	   decline	   (10,	   38-­‐47),	   cancer	   (31,	   48-­‐103)	   and	  
immunodeficiency	   (104-­‐109).	   To	   determine	   whether	   those	   benefits	   could	   be	   applied	   to	  
humans,	   studies	   in	   non-­‐human	   primates	   were	   initiated	   in	   1987	   and	   1989	   (110,	   111).	  
Further	  studies	  in	  non-­‐human	  primates	  demonstrated	  that	  30%	  CR	  decreased	  age-­‐related	  
mortality	  by	  65-­‐67%	  (112,	  113),	  decreased	  cardiovascular	  disease	  (CVD)	  incidence	  by	  50%	  
(112),	  decreased	  incidence	  of	  cancer	  (112,	  114)	  by	  50%	  (112),	  and	  that	  CR	  attenuated	  age-­‐
related	   cardiometabolic	   diseases	   (112,	   114-­‐133),	   cognitive	   decline	   (112,	   134,	   135),	   and	  
immunodeficiency	   (109,	   136).	   In	   humans,	   an	   observational	   study	   established	   in	   1978	  
reported	  lower	  mortality	  rates	  related	  to	  heart	  diseases	  (-­‐59%),	  cerebrovascular	  diseases	  
(-­‐59%)	   and	   cancer	   (-­‐69%)	   in	   Okinawans	   who	   consumed	   less	   energy	   than	   the	   Japanese	  
average	   (137).	   Following	   that	   hallmark	   study,	   several	   additional	   observational	   and	  
experimental	   studies	   in	   humans	   reported	   an	   attenuating	   effect	   of	   CR	   on	   age-­‐related	  
cardiometabolic	  diseases	  (2,	  138-­‐168),	  cognitive	  decline	  (169-­‐173)	  and	  cancer	  (150,	  174-­‐
177).	   This	   review	   focuses	   on	   the	   beneficial	   effects	   of	   CR	   on	   cardiometabolic	   health,	   the	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nervous	  system,	  cancer	  prevention	  and	  tumor	  regression,	  as	  well	  as	  the	  immune	  system.	  In	  
addition,	   the	  modulating	   effects	   of	   CR	   and	   its	  molecular	  mechanisms	   on	   the	   age-­‐related	  
decline	  in	  mitochondrial	  function,	  as	  well	  as	  epigenetic	  regulations	  linking	  CR	  to	  anti-­‐aging	  
are	  discussed.	  	  
	  
3.2	  CR	  and	  cardiometabolic	  health	  
The	   benefits	   of	   CR	   on	   age-­‐related	   cardiometabolic	   diseases	   have	   primarily	   been	  
studied	  as	  related	  to	  the	  attenuation	  of	  atherosclerosis	  risk	  factors	  because	  atherosclerosis	  
is	   one	   of	   the	   most	   common	   causes	   of	   death	   and	   disability	   throughout	   the	   world	   (178).	  
Atherosclerosis	   is	   an	   inflammatory	   condition	   of	   the	   endothelium,	   leading	   to	   endothelial	  
injury	   and	   dysfunction	   (179,	   180),	   and	   thus	   narrowing	   the	   lumen	   of	   arteries	   and	  
obstructing	   the	   blood	   supply	   (181).	   Classic	   risk	   factors	   for	   atherosclerotic	   diseases	  
(cardiovascular,	   cerebrovascular,	   and	   peripheral	   vascular	   diseases)	   include	   insulin	  
resistance	   and	   associated	   increases	   in	   	   blood	   pressure	   (BP)	   and	   dyslipidemia	   (high	   LDL	  
cholesterol,	  low	  HDL	  cholesterol	  and	  high	  triglyceride)	  (182-­‐185).	  In	  addition,	  	  elevation	  in	  
inflammatory	   markers,	   including	   CRP,	   cytokines,	   hemostasis	   factors	   (such	   as	   factor	   VII,	  
fibrinogen,	   and	   PAI-­‐1)	   and	   homocysteine,	   are	   predictive	   of	   atherosclerosis	   events	   (186-­‐
188).	  
	  
3.2.1	  CR	  improves	  insulin	  sensitivity.	  
Elevated	  plasma	  insulin	  and	  small	  elevations	  of	  glucose	  are	  characteristics	  of	  insulin	  
resistance	  (189).	  	  Aging	  is	  associated	  with	  increased	  incidence	  of	  	  insulin	  resistance	  (190-­‐
192)	   and	   is	   associated	   with	   	   the	   increases	   in	   visceral	   adiposity	   and	   proinflammatory	  
cytokines	  that	  interferes	  with	  insulin	  signaling	  (193).	  Reciprocally,	  insulin	  resistance	  leads	  
to	   aging	   as	   well	   (194,	   195).	   High	   plasma	   glucose	   contributes	   to	   aging	   because	   of	   the	  
associated	   hyperglycemia-­‐induced	   oxidative	   stress	   (194).	   Excessive	   glucose	   increases	  
reactive	   oxygen	   species	   (ROS)	   production,	   as	   caused	   by	   overload	   of	   mitochondrial	  
phosphorylation	   (OXPHOS)	   and	   shunting	   of	   physiological	   glycolysis	   to	   other	   pathways,	  
including	   enolization	   and	  𝛼-­‐ketoaldehyde	   formation,	   protein	   kinase	   C	   (PKC)	   activation,	  
dicarbonyl	  formation	  and	  glycation,	  and	  sorbitol	  and	  hexosamine	  metabolisms	  (194).	  High	  
plasma	   insulin	   also	   contributes	   to	   aging	   via	   its	  mitogenic	   action	   (195).	   Excessive	   insulin	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expedites	  the	  appearance	  of	  later	  generations	  of	  cells,	  which	  are	  physiologically	  present	  at	  
a	  later	  age	  of	  life,	  causing	  early	  onset	  of	  age-­‐related	  diseases	  (195).	  	  
Several	  studies	  in	  rodents	  (29,	  31,	  33-­‐37),	  non-­‐human	  primates	  (112,	  114-­‐118,	  120,	  
122,	  126-­‐133)	  and	  humans	  (2,	  142,	  143,	  146,	  148,	  149,	  151-­‐154,	  156,	  163,	  165,	  168,	  196)	  
have	  demonstrated	  that	  CR	  in	  lean	  and	  obese	  subjects	  improved	  insulin	  sensitivity.	  Several	  
mechanisms	   by	   which	   CR	   improves	   insulin	   sensitivity	   have	   been	   proposed.	   First,	   CR	  
decreases	   circulating	   fatty	   acids	   (180),	   which	   are	   substances	   that	   inhibit	   1)	   insulin-­‐
stimulated	   glucose	   uptake	   at	   the	   level	   of	   glucose	   transport	   and/or	   phosphorylation,	   2)	  
insulin-­‐stimulated	   glycogen	   synthesis	   and	   3)	   insulin-­‐stimulated	   glucose	   oxidation	   (197).	  
Second,	  CR	  limits	  accumulation	  of	  intramyocellular	  triacylglycerols	  (180),	  lipids	  that	  inhibit	  
glucose	  uptake	  to	  skeletal	  muscle	  (198)	  and	  therefore	  induce	  insulin	  resistance	  (198-­‐200).	  
CR	  also	  reduces	  hepatic	  diacylglycerols	  (34),	  lipids	  that	  activate	  PKC	  which	  inhibits	  insulin-­‐
stimulated	   insulin	   receptor	   kinase	   phosphorylation,	   and	   therefore	   impairs	   activation	   of	  
downstream	   insulin	   signaling	   (201-­‐203).	   In	   addition,	   CR	   decreases	   levels	   of	  
proinflammatory	   cytokines	   (204,	   205),	   substances	   that	   inhibit	   insulin	   receptor	   signaling	  
and	  glucose	  transport	  in	  insulin-­‐sensitive	  tissues	  (206,	  207).	  Moreover,	  CR	  increases	  Akt2	  
activation,	   and	   therefore	   enhances	   insulin-­‐stimulated	   glucose	   uptake	   to	   skeletal	   muscle	  
(37).	  	  
	  
3.2.2	  CR	  decreases	  BP.	  
Arterial	   stiffness	   increased	  with	  age	   (208-­‐212),	   leading	   to	  age-­‐related	  elevated	  BP	  
(208,	  210-­‐213)	   in	  humans.	   It	  has	  been	  documented	   that	  CR	  decreases	  BP	   in	  rodents	   (28,	  
30,	   32)	   and	  non-­‐human	  primates	   (124).	   CR	  decreases	   systolic	   (SBP)	   and	  diastolic	   (DBP)	  
blood	   pressures	   in	   both	   non-­‐obese	   and	   obese	   humans	   as	  well	   (138,	   140,	   143,	   144,	   151,	  
158,	  159,	  161,	  163,	  164,	  166).	  SBP	  and	  DPB	  were	  lower	  in	  non-­‐obese	  and	  obese	  people	  who	  
completed	   CR	   compared	   to	   non-­‐CR	   controls	   (139,	   145,	   146,	   152,	   155,	   162).	   Potential	  
mechanisms	  by	  which	  CR	  decreases	  BP	  may	  involve	  factors	  that	  mitigate	  elevated	  BP.	  CR	  
decreases	   plasma	   norepinephrine	   concentration	   and	   excretion	   of	   catecholamines	   (214-­‐
216),	  decreases	  sympathetic	  nervous	  activity	  (145,	  215,	  216),	  ameliorates	  aging-­‐associated	  
decrease	   in	   diastolic	   function	   (155),	   reduces	   arterial	   stiffness	   (166),	   modulates	   the	  
sympathetic-­‐renin-­‐angiotensin	   axis	   (185)	   and	   stimulates	   the	   adiponectin/AMPK/eNOS	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signaling	  axis	  (32).	  
	  
3.2.3	  CR	  improves	  lipid	  profile.	  
Total	  cholesterol,	  LDL	  cholesterol	  and	  triglycerides	  are	  atherogenic	  stimuli,	  whereas	  
HDL	   cholesterol	   is	   protective	   against	   atherosclerosis	   (217).	   Total	   cholesterol,	   LDL	  
cholesterol	   and	   triglycerides	   in	   humans	   increase	   with	   age	   until	   middle-­‐age	   and	   then	  
gradually	  decrease	  (218-­‐223),	  but	  there	  is	  no	  specific	  pattern	  of	  age-­‐related	  change	  in	  HDL	  
cholesterol	   (218-­‐222,	  224,	  225).	  CR	   reduces	  plasma	   total	   cholesterol	   and	   triglycerides	   in	  
mice	   (29).	   In	  monkeys,	  CR	   is	  associated	  with	   lower	   levels	  of	   total	   cholesterol	   (114,	  124),	  
LDL	   cholesterol	   (128)	   and	   triglycerides	   (114,	   121,	   124).	   In	   addition,	   CR	   increases	   HDL	  
cholesterol	   in	   monkeys	   (121).	   Like	   rodents	   and	   monkeys,	   CR	   improves	   lipid	   profiles	   in	  
humans.	   	   CR	   decreases	   total	   cholesterol	   and	   triglycerides	   (142-­‐144,	   147,	   151,	   152,	   156-­‐
158,	   160-­‐163),	   reduces	   LDL	   cholesterol	   (144,	   147,	   151,	   152,	   156-­‐158,	   160-­‐162),	   and	  
increases	   HDL	   cholesterol	   (141,	   142,	   144-­‐146,	   151,	   152,	   156,	   160-­‐163).	   A	   potential	  
mechanism	   responsible	   for	   CR-­‐induced	   favorable	   lipid	   profiles	   is	   the	   improvement	   of	  
lipoprotein	  metabolism	  caused	  by	  a	  reduction	  in	  circulating	  fatty	  acids	  after	  CR	  (226).	  	  
	  
3.2.4	  CR	  reduces	  inflammation.	  
Chronic	   inflammation	   increases	   with	   aging	   (227,	   228).	   The	   production	   of	  
proinflammatory	   cytokines	   by	   mononuclear	   leukocytes	   in	   response	   to	   stimulation	  
increases	  with	   aging	   as	  well	   (227).	   Several	   human	   studies	  have	   found	   that	  CR	  decreases	  
various	  markers	  of	  inflammation	  in	  plasma,	  including	  CRP	  (152,	  159,	  161,	  162,	  229),	  IL-­‐6	  
(152,	  158,	  159,	  161,	  230),	  TNF-­‐𝛼	  (152,	  158,	  159,	  161),	  TGF-­‐𝛽1	  (159),	  and	  PAI-­‐1	  (231,	  232).	  
	  
3.3	  CR	  attenuates	  the	  age-­‐related	  decline	  in	  cognitive	  function.	  	  
Several	   studies	   in	   rodents	   found	   that	   CR	   decelerated	   age-­‐related	   changes	   in	  
cognitive	   function,	   including	   learning	  (38-­‐43,	  47),	  memory	  (40),	  motor	  strength	  (10)	  and	  
motor	   coordination	   (10,	   39,	   42,	   46),	   as	   well	   as	   behavior	   alteration	   (10).	   In	   non-­‐human	  
primates,	  higher	  locomotor	  activity	  (134,	  233)	  and	  increased	  memory	  (233)	  were	  observed	  
after	   CR.	   In	   addition,	   CR	   reduced	   age-­‐related	   brain	   atrophy	   in	   rhesus	  monkeys	   after	   20	  
years	  of	  follow-­‐up	  (112).	  In	  humans,	  30%	  CR	  was	  associated	  with	  20%	  increase	  in	  verbal	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memory	  score	  (173).	  The	  benefits	  of	  CR	  on	  cognitive	  function	  are	  primarily	  associated	  with	  
synaptic	  plasticity,	  neurogenesis	  and	  protective	  effects	  against	  neurodegenerative	  diseases	  
(234,	  235).	  	  
	  
3.3.1	  CR	  promotes	  synaptic	  plasticity.	  
The	   term	   “synaptic	   plasticity”	   refers	   to	   changes	   in	   the	   numbers,	   structure,	   and	  
functional	  status	  of	  synapses	  as	  adaptive	  responses	  to	  a	  range	  of	  environmental	  challenges	  
(236).	   Synapses	   are	   highly	   specialized	   sites	   of	   interneuronal	   signal	   transduction	   that	  
dictate	  the	   immediate	   functions	  and	   long-­‐term	  plasticity	  of	   the	  brain,	  and	  they	  are	  highly	  
prone	  to	  degeneration	  during	  aging	  (234).	  Several	  previous	  studies	  have	  suggested	  that	  CR	  
enhances	   synaptic	   function	   and	   increases	   synaptic	   resistance	   to	   aging-­‐induced	  
degeneration	  in	  rodents.	  In	  rats,	  CR	  prevents	  age-­‐related	  deficits	  in	  long-­‐term	  potentiation	  
(237,	  238),	  a	  synaptic	  activity	  that	  produces	  a	  long-­‐lasting	  increase	  in	  signal	  transmission	  
between	  two	  neurons	  (239)	  and	  is	  believed	  to	  correlate	  with	  learning	  and	  memory	  (235).	  
Additionally,	   CR	   stabilizes	   the	   levels	   of	   presynaptic	   proteins	   (GAP-­‐43,	   SPH	   and	   alpha-­‐
Synuclein)	  in	  aged	  rats	  (240).	  The	  synaptic	  terminals	  of	  rats	  maintained	  on	  CR,	  theirs	  are	  
more	  resistant	  to	  oxidative	  impairment	  of	  glucose	  and	  glutamate	  transportation	  across	  the	  
cell	  membrane	  and	  exhibit	  enhanced	  mitochondrial	  function	  (241).	  Beneficial	  effects	  of	  CR	  
on	  neurotransmitters	   released	   from	  synapses	  and	  neurotransmitter	   receptors	   located	  on	  
synapses	   have	   also	   been	  documented.	   CR	  prevents	   age-­‐related	   changes	   in	   serotonin	   and	  
dopamine	   levels	   in	   the	   cerebral	   cortex	   of	   rats	   (242),	   enhances	   evoked	   dopamine	  
accumulation	   in	   the	   striatum	  of	   aged	   rats	   (243),	   and	   prevents	   the	   age-­‐related	   decline	   in	  
NR1	  and	  GluR1	  subunits	  of	  NMDA	  and	  AMPA	  receptors	   in	  rats,	  respectively	  (244).	  Brain-­‐
derived	   neurotrophic	   factor	   (BDNF),	   a	   protein	   that	   helps	   protect	   neurons	   against	  
excitotoxic,	   oxidative	   and	   metabolic	   insults	   (234,	   245,	   246),	   also	   regulates	   synaptic	  
plasticity	  and	  might	  therefore	  facilitate	  learning	  and	  memory	  (247).	  A	  few	  previous	  studies	  
also	   demonstrated	   that	   rodents	   maintained	   on	   CR	   had	   increased	   BDNF	   levels	   in	  
hippocampal	  and	  cortical	  neurons	  (245,	  246,	  248-­‐250).	  
	  
3.3.2	  CR	  induces	  neurogenesis.	  
The	  capacity	  of	  the	  brain	  for	  neurogenesis	  decreases	  with	  aging	  (251).	  CR	  has	  been	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shown	  to	  increase	  the	  number	  of	  newly	  generated	  neural	  cells	  in	  the	  brain	  of	  rodents	  (248-­‐
250).	   CR	   promotes	   survival	   of	   newly	   generated	   neurons	   (248,	   250).	   Lee	   and	   colleagues	  
(249)	  demonstrated	   that	  neurogenesis	   requires	  BDNF.	  As	  previously	  mentioned,	   rodents	  
maintained	  on	  CR	  had	   increased	  BDNF	   levels	   in	   hippocampal	   and	   cortical	   neurons	   (245,	  
246,	  248-­‐250).	  
	  
3.3.3	  CR	  is	  protective	  against	  age-­‐related	  neurodegenerative	  diseases.	  
Initial	   research	   documenting	   the	   neuroprotective	   effect	   of	   CR	   found	   that	   CR	  
attenuated	   the	   age-­‐related	   loss	   of	   spiral	   ganglion	   neurons	   in	   C57BL/6	  mice	   (252).	   After	  
that,	   rodent	   studies	   evaluated	   the	   effects	   of	   CR	   on	   common	   human	   age-­‐related	  
neurodegenerative	   diseases,	   including	   Alzheimer’s	   and	   Parkinson’s	   diseases,	   and	  
demonstrated	  that	  CR	  protected	  against	  these	  diseases	  (234,	  235).	  In	  Alzheimer’s	  disease	  
rodent	   models,	   CR	   ameliorated	   age-­‐related	   behavioral	   deficits	   in	   the	   triple-­‐transgenic	  
mouse	  model	   (44)	   and	   double	   knockout	   of	   presenilin-­‐1	   and	   presenilin-­‐2	   (cDKO)	  mouse	  
model	  (45).	  Wu	  and	  colleagues	  (45)	  also	  showed	  that	  CR	  attenuated	  ventricle	  enlargement,	  
caspase-­‐3	   activation	   and	   astrogliosis,	   and	   reduced	   the	   induction	   of	   tau	  
hyperphosphorylation	  in	  the	  cDKO	  mice.	  In	  addition,	  hippocampal	  neurons	  of	  presenilin-­‐1	  
mutant	  mice	  maintained	  on	  CR	  showed	  increased	  resistance	  to	  excitotoxic	  injury	  compared	  
with	   ad	   libitum-­‐fed	  mice	   (253),	   and	   this	   effect	   of	   CR	  was	   similar	   in	   rats	   that	   contracted	  
excitotoxin-­‐induced	  Alzheimer’s	  desease	  (254).	  Zhu	  and	  colleagues	  (253)	  also	  showed	  that	  
levels	  of	  oxidative	  stress	  in	  the	  hippocampus	  of	  presenilin-­‐1	  mutant	  mice	  maintained	  on	  CR	  
were	   lower	   than	   their	   ad	   libitum	   counterparts,	   suggesting	   that	   suppression	   of	   oxidative	  
stress	   is	   a	   mechanism	   responsible	   for	   the	   neuroprotective	   effects	   of	   CR	   on	   Alzheimer’s	  
disease	   incidence.	   Another	   potential	   mechanism	   by	   which	   CR	   protects	   neurons	   from	  
Alzheimer’s	   disease	   is	   that	   CR	   attenuates	  𝛽-­‐amyloid	   neuropathology,	   which	   has	   been	  
observed	  in	  mice	  (255)	  and	  monkeys	  (135).	  	  
In	   humans,	   epidemiologic	   studies	   revealed	   a	   positive	   correlation	   between	   caloric	  
intake	   and	   Alzheimer’s	   disease	   (169,	   171).	   Moreover,	   a	   study	   in	   humans	   found	   that	   for	  
every	  1-­‐kg/m2	  increase	  in	  BMI	  at	  age	  70	  years,	  Alzheimer’s	  disease	  risk	  increases	  by	  36%	  
(172).	   In	   a	  Parkinson’s	  disease	   rodent	  model,	   the	  nigro-­‐striatal	  dopaminergic	  neurons	  of	  
mice	  maintained	  on	  CR	  were	   less	   vulnerable	   to	  MPTP	   toxicity,	   as	   since	   there	  were	  more	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survived	  dopaminergic	  neuron	  survival	  was	  higher	  and	  motor	  deficits	  lower	  after	  exposure	  
to	   MPTP	   when	   compared	   to	   non-­‐CR	   animals	   (256).	   Similarly,	   a	   case-­‐control	   study	   in	  
humans	  observed	  higher	  caloric	  intake	  in	  patients	  with	  Parkinson’s	  disease	  (170).	  	  
	  
3.4	  CR	  has	  anti-­‐cancer	  effects.	  
Aging	  is	  associated	  with	  increased	  cancer	  incidence	  (257,	  258),	  especially	  cancer	  of	  
the	  breast,	   lung,	  prostate,	  and	  colon	  (258).	  The	  age-­‐associated	  increased	  cancer	  incidence	  
is	  caused	  by	  increased	  DNA	  damage	  (259),	  decreased	  DNA	  repair	  (258),	  decline	  in	  immune	  
function	   (258),	   decreased	   antitumor	   action	   (258),	   tumor-­‐suppressor	   gene	   defects	   (258)	  
and	   aberrant	   DNA	   methylation	   (260,	   261)	   that	   increases	   expression	   of	   oncogenes	   (4).	  
Numerous	   rodent	   studies	   have	   demonstrated	   that	   CR	   can	   prevent	   cancer	   and	   promote	  
tumor	  regression	  (102).	  These	  effects	  have	  been	  documented	   in	  both	  solid	  and	   lymphoid	  
cancer.	   Rodents	   maintained	   on	   CR	   experienced	   26-­‐94%	   lower	   incidence	   of	   mammary	  
cancer	  (53,	  60,	  62,	  65,	  71,	  75,	  77,	  78,	  82,	  99,	  100),	  prostate	  cancer	  (87),	   liver	  cancer	  (55,	  
58),	   skin	   cancer	   (73,	   92)	   and	   lymphoid	   cancer	   (52,	   56).	   In	   tumor-­‐induced	   models	   of	  
rodents,	  those	  maintained	  on	  CR	  demonstrated	  lesser	  progression	  of	  mammary	  tumor	  (57,	  
83,	  88,	  91,	  93,	  101,	  103),	  prostate	  tumor	  (67,	  72,	  74,	  80,	  81,	  95),	  brain	  tumor	  (69,	  79,	  84,	  
90,	  97),	  pancreatic	  tumor	  (89,	  98),	  hepatic	  tumor	  (54,	  66,	  85),	  intestinal	  tumor	  (51,	  68,	  94,	  
96)	   and	   lymphoid	   tumor	   (52,	   63).	   A	   meta-­‐analysis	   evaluating	   58	   rodent	   and	   1	   chicken	  
study	  demonstrated	   that	  CR	  was	  associated	  with	  80%	   lower	  cancer	   incidence	   (102).	  The	  
anti-­‐cancerous	   effect	   of	   CR	  has	   also	  been	  observed	   in	   longitudinal	   studies	  of	   non-­‐human	  
primates.	   Rhesus	  monkeys	  maintained	   on	   30%	   CR	   had	   50%	   (112)	   lower	   risk	   of	   cancer	  
incidence	  after	  more	   than	  20	  years	  of	   follow-­‐up	   (112,	  114).	   In	  humans,	   an	  observational	  
study	  reported	  69%	  lower	  cancer	  mortality	  in	  Okinawans	  who	  consumed	  less	  energy	  than	  
the	  Japanese	  average	  (137).	  Another	  study	  also	  found	  that	  the	  Okinawans	  experienced	  68-­‐
83%	   lower	   hormone-­‐dependent	   cancer	   mortality	   as	   compared	   with	   people	   from	   USA,	  
Sweden,	  Greece	  and	  Italy	  (150).	  A	  study	  in	  women	  with	  a	  history	  of	  anorexia	  nervosa	  and	  
low	  BMI	  demonstrated	  50%	  reduction	  in	  the	  incidence	  of	  breast	  cancer,	  suggesting	  that	  CR	  
is	   protective	   against	   breast	   cancer	   in	   humans	   (174).	   Positive	   correlations	   of	   BMI	   with	  
incident	  cancers	  of	  uterus,	  cervix,	  gall	  bladder,	  kidney,	  thyroid	  and	  bone	  marrow	  were	  also	  
observed	   in	   humans	   (177).	   Moreover,	   the	   protective	   effects	   of	   CR	   against	   breast	   cancer	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related-­‐mortality	   (175),	   breast	   cancer	   recurrence	   (175),	   as	   well	   as	   prostate	   tumor	  
recurrence	   (176)	   have	   been	   documented.	   Several	   mechanisms	   by	   which	   CR	   protects	  
against	   cancer	   have	   been	   discovered	   (262),	   including	   1)	   a	   reduction	   in	   IGF-­‐1	   level	   (59),	  
resulting	  in	  increased	  cell	  apoptosis	  (263),	  2)	  an	  activation	  of	  AMPK	  (264)	  that	  can	  inhibit	  
cell	   growth,	   cell	   proliferation	   and	   tumorigenesis	   (265),	   3)	   reversal	   of	   the	   aging-­‐induced	  
aberrant	  DNA	  methylation	  (260)	   that	  can	  silence	   the	  expression	  of	  oncogenes	   (4)	  and	  4)	  
reduced	   accumulation	   of	   oxidized	   DNA	   and	   protein	   (266-­‐268)	   that	   cause	   genomic	  
instability	  (269),	  a	  characteristic	  of	  most	  cancer	  cells	  (269,	  270).	  
	  
3.5	  CR	  decelerates	  age-­‐induced	  immunodeficiency.	  
Prior	   studies	   in	   rodents	   and	   non-­‐human	   primates	   demonstrated	   the	   beneficial	  
effects	  of	  CR	  on	  the	  delay	  of	  immunosenescence	  (109).	  In	  rodents,	  it	  has	  been	  show	  that	  CR	  
maintains	  naive	  CD4	  and	  CD8	  T	  cells,	  which	  represent	   the	  body’s	  reserve	   to	  combat	  new	  
pathogens,	   in	   peripheral	   blood	   and	   spleen	   (107).	   A	   potential	  mechanism	   responsible	   for	  
their	  maintenance	  by	  CR	   is	   increased	  thymic	  production	  (107).	   In	  addition,	  CR	  maintains	  
the	  proliferative	  capacity	  of	  T	  cells	  in	  rodents	  (104-­‐106,	  108),	  which	  is	  most	  likely	  caused	  
by	   increased	  apoptosis	  of	  old	  cells	   in	   the	  aged	  CR	  animals	   (105,	  106,	  108)	  and	   increased	  
resistance	  of	  T	  cells	   to	  oxidative	   stress	   (271).	   In	  non-­‐human	  primates,	  CR	  also	  preserves	  
naive	  T	  cells	  and	  T	  cell	  proliferation	  in	  aged	  animals	  (109,	  136),	  and	  therefore	  preserves	  T	  
cell	   receptor	   diversity	   (136).	   Furthermore,	   CR	   improves	   T	   cell	   function	   and	   reduces	   the	  
production	  of	  proinflammatory	  cytokines	  from	  memory	  T	  cells	  (136).	  	  
	  
3.6	  The	  mitochondrial	   theory	  of	   aging	   and	   the	  modulating	   effect	   of	   CR	  on	   the	   age-­‐
related	  decline	  in	  mitochondrial	  function	  	  
Because	   mitochondria	   act	   as	   a	   central	   regulator	   of	   nutrient	   utilization	   (272),	  
mechanisms	   by	   which	   CR	   delays	   aging	   are	   likely	   associated	   with	   modulation	   of	  
mitochondrial	  function	  (273).	  Several	  modulating	  effects	  of	  CR	  on	  the	  age-­‐related	  decrease	  
in	  mitochondrial	   function	  have	  been	  documented,	   including	  antioxidant	  effects,	   increased	  
resistance	   to	   age-­‐related	   damage	   of	   mitochondrial	   DNA	   (mtDNA),	   improvement	   of	  
mitochondrial	   respiratory	   function	   and	   coupling	   efficiency	   of	   mitochondrial	   OXPHOS,	   as	  
well	  as	  attenuation	  of	  the	  age-­‐induced	  reduction	  in	  mitochondrial	  turnover	  (274,	  275).	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3.6.1	  The	  mitochondrial	  theory	  of	  aging	  	  
Cellular	  aging	  is	  associated	  with	  mitochondrial	  damage	  induced	  by	  ROS	  production	  
(276-­‐285).	   The	   age-­‐related	   increase	   in	   the	   rate	   of	   ROS	   production	   leads	   to	   oxidative	  
damage,	   somatic	  mutations	   and	   decreased	   transcription	   of	  mtDNA	   (286-­‐291),	   causing	   a	  
progressive	  decline	   in	  the	  bioenergetic	   function	  of	  cells	  with	  aging	  (292,	  293).	   It	  has	  also	  
been	  demonstrated	  that	  the	  somatic	  mutations	  and	  decreased	  transcription	  of	  mtDNA	  due	  
to	   ROS-­‐induced	   oxidative	   damage	   in	   aged	   tissues	   impair	   OXPHOS	   and	   mitochondrial	  
respiration	   (294-­‐296)	   through	   electron	   leakage	   from	   Complex	   I	   and	   Complex	   III	   of	   the	  
respiratory	   chain	   (297,	   298),	   resulting	   in	   further	   overproduction	   of	   ROS,	   and	   further	  
increasing	   oxidative	   damage,	   i.e.	   aging-­‐induced	   decline	   in	   mitochondrial	   function	   is	   a	  
vicious	  cycle	   (289,	  299-­‐301).	  Moreover,	   the	   rate	  of	  mitochondrial	   turnover	  declines	  with	  
aging,	  resulting	  in	  an	  age-­‐associated	  accumulation	  of	  mitochondria	  with	  aberrant	  function	  
(302-­‐304).	  	  
	  
3.6.2	  Antioxidant	  effects	  of	  CR	  
A	   reduction	   in	   ROS	   production	   by	   CR	   has	   been	   documented	   in	   mitochondria	   of	  
various	  organs	  of	  rodents,	  including	  rat	  liver	  (305,	  306),	  rat	  skeletal	  muscle	  (307),	  mouse	  
liver	  (308),	  and	  rat	  brain	  (309).	  Complex	  I	  of	  the	  mitochondrial	  electron	  transport	  system	  
is	   a	   specific	   site	   where	   CR	   reduces	   ROS	   production	   (306,	   310-­‐312).	   In	   addition,	   CR	  
attenuates	   the	   increase	   in	   ROS	   normally	   seen	   with	   aging	   (313,	   314).	   A	   mechanism	  
responsible	   for	   CR-­‐induced	   decreased	   ROS	   production	   is	   the	   reduction	   in	  mitochondrial	  
proton	   leakage	   (306,	   313,	   315,	   316).	   A	   study	   in	   mice	   suggested	   that	   the	   reduction	   in	  
mitochondrial	  proton	  leakage	  was	  due	  to	  a	  reduction	  in	  polyunsaturated	  fatty	  acid	  (PUFA)	  
in	  the	  mitochondrial	  membrane	  by	  CR	  (317).	  
	  
3.6.3	  CR	  may	  be	  protective	  against	  age-­‐related	  damage	  of	  mtDNA.	  
Gredilla	  and	  colleagues	  (310)	  showed	  that	  CR	  was	  associated	  with	  lower	  8-­‐oxo-­‐dG,	  
an	   indicator	   of	   mtDNA	   oxidative	   damage,	   in	   rat	   heart.	   This	   effect	   of	   CR	   has	   also	   been	  
documented	   in	   skeletal	   muscle.	   Skeletal	   muscle	   8-­‐oxo-­‐dG	   was	   lower	   in	   aged	   CR	   vs.	   ad	  
libitum	   fed	   mice	   due	   to	   the	   protective	   effect	   of	   CR	   against	   the	   aging-­‐associated	   rise	   in	  
oxidant	  production	  (314).	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3.6.4	   CR	   improves	  mitochondrial	   respiratory	   function	   and	   the	   coupling	   efficiency	   of	  
mitochondrial	  OXPHOS.	  
It	  has	  been	  demonstrated	  that	  CR	  induces	  more	  efficient	  mitochondrial	  respiratory	  
function	  as	  skeletal	  muscle	  (314,	  318,	  319)	  and	  brain	  tissue	  (320)	  of	  CR	  animals	  exhibit	  a	  
greater	  mitochondrial	  respiratory	  capacity.	  This	  beneficial	  effect	   is	  mediated	  by	  a	  greater	  
affinity	  of	  complex	  IV	  for	  O2	  that	  is	  induced	  by	  CR	  (318,	  321)	  and	  an	  increase	  in	  expression	  
of	   electron	   transport	   chain	   (ETC)	   complexes	   (319).	   CR	   also	   improves	   the	   coupling	  
efficiency	  of	  mitochondrial	  OXPHOS.	  Lanza	  and	   colleagues	   (314)	  demonstrated	   that	   aged	  
mice	   maintained	   on	   CR	   possessed	   a	   greater	   mitochondrial	   coupling	   efficiency	   of	  
mitochondrial	  OXPHOS	  in	  skeletal	  muscle	  than	  their	  ad	  libitum	  fed	  counterparts.	  
	  
3.6.5	  CR	  attenuates	  age-­‐related	  decline	  in	  mitochondrial	  turnover.	  
Mitochondrial	   turnover	   depends	   on	   a	   balance	   between	   mitochondrial	   biogenesis	  
and	   autophagy	   (322).	   A	   previous	   study	   in	   mice	   demonstrated	   that	   CR	   increases	   mRNA	  
markers	   of	   mitochondrial	   biogenesis,	   including	   PGC-­‐1α,	   NRF1,	   TFAM,	   MFN1	   and	   MFN2	  
(323).	  A	  study	  in	  human	  skeletal	  muscle	  also	  demonstrated	  that	  CR	  increases	  expression	  of	  
genes	  encoding	  proteins	  involved	  in	  mitochondrial	  biogenesis,	  including	  PGC-­‐1α	  and	  TFAM	  
(324).	  A	  study	   in	   rats	   found	   that	   life-­‐long	  CR	  reversed	  aging-­‐induced	  decrease	   in	  mtDNA	  
count	   number,	   an	   indicator	   of	  mitochondrial	   biogenesis	   (324,	   325),	   in	   liver	   and	   skeletal	  
muscle	  of	  rats	  and	  increased	  mtDNA	  count	  number	  in	  rat	  brain	  (326).	  Another	  study	  in	  rats	  
which	   assessed	   autophagic	   vacuoles	   and	   expression	   of	   autophagy	   related	   proteins	  
documented	  that	  CR	  prevented	  the	  age-­‐related	  decline	  in	  autophagy	  in	  rat	  hepatocytes	  and	  
cardiomyocytes	  (274).	  	  However,	  there	  has	  been	  some	  data	  that	  questions	  the	  effect	  of	  CR	  
on	  mitochondrial	  biogenesis,	  at	  least	  in	  rats	  (327).	  
	  
3.6.6	  Mechanisms	  by	  which	  CR	  improves	  mitochondrial	  function	  
CR	   improves	  mitochondrial	   function	   through	  multiple	   pathways.	   For	   example,	   CR	  
activates	  mitochondrial	  SIRT3,	  resulting	  in	  the	  deacetylation	  of	  several	  targets,	  including	  1)	  
isocitrate	   dehydrogenase	   2	   (328),	   which	   is	   essential	   for	   cellular	   metabolism	   in	   lipid	  
synthesis,	   cellular	   defense	   against	   oxidative	   stress,	   oxidative	   respiration,	   and	   oxygen-­‐
sensing	   signal	   transduction	   (329),	   2)	   cyclophilin	   D,	   resulting	   in	   increased	   resistance	   to	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mitochondrial	   permeability	   transition,	   and	   consequently	   reduced	   activation	   of	  
mitochondrial-­‐mediated	   pathways	   of	   apoptosis	   (330),	   3)	   SOD2	   which	   helps	   reduce	  
oxidative	  stress	  (331),	  4)	  LCAD	  (332),	  a	  key	  enzyme	  in	  beta-­‐oxidation	  (333),	  5)	  respiratory	  
complex	  II	  that	  is	  responsible	  for	  OXPHOS	  (334)	  and	  6)	  two	  subunits	  of	  the	  mitochondrial	  
electron	   transport	   complexes:	  NDUFS1	  and	   the	   cytochrome	  bc	  1	   complex	  Rieske	   subunit	  
(335).	   This	   effect	   is	   mediated	   by	   an	   elevated	   NAD+-­‐to-­‐NADH	   ratio	   secondary	   to	   the	  
energetic	   stress	   imposed	   by	   CR	   (336,	   337).	   In	   addition,	   previous	   studies	   have	  
demonstrated	  that	  SIRT1	  is	  required	  to	  achieve	  the	  beneficial	  effects	  of	  CR	  (338,	  339).	  CR	  
increased	   AMPK-­‐induced	   phosphorylation	   at	   Thr177	   and	   Ser538	   residues	   (340)	   and	  
subsequent	   deacetylation	   by	   SIRT1	   (341,	   342),	  which	   facilitates	   PGC-­‐1α	   translocation	   to	  
the	   nucleus	   (275),	   resulting	   in	   increased	  mitochondrial	   biogenesis	   (320,	   323,	   343-­‐346).	  
However,	  this	  mechanism	  is	  still	  controversial	  as	  a	  few	  studies	  found	  no	  increase	  in	  PGC-­‐1α	  
activity	   (347,	  348)	  and	  no	   increase	   in	  mitochondrial	  biogenesis	   (319,	  327,	  349)	  with	  CR.	  
Modulation	  of	  age-­‐related	  changes	   in	   lipid	  membrane	  composition	   is	  another	  mechanism	  
related	  to	  the	  beneficial	  effect	  of	  CR	  on	  mitochondrial	  function	  (275).	  CR	  increases	  essential	  
fatty	  acids	  while	  attenuating	  highly	  unsaturated	  fatty	  acids	  in	  rat	  liver	  mitochondria	  (350)	  
and	  heart	  (351),	  therefore	  reducing	  lipid	  peroxidizability.	  	  
	  
3.7	  Epigenetic	  regulations	  linking	  to	  anti-­‐aging	  effects	  of	  CR	  
Epigenetic	   regulations	   have	   been	   recognized	   as	   major	   contributors	   to	   CR-­‐related	  
longevity	   (4).	   These	   regulations	   include	   DNA	   methylation	   and	   histone	   modification,	  
resulting	  in	  regulation	  of	  age-­‐related	  gene	  expression	  (352,	  353).	  
	  
3.7.1	  CR	  and	  DNA	  methylation	  
DNA	  methylation	  plays	  an	   important	  role	   in	  the	  regulation	  of	  gene	  expression	  and	  
maintenance	   of	   DNA	   integrity	   and	   stability	   in	   various	   biological	   processes	   (4,	   354-­‐356).	  
Two	   major	   changes	   in	   DNA	   methylation	   occur	   during	   aging	   (4).	   These	   changes	   involve	  
globally	  decreased	   (357-­‐362)	  but	   locally	   increased	   (362,	  363)	  DNA	  methylation	  status	  of	  
age-­‐related	  genes,	  such	  as	  RUNX3	  and	  TIG1,	  leading	  to	  a	  reduced	  capability	  for	  homeostasis	  
and	  loss	  of	  chromatin	  integrity,	  predominantly	  due	  to	  aberrant	  gene	  expression	  (364).	  CR	  
reverses	   aberrant	  DNA	  methylation	  during	   aging	   (260,	  261)	  by	   increasing	  DNMT1	   (365)	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and	  DNMT3b	  (366)	  activity	  and	  is	  associated	  with	  changes	  in	  specific	  gene	  loci	  rather	  than	  
globally	   patterned	   changes	   (261).	   The	   reverse	   effect	   results	   in	   hypermethylation	   and	  
consequently	   silences	   the	   expression	   of	   oncogenes	   such	   as	   H-­‐Ras	   (367),	   as	   well	   as	  
metabolism-­‐related	   genes	   such	   as	   TNF-­‐𝛼 	  (368),	   WT1	   (369)	   and	   ATP10A	   (370).	   The	  
silencing	  of	  expression	  leads	  to	  cancer	  prevention	  and	  good	  metabolic	  health	  (4).	  	  
	  
3.7.2	  CR	  and	  histone	  modification	  
Histone	   is	   a	   protein	   found	   in	   eukaryotic	   cell	   nuclei	   that	   packages	   and	   orders	   the	  
DNA	  into	  nucleosomes	  (371,	  372),	  the	  basic	  structure	  of	  the	  chromatin	  unit	  (373).	  Histone	  
modifications	  are	  associated	  with	  both	  gene	  activation	  and	  gene	  repression	  (4)	  and	  affect	  
nucleosomes	  by	  directly	  changing	  nucleosome	  configuration	  (373).	  Histone	  acetylation	  and	  
deacetylation	   are	   the	   most	   prevalent	   mechanisms	   of	   histone	   modifications	   (353).	   In	  
addition	  to	  histone	  acetylation	  and	  deacetylation,	  histone	  methylation	  is	  another	  important	  
modification	  that	  regulates	  gene	  expression	  (374).	  
	  
3.7.2.1	  Histone	  acetylation	  and	  deacetylation	  
Histone	   acetylation	   and	   deacetylation	   processes	   are	   catalyzed	   by	   the	   specific	  
enzymes	   histone	   acetyltransferase	   (HAT)	   and	   histone	   deacetylase	   (HDAC),	   respectively	  
(374,	  375).	  Because	  it	  has	  been	  widely	  accepted	  that	  HDAC	  activity	  is	  increased	  during	  CR,	  
global	  deacetylation	  has	  been	  suggested	  as	  a	  protective	  mechanism	  of	  CR	  against	  metabolic	  
alterations	  and	  aging	  (365).	  At	  least	  four	  classes	  of	  the	  HDAC	  family	  have	  been	  identified:	  
class	  I	  HDAC	  (HDAC1,	  HDAC2,	  HDAC3	  and	  HDAC8),	  class	  II	  HDAC	  (HDAC4,	  HDAC5,	  HDAC6,	  
HDAC7,	  HDAC9	  and	  HDAC10),	  class	  III	  HDAC	  (SIRT1,	  2,	  3,	  4,	  5,	  6	  and	  7)	  and	  class	  IV	  HDAC	  
(HDAC11)	  (4).	  Among	  all	  HDACs,	  activation	  of	  SIRT1,	  which	  is	  a	  class	  III	  NAD+-­‐dependent	  
HDAC,	  is	  found	  in	  diverse	  CR	  models	  of	  animals,	  humans	  and	  in	  vitro	  system	  (12,	  19,	  341,	  
365,	  376-­‐382).	  Two	  potential	  mechanisms	  by	  which	  SIRT1	  mediates	  CR-­‐induced	  metabolic	  
alterations	   and	   subsequent	   delay	   aging	   have	   been	   identified	   (4).	   First,	   SIRT1	   activation	  
negatively	   regulates	   proapoptotic	   factors	   such	   as	   p53,	   Ku70	   and	   FoxO,	   resulting	   in	  
increased	  stress	  resistance	  (383-­‐389).	  Second,	  SIRT1	  activation	  regulates	  key	  metabolism-­‐
associated	   genes	   such	   as	   PGC-­‐1𝛼,	   leading	   to	   inhibition	   of	   adipogenesis	   and	   increased	  
insulin	   secretion	   from	  pancreatic	  𝛽-­‐cells,	  which	   facilitates	   stress	   resistance	  and	   longevity	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(390,	   391).	   Potential	   mechanisms	   are	   not	   limited	   to	   SIRT1,	   as	   previous	   studies	   also	  
demonstrated	   that	   altered	  binding	  enrichment	  of	  HDAC1	  on	   the	  promoter	   region	  of	   age-­‐
related	  genes	  such	  as	  p16INK4a	  and	  hTERT	  leads	  to	  gene	  expression	  changes	  and	  contributes	  
to	  longevity	  under	  CR	  condition	  (365,	  392,	  393).	  	  
	  
3.7.2.2	  Histone	  methylation	  
CR-­‐induced	   histone	   methylation	   can	   regulate	   expression	   changes	   in	   age-­‐related	  
genes,	  including	  p16INK4a	  and	  hTERT,	  contributing	  to	  longevity	  (365,	  382,	  394-­‐396).	  Unlike	  
histone	   acetylation	   and	   deacetylation,	  which	   are	   always	   associated	  with	   open	   chromatin	  
status	   and	   subsequent	   gene	   activation,	   differentially	  methylated	   forms	   of	   histones	   show	  
unique	   association	   patterns	   with	   specific	   proteins	   that	   recognize	   these	   markers,	   and	  
therefore	   lead	   to	   gene	   silencing	   or	   activating	   effects	   (353,	   365,	   397).	   Specific	   histone	  
methylation	   can	   also	   act	   as	   a	   transcription	   modulator	   by	   interacting	   with	   different	  
transcription	  factors	  and	  may	  regulate	  the	  CR-­‐induced	  aging	  delay	  (394-­‐396).	  
	  
3.8	  Summary	  
• CR	   is	   defined	   as	   a	   reduction	   in	   caloric	   intake,	   typically	   by	   20–40%	   of	   ad	   libitum	  
consumption,	   whereas	   protein	   and	   micronutrients	   intake	   are	   sufficient	   to	   avoid	  
malnutrition.	  	  
• CR	  without	  malnutrition	  is	  a	  widely	  accepted	  non-­‐genetic	  paradigm	  to	  increase	  lifespan.	  
• It	  has	  been	  suggested	  that	  CR	  extends	  lifespan	  by	  attenuating	  age-­‐related	  diseases	  and	  
pathologies	   such	   as	   insulin	   resistance,	   hypertension,	   dyslipidemia,	   chronic	  
inflammation,	  cognitive	  decline,	  cancer	  and	  immunodeficiency.	  
• Mechanisms	   by	   which	   CR	   delays	   aging	   are	   likely	   associated	   with	   modulation	   of	  
mitochondrial	   function.	   CR	   has	   antioxidant	   effects,	   attenuates	   age-­‐related	   oxidative	  
damage	   to	   mtDNA,	   improves	   mitochondrial	   respiratory	   function	   and	   the	   coupling	  
efficiency	   of	   mitochondrial	   OXPHOS,	   and	   prevents	   the	   age-­‐related	   decline	   in	  
mitochondrial	  turnover.	  
• Several	   mechanisms	   by	   which	   CR	   alters	   mitochondrial	   function	   were	   reviewed,	  
including	   activation	   of	   mitochondrial	   SIRT3,	   which	   results	   in	   the	   deacetylation	   of	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several	  targets,	  and	  modulation	  of	  age-­‐related	  changes	  in	  lipid	  membrane	  composition.	  
However,	   the	   mechanism	   by	   which	   CR	   increases	   PGC-­‐1α 	  activity	   and	   therefore	  
mitochondrial	   biogenesis	   through	   phosphorylation	   by	   AMPK	   and	   subsequent	  
deacetylation	  by	  SIRT1	  is	  still	  controversial.	  
• Epigenetic	   regulations	   have	   been	   recognized	   as	   major	   contributors	   to	   CR-­‐related	  
longevity.	  Regulations	   include	  DNA	  methylation	  and	  histone	  modification,	   resulting	   in	  
alteration	  of	  age-­‐related	  gene	  expression.	  Histone	  acetylation	  and	  deacetylation	  are	  the	  
most	  prevalent	  mechanisms	  of	  histone	  modifications.	  In	  addition	  to	  histone	  acetylation,	  
histone	  methylation	  is	  another	  important	  modification.	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  on	  metabolites	  in	  human	  plasma	  
	  
	  4.1	  Introduction	  
Intrinsic	   cardiorespiratory	   fitness	   (VO2max)	   is	   highly	   positively	   related	   to	   human	  
lifespan	   and	   negatively	   related	   to	   all-­‐cause	   mortality	   and	   cardiovascular	   disease	   (CVD)	  
regardless	  of	  age,	  sex,	  race,	  and	  other	  risk	  factors	  as	  reviewed	  in	  chapter	  2.	  Approximately	  
50%	   of	   the	   variation	   in	   the	   intrinsic	   (untrained)	   VO2max	   in	   the	   untrained	   state,	   after	  
adjusting	  for	  age,	  sex,	  body	  mass,	  and	  body	  composition	  is	  thought	  to	  be	  genetic	  (1).	  Rats	  
bred	  for	  high	  or	  low	  VO2max	  (high	  capacity	  running	  (HCR)	  and	  low	  capacity	  running	  (LCR)	  
rats)	   show	   divergence	   in	   skeletal	   muscle	   oxidative	   capacity	   and	   multiple	   aspects	   of	  
metabolic	  health,	  including	  more	  insulin	  sensitivity,	  lower	  plasma	  triglyceride	  level,	  lower	  
blood	   pressure	   (BP),	   lower	   visceral	   adiposity,	   as	   well	   as	   lower	   body	   weight	   (2-­‐5).	  
Paralleling	  the	  observations	  in	  humans	  with	  high	  VO2max,	  HCR	  rats	  have	  a	  23-­‐40%	  longer	  
median	  and	  absolute	  lifespan	  (6)	  and	  show	  evidence	  of	  slowed	  aging	  with	  reduced	  changes	  
in	  skeletal	  muscle	  gene	  expression	  with	  age	  (7).	  	  
Mitochondria	  are	  central	  to	   intermediary	  metabolism	  in	  all	  cells	  and	  play	  a	  role	   in	  
the	  normal	  aging	  process.	  Mitochondrial	  dysfunction	  in	  aging	  is	  thought	  to	  be	  the	  result	  in	  
decreased	   oxidative	   phosphorylation	   (OXPHOS)	   efficiency,	   increase	   in	   the	   production	   of	  
reactive	   oxygen	   species	   (ROS),	   decrease	   in	   anti-­‐oxidant	   effect,	   as	   well	   as	   a	   reduction	   in	  
mitochondrial	   turnover	  due	   to	  decreased	  mitochondrial	  biogenesis	  and	  mitophagy	  (8,	  9),	  
resulting	   in	   a	   shortened	   lifespan	   (9-­‐11).	   Over-­‐nutrition,	   as	   seen	   in	   obesity,	   can	   lead	   to	  
‘accelerated	   aging’	   (12).	   Recent	   metabolite	   profiling	   studies	   have	   shown	   a	   relationship	  
between	   obesity	   and	   changes	   in	   multiple	   metabolites	   in	   the	   blood,	   most	   notably	   the	  
essential	  branched-­‐chain	  amino	  acids	  (BCAAs)	  and	  aromatic	  amino	  acids,	  fatty	  acids	  (FAs)	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and	   their	   downstream	   metabolites	   acylcarnitines,	   all	   formed	   as	   part	   of	   mitochondrial	  
catabolism	  (13-­‐21).	  The	  alterations	  in	  these	  metabolite,	  and	  others,	  likely	  reflect	  changes	  in	  
the	  balance	  of	  cellular	  metabolite	  uptake	  and	  their	  ultimate	  metabolism.	  The	  oxidation	  of	  
both	  FAs	  and	  BCAAs	  are	  dependent	  upon	  the	  availability	  of	  oxidized	  NAD+	  and	  FAD	  in	  the	  
mitochondria	  to	  accept	  electrons	  and	  donate	  them	  to	  the	  electron	  transport	  chain	  for	  ATP	  
synthesis	  (22).	  With	  a	  high	  cellular	  energy	  state	  as	  seen	  in	  obesity,	  ADP	  levels	  are	  limited	  
and	  OXPHOS	   slows,	  with	   the	   resultant	   generation	   of	  ROS	   and	   a	   decline	   in	  mitochondrial	  
mass,	   function	   and	   turnover	   (22).	   Experimental	   high	   fat	   feeding	   in	   mice	   reduced	   both	  
healthspan	   and	   lifespan	   (12).	   Conversely,	   caloric	   restriction	   (CR)	   can	  markedly	   improve	  
cellular	  energetics	  and	  mitochondrial	  function	  as	  reviewed	  in	  chapter	  3.	  	  
While	   high	   VO2max	   and	   CR	   both	   are	   associated	   with	   increased	   longevity	   and	  
alterations	   in	   mitochondrial	   function,	   it	   is	   unclear	   if	   there	   is	   a	   link	   between	   the	   two	  
phenomena.	  To	  address	  the	  possible	  interconnectedness	  in	  humans,	  we	  asked	  whether	  we	  
could	   detect	   a	  modulation	   by	   increased	   VO2max	   in	   the	   observed	   age-­‐related	   changes	   in	  
blood	   metabolites	   (23).	   Further,	   we	   asked	   whether	   CR	   alters	   metabolism	   in	   a	   similar	  
matter.	   To	   do	   this	   we	   investigated	   the	   relationships	   between	   age,	   VO2max	   and	   a	   set	   of	  
plasma	  metabolites	  that	  have	  been	  associated	  with	  aging,	  insulin	  resistance	  and/or	  risk	  of	  
type	  2	   diabetes	  mellitus	   (DM)	   and	  CVD.	  The	   levels	   of	   amino	   acids	   (AAs),	   free	   fatty	   acids	  
(FFAs)	   and	   their	  metabolites	   generated	  by	  mitochondrial	  metabolism	  were	  measured	  by	  
targeted	   metabolomics	   profiling	   in	   plasma	   in	   non-­‐obese	   individuals	   and	   obese	   people	  
before	  and	  after	  aggressive	  CR	  to	  induce	  weight	  loss.	  In	  an	  attempt	  to	  lessen	  diet	  influences	  
on	  the	  metabolite	  levels,	  subjects	  consumed	  a	  standardized	  isocaloric	  diet	  for	  3	  days	  prior	  
to	   sampling.	   The	   results	   suggest	   that	   age	   related	   changes	   in	   the	   metabolite	   levels	   are	  
slowed	  with	  higher	  VO2max.	  The	  data	  also	  suggests	  that	  CR	  improves	  apparent	  ‘metabolic	  
age’.	  	  
	  
4.2	  Materials	  and	  methods	  
	  
4.2.1	  Participants	  
Participants	   in	   this	   study	   were	   enrolled	   as	   a	   part	   of	   “Investigational	   Weight	  
Management	  Clinic	  (IWMC)”	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Inclusion	  criteria	  
1. Males	  or	  females	  whose	  age	  were	  18-­‐85	  years	  old.	  	  
a. Subjects	   whose	   BMI	   was	   18.5-­‐28.0	   kg/m2	   were	   categorized	   as	   “non-­‐obese”	  
group.	  Subjects	  in	  this	  group	  must	  be	  non-­‐diabetic.	  
b. Subjects	  whose	  BMI	  was	  equal	  or	  greater	  than	  30.0	  kg/m2	  were	  categorized	  as	  
“obese”	  group.	  
2. Able	  and	  willing	  to	  provide	  written	  informed	  consent	  for	  the	  trial.	  
Exclusion	  criteria	  
1. Evidence	  of	  inherited	  disorders	  of	  lipid	  metabolism.	  
2. History	  of	  cancer	  within	  the	  last	  5	  years	  
3. Human	  immunodeficiency	  virus	  (HIV)	  antibody	  positive.	  
4. Patients	  with	  solid	  organ	  transplants.	  
5. Participation	  in	  any	  other	  clinical	  trial	  within	  90	  days	  of	  entry	  into	  this	  trial.	  
6. Pregnant	  or	  lactating	  females.	  	  
7. Uncontrolled	  thyroid	  disease	  
8. Unstable	  angina	  or	  New	  York	  Heart	  Association	  class	  II	  failure	  or	  above	  
9. Gastrointestinal	  disease	  specifically	  GI	  motility	  disorders	  
10. Unstable	   neuropsychiatric	   disease	   including	   major	   depression/anxiety,	   eating	  
disorder	  such	  as	  bulimia	  or	  anorexia	  	  
11. End	  stage	  renal	  or	  hepatic	  disease	  
12. Autoimmune	  disorders	  	  
13. Body	  weight	  fluctuation	  of	  more	  than	  5	  kg	  in	  the	  previous	  3	  months	  
14. Prior	  bariatric	  surgery	  
15. A	   history	   or	   current	   alcohol/substance	   abuse	   and	   change	   in	   smoking	   habits	   or	  
cessation	  in	  the	  past	  6	  months.	  	  	  
16. Women	  of	  childbearing	  age	  must	  use	  a	  reliable	  form	  of	  contraception.	  	  	  
17. Any	   medical	   condition,	   which	   in	   the	   opinion	   of	   the	   investigator	   would	   make	   the	  
patient	  unsuitable	  for	  recruitment,	  or	  could	  interfere	  with	  the	  patient	  participating	  
in	  or	  completing	  the	  protocol.	  
18. Unwilling	  or	  unable	  to	  consent	  for	  the	  study.	  
CR	  was	  applied	  only	  for	  the	  obese	  group.	   Indeed,	  non-­‐obese	  subjects	  were	  studied	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only	   once	   as	   the	   control	   group.	   All	   studies	   were	   approved	   by	   the	   Institutional	   Review	  
Board	  of	  the	  University	  of	  Michigan	  and	  all	  subjects	  gave	  informed	  consent.	  	  
	  	  
4.2.2	  CR	  protocol	  
The	   protocol	   lasted	   100	  weeks	   with	   1	   assessment	   visit	   (visit	   0)	   and	   26	   program	  
visits	  (visit	  1-­‐26)	  and	  was	  divided	  into	  2	  sections.	  	  
1. Rapid	  weight	  loss	  section	  
Participants	   received	   800	   kcal/day	   (5	   packs)	   of	   high-­‐protein	   liquid	   shake	   (HMR®	  
800)	  approximately	  containing	  16	  g	  of	  protein,	  21	  g	  of	  carbohydrate	  and	  2	  g	  of	   fat	  
per	  pack.	  They	  were	  also	  encouraged	  to	  have	  at	   least	  150	  min/week	  of	  exercise	  at	  
intervals	  at	  their	  convenience.	  The	  goal	  is	  at	  least	  15%	  of	  weight	  loss,	  which	  usually	  
takes	  12	  to	  16	  weeks.	  
2. Weight	  maintenance	  section	  	  
After	  achieving	  the	  goal,	  participants	  received	  1,200-­‐1,800	  kcal/day	  of	  regular	  diet	  
plus	   partial	   meal	   replacement	   with	   high-­‐protein	   liquid	   shake	   (HMR®	   800)	   and	  
maintained	  the	  same	  exercise.	  The	  study	  was	  ended	  at	  week	  100.	  
Our	  assessment	  was	  focused	  only	  on	  the	  time	  point	  at	  baseline	  before	  CR	  (week	  0)	  
and	   at	   the	   end	   of	   rapid	   weight	   loss	   section	   (week	   12	   to	   16).	   The	   assessment	   included	  
demographic	   data,	   body	   mass	   index	   (BMI),	   body	   composition,	   VO2max,	   resting	   energy	  
expenditure	   (REE),	   respiratory	   quotient	   at	   rest	   (RQR),	   respiratory	   quotient	   at	   VO2max	  
(RQE),	   fasting	   plasma	   glucose	   and	   insulin,	   HOMA-­‐IR	   ((fasting	   plasma	   glucose	   x	   fasting	  
plasma	  insulin)/405),	  as	  well	  as	  fasting	  plasma	  metabolites,	  including	  AAs,	  branched-­‐chain	  
ketoacids	  (BCKAs),	  FFAs	  and	  acylcarnitines.	  
	  
4.2.3	  Body	  composition	  	  
Body	   composition	   was	   measured	   by	   dual	   energy	   x-­‐ray	   absorptiometry	   (Lunar	  
Prodigy	  ADVANCE	  Plus,	  GE	  Healthcare,	  Chicago,	  IL).	  	  
	  
4.2.4	  Exercise	  testing	  for	  VO2max,	  REE,	  RQR	  and	  RQE	  
The	   equipment	   for	   the	   exercise	   test	   included	   3	   complete	   metabolic	   carts	   (Viasys	  
Healthcare	   Vmax	   Encore	   VS	   29n,	   ParvoMedics	   TrueOne	   2400	   and	   Physiodyne	  Max	   II),	   2	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treadmills	   (Trackmaster),	   2	   portable/wearable	  metabolic	   mask	   systems	   (COSMED	   K4B2	  
and	   COSMED	   Fitmate),	   12	   lead	   ECG	   (Quentin),	   POLAR	  T2	   technology	   system	   (heart	   rate	  
monitor	   and	   capture)	   and	   SenseWear®	  monitors	   (Bodymedia	   Inc.,	   Pittsburgh,	   PA,	   USA).	  
VO2max	  was	  assessed	  using	  modified	  Bruce	  protocol	  described	  elsewhere	  (24).	  Ventilation	  
volume	   and	   respiratory	   gas	   exchange	   were	   continuously	   monitored	   as	   well	   to	   calculate	  
RQR	  and	  RQE.	  	  
	  
4.2.5	  Mixed	  Meal	  Tolerance	  Test	  (MMTT)	  
Fasting	   plasma	   for	   all	   analyses	   were	   obtained	   during	   MMTT.	   To	   minimize	  
interpersonal	  variation	  during	  the	  test,	  all	  subjects	  were	  provided	  an	  isocaloric	  diet	  menu	  
containing	  a	  macronutrient	  mix	  at	  the	  50th	  percentile	  for	  Americans	  that	  was	  consumed	  for	  
3	   days	   prior	   to	   testing.	   Following	   a	   12-­‐hour	   overnight	   fast,	   blood	   was	   collected	   from	   a	  
peripheral	  venous	  catheter	  placed	  in	  either	  in	  the	  arm	  (antecubital)	  or	  hand	  (0	  min).	  	  	  Each	  
participant	   then	  consumed	  a	   liquid	  mixed	  meal	   (237	  ml	  of	  Ensure®	  Original	  Therapeutic	  
Nutrition	  containing	  22%	  of	  fat,	  64%	  of	  carbohydrate	  and	  14%	  of	  protein)	  within	  10	  min.	  
In	  addition	  to	  the	  initial	  fasting	  sample	  (0	  min),	  venous	  blood	  was	  obtained	  15,	  30,	  60,	  90,	  
120,	  150	  and	  180	  min	  after	  mixed	  meal	  consumption.	  
	  
4.2.6	  Plasma	  glucose	  and	  insulin	  
Plasma	  glucose	  and	  insulin	  were	  measured	  by	  the	  Michigan	  Diabetes	  Research	  and	  
Training	   Center	   (MDRTC).	   	   Plasma	   glucose	   analysis	   was	   performed	   on	   a	   Cobas	   Mira	  
Chemistry	  Analyzer	  (Roche	  Diagnostics	  Corporation,	   Indianapolis,	   IN,	  USA).	  Reagents	  and	  
calibrators	  used	  for	  the	  analysis	  were	  from	  Sekisui	  Diagnostic	  LLC	  (Lexington,	  MA).	  	  Plasma	  
insulin	  was	  analyzed	  by	  a	  double-­‐antibody	  radioimmunoassay	  using	  an	  125I-­‐Human	  insulin	  
tracer	   (Linco	   Research,	   St.	   Charles,	   MO,	   USA),	   a	   guinea	   pig	   anti-­‐porcine	   insulin	   first	  
antibody	   (MDRTC,	  68.5%	  cross-­‐reaction	   to	  human	  proinsulin)	  and	  a	  goat	  anti-­‐guinea	  pig	  
gamma	   globulin-­‐PEG	   second	   antibody	   (MDRTC)	   and	   standardized	   against	   the	   Human	  
Insulin	   International	   Reference	   Preparation	   (National	   Institute	   for	   Biological	   Standards	  
and	  Control).	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4.2.7	  Plasma	  metabolomics	  
Targeted	  metabolomic	  approach	  was	  used	  to	  study	  metabolites	  listed	  in	  Table	  A4.1	  
of	   appendices.	   The	   study	   was	   quality	   controlled	   by	   reference	   human	   plasma	   samples	  
obtained	  from	  the	  American	  Red	  Cross.	  Seventy	  μl	  of	  plasma	  was	  extracted	  by	  adding	  280	  
μl	  of	  extraction	  solvent	  (1:1:1	  methanol:	  acetonitrile:	  acetone)	  containing	  internal	  standard	  
mixture	  (see	  Table	  A4.2	  of	  appendices),	  vortexing	  for	  10	  sec,	  allowing	  to	  rest	  on	  ice	  for	  5	  
min,	  and	  then	  centrifuging	  at	  4	  °C	  for	  10	  min.	  The	  supernatant	  was	  divided	  into	  2	  aliquots	  
(140	  μl	  each)	  and	  dried	  by	  vacuum	  centrifuge	  at	  45	  °C.	  One	  aliquot	  was	  reconstituted	  using	  
140	  μl	  of	  8:2	  methanol:water	  for	  AA	  analysis.	  Another	  was	  reconstituted	  using	  140	  μl	  of	  8:2	  
water:methanol	  for	  BCKA,	  FFA	  	  and	  acylcarnitine	  analysis.	  	  
All	   metabolites	   were	   analyzed	   by	   liquid	   chromatography-­‐mass	   spectrometry	   (LC-­‐
MS)	   using	   an	  Agilent	   1200	  LC	   connected	   to	   an	  Agilent	   6410	   tandem	  quadrupole	  MS.	  MS	  
parameters	  were	  as	  follows:	  capillary	  voltage	  4000	  V,	  gas	  temperature	  325	  °C,	  gas	  flow	  10	  
l/min	  and	  nebulizer	  pressure	  40	  psi.	  Mobile	  phase	  A	  was	  0.1%	  of	  formic	  acid	  in	  water	  and	  
mobile	  phase	  B	  was	  0.1%	  of	  formic	  acid	  in	  acetonitrile.	  
For	   AA	   analysis,	   hydrophilic	   interaction	   chromatography	   (HILIC)	   was	   performed	  
using	  a	  VWR	  Cogent	  Diamond	  Hydride	  column,	  4	  μm	  particle	  size,	  150	  mm	  x	  2.1	  mm	  inner	  
diameter	  (i.d.)	  (Radnor,	  PA).	  The	  flow	  rate	  was	  0.25	  ml/min	  and	  the	  gradient	  consisted	  of	  
an	  11-­‐min	  linear	  ramp	  from	  95	  to	  25%	  B,	  2	  min	  at	  10%	  B	  and	  7	  min	  of	  re-­‐equilibration	  at	  
95%	  B.	  Detection	  was	  performed	  using	  multiple	  reaction	  monitoring	  (MRM)	  in	  positive	  ion	  
mode	  (see	  details	  in	  Table	  A4.3	  of	  appendices).	  	  
For	   BCKA,	   FFA	   and	   acylcarnitine	   analysis,	   reversed-­‐phase	   liquid	   chromatography	  
(RPLC)	  was	  performed	  using	  a	  Waters	  Acquity	  HSS	  T3	  column,	  1.8	  μm	  particle	  size,	  2.1	  x	  
100	  mm	  i.d.	  (Milford,	  MA),	  with	  a	  flow	  rate	  of	  0.25	  ml/min.	  	  For	  BCKA	  and	  FFA,	  the	  gradient	  
consisted	  of	   a	  10-­‐min	   linear	   ramp	   from	  0	   to	  100%	  B,	  5	  min	  at	  100%	  B	  and	  8	  min	  of	   re-­‐
equilibration	   at	   0%	   B.	   Detection	   was	   performed	   using	   selected	   ion	  monitoring	   (SIM)	   in	  
negative	  ion	  mode	  (see	  details	  in	  Table	  A4.4	  of	  appendices).	  For	  acylcarnitine	  analysis,	  the	  
same	  column	  was	  used	  with	  the	  following	  gradient:	  7-­‐min	  linear	  ramp	  from	  0	  to	  80%	  B,	  3	  
min	  at	  100%	  B	  and	  5	  min	  of	  re-­‐equilibration	  at	  0%	  B.	  MRM	  in	  positive	  ion	  mode	  was	  used	  
with	  precursor/product	  ion	  transitions	  specified	  elsewhere	  (25).	  	  
	   98	  
Acylcarnitine	  species	  present	  in	  the	  internal	  standard	  mix	  (NSK-­‐B)	  were	  reported	  as	  
absolute	   concentration	   as	   determined	   by	   isotope	   dilution	   MS	   (peak	   area	   of	   unlabeled	  
compound-­‐to-­‐peak	  area	  of	   internal	   standard	  x	   concentration	  of	   internal	   standard).	  Other	  
acylcarnitine	   species	   were	   reported	   as	   relative	   concentration	   (peak	   area	   of	   biological	  
compound-­‐to-­‐peak	  area	  of	   internal	  standard	  with	  closest	  matching	  RT	  x	  concentration	  of	  
internal	   standard).	   Metabolites	   other	   than	   acylcarnitines	   with	   exact-­‐matching	   stable	  
isotope	  internal	  standards	  were	  quantitated	  by	  calibration	  curves	  using	  peak	  area	  ratios	  to	  
their	  internal	  standards.	  	  Other	  metabolites	  without	  exact-­‐matching	  stable	  isotope	  internal	  
standards	   were	   quantitated	   using	   the	   ratio	   of	   their	   peak	   area	   to	   that	   of	   the	   internal	  
standard	   with	   closest	   matching	   retention	   time	   (RT),	   as	   indicated	   in	   Table	   A4.5	   of	  
appendices.	  	  Metabolite	  concentrations	  used	  for	  calibration	  curves	  are	  listed	  in	  Table	  A4.5	  
of	   appendices.	   Metabolite	   peak	   areas	   were	   determined	   using	   Agilent	   Masshunter	  
Quantitative	  Analysis	  software	  for	  triple	  quadrupole	  MS	  version	  B.07.00.	  
	  
4.2.8	  Statistical	  analyses	  
All	  figures	  were	  depicted	  using	  Prism	  7	  Version	  7.0a.	  P-­‐value	  <0.050	  was	  considered	  
statistically	   significant.	   Comparison	   of	   the	   assessments	   between	   the	   non-­‐obese	   and	   the	  
obese	   groups	   were	   analyzed	   using	   unpaired-­‐two-­‐tailed	   student’s	   t	   tests.	   For	   the	  
comparison	   between	   obese	   subjects	   at	   baseline	   and	   after	   CR,	  we	   used	   paired-­‐two-­‐tailed	  
student’s	  t	  tests.	  All	  metabolomic	  data	  were	  reported	  as	  average±standard	  error	  of	  mean	  
(SEM).	  	  
Correlations	  of	  metabolites	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  
per	  FFM	  at	  baseline]	  were	  analyzed	  by	  Multivariate	  Analysis	  of	  Variance	   (MANOVA)	  and	  
Analysis	  of	  Variance	   (ANOVA).	  We	  employed	  MANOVA	   to	   compare	  means	  of	  metabolites	  
grouped	   based	   on	   their	   correlations.	   It	   uses	   the	   covariance	   between	   the	   metabolites	  
considered	   in	   a	   group	   to	   test	   the	   statistical	   significance	   of	   the	   mean	   differences	   across	  
different	   experimental	   conditions.	   MANOVA	   is	   a	   procedure	   for	   comparing	   multivariate	  
sample	   means.	  MANOVA	   is	   simply	   an	   ANOVA	   with	   several	   dependent	   variables.	  	  It	   uses	  
the	  covariance	  between	  outcome	  variables	  in	  testing	  the	  statistical	  significance	  of	  the	  mean	  
differences.	   The	   groups	   of	   metabolites	   considered	   in	   our	   analysis	   were	   identified	   by	  
calculating	  correlations	  amongst	  them,	  then	  thresholding	  them	  by	  testing	  whether	  they	  are	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different	   than	   zero	   by	   employing	   Fisher’s	   z-­‐transform	   test	   and	   controlling	   the	   False	  
Discovery	  Rate	  at	  the	  10%	  level,	  followed	  by	  applying	  agglomerative	  clustering.	  In	  carrying	  
out	   the	  MANOVA	   testing,	  we	   used	   the	   so	   called	  Type	   II	   tests	   that	   test	   for	   an	   effect	   after	  
testing	  for	  another	  one.	  To	  clarify	  this	  point,	  we	  provided	  a	  simple	  example.	  Suppose	  that	  
we	  are	  interested	  in	  testing	  the	  effect	  of	  covariate	  for	  a	  particular	  group	  of	  metabolites,	  as	  a	  
function	  of	  sex,	  race,	  age,	  diabetes	  status,	  VO2max	  and	  BMI.	  Then,	  the	  p-­‐value	  obtained	  for	  
the	   BMI	   covariate	   shows	   the	   significance	   controlling	   for	   the	   presence	   of	   the	   remaining	  
variables	  in	  the	  model.	  Finally,	  once	  groups	  of	  metabolites	  were	  identified	  as	  significantly	  
differential,	  we	  further	  examined	  the	  impact	  of	  covariates	  on	  each	  metabolite	  in	  the	  group,	  
by	  employing	   the	   standard	   t-­‐test	   in	   a	   regression	   test	   (ANOVA)	   for	   the	  null	   hypothesis	  of	  




4.3.1	  Participant	  characteristics	  	  
Participant	   characteristics	   are	   detailed	   in	   Table	   4.1.	   Twenty-­‐eight	   non-­‐obese	   (14	  
males	  and	  14	  females)	  and	  124	  obese	  (56	  males	  and	  68	  females)	  individuals	  participated	  in	  
this	   study.	   Most	   were	   Caucasian	   (92.8%	   of	   non-­‐obese	   and	   93.6%	   of	   obese).	   Obese	  
individuals	   were	   heavier	   (39.7±0.43	   vs.	   22.5±0.39	   kg/m2)	   and	   older	   (50±0.79	   vs.	   43±	  
2.04	  years	  of	  age).	   	  Among	  124	  obese	  subjects,	  47	  of	  them	  had	  type	  2	  DM	  and	  32	  of	  them	  
received	   1	   or	   more	   anti-­‐diabetic	   drugs	   prior	   to	   the	   enrollment.	   An	   additional	   6	   obese	  
subjects	  began	  anti-­‐diabetic	  drug(s)	   after	   type	  2	  DM	  was	  diagnosed	  during	   testing.	  Body	  
weight	  decreased	  by	  17.8±0.56%	  with	  CR	  (range	  4.1-­‐35.7%).	  	  	  
	  
4.3.2	  Non-­‐metabolite	  parameters	  	  
Non-­‐metabolite	  parameters	  are	  detailed	   in	  Table	  4.1.	  The	  obese	  group	  had	  higher	  
lean	   and	   fat	   mass	   and	   fat	   percentage.	   The	   obese	   group	   also	   had	   higher	   fasting	   plasma	  
glucose	  and	  insulin,	  and	  HOMA-­‐IR	  and	  these	  values	  continued	  to	  be	  higher	  after	  removal	  of	  
diabetic	   individuals	   (p-­‐value	   <0.001	   in	   both	   male	   and	   female).	   These	   parameters	  
significantly	  improved	  after	  CR,	  but	  continued	  to	  be	  significantly	  different	  than	  non-­‐obese.	  	  
Total	  REE	  and	  REE	  corrected	  for	  lean+bone	  (fat-­‐free)	  mass	  (FFM)	  was	  higher	  in	  obese	  than	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non-­‐obese	  males,	  but	  was	  not	  different	  after	  correcting	  for	  lean	  mass	  in	  the	  females	  (Table	  
4.1).	  Average	  REE	  and	  corrected	  REE	  fell	  significantly	  following	  weight	  loss,	   indicating	  an	  
increased	  oxidation	  of	  FAs,	   despite	   an	   isocaloric	  diet	   for	  3	  days	  prior	   to	   testing.	  VO2max	  
corrected	  for	  FFM	  was	  lower	  in	  obese	  individuals	  than	  the	  non-­‐obese.	  Because	  VO2max	  per	  
FFM	  negatively	  correlated	  with	  age	  (r	  =	   -­‐0.42;	  p-­‐value	  =	  0.023	  for	  non-­‐obese	  group,	  r	  =	   -­‐
0.47;	  p-­‐value	  <0.001	   for	  obese	  group	  at	  baseline	  and	   r	  =	   -­‐0.53;	  p-­‐value	  <0.001	   for	  obese	  
group	   after	   CR)	   and	   the	   average	   age	   of	   our	   obese	   subjects	   were	   higher,	   we	   examined	  
VO2max	  per	  FFM	  between	  non-­‐obese	  and	  obese	  subjects	   in	  sub-­‐group	  of	  our	  participants	  
with	  ages	  >35	  years	  (n	  =	  54	  obese	  males,	  n	  =	  63	  obese	  females,	  n	  =	  8	  non-­‐obese	  males	  and	  
n	  =	  11	  non-­‐obese	  females).	  VO2max	  per	  FFM	  was	  still	  significantly	  lower	  in	  the	  obese	  group	  
(Table	  A4.6	  of	  appendices).	  	  After	  CR	  in	  the	  obese,	  VO2max	  per	  FFM	  was	  increased	  slightly,	  
but	   significantly	   compared	   to	   baseline.	   	   The	   correlation	   of	   VO2max	   per	   FFM	   between	   at	  
baseline	  and	  after	  CR	  was	  significantly	  positive	  (r	  =	  0.689;	  p-­‐value	  <0.001).	  	  We	  detected	  no	  
difference	  in	  the	  RQE	  between	  non-­‐obese	  and	  obese	  or	  in	  obese	  after	  CR.	  	  	  
	  
4.3.3	  Metabolites	  and	  their	  difference	  between	  groups	  	  
Concentrations	   of	   all	   AA-­‐related	  metabolites	   are	   detailed	   in	   Table	   4.2.	   Consistent	  
with	  insulin	  resistance	  profiles	  (glucose,	   insulin	  and	  HOMA-­‐IR),	  previously	  proved	  insulin	  
resistance-­‐related	   AAs,	   including	   BCAAs	   (isoleucine+leucine	   and	   valine),	   aromatic	   AAs	  
(phenylalanine	  and	  tyrosine),	  alanine	  and	  glutamic	  acid	  (13-­‐21),	  were	  significantly	  higher	  
in	   obese	   subjects.	   These	   AAs	   decreased	   significantly	   after	   CR.	   Methionine,	   which	   is	   also	  
correlated	  with	  insulin	  resistance	  (26),	  was	  not	  significantly	  different	  between	  groups,	  but	  
CR	   decreased	   the	   level.	   Previously	   proved	   insulin	   sensitivity-­‐related	   AAs	   include	  
asparagine,	   glutamine-­‐to-­‐glutamic	   acid	   ratio,	   glutamine,	   glycine	   and	   serine	   (17,	   27,	   28).	  
Asparagine,	  glutamine-­‐to-­‐glutamic	  acid	  ratio,	  glutamine	  and	  serine	  levels	  were	  significantly	  
lower	   in	   the	   obese	   group.	   Glycine	   was	   lower	   in	   obese	   male	   than	   non-­‐obese	   male	  
participants,	   but	   there	   was	   no	   significant	   difference	   between	   groups	   in	   females.	   CR	  
increased	   the	   levels	   of	   all	   these	  5	  markers,	   yet	   glutamine-­‐to-­‐glutamic	   acid	   ratio	  was	   still	  
significantly	  lower	  than	  what	  we	  found	  in	  non-­‐obese	  participants.	  Ketovaline	  was	  the	  only	  
BCKA	   that	   was	   significantly	   higher	   in	   obese	   subjects	   and	   this	   was	   found	   only	   in	   male	  
participants.	  CR	  decreased	  ketoisoleucine+ketoleucine	  and	  ketovaline	   levels.	  C3	   carnitine	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and	  C5	  carnitine	  are	  intermediate	  metabolites	  of	  valine	  and	  isoleucine+leucine	  catabolism,	  
respectively.	  Like	  their	  substrates,	  C3	  carnitine	  and	  C5	  carnitine	  are	  known	  as	  markers	  of	  
insulin	  resistance	  (20,	  21).	  C3	  carnitine	  and	  C5	  carnitine	  were	  significantly	  higher	  in	  obese	  
participants.	  Their	   levels	  decreased	  after	  CR.	  To	  evaluate	  mitochondrial	  capacity	  of	  BCAA	  
catabolism,	  we	  inferred	  fluxes	  by	  calculating	  ratios	  of	  C3	  carnitine	  and	  C5	  carnitine	  to	  their	  
substrates	   and	   ketoacids	   of	   the	   substrates.	   Higher	   ratio	   means	   lower	   mitochondrial	  
capacity	   of	   BCAA	   catabolism	   since	   there	   were	   more	   accumulations	   of	   intermediate	  
metabolites.	  We	  found	  that	  C3	  carnitine-­‐to-­‐valine	  ratio,	  C3	  carnitine-­‐to-­‐ketovaline	  ratio	  and	  
C5	   carnitine-­‐to-­‐ketoisoleucine+ketoleucine	   ratio	   were	   significantly	   higher	   in	   obese	  
participants.	   C5	   carnitine-­‐to-­‐isoleucine+leucine	   ratio	   showed	   a	   higher	   trend	   (p-­‐value	   =	  
0.051)	  in	  the	  obese	  group.	  	  
Concentrations	   of	   all	   FA-­‐related	   metabolites	   are	   detailed	   in	   Table	   4.2.	   Oleic	   acid	  
levels	   were	   not	   different	   between	   groups.	   Obese	   male	   subjects	   had	   significantly	   higher	  
palmitic	   acid	   level	   than	   the	   non-­‐obese	  males,	   but	   the	   difference	  was	   not	   found	   between	  
groups	  in	  females.	  After	  CR,	  oleic	  acid	  remained	  unchanged	  whereas	  palmitic	  acid	  showed	  a	  
trend	   of	   reduction	   in	   female	   subjects	   (p-­‐value	   =	   0.051).	   Long-­‐chain	   acylcarnitine	   levels	  
reflect	   coming	   of	   FAs	   into	   the	   mitochondria	   via	   carnitine	   shuttle	   (29).	   C18:0	   carnitine,	  
C20:0	  carnitine	  and	  C20:1	  carnitine	  were	  significantly	  lower	  in	  obese	  subjects.	  Other	  long-­‐
chain	   acylcarnitines	  were	  not	   significantly	  different	   between	   groups.	   CR	   increased	  C18:1	  
carnitine,	  C18:2	  carnitine,	  C20:0	  carnitine,	  C20:1	  carnitine,	  C20:2	  carnitine,	  C20:3	  carnitine	  
and	  C20:4	  carnitine	  levels	  whereas	  other	  long-­‐chain	  acylcarnitines	  remained	  unaltered.	  We	  
also	   inferred	   fluxes	   by	   calculating	   ratios	   of	   C16:0	   carnitine	   and	   C18:1	   carnitine,	   which	  
reflect	   coming-­‐in	   of	   palmitic	   acid	   (16:0	   FA)	   and	   oleic	   acid	   (18:1	   FA)	   respectively,	   to	   the	  
levels	   of	   palmitic	   acid	   and	   oleic	   acid.	   Straightforwardly,	   higher	   ratio	   represents	   higher	  
coming	  of	  FAs	  into	  the	  mitochondria.	  We	  found	  that	  C16:0	  carnitine-­‐to-­‐palmitic	  acid	  ratio	  
was	   significantly	   lower	   in	   obese	  participants.	   C18:1	   carnitine-­‐to-­‐oleic	   acid	   ratio	  was	   also	  
lower	  in	  obese	  subjects	  but	  did	  not	  reach	  statistically	  significance	  (p-­‐value	  =	  0.125).	  Both	  
C16:0	   carnitine-­‐to-­‐palmitic	   acid	   ratio	   and	   C18:1	   carnitine-­‐to-­‐oleic	   acid	   ratio	   were	  
significantly	   increased	   after	   CR.	  Medium-­‐chain	   (C6-­‐C14)	   acylcarnitine	   levels	   reflect	   fatty	  
acid	   oxidation	   (FAO)	   in	   the	  mitochondria	   (29).	   It	   is	   already	   known	   that	   FAO	   consists	   of	  
several	   steps,	   but	   which	   steps	   are	   rate-­‐limiting	   is	   still	   unclear.	   Here	   we	   identified	   rate-­‐
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limiting	   steps	   by	   the	   average	   concentration	   of	   all	   medium-­‐chain	   acylcarnitines	   in	   non-­‐
obese,	   obese	   at	   baseline	   and	   after	   CR.	   We	   found	   that	   C10:0	   carnitine	   had	   the	   highest	  
concentration	   in	   every	   group	   (Figure	  A4.1	  of	   appendices).	  Therefore,	  we	  determined	   the	  
shortening	  of	  C10:0	  carnitine	   to	  get	  C8:0	  carnitine	  as	  a	  starting	  point	  of	   the	  rate-­‐limiting	  
step	   of	   FAO.	   After	   identifying	   the	   rate-­‐limiting	   step,	   we	   again	   inferred	   a	   flux	   using	   C8:0	  
carnitine-­‐to-­‐C10:0	  carnitine	   ratio	   to	  evaluate	  mitochondrial	   capacity	  of	  FAO.	  Higher	   ratio	  
means	   lower	   mitochondrial	   capacity	   of	   FAO,	   i.e.	   incomplete	   FAO	   since	   there	   was	   more	  
accumulation	  of	  the	  first	  product	  of	  the	  rate-­‐limiting	  step.	  We	  found	  that	  C8:0	  carnitine-­‐to-­‐
C10:0	   carnitine	   ratio	   was	   significantly	   higher	   in	   the	   obese	   group	   and	   CR	   decreased	   the	  
level.	   C8:1	   carnitine	   was	   significantly	   higher	   in	   obese	   subjects.	   C6:0	   carnitine	   was	  
significantly	   higher	   in	   obese	   males,	   but	   not	   in	   obese	   females.	   C10:0	   carnitine,	   C12:0	  
carnitine	   and	   C14:2	   carnitine	  were	   significantly	   lower	   in	   the	   obese	   group.	   The	   levels	   of	  
C8:0	   carnitine,	   C10:1	   carnitine,	   C12:1	   carnitine,	   C12-­‐OH	   carnitine,	   C14:0	   carnitine,	   C14:1	  
carnitine,	   C14-­‐OH	   carnitine,	   C16:1	   carnitine	   and	   C16-­‐OH	   carnitine	  were	   not	   significantly	  
different	   between	   groups.	  After	   CR,	   C6:0	   carnitine,	   C8:1	   carnitine,	   C12:0	   carnitine,	   C12:1	  
carnitine	  and	  C14:0	   carnitine	  were	   significantly	  decreased	  whereas	  C8:0	   carnitine,	  C10:0	  
carnitine,	   C10:1	   carnitine,	   C12-­‐OH	   carnitine,	   C14:1	   carnitine,	   C14:2	   carnitine,	   C14-­‐OH	  
carnitine,	  C16:1	  carnitine	  and	  C16-­‐OH	  carnitine	  remained	  unchanged.	  	  
	  
4.3.4	  Effects	  of	  age	  and	  VO2max	  on	  metabolite	  levels	  
We	  noted	   that	  groups	  of	   the	  metabolites	  had	  significant	   covariance	   in	   the	  plasma,	  
which	   was	   not	   surprising	   given	   the	   chemical	   similarities	   and	   the	   convergence	   of	   the	  
metabolic	  pathways	  used	  in	  the	  oxidation	  of	  FAs	  and	  AAs	  in	  the	  mitochondria.	  	  To	  enhance	  
our	  signal	   for	  specific	  metabolic	  pathways	   that	  are	  affected	  by	  age	  and	  VO2max,	  we	  used	  
MANOVA,	  grouping	  the	  metabolites	  by	  clustering	  their	  covariance	  and	  then	  assessing	  how	  
the	  metabolites	  in	  each	  group	  were	  affected	  by	  age	  and/or	  VO2max	  and	  the	  interactions	  of	  
the	   terms.	  All	  metabolites	   and	   insulin	   resistance	   profiles	   at	   baseline	   from	   the	   non-­‐obese	  
and	  obese	  groups	   formed	  4	  groups	  after	  hierarchal	  clustering	  (Figure	  4.1	  and	  Table	  4.3).	  
Group	  I	  mainly	  consisted	  of	  basic	  AAs,	  long-­‐chain	  saturated	  acylcarnitines,	  as	  well	  as	  ratios	  
of	  C16:0	  carnitine	  and	  C18:1	  carnitine	  to	  their	  FA	  substrates.	  Group	  II	  mainly	  consisted	  of	  
BCAAs,	  aromatic	  AAs,	  BCKAs	  and	  insulin	  resistance	  profiles.	  Group	  III	  mostly	  consisted	  of	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acylcarnitine	  intermediates	  of	  BCAAs	  and	  ratios	  to	  their	  substrates.	  Group	  IV	  consisted	  of	  
FFAs,	   long-­‐chain	   and	   medium-­‐chain	   acylcarnitines,	   as	   well	   as	   C2	   carnitine.	   	   We	   then	  
calculated	   the	   effects	   of	   age	   and/or	   VO2max	   on	   metabolite	   levels,	   after	   correction	   for	  
clinical	   variables	   including	   sex,	   race,	   group	   of	   subjects,	   diabetes	   status	   and	   BMI.	   Results	  
were	  considered	  significant	  when	  correlations	  of	  age	  and/or	  VO2max	  vs.	  metabolite	  cluster	  
were	   significant	   using	   MANOVA.	   In	   each	   cluster	   of	   metabolites	   that	   were	   significantly	  
affected	   by	   age	   and/or	   VO2max	   from	  MANOVA,	   ANOVA	  was	   then	   used	   to	   identify	  which	  
metabolites	  drove	  the	  significance	  of	  the	  group.	  Metabolites	  were	  considered	  as	  drivers	  of	  
the	  group	  if	  their	  correlations	  vs.	  age	  and/or	  VO2max	  were	  significant	  from	  ANOVA.	  	  Since	  
VO2max	  is	  a	  function	  of	  FFM	  (30,	  31)	  and	  fat	  mass	  does	  not	  have	  any	  effect	  on	  VO2max	  (31),	  
VO2max	  adjusted	  by	  FFM	  (VO2max	  per	  FFM)	  was	  used	  for	  the	  analysis.	  
	  
4.3.4.1	  Age	  determines	  metabolite	  levels.	  
From	  MANOVA,	  we	  found	  that	  correlations	  between	  age	  and	  all	  4	  metabolite	  groups	  
at	  baseline	  were	  significant	  (Figure	  4.2	  and	  Table	  A4.7	  of	  appendices).	  Using	  ANOVA,	  Group	  
I	   displayed	   significantly	   positive	   correlations	   of	   age	   vs.	   glycine,	   C18:0	   carnitine,	   C20:0	  
carnitine	  and	  C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio,	  whereas	  significantly	  negative	  correlations	  
of	  age	  vs.	  histidine	  and	  threonine	  were	  found.	  In	  Group	  II,	  there	  was	  a	  significantly	  positive	  
correlation	   between	   age	   and	   C8:0	   carnitine-­‐to-­‐C10:0	   carnitine	   ratio,	   but	   significantly	  
negative	   correlations	   of	   age	   vs.	   isoleucine+leucine	   and	   ketoisoleucine+ketoleucine	   were	  
observed.	  The	  correlations	  between	  age	  and	  all	  metabolites	  in	  Group	  III	  were	  positive	  and	  
the	  significances	  were	   found	  in	  L-­‐carnitine	  and	  ratios	  of	  C5	  carnitine	  to	   its	  substrates.	  As	  
with	  Group	  III,	  the	  correlations	  between	  age	  and	  metabolites	  in	  Group	  IV	  were	  all	  positive	  
and	   the	   significances	   were	   found	   in	   C6	   carnitine,	   C8:0	   carnitine,	   C10:0	   carnitine,	   C10:1	  
carnitine,	   C16:1	   carnitine,	   C18:1	   carnitine,	   C18:2	   carnitine,	   C18:2-­‐OH	   carnitine,	   C20:1	  
carnitine,	  C20:2	  carnitine,	  C20:3	  carnitine	  and	  C20:4	  carnitine	  (Figure	  4.2	  and	  Table	  A4.7	  of	  
appendices).	  
	  
4.3.4.2	  Regardless	  of	  age,	  VO2max	  also	  determines	  metabolite	  levels.	  
VO2max	   falls	  with	   age	   (32-­‐34)	   and	   thus	   in	  modeling	   changes	   in	  metabolite	   levels	  
with	  VO2max	  were	  adjusted	  for	  age.	  From	  MANOVA,	  significant	  correlations	  of	  VO2max	  per	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FFM	  at	  baseline	  vs.	  Group	  II	  and	   IV	  at	  baseline	  were	   found	  (Figure	  4.2	  and	  Table	  A4.7	  of	  
appendices).	   Using	   ANOVA,	   Group	   II	   demonstrated	   significantly	   positive	   correlation	  
between	  VO2max	  per	  FFM	  at	  baseline	  and	  tryptophan	  but	  significantly	  negative	  correlation	  
with	  proline.	   In	  Group	  IV,	   there	  were	  significantly	  negative	  correlations	  between	  VO2max	  
per	   FFM	   at	   baseline	   and	   C2	   carnitine	   as	   well	   as	   several	   medium-­‐chain	   acylcarnitines	  
including	  C6	   carnitine,	  C12:0	   carnitine,	  C14:0	   carnitine	  and	  C16-­‐OH	  carnitine	   (Figure	  4.2	  
and	  Table	  A4.7	  of	  appendices).	  	  
	  
4.3.4.3	  VO2max	  counteracts	  age-­‐induced	  increase	  in	  FA-­‐related	  metabolites.	  
To	  identify	  how	  VO2max	  alters	  effects	  of	  age	  on	  metabolites	  levels,	  we	  assessed	  the	  
correlation	   between	   [age	   x	   VO2max	   per	   FFM	   at	   baseline]	   and	   metabolite	   levels.	   From	  
MANOVA,	  significantly	  correlations	  between	  [age	  x	  VO2max	  per	  FFM	  at	  baseline]	  and	  Group	  
IV	   at	   baseline	  were	   identified	   (Figure	   4.2	   and	  Table	  A4.7	   of	   appendices).	   	   Using	  ANOVA,	  
correlations	  were	   all	   negative	   and	   significance	  was	   found	   in	   oleic	   acid,	   several	  medium-­‐
chain	   acylcarnitines	   including	   C6	   carnitine,	   C10:1	   carnitine,	   C12:0	   carnitine,	   C12:1	  
carnitine,	   C12-­‐OH	   carnitine,	   C14:0	   carnitine,	   C14:1	   carnitine,	   C14:2	   carnitine,	   C14-­‐OH	  
carnitine,	  C16:1	  carnitine	  and	  C16-­‐OH	  carnitine,	  as	  well	  as	   two	   long-­‐chain	  acylcarnitines:	  
C18:1	   carnitine	   and	   C18:2-­‐OH	   carnitine	   (Figure	   4.2	   and	   Table	   A4.7	   of	   appendices),	  
suggesting	   that	   not	   only	   VO2max	   determines	   FA-­‐related	   metabolite	   levels,	   but	   it	   also	  
counteracts	  age-­‐induced	  increase	  in	  FA-­‐related	  metabolites	  since	  the	  correlation	  between	  
age	  and	  all	  metabolites	  in	  Group	  IV	  were	  positive	  (as	  shown	  earlier).	  In	  other	  words,	  high	  
VO2max	  delays	  metabolic	  aging.	  The	  counteracting	  effect	  was	  dominant	   in	  medium-­‐chain	  
acylcarnitines	  because	  ANOVA	  showed	   that	   significant	   correlations	  of	   [age	  x	  VO2max	  per	  
FFM	  at	  baseline]	  were	  mostly	  found	  in	  those	  metabolites.	  
	  
4.3.5	  Effects	  of	  CR	  on	  age-­‐	  and	  VO2max-­‐related	  changes	  in	  metabolite	  levels	  
To	   assess	   how	   CR	   alters	   the	   effects	   of	   age	   and	   VO2max	   on	   metabolite	   levels,	   we	  
identified	  the	  effects	  of	  age,	  VO2max	  per	  FFM	  and	  [age	  x	  VO2max	  per	  FFM]	  on	  metabolite	  
levels	  only	  in	  obese	  subjects	  at	  baseline	  and	  compared	  with	  those	  effects	  in	  obese	  subjects	  
after	  CR.	  Because	  one	  of	  our	  objectives	  was	  to	  study	  effects	  of	  intrinsic	  VO2max,	  we	  always	  
used	  VO2max	  per	  FFM	  at	  baseline	  for	  the	  analysis	  even	  after	  CR.	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All	  metabolites	  and	  insulin	  resistance	  profiles	  after	  CR	  could	  be	  hierarchal	  clustered	  
into	   4	   groups	   according	   to	   their	   correlations	   with	   each	   other,	   and	   metabolites	   in	   each	  
group	  were	  identical	  as	  those	  of	  baseline	  condition	  (Figure	  4.1	  and	  Table	  4.3).	  As	  described	  
earlier,	  the	  effects	  of	  age	  and/or	  VO2max	  were	  considered	  significant	  using	  MANOVA,	  and	  
driving	  metabolites	  of	  the	  group	  were	  identified	  using	  ANOVA.	  
	  
4.3.5.1	  Effects	  of	  age	  on	  metabolite	  levels	  persist	  after	  CR.	  
From	  MANOVA,	  we	  found	  that	  correlations	  between	  age	  and	  all	  4	  metabolite	  groups	  
after	  CR	  were	  significant	  as	  in	  baseline	  condition	  (Figure	  4.4	  and	  Table	  A4.9	  of	  appendices).	  
Using	   ANOVA,	   Group	   I	   displayed	   significantly	   positive	   correlations	   of	   age	   vs.	   glutamine,	  
glycine	   and	   C20:0	   carnitine.	   In	   Group	   II,	   there	   was	   a	   significantly	   positive	   correlation	  
between	   age	   and	   glucose,	   but	   significantly	   negative	   correlations	   of	   age	   vs.	  
isoleucine+leucine	   and	   ketoisoleucine+ketoleucine	   were	   observed.	   The	   correlations	  
between	  age	  and	  all	  metabolites	   in	  Group	  III	  were	  all	  positive	  and	  the	  significances	  were	  
found	  in	  C3	  carnitine,	  C4	  carnitine	  as	  well	  as	  ratios	  of	  C3	  carnitine	  and	  C5	  carnitine	  to	  their	  
substrates.	   As	  with	   Group	   III,	   the	   correlations	   between	   age	   and	  metabolites	   in	   Group	   IV	  
were	   all	   positive	   and	   the	   significances	   were	   found	   in	   C2	   carnitine,	   C6	   carnitine,	   C8:0	  
carnitine,	  C10:0	  carnitine,	  C10:1	  carnitine,	  C12:0	  carnitine,	  C12:1	  carnitine,	  C14:0	  carnitine,	  
C14:1	   carnitine,	   C14:2	   carnitine,	   C16:1	   carnitine,	   C18:1	   carnitine,	   C18:2	   carnitine,	   C18:2-­‐
OH	  carnitine,	  C20:1	  carnitine,	  C20:2	  carnitine,	  C20:3	  carnitine	  and	  C20:4	  carnitine	  (Figure	  
4.4	  and	  Table	  A4.9	  of	  appendices).	  
	  
4.3.5.2	  CR	  overwhelms	  effects	  of	  VO2max	  on	  FA-­‐related	  metabolite	  levels.	  	  
From	   MANOVA,	   there	   was	   a	   significant	   correlation	   between	   VO2max	   per	   FFM	   at	  
baseline	  and	  group	   IV	   that	  mainly	  consists	  of	  FA-­‐related	  metabolites	   in	  obese	  subjects	  at	  
baseline	  (Figure	  4.3	  and	  Table	  A4.8	  of	  appendices).	  Using	  ANOVA,	  there	  were	  significantly	  
negative	   correlations	   between	   VO2max	   per	   FFM	   at	   baseline	   and	   C2	   carnitine	   as	   well	   as	  
several	   medium-­‐chain	   acylcarnitines	   including	   C6	   carnitine,	   C12:0	   carnitine,	   C12-­‐OH	  
carnitine,	   C14:0	   carnitine,	   C14-­‐OH	   carnitine	   and	   C16-­‐OH	   carnitine.	   However,	   the	  
significance	   was	   not	   found	   in	   obese	   subjects	   after	   CR	   (Figure	   4.4	   and	   Table	   A4.9	   of	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appendices),	  suggesting	  that	  CR	  weakened	  the	  effects	  of	  VO2max	  on	  FA-­‐related	  metabolite	  
levels.	  
	  
4.3.5.3	  CR	  also	  weakens	  the	  counteracting	  effects	  of	  VO2max	  on	  age-­‐induced	  increase	  in	  FA-­‐
related	  metabolites.	  	  	  
From	  MANOVA,	   there	  was	  a	   trend	  of	  correlation	  (p-­‐value	  =	  0.116)	  between	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]	  and	  Group	  IV	  that	  mainly	  consists	  of	  FA-­‐related	  metabolites	  
in	  obese	  subjects	  at	  baseline	  (Figure	  4.3	  and	  Table	  A4.8	  of	  appendices).	  Using	  ANOVA,	  there	  
were	   significantly	  negative	   correlations	  of	   several	  medium-­‐chain	  acylcarnitines	   including	  
C6	   carnitine,	   C8:0	   carnitine,	   C10:0	   carnitine,	   C10:1	   carnitine,	   C12:0	   carnitine,	   C12:1	  
carnitine,	   C12-­‐OH	   carnitine,	   C14:0	   carnitine,	   C14:1	   carnitine,	   C14:2	   carnitine,	   C16:1	  
carnitine	  and	  C16-­‐OH	  carnitine,	  as	  well	  as	  2	  long-­‐chain	  acylcarnitines:	  C18:2-­‐OH	  carnitine	  
and	  C20:4	   carnitine	   (Figure	   4.3	   and	  Table	  A4.8	   of	   appendices).	   This	   counteracting	   effect	  
was	   dominant	   in	   medium-­‐chain	   acylcarnitines	   because	   ANOVA	   showed	   that	   significant	  
correlations	  of	  [age	  x	  VO2max	  per	  FFM	  at	  baseline]	  were	  mostly	  found	  in	  those	  metabolites.	  
However,	  the	  trend	  of	  correlation	  was	  not	  found	  (p-­‐value	  =	  0.494)	  in	  obese	  subjects	  after	  
CR	   (Figure	   4.4	   and	   Table	   A4.9	   of	   appendices),	   suggesting	   that	   CR	   weakened	   the	  
counteracting	  effects	  of	  VO2max	  on	  age-­‐induced	  increase	  in	  FA-­‐related	  metabolites.	  
	  
4.3.6	  Not	  only	  high	  VO2max,	  but	  CR	  also	  delays	  age-­‐induced	  increase	  in	  medium-­‐chain	  
acylcarnitines.	  
As	   shown	   earlier,	   high	   VO2max	   delays	   metabolic	   aging,	   especially	   age-­‐induced	  
increase	   in	  medium-­‐chain	   acylcarnitines.	   Indeed,	   at	   any	   age,	   people	  with	   higher	  VO2max	  
have	   lower	   levels	   of	   medium-­‐chain	   acylcarnitines.	   Because	   several	   medium-­‐chain	  
acylcarnitine	   levels	   were	   significantly	   lower	   after	   CR	   including	   C6:0	   carnitine,	   C12:0	  
carnitine,	  C12:1	  carnitine,	  and	  C14:0	  carnitine	  (Figure	  4.5),	  it	  is	  suggestive	  that	  CR	  acts	  like	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4.4	  Discussion	  
Using	  quantitative	  targeted	  metabolomics,	  we	  identified	  expected	  changes	  in	  AA	  and	  
FA	  metabolism	  due	  to	  obesity	  and	  CR,	  as	  well	  as	  assessed	  the	  effects	  of	  age	  and	  VO2max	  on	  
metabolites	   and	   how	   these	   factors	   interacted.	   To	   reduce	   metabolite	   variation	   between	  
subjects	  and	  before	  and	  after	  CR,	  we	  provided	  every	  subject	  with	  a	  personalized	  diet	  plan	  
to	  reduced	  diet-­‐	  and	  energy-­‐related	  changes	  in	  metabolite	  levels	  to	  increase	  our	  ability	  to	  
see	   changes	   related	   to	   age	   and	  VO2max.	   All	   studies	  were	   done	   on	   fasting	   plasma.	   In	   the	  
fasting	   state,	  more	   FAs	   and	  many	  AAs	   are	   entering	   the	   blood,	   increasing	   delivery	   to	   the	  
tissues	  for	  oxidation.	  This	  state	  provides	  an	  ideal	  state	  to	  probe	  whole	  body	  mitochondrial	  
oxidative	  capacity.	  	  	  	  
We	   found	   that	   VO2max	   per	   FFM	   was	   lower	   in	   the	   obese	   group,	   consistent	   with	  
several	  previous	  cross-­‐sectional	  and	  longitudinal	  studies	  which	  found	  that	  higher	  VO2max	  
is	   associated	   with	   lower	   BMI	   in	   both	   lean	   and	   obese	   humans	   (35-­‐40).	   	   CR	   slightly,	   but	  
significantly	  increased	  VO2max	  per	  FFM	  in	  our	  obese	  subjects	  as	  previously	  found	  (41,	  42)	  
and	   likely	  was	  due	   to	  an	   increase	   in	  pulmonary	  (43-­‐46)	  and	  cardiac	  (43,	  47-­‐49)	   function	  
following	  to	  weight	  loss.	  However,	  the	  VO2max	  after	  CR	  was	  highly	  correlated	  to	  pre-­‐weight	  
loss	  levels,	  consistent	  with	  a	  genetically	  driven	  component	  to	  VO2max	  (1,	  50-­‐59).	  	  	  
Changes	   in	   several	   AAs	   and	   BCAAs	   intermediates	   due	   to	   obesity	   and	   CR	   were	  
demonstrated	   in	  this	  study.	  Consistent	  with	   insulin	  resistance	  profiles,	   insulin	  resistance-­‐
related	   AAs	   and	   their	   intermediates	   were	   significantly	   higher	   in	   obese	   subjects,	   but	   CR	  
decreased	  their	  levels.	  It	  was	  not	  surprising	  that	  our	  results	  were	  consistent	  with	  previous	  
human	   studies	   (21,	   60,	   61).	   Oppositely,	   insulin	   sensitivity-­‐related	   AAs	   (asparagine,	  
glutamine-­‐to-­‐glutamic	  acid	  ratio,	  glutamine,	  glycine	  and	  serine)	  were	  significantly	  lower	  in	  
obese	   subjects,	   yet	   CR	   increased	   their	   levels.	   Our	   results	   were	   again	   consistent	   with	   a	  
previous	  study	  in	  humans	  (21).	  To	  our	  knowledge,	  this	  is	  the	  first	  study	  that	  infers	  fluxes	  to	  
assess	  mitochondrial	  capacity	  of	  BCAA	  catabolism	  in	  humans.	  The	  inferred	  fluxes	  showed	  
that	  obesity	  was	  associated	  with	  decrease	   in	  mitochondrial	   capacity	  of	  BCAA	  catabolism,	  
but	   this	   was	   improved	   after	   CR.	   This	   effect	   of	   CR	   is	   possibly	   not	   only	   due	   to	   improved	  
insulin	   sensitivity,	   but	   also	   increased	   mitochondrial	   protein	   deacetylation	   since	  
mitochondrial	   protein	   deacetylation	   was	   found	   to	   be	   associated	   with	   increased	  
mitochondrial	   capacity	   of	   BCAA	   catabolism	   (62)	   and	   because	   CR	   can	   increase	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mitochondrial	  protein	  deacetylation	  via	  SIRT1	  (63)	  and	  SIRT3	  (64)	  activation.	  
Unlike	  other	  previous	   studies	   in	  humans	   (21,	  65),	  we	  did	  not	   see	  elevated	   fasting	  
plasma	  FFAs	  in	  obese	  participants	  and	  no	  significant	  changes	  in	  those	  levels	  after	  CR.	  This	  
may	  be	  due	  to	  the	  isocaloric	  diet	  prescription	  that	  the	  participants	  were	  provided.	  	  Despite	  
similar	  levels	  of	  fasting	  FFAs	  between	  non-­‐obese	  and	  obese	  subjects,	  we	  found	  lower	  long-­‐
chain	  acylcarnitine	  levels	  as	  well	  as	   long-­‐chain	  acylcarnitine-­‐to-­‐its	  FFA	  substrate	  ratios	  in	  
the	  obese	  group,	  increasing	  after	  CR.	  The	  apparent	  whole	  body	  reduction	  in	  FA	  influx	  into	  
mitochondria	  may	  be	  due	  to	  decreases	  in	  skeletal	  muscle	  uptake	  of	  FAs	  (66),	  increases	  in	  
skeletal	  muscle	  malonyl-­‐CoA	   (67,	   68),	   as	   well	   as	   reduction	   in	   AMPK	   (69-­‐71)	   and	   CPT-­‐1	  
activity	  in	  skeletal	  muscle	  of	  obese	  individuals	  (69-­‐72),	  with	  improved	  influx	  after	  CR.	  	  As	  
an	   indicator	   of	   mitochondrial	   FA	   oxidative	   capacity,	   we	   found	   C8:0	   carnitine-­‐to-­‐C10:0	  
carnitine	   ratio	   was	   significantly	   higher	   in	   obese	   subjects	   compared	   to	   non-­‐obese,	   with	  
significant	   reduction	   in	   the	   ratio	  after	  CR.	  This	   suggests	   that	  despite	  higher	   influx	  of	  FAs	  
into	   the	  mitochondria,	   CR	   improves	   the	   capacity	   of	   the	  mitochondria	   to	   oxidize	   the	   FAs.	  	  
Reduction	  in	  several	  medium-­‐chain	  acylcarnitine	  levels	  despite	  higher	  levels	  of	  long-­‐chain	  
acylcarnitines	  after	  CR	  also	  reflects	   improvement	  of	   incomplete	  FAO	  by	  CR.	   	  Whether	  the	  
relative	   decrease	   in	   FAO	   reflects	   a	   ‘defect’	   in	   mitochondrial	   function	   in	   obesity	   (73),	   or	  
simply	  reflect	  the	  mismatch	  of	  fuel	  delivery	  to	  mitochondria	  to	  need	  for	  ATP	  generation	  is	  
somewhat	  controversial	   (74),	   the	   improvement	  of	  FAO	   in	  CR	  would	  suggest	  any	   intrinsic	  
defect	   is	   amplified	   by	   nutrient	   overload	   and	   improved	   with	   CR.	   	   Reduction	   in	   several	  
medium-­‐chain	   acylcarnitine	   levels	  despite	  higher	   levels	   of	   long-­‐chain	   acylcarnitines	   after	  
CR	  also	  reflects	   improvement	  of	   incomplete	  FAO	  by	  CR.	  As	  with	  the	  effect	  of	  CR	  on	  BCAA	  
catabolism,	   the	   effect	   of	   CR	   on	   FAO	   is	   possibly	   associated	  with	   increased	  mitochondrial	  
protein	  deacetylation	  since	  mitochondrial	  protein	  deacetylation	  was	  found	  to	  be	  associated	  
with	   increased	   mitochondrial	   capacity	   of	   FAO	   (62)	   and	   because	   CR	   can	   increase	  
mitochondrial	   protein	   deacetylation	   via	   SIRT1	   (63)	   and	   SIRT3	   (64)	   activation.	   Although	  
medium-­‐chain	   acylcarnitine	   levels	   decreased	   after	   CR,	   we	   found	   higher	   levels	   of	   those	  
metabolites	   in	   non-­‐obese	   participants.	   This	  may	   be	   due	   to	  much	   higher	   coming-­‐in	   of	   FA	  
substrates	  into	  the	  mitochondria	  as	  compared	  with	  those	  of	  obese	  subjects	  at	  both	  baseline	  
and	  after	  CR,	  leading	  to	  higher	  FA	  intermediates	  despite	  more	  complete	  FAO	  (29),	  but	  the	  
significantly	  lower	  plasma	  C8:0	  carnitine-­‐to-­‐C10:0	  carnitine	  ratio	  in	  non-­‐obese	  than	  either	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the	  obese	  or	  CR	  plasma	  indicates	  a	  better	  capacity	  for	  FAO.	  Further	  fluxomic	  study	  will	  be	  
helpful	  to	  prove	  this	  explanation.	  
Our	  primary	  goal	  in	  this	  study	  was	  to	  ascertain	  evidence	  that	  VO2max	  could	  alter	  the	  
age-­‐related	  changes	  in	  mitochondrial	  metabolism.	  A	  previous	  study	  in	  human	  also	  revealed	  
that	   people	   with	   high	   cardiorespiratory	   fitness	   (classified	   using	   metabolic	   equivalent	  
(METs))	  had	  a	  delayed	  development	  of	  dyslipidemia	  (75)	  and	  hypertension	  (76)	  compared	  
with	  their	  lower	  counterparts	  and	  a	  separate	  studies	  found	  that	  people	  with	  higher	  VO2max	  
had	   slower	   increase	   in	   age-­‐related	   arterial	   stiffness	   (77)	   after	   2	   years	   of	   follow-­‐up.	   Our	  
models	  suggest	  that	  higher	  VO2max	  has	  an	  effect	  to	  delay	  metabolic	  aging.	  Using	  MANOVA	  
to	   leverage	  the	  correlations	  of	  plasma	  metabolites,	  we	  found	  that	  each	  of	   the	  4	  groups	  of	  
identified	  metabolites	  varied	  with	  age	  and	  2	  of	  4	  groups	  varied	  with	  VO2max	  after	  adjusting	  
for	  clinical	  variables	  and	  age	  when	  assessed	  over	  both	  non-­‐obese	  and	  obese	  groups	  (Figure	  
4.2).	  These	  groups	  contained	  AAs	  that	  previously	  proved	  associated	  with	  insulin	  resistance	  
(BCAA	   and	   aromatic	   AAs	   (Group	   II))	   as	   well	   as	   acylcarnitines	   (Group	   IV).	   This	   result	  
indicates	  that	  age	  affects	  metabolism,	  independent	  of	  VO2max	  and	  further,	  VO2max	  has	  an	  
important	  effect	  on	  metabolite	  levels,	  independent	  of	  age,	  BMI,	  sex,	  race	  or	  diabetes	  status.	  
The	  effect	  of	  higher	  VO2max	  to	  modulate	  age-­‐dependent	  changes	  in	  metabolite	  levels	  was	  
most	   robustly	   seen	   in	   FA-­‐related	   metabolites	   levels	   in	   which	   rose	   with	   age	   and	   were	  
reduced	   in	   the	   face	   of	   VO2max.	   CR	   reversed	   the	   alterations	   in	   metabolites	   that	   were	  
observed	  in	  obesity,	  with	  the	  exception	  of	  medium-­‐chain	  acylcarnitine	  levels	  (Figure	  4.5).	  
However,	   FA-­‐related	   metabolites	   were	   not	   significantly	   affected	   by	   VO2max	   after	   CR	  
(Figure	   4.4),	   suggesting	   that	   the	   effect	   of	   VO2max	   on	   metabolite	   levels	   are	   through	   a	  
separate	  pathway	  from	  that	  seen	  in	  CR.	  	  Indeed,	  this	  is	  consistent	  with	  the	  observation	  that	  
CR	   is	   associated	   with	   improvements	   in	   insulin	   sensitivity	   but	   is	   not	   associated	   with	  
mitochondrial	  function	  (78).	  	  	  
How	   does	   higher	   VO2max	   alter	   age-­‐related	   changes	   in	   metabolite	   levels	   and	   are	  
these	  changes	  indicative	  of	  the	  apparent	  longevity	  effect	  of	  higher	  VO2max?	  	  These	  studies	  
were	   prompted	   by	   our	   findings	   in	   the	   rat	   genetic	   model	   of	   aerobic	   treadmill	   running	  
capacity	  (79).	  	  The	  HCR	  rats	  have	  a	  greater	  capacity	  for	  FAO	  during	  exercise	  (62)	  and	  have	  
an	   increase	   in	   gene	   expression	   (7)	   and	   proteomic	   profiles	   (62)	   that	   are	   associated	  with	  
upregulation	  of	  genes	  for	  FAO	  and	  BCAA	  catabolism.	  	  Importantly,	  the	  increased	  longevity	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in	  HCR	  rats	  (6)	  is	  associated	  with	  a	  delay	  in	  the	  age-­‐dependent	  changes	  in	  gene	  expression	  
(7).	  	  In	  humans,	  studies	  have	  shown	  that	  higher	  VO2max	  is	  associated	  with	  increased	  ability	  
to	  oxidize	  FAs	  (80)	  and	  an	  increased	  expression	  of	  genes	  associated	  with	  OXPHOS	  and	  FAO	  
is	  found	  in	  human	  skeletal	  muscle	  of	  individuals	  with	  higher	  VO2max	  (81).	  One	  possibility	  
is	  that	  changes	  in	  fuel	  selection	  towards	  FAs	  is	  associated	  with	  reduced	  generation	  of	  ROS	  
and	  it	  has	  been	  suggested	  that	  this	  occurs	  through	  an	  increased	  proportion	  of	  electron	  flux	  
through	  complex	  II,	  bypassing	  ROS	  production	  associated	  complex	  I	  (82).	  	  
	  
4.5	  Summary	  	  
In	   summary,	   we	   present	   the	   first	   evidence	   that	   in	   people,	   a	   higher	   VO2max	   is	  
associated	  with	  delayed	  metabolic	  aging	  and	  this	  effect	  may	  be	  separate	  from	  the	  effect	  of	  
CR	   to	  alter	  aging.	   	  The	  primary	  effect	   is	   seems	   to	  be	  on	  mitochondrial	   capacity	   for	  BCAA	  
catabolism	  and	  FAO.	   	  CR	  also	  improves	  metabolism,	  and	  seems	  to	  improve	  metabolic	  age.	  
Thus,	  high	  VO2max	  and	  CR	  can	  delay	  metabolic	  aging,	  consistent	  with	  a	  ‘younger	  metabolic	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Table	   4.1	   Participant	   characteristics	   and	   non-­‐metabolite	   parameters.	   Data	   were	   reported	   as	   average	  
(minimum-­‐maximum).	  $	  =	  p-­‐value	  <0.050;	  NA	  =	  not	  applicable	  
Character-­‐




















subjects	   28	   124	   NA	   NA	   NA	  
Male/female	  	   14/14	   56/68	   NA	   NA	   NA	  
Race	  (n)	  
	  	  Caucasian	  
	  	  African	  	  
	  	  American	  
	  	  Hawaiian	  
































	  	  	  Male	  
	  	  	  Female	  






















	  	  	  Male	  
	  	  	  Female	  


























loss	  after	  CR	  
	  	  	  Male	  
	  	  	  Female	  



























type	  2	  DM	  
	  	  	  Male	  
	  	  	  Female	  































	  	  	  Male	  
	  	  	  Female	  



















































	  	  	  Male	  
	  	  	  Female	  


































	  	  	  Male	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  All	  	  	   49.8	  (33.1-­‐67.6)	   62.6	  (42.0-­‐101.1)	   58.8	  (38.9-­‐90.1)	   <0.001$	   <0.001$	   <0.001$	  
Fat	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  

























%	  Total	  body	  
fat	  
	  	  	  Male	  
	  	  	  Female	  



































	  	  	  Male	  
	  	  	  Female	  















































	  	  	  Male	  
	  	  	  Female	  



















































	  	  	  Male	  
	  	  	  Female	  







































































	  	  	  Male	  
	  	  	  	  
	  	  	  Female	  
	  	  



























































free	  mass	  	  
(kCal/kg)	  
	  	  	  Male	  
	  	  	  Female	  












































































	  	  	  Male	  
	  	  	  Female	  























	  	  	  Male	  
	  	  	  Female	  













































	  	  	  Male	  
	  	  	  Female	  



































	  	  	  Male	  
	  	  	  
	  	  	  Female	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Table	  4.2	  Concentration	  of	  metabolites.	  Data	  were	  reported	  as	  average±SEM.	  $	  =	  p-­‐value	  <0.050	  




















	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  

























Aspartic	  acid	  (μM)	   	  
	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  
































	  	  Male	  
	  	  Female	  


























glutamic	  acid	  ratio	  
	  	  Male	  
	  	  Female	  
































	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  
































	  	  Male	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  All	   186.10±4.40	   213.51±2.67	   204.39±3.14	   <0.001$	   0.009$	   0.001$	  
Methionine	  (μM)	  
	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  
































	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  


























	  	  Male	  
	  	  Female	  














































	  	  Male	  
	  	  Female	  
































	  	  Male	  
	  	  Female	  













































Oleic	  acid	  (μM)	  
	  	  Male	  
	  	  Female	  

























Palmitic	  acid	  (μM)	  
	  	  Male	  
	  	  Female	  













































	  	  Male	  
	  	  Female	  

























C2	  carnitine	  (μM)	  
	  	  Male	  
	  	  Female	  

























C3	  carnitine	  (nM)	  
	  	  Male	  
	  	  Female	  

























C4	  carnitine	  (nM)	  
	  	  Male	  
	  	  Female	  

























C5	  carnitine	  (nM)	  
	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  































C6	  carnitine	  (nM)	  
	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	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  Male	  
	  	  Female	  






















	  	  Male	  
	  	  Female	  







































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	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C16:0	  carnitine	  
(nM)	  
	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	  
	  	  Female	  

































	  	  Male	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  All	   1.99±0.12	   2.20±0.06	   2.38±0.07	   0.116	   0.016$	   0.002$	  
C20:4	  carnitine	  
(nM)	  
	  	  Male	  
	  	  Female	  
























































	  	  Male	  	  
	  	  Female	  






































to-­‐oleic	  acid	  ratio	  
(x10-­‐4)	  
	  	  Male	  
	  	  Female	  





































C3	  and	  C5	  
carnitine-­‐to-­‐
substrate	  ratios	  




















valine	  ratio	  	  
(x10-­‐3)	  
	  	  Male	  
	  	  Female	  








































	  	  Male	  
	  	  Female	  








































	  	  Male	  
	  	  Female	  







































toleucine	  ratio	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Table	   4.3	   Groups	   of	   metabolites	   and	   insulin	   resistance	   profiles	   according	   to	   their	   correlations	   with	   each	  
other	  
Groups	   Lists	  of	  metabolites	  and	  insulin	  resistance	  profiles	  	  
I	   • Arginine,	  asparagine,	  glutamine,	  glutamine-­‐to-­‐glutamic	  acid	  ratio,	  glycine,	  histidine,	  serine,	  
threonine	  
• C18:0	  carnitine,	  C20:0	  carnitine	  	  
• C16:0	  carnitine-­‐to-­‐palmitic	  acid	  ratio,	  C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  
II	   • Glucose,	  insulin,	  HOMA-­‐IR	  	  
• Alanine,	   aspartic	   acid,	   glutamic	   acid,	   isoleucine+leucine,	   lysine,	   methionine,	   proline,	  
phenylalanine,	  tryptophan,	  tyrosine,	  valine	  
• Ketoisoleucine+ketoleucine,	  ketovaline	  
• C5-­‐DC	  carnitine	  
• C8:0-­‐to-­‐C10:0	  carnitine	  ratio	  
III	   • L-­‐carnitine,	  C3	  carnitine,	  C4	  carnitine,	  C5	  carnitine,	  C8:1	  carnitine	  
• C3	   carnitine-­‐to-­‐valine	   ratio,	   C3	   carnitine-­‐to-­‐ketovaline	   ratio,	   C5	   carnitine-­‐to-­‐
isoleucine+leucine	  ratio,	  C5	  carnitine-­‐to-­‐ketoisoleucine+ketoleucine	  ratio	  
IV	   • Palmitic	  acid,	  oleic	  acid	  
• C2	  carnitine,	  C6	  carnitine,	  C8:0	  carnitine,	  C10:0	  carnitine,	  C10:1	  carnitine,	  C12:0	  carnitine,	  
C12:1	   carnitine,	   C12-­‐OH	  carnitine,	   C14:0	   carnitine,	   C14:1	   carnitine,	   C14:2	   carnitine,	   C14-­‐
OH	   carnitine,	   C16:0	   carnitine,	   C16:1	   carnitine,	   C16-­‐OH	   carnitine,	   C18:1	   carnitine,	   C18:2	  
















	  	  Male	  
	  	  Female	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Figure	  4.2	  Correlations	  of	  metabolites	  and	  insulin	  resistance	  profiles	  at	  baseline	  	  (non-­‐obese	  and	  obese	  subjects)	  
vs.	  age,	  VO2	  max	  per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline].	  *	  =	  p-­‐value	  of	  ANOVA;	  $	  =	  p-­‐value	  of	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Figure	  4.3	  Correlations	  of	  metabolites	  and	  insulin	  resistance	  profiles	  in	  obese	  subjects	  at	  baseline	  vs.	  age,	  VO2	  max	  
per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline].	  *	  =	  p-­‐value	  of	  ANOVA;	  $	  =	  p-­‐value	  of	  ANOVA	  <0.050;	  #	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Figure	  4.4	  Correlations	  of	  metabolites	  and	  insulin	  resistance	  profiles	  in	  obese	  subjects	  after	  CR	  vs.	  age,	  VO2	  max	  
per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline].	  *	  =	  p-­‐value	  of	  ANOVA;	  $	  =	  p-­‐value	  of	  ANOVA	  <0.050;	  #	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Effects	  of	  intrinsic	  cardiorespiratory	  fitness	  
and	  caloric	  restriction	  on	  mitochondrial	  DNA	  
and	  metabolites	  in	  human	  skeletal	  muscle	  
	  
5.1	  Introduction	  
The	  studies	  presented	  in	  chapter	  4	  demonstrate	  that	  1)	  metabolism	  as	  reflected	  in	  
the	   metabolome,	   changes	   with	   age,	   2)	   high	   intrinsic	   cardiorespiratory	   fitness	   (VO2max)	  
was	   directly	   associated	  with	  more	   complete	   fatty	   acid	   oxidation	   (FAO)	   and	   delayed	   age-­‐
related	  incomplete	  FAO,	  and	  3)	  caloric	  restriction	  (CR)	  was	  associated	  with	  more	  complete	  
FAO,	  i.e.	  delayed	  metabolic	  aging.	  In	  brief,	  the	  effects	  of	  high	  VO2max	  and	  CR	  are	  consistent	  
with	   a	   younger	  metabolic	   state.	   To	   understand	   how	  metabolism	  decreases	  with	   age	   and	  
how	  high	  VO2max	  and	  CR	  delay	  metabolic	  aging,	  in-­‐depth	  study	  of	  skeletal	  muscle,	  a	  major	  
organ	   that	   influences	   VO2max	   and	   is	   responsible	   for	   nutrient	   metabolism,	   is	   necessary.	  
Here	   we	   studied	   mitochondrial	   DNA	   (mtDNA)	   deletion	   ratio	   because	   mtDNA	   can	   be	  
damaged	  (deleted)	  by	  aging-­‐induced	  oxidative	  stress	  (1-­‐4).	  We	  also	  studied	  mtDNA	  count	  
number,	  which	  is	  an	  indicator	  of	  mitochondrial	  biogenesis	  (5)	  and	  declines	  with	  age	  (6-­‐9).	  	  
Previous	   work	   in	   humans	   has	   found	   that	   mtDNA	   deletion	   increases	   with	   age,	  
especially	  at	  the	  major	  arc	  region,	  possibly	  due	  to	  aging-­‐induced	  oxidative	  stress	  (10-­‐17).	  A	  
study	   in	   human	   plasma	   demonstrated	   that	   higher	   VO2max	   was	   associated	   with	   lower	  
markers	  of	  oxidative	   stress	   (MDA	  and	  8-­‐iso-­‐PGF2α)	  as	  well	   as	  markers	  of	  oxidative	  DNA	  
damage	  (8-­‐OHdG)	  (18).	  In	  the	  rat	  genetic	  model	  of	  aerobic	  treadmill	  running	  capacity,	  rats	  
selected	   for	   increased	   VO2max	   (HCR	   rats)	   exhibited	   lower	   4-­‐HNE	   (19)	   and	   8dOHG	   (20),	  
markers	  of	  oxidative	  stress	  and	  oxidative	  DNA	  damage,	  respectively,	  in	  skeletal	  muscle.	  CR	  
prevented	  aging-­‐induced	  oxidative	  damage	  to	  mouse	  skeletal	  muscle	  mitochondria	  as	  well	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(21).	   In	   addition,	   livers	   of	   CR	   rats	   displayed	   lower	   8-­‐oxo-­‐dG,	   a	  marker	   of	   oxidative	  DNA	  
damage,	  than	  those	  of	  the	  control	  rats	  (22).	  	  
Research	  in	  human	  skeletal	  muscle	  (23),	  rat	  skeletal	  muscle	  (24)	  and	  rat	  liver	  (24)	  
have	   demonstrated	   that	  mtDNA	   count	   number,	   an	   indicator	   of	  mitochondrial	   biogenesis	  
(5),	  decreases	  with	  age.	  A	  positive	  correlation	  between	  mtDNA	  count	  number	  and	  VO2max	  
was	  observed	  in	  human	  skeletal	  muscle	  (23).	  MtDNA	  count	  number	  was	  higher	  in	  skeletal	  
muscle	   of	   HCR	   rats	   as	   well	   (25).	   Life-­‐long	   CR	   reversed	   the	   aging-­‐induced	   decrease	   in	  
mtDNA	   count	   number	   in	   liver	   and	   skeletal	   muscle	   of	   rats	   and	   increased	   mtDNA	   count	  
number	  in	  rat	  brain	  (24).	  	  
In	  this	  study,	  we	  tested	  the	  hypothesis	  that	  our	  observations	  in	  chapter	  4	  that	  high	  
VO2max	   and	   CR	   delay	   metabolic	   aging	   by	   slowing	   aging-­‐induced	   mtDNA	   deletion	   and	  
aging-­‐induced	   decreases	   mitochondrial	   biogenesis,	   which	   potentially	   leads	   to	   good	  
metabolic	  health	  and	  longevity.	  In	  addition	  to	  metabolomic	  analyses,	  we	  evaluated	  mtDNA	  
deletion	   ratio	   and	   mtDNA	   count	   number	   in	   skeletal	   muscle	   of	   obese	   participants	   both	  
before	  and	  after	  CR.	  Non-­‐obese	  subjects	  served	  as	  controls.	  	  
	  
5.2	  Materials	  and	  methods	  
Enrollment	   criteria,	   CR	   protocol,	   body	   composition	   assessment,	   exercise	   testing,	  
mixed	  meal	  tolerance	  test	  (MMTT)	  as	  well	  as	  plasma	  glucose	  and	  plasma	  insulin	  analyses	  
techniques	  were	  described	  in	  chapter	  4.	  
	  
5.2.1	  Skeletal	  muscle	  biopsy	  and	  metabolite	  extraction	  in	  skeletal	  muscle	  	  
Vastus	  lateralis	  muscle	  was	  obtained	  via	  suction-­‐modified	  Bergström	  muscle	  biopsy	  
technique	  at	  120-­‐min	  of	  MMTT,	  flash	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C.	  Nine	  to	  
14	   mg	   of	   frozen	   skeletal	   muscle	   tissues	   were	   extracted	   by	   adding	   270	   to	   420	   μl	  
(approximately	   30	   μl	   per	   1	   mg	   of	   skeletal	   muscle	   tissue)	   of	   extraction	   solvent	   (7:2:1	  
methanol:water:chloroform)	   containing	   an	   internal	   standard	   mixture	   (see	   Table	   A5.1	   of	  
appendices).	  The	  samples	  were	  sonicated	  for	  30	  seconds,	  allowed	  to	  rest	  on	  ice	  for	  5	  min,	  
and	   then	   centrifuged	   at	   4	   °C	   for	   10	   min.	   The	   supernatant	   was	   transferred	   to	   an	  
autosampler	  vial	   for	  analysis	  via	  mass	  spectrometry.	  The	   tissue	  pellet	  was	  dried	  at	  45	  °C	  
for	  data	  normalization	  and	  mtDNA	  analysis.	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5.2.2	  Mass	  spectrometry	  (MS)	  protocols	  for	  metabolomics	  
A	  targeted	  metabolomic	  approach	  was	  used	  to	  study	  metabolites	  listed	  in	  Table	  A5.2	  
of	   appendices.	   All	   targeted	   metabolites	   were	   analyzed	   by	   liquid	   chromatography-­‐mass	  
spectrometry	   (LC-­‐MS)	   using	   an	   Agilent	   1200	   LC	   connected	   to	   an	   Agilent	   6410	   triple	  
quadrupole	  MS.	  MS	  parameters	  were	  as	  follows:	  capillary	  voltage	  4000	  V,	  gas	  temperature	  
325	  °C,	  gas	  flow	  10	  l/min,	  and	  nebulizer	  pressure	  40	  psi.	  For	  analysis	  of	  amino	  acids	  (AAs),	  
oleic	   acid,	   glycolysis	   metabolites,	   TCA	   cycle	   metabolites	   and	   nucleotides,	   hydrophilic	  
interaction	  chromatography	  was	  performed	  using	  a	  Phenomenex	  Luna	  NH2	  column,	  3	  μm	  
particle	  size,	  150	  mm	  x	  1	  mm	  inner	  diameter	  (i.d.)	  (Torrance,	  CA).	  The	  flow	  rate	  was	  0.07	  
ml/min	  at	  0	  to	  21	  min	  and	  0.09	  ml/min	  at	  21	  to	  27	  min.	  The	  gradient	  consisted	  of	  a	  10-­‐min	  
linear	   ramp	   from	  80	   to	   0%	  B,	   4	  min	   at	   0%	  B,	   and	   13	  min	   of	   re-­‐equilibration	   at	   80%	  B.	  
Detection	  was	  performed	  using	  multiple	  reaction	  monitoring	  (MRM)	  in	  negative	  ion	  mode	  
described	   in	  Table	  A5.3	   of	   appendices.	  Mobile	   phase	  A	  was	   5	  mM	  ammonium	  acetate	   in	  
water	   with	   pH	   9.9	   and	   mobile	   phase	   B	   was	   acetonitrile.	   For	   acylcarnitine	   analysis,	  
reversed-­‐phase	  liquid	  chromatography	  (RPLC)	  was	  performed	  using	  a	  Waters	  Acquity	  HSS	  
T3	  column,	  1.8	  μm	  particle	  size,	  2.1	  x	  100	  mm	  i.d.	   (Milford,	  MA),	  with	  a	   flow	  rate	  of	  0.25	  
ml/min.	  The	  gradient	  consisted	  of	  a	  7-­‐min	  linear	  ramp	  from	  0	  to	  80%	  B,	  3	  min	  at	  100%	  B,	  
and	   5	   min	   of	   re-­‐equilibration	   at	   0%	   B.	   MRM	   in	   positive	   ion	   mode	   was	   used	   with	  
precursor/product	   ion	   transitions	   specified	   elsewhere	   (26).	  Mobile	  phase	  A	  was	  0.1%	  of	  
formic	  acid	  in	  water	  and	  mobile	  phase	  B	  was	  0.1%	  of	  formic	  acid	  in	  acetonitrile.	  	  
All	  untargeted	  metabolites	  were	  analyzed	  by	  LC-­‐MS	  using	  an	  Agilent	  1260	   infinity	  
LC	   connected	   to	   an	   Agilent	   6520	   quadrupole	   time-­‐of-­‐flight	   MS.	   MS	   parameters	   were	   as	  
follows:	   full-­‐scan	   negative	   ion	  mode	   (m/z	   50	   to	   1,200),	   acquisition	   rate	   1	   spectrum/sec,	  
capillary	  voltage	  3500	  V,	  gas	  temperature	  350	  °C,	  drying	  gas	  10	  l/min,	  nebulizer	  pressure	  
20	   psig,	   and	   reference	   mass	   correction	   enabled.	   RPLC	   was	   performed	   using	   a	   Waters	  
Acquity	  HSS	  T3	  column,	  1.8	  μm	  particle	  size,	  2.1	  x	  100	  mm	  i.d.	  (Milford,	  MA),	  with	  a	  flow	  
rate	  of	  0.25	  ml/min.	  The	  gradient	  consisted	  of	  a	  7-­‐min	  linear	  ramp	  from	  0	  to	  99%	  B,	  3	  min	  
at	  99%	  B,	  and	  5	  min	  of	  re-­‐equilibration	  at	  0%	  B.	  Mobile	  phase	  A	  was	  0.1%	  of	  formic	  acid	  in	  
water	  and	  mobile	  phase	  B	  was	  0.1%	  of	  formic	  acid	  in	  8:2	  of	  isopropanol:acetonitrile.	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5.2.3	  Targeted	  metabolite	  quantification	  
Peak	   areas	   of	   targeted	   metabolites	   were	   obtained	   using	   Agilent	   Masshunter	  
Quantitative	   Analysis	   software	   for	   triple	   quadrupole	   MS	   version	   B.07.00.	   Peaks	   were	  
identified	   by	   comparison	   of	   accurate	   mass	   and	   retention	   time	   with	   those	   of	   authentic	  
standards	  analyzed	  using	  the	  same	  method.	  	  	  Peaks	  were	  quantified	  by	  peak	  area	  using	  the	  
‘Agile2’	   peak	   integrator.	   Concentrations	   of	   metabolites	   other	   than	   acylcarnitines	   with	  
exact-­‐matching	   internal	   standards	  were	   then	  quantified	  by	   calibration	   curves	  using	  peak	  
area	   ratios	   to	   their	   internal	   standards.	   Concentrations	   of	   metabolites	   other	   than	  
acylcarnitines	   without	   exact-­‐matching	   internal	   standards	   were	   quantified	   by	   method	   of	  
external	  calibration	  (see	  appendices)	  after	   instrument	  drift	  correction	  of	  their	  peak	  areas	  
using	   the	   quadratic	   drift-­‐correction	   (method	   described	   in	   chapter	   6).	   Metabolite	  
concentrations	   used	   for	   calibration	   curves	   are	   listed	   in	   Table	   A5.4	   of	   appendices.	  
Concentrations	   of	   acylcarnitine	   species	   presented	   in	   the	   internal	   standard	   mix	   (NSK-­‐B)	  
were	  quantified	  using	  peak	  area	  of	  unlabeled	  compound-­‐to-­‐peak	  area	  of	  internal	  standard	  
multiplied	   by	   concentration	   of	   internal	   standard.	   	   Concentrations	   of	   other	   acylcarnitine	  
species	  were	  quantified	  using	  peak	   area	   of	   biological	   compound-­‐to-­‐peak	   area	   of	   internal	  
standard	   with	   the	   closest	   matching	   retention	   time	   multiplied	   by	   concentration	   of	   the	  
internal	   standard.	   The	   concentrations	   of	   all	   targeted	   metabolites	   as	  𝜇M	   (pmol/𝜇l)	   were	  
then	  multiplied	  by	  the	  volume	  (µμl)	  of	  extraction	  solvent	  added	  to	  the	  sample	  and	  divided	  by	  
the	  dried	  skeletal	  muscle	  tissue	  mass.	  The	  finalized	  data	  were	  reported	  as	  pmol/mg.	  	  
	  
5.2.4	  Untargeted	  metabolite	  selection,	  quantification	  and	  annotation	  
Untargeted	   features	   were	   initially	   identified	   and	   their	   peak	   areas	   were	   initially	  
quantified	   using	   Profinder	   version	   B.08.00	   (Agilent	   Technologies,	   Santa	   Clara,	   CA).	   To	  
select	   candidate	   features	   for	   exact	  quantification,	  Pearson’s	   correlation	  was	   then	  used	   to	  
identify	   those	   features	   that	   correlated	   with	   age	   and	   metabolites,	   as	   well	   as	   between	  
VO2max	   per	   FFM.	   Features	   that	   were	   correlated	   with	   either	   age	   or	   VO2max	   per	   FFM	   at	  
baseline	   with	   p-­‐value	  ≤0.10	   were	   re-­‐quantified	   using	   Agilent	   Masshunter	   Quantitative	  
Analysis	   software	   for	   quadrupole	   time-­‐of-­‐flight	   MS	   version	   B.07.00.	   Peaks	   were	   re-­‐
quantified	   by	   peak	   area	   using	   the	   ‘Agile2’	   or	   ‘spectrum	   summation’	   peak	   integrator.	  
Duplicated	   features	   and	   noise	   spectra	   were	   visually	   identified	   and	   discarded	   during	   re-­‐
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quantitation.	   Peak	   areas	   of	   finally	   selected	   untargeted	   metabolites	   were	   corrected	   for	  
instrument	  drift	  using	  LOESS	  drift-­‐correction	  method	  described	  elsewhere	  (27).	  Then,	  the	  
corrected	   peak	   area	   was	   multiplied	   by	   the	   volume	   of	   extraction	   solvent	   added	   to	   the	  
sample	   and	   divided	   by	   the	   dried	   skeletal	   muscle	   tissue	   mass,	   the	   result	   of	   which	   was	  
termed	   the	   ‘normalized	   peak	   area’.	   Metabolite	   annotation	   was	   completed	   using	   Human	  
Metabolome	   Database	   (www.hmdb.ca)	   and	   LIPID	   MAPS	   Lipidomics	   Gateway	  
(www.lipidmaps.org).	  
	  
5.2.5	  mtDNA	  deletion	  ratio	  and	  mtDNA	  count	  number	  analyses	  
MtDNA	  deletion	  ratio	  and	  mtDNA	  count	  number	  were	  assessed	  in	  the	  dried	  skeletal	  
muscle	   tissue	   pellet.	   Total	   DNA	   was	   extracted	   using	   a	   DNeasy	   Blood	   and	   Tissue	   Kit	  
purchased	   from	   Qiagen	   (Valencia,	   CA).	   Using	   real-­‐time	   qPCR	   (Thermo	   Fisher	   Scientific	  
Applied	  Biosystems®	  7500),	  the	  cycling	  time	  of	  mtDNA	  at	  the	  major	  arc	  (mtDNA	  major	  arc;	  
targeted	  DNA),	  mtDNA	  at	   the	  minor	  arc	   (mtDNA	  minor	  arc;	  controlled	  DNA)	  and	  nuclear	  
DNA	  at	  the	  𝛽2M	  gene	  (nDNA;	  controlled	  DNA)	  were	  measured	  in	  duplicate	  in	  each	  sample.	  
The	  mixture	  for	  PCR	  analysis	  of	  each	  specific	  DNA	  consisted	  of	  2	  μl	  of	  extracted	  total	  DNA,	  
10	  μl	  of	  Thermo	  Fisher	  Scientific	  SYBR	  Green	  Real-­‐Time	  PCR	  Master	  Mixes,	  6	  μl	  of	  water,	  
and	  2	  μl	  of	  2	  mM	  (1	  mM	  of	   forward	  sequence	  and	  1	  mM	  of	  reverse	  sequence)	  of	  specific	  
DNA	   primers	   (see	   Table	   A5.5	   of	   appendices).	   The	   cycling	   time	   from	   each	   batch	   (42	  
samples)	   was	   then	   normalized	   by	   the	   median	   cycling	   time	   of	   a	   human	   pooled	   sample	  
(generated	   by	   combining	   aliquots	   of	   total	   DNA	   extracted	   from	   human	   skeletal	   muscle	  
samples),	   which	   was	   analyzed	   in	   duplicate	   in	   each	   batch.	   Finally,	   the	   amount	   of	   each	  
specific	  DNA	  was	   calculated	  using	   the	   formula	  1/(2average	   cycling	  time).	  MtDNA	  deletion	   ratio	  
was	   calculated	   as	   ‘the	   amount	  of	  mtDNA	  minor	   arc-­‐the	   amount	  of	  mtDNA	  major	   arc/the	  
amount	  of	  mtDNA	  minor	  arc’	  (5)	  and	  mtDNA	  count	  number	  was	  calculated	  as	  ‘the	  amount	  
of	  mtDNA	  major	  arc/the	  amount	  of	  nDNA’	  (5).	  
	  
5.2.6	  Statistical	  analyses	  
Comparison	   between	   the	   non-­‐obese	   and	   the	   obese	   groups	   were	   completed	   using	  
unpaired-­‐two-­‐tailed	   student’s	   t	   tests.	   Paired-­‐two-­‐tailed	   student’s	   t	   tests	   were	   utilized	   to	  
compare	  baseline	  to	  post-­‐CR	  within	  obese	  subjects.	  All	  metabolomics	  data	  are	  reported	  as	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average	  ±standard	  error	  of	  mean	  (SEM).	  Correlations	  between	  independent	  variables	  (age,	  
VO2max	   per	   FFM	   at	   baseline	   and	   [age	   x	   VO2max	   per	   FFM	   at	   baseline])	   vs.	   dependent	  
variables	  (metabolite	  levels	  and	  mtDNA	  profiles)	  were	  evaluated	  by	  ANOVA	  using	  RStudio	  
version	  1.0.136	  (©2009-­‐2016	  RStudio,	  Inc.).	  All	  figures	  were	  created	  using	  Prism	  7	  Version	  





5.3.1	  Participant	  characteristics	  	  
Participant	  characteristics	  are	  detailed	  in	  Tables	  5.1	  and	  5.2.	  Ninety-­‐nine	  obese	  (40	  
males	  and	  59	  females)	  and	  15	  non-­‐obese	  (7	  males	  and	  8	  females)	  individuals	  participated	  
in	   this	   study.	   Most	   of	   them	   were	   Caucasian	   (92.9%	   of	   obese	   and	   93.3%	   of	   non-­‐obese	  
subjects).	   Age	   was	   not	   significantly	   different	   between	   groups.	   Obese	   individuals	   were	  
heavier	  (39.5±0.5	  vs.	  23.1±0.5	  kg/m2).	  	  Among	  the	  99	  obese	  subjects,	  35	  of	  them	  had	  type	  
2	   diabetes	   and	   28	   were	   prescribed	   1	   or	   more	   anti-­‐diabetic	   drugs	   prior	   to	   enrollment.	  
Forty-­‐one	   of	   99	   obese	   individuals	   completed	  muscle	   biopsies	   after	   CR.	   Among	   these	   41	  
participants,	   body	   weight	   decreased	   by	   17.2±1.3%	   with	   CR	   (range	   4.3-­‐34.4%)	   and	   1	  
person	  stopped	  anti-­‐diabetic	  drugs.	  
	  
5.3.2	  Non-­‐metabolite	  parameters	  	  
Non-­‐metabolite	  parameters	  are	   listed	   in	  Table	  5.1	  (all	  participants	  at	  baseline	  and	  
41	   obese	   participants	   after	   CR)	   and	   Table	   5.2	   (41	   obese	   participants	   at	   baseline	   vs.	   41	  
obese	   participants	   after	   CR).	   Lean	   mass,	   fat	   mass	   and	   total	   body	   adiposity	   (%	   fat)	   was	  
higher	   in	   obese	   vs.	   non-­‐obese.	  Resting	   energy	   expenditure	   (REE),	   fasting	  plasma	  glucose	  
and	   insulin,	   as	   well	   as	   HOMA-­‐IR	   were	   also	   higher	   in	   obese	   participants.	   All	   of	   these	  
parameters	  changed	  significantly	  with	  CR	  and	  became	  closer	  in	  value	  to	  those	  of	  non-­‐obese	  
subjects.	   After	   correcting	   REE	   by	   lean+bone	   (fat-­‐free)	   mass	   (FFM),	   REE	   did	   not	   differ	  
between	   obese	   subjects	   at	   baseline	   and	   non-­‐obese	   and	   remained	   decreased	   after	   CR.	  
Absolute	   VO2max	   (l/min)	   did	   not	   differ	   between	   groups.	   	   After	   correcting	   for	   FFM,	  
however,	  VO2max	  was	  lower	  in	  the	  obese	  group.	  When	  compared	  to	  baseline,	  VO2max	  per	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FFM	   was	   higher	   after	   CR.	   Baseline	   and	   post-­‐CR	   VO2max	   per	   FFM	   were	   significantly	  
positively	   correlated	   (r	   =	   0.727,	   p-­‐value	  <0.001).	  Respiratory	  quotient	   at	   rest	   (RQR)	   and	  
respiratory	  quotient	  at	  VO2max	  (RQE)	  were	  not	  significantly	  different	  between	  groups.	  	  
	  
5.3.3	  Targeted	  metabolites	  and	  their	  differences	  between	  groups	  
Targeted	  metabolites	  in	  this	  study	  included	  AAs,	  branched-­‐chain	  amino	  acid	  (BCAA)	  
intermediates	   (C3	   and	   C5	   carnitines),	   oleic	   acid,	   fatty	   acid	   (FA)	   intermediates	  
(acylcarnitines),	   glycolysis	   pathway	   metabolites,	   TCA	   cycle	   metabolites	   and	   nucleotides.	  
Concentrations	   of	  metabolites	   are	   listed	   in	   Table	   5.3	   (all	   participants	   at	   baseline	   and	   41	  
obese	  participants	  after	  CR)	  and	  Table	  5.4	  (41	  obese	  participants	  at	  baseline	  vs.	  41	  obese	  
participants	  after	  CR). 
Lysine	  was	  higher	  in	  the	  obese	  group,	  and	  decreased	  after	  CR	  in	  females.	  Valine	  was	  
higher	   in	  obese	  males	  and	  non-­‐significantly	   trended	  (p-­‐value	  =	  0.060)	  higher	   in	  all	  obese	  
vs.	  non-­‐obese	  participants.	  C3	  carnitine,	  an	  degradation	  product	  valine,	  was	  higher	  in	  obese	  
males	   as	   well.	   Isoleucine+leucine	   was	   significantly	   decreased	   in	   obese	   female	   after	   CR.	  
Asparagine,	  glutamine,	  glycine,	  histidine,	  and	  serine	  were	  significantly	   lower	   in	  the	  obese	  
group,	  and	  CR	  increased	  their	  levels.	  Glutamine-­‐to-­‐glutamic	  acid	  ratio	  was	  lower	  in	  obese	  
males	   and	   non-­‐significantly	   trended	   (p-­‐value	   =	   0.070)	   lower	   in	   all	   obese	   vs.	   non-­‐obese	  
participants.	  Methionine	  was	  lower	  in	  obese	  vs.	  non-­‐obese	  females.	  	  
To	   evaluate	   mitochondrial	   capacity	   of	   BCAA	   catabolism,	   we	   inferred	   a	   flux	  
parameter	  by	   calculating	   the	   ratio	   of	   C3	   and	  C5	   carnitines	   to	   their	   substrates,	  which	   are	  
valine	   and	   isoleucine+leucine,	   respectively.	   A	   higher	   ratio	   implies	   lower	   mitochondrial	  
capacity	   for	   BCAA	   catabolism	   reflected	   in	   the	   greater	   accumulation	   of	   intermediate	  
metabolites.	   The	   C3	   carnitine-­‐to-­‐valine	   ratio	   was	   significantly	   higher	   in	   obese	   males	  
compared	   to	   non-­‐obese	   males;	   CR	   decreased	   C5	   carnitine-­‐to-­‐isoleucine+leucine	   ratio	   in	  
both	  sexes.	  	  
Oleic	   acid	   level	   did	   not	   differ	   between	   groups.	   C20:0	   carnitine	   was	   significantly	  
lower	  in	  obese	  subjects.	  CR	  significantly	  increased	  C16-­‐OH	  carnitine	  level.	  C18:0	  carnitine,	  
C20:0	  carnitine,	  C20:2	  carnitine	  and	  C20:4	  carnitines	  non-­‐significantly	  trended	  (p-­‐value	  =	  
0.068-­‐0.082)	  higher	   after	  CR.	  To	  evaluate	  mitochondrial	   capacity	  of	   in-­‐coming	  oleic	   acid,	  
we	  inferred	  a	  flux	  by	  calculating	  the	  ratio	  of	  C18:1	  carnitine,	  which	  is	  converted	  from	  oleic	  
	   142	  
acid	   during	   its	   carnitine	   shuttle,	   to	   the	   levels	   of	   oleic	   acid.	   	   A	   higher	   ratio	   represents	  
represents	   an	   increased	   uptake	   of	   oleic	   acid	   into	   the	  mitochondria.	  We	   found	   the	   C18:1	  
carnitine-­‐to-­‐oleic	  acid	  ratio	  was	  significantly	  lower	  in	  obese	  subjects	  and	  was	  not	  changed	  
by	  CR.	  	  
Several	  medium-­‐	  (C6-­‐C14)	  and	  short	  -­‐chain	  (C2	  and	  C4)	  acylcarnitines	  were	  lower	  
in	   obese	   participants,	   including	   C2	   carnitine,	   C4	   carnitine,	   C6	   carnitine,	   C8:0	   carnitine,	  
C10:0	  carnitine	  and	  C10:1	  carnitine.	  After	  CR,	  C12-­‐OH	  carnitine	  and	  C14-­‐OH	  carnitine	  were	  
significantly	  higher	  whereas	  other	  medium	  and	  short	  even-­‐chain	  acylcarnitines	  remained	  
unchanged.	  
Glycolysis	   metabolites	   did	   not	   differ	   between	   groups.	   To	   evaluate	   glycolysis	  
capacity,	  we	   inferred	  a	   flux	  by	  calculating	   the	  ratio	  of	   fructose	  1,6-­‐bisphosphate	  (FBP)	   to	  
glucose-­‐6-­‐phosphate+fructose-­‐6-­‐phosphate	   (G6P+F6P),	   which	   is	   a	   rate-­‐limiting	   step	   of	  
glycolysis	   via	   phosphofructokinase	   (PFK)	   enzyme	   (28).	   This	   inferred	   flux	   did	   not	   differ	  
between	  groups.	  
Among	  TCA	  cycle	  metabolites,	  citrate	  was	  lower	  in	  OB	  subjects.	  CR	  increased	  citrate	  
level	  such	  that	  it	  no	  longer	  differed	  from	  NOB	  participants.	  	  	  
AMP,	  ADP	  and	  NAD+	  were	  significantly	  lower	  in	  the	  obese	  group,	  and	  CR	  increased	  
AMP	  level.	  ATP	  non-­‐significantly	  trended	  (p-­‐value	  =	  0.070)	  lower	  in	  obese	  subjects.	  NADH	  
was	  significant	  lower	  in	  obese	  males.	  NAD+-­‐to-­‐NADH	  ratio	  decreased	  significantly	  after	  CR.	  
FAD	  was	  significantly	  lower	  in	  the	  obese	  group	  and	  was	  increased	  in	  obese	  males	  after	  CR.	  
	  
5.3.4	  Untargeted	  metabolites	  and	  their	  differences	  between	  groups	  
Out	  of	  4,150	   features	   identified	   in	  Profinder,	  1,700	  of	   them	  were	  present	   in	  more	  
than	  70%	  of	  all	  quality	  control	  (QC)	  samples	  and	  were	  selected	  for	  inclusion	  in	  Pearson’s	  
correlation.	   Of	   these	   1,700	   features,	   410	   (~24%)	   were	   correlated	   with	   either	   age	   or	  
VO2max	   per	   FFM	   at	   baseline	   (p	  ≤0.10)	   and	   were	   then	   re-­‐quantified	   using	   Agilent	  
Masshunter	   Quantitative	   Analysis	   software.	   Duplicate	   features	   and	   noise	   spectra	   were	  
discarded	   during	   re-­‐quantification,	   and	   212	   remaining	   features	   were	   included	   in	   final	  
analysis	   (Table	  A5.6	   of	   appendices).	   To	   test	   reliability	   of	   re-­‐quantification,	  we	   calculated	  
Pearson’s	  correlation	  of	  6	  metabolites	  that	  were	  detected	  in	  both	  targeted	  and	  untargeted	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metabolomics.	   	   Significantly	   positive	   correlations	   were	   found	   in	   all	   6	   metabolites	   (r	   =	  
0.716-­‐0.975,	  p-­‐value	  <0.001),	  suggesting	  that	  re-­‐quantification	  was	  reliable.	  
Of	  these	  212	  features,	  60	  differed	  between	  obese	  and	  non-­‐obese	  participants	  (Table	  
5.5).	  Features	  that	  were	  significantly	  lower	  in	  obese	  subjects	  include	  glycyl-­‐phenylalanine,	  
N-­‐(4-­‐aminobutyryl)-­‐l-­‐histidine,	  3-­‐hydroxypentadecanoic	  acid,	  ketooleic	  acid,	  lysoPA(16:0),	  
lysoPA(18:0),	   lysoPA(18:2),	   PA(36:3),	   PA(O-­‐42:6),	   lysoPC(20:3),	   lysoPC(22:2),	  
lysoPE(20:0),	  lysoPE(20:1),	  lysoPE(20:4),	  lysoPE(P-­‐16:0),	  PE(36:3),	  PE(36:4),	  PE(38:4)OH,	  
PE(P-­‐36:4),	   PE(P-­‐38:5),	   PE(O-­‐44:6),	   PG(34:1),	   PG(P-­‐36:5),	   PS(O-­‐36:3),	   PI(38:4),	   PI-­‐
ceramide(d28:2),	   ceramide(d40:1),	   ceramide(t42:0),	   lactosyl	   sphingosine(d16:1),	  
fumarate,	   nicotinate	   beta-­‐d-­‐ribonucleotide,	   2-­‐keto-­‐6-­‐acetamidocaproate,	   3-­‐
hydroxydodecanedioic	   acid,	   5,6-­‐dihydroxyindole-­‐2-­‐carboxylic	   acid,	   calcitroic	   acid,	  
neuromedin	  N,	   phosphocreatine,	   reduced	   glutathione,	   vanillin	  4-­‐sulfate	   and	  17	  unknown	  
features.	   Features	   that	   were	   significantly	   higher	   in	   the	   obese	   group	   included	   carnosine,	  
tryptophyl-­‐valine	  and	  2	  unknown	  metabolites.	  	  
Of	  these	  212	  features,	  34	  were	  significantly	  changed	  after	  CR	  (Table	  5.6).	  Features	  
that	   were	   significantly	   lower	   after	   CR	   included	   tryptophyl-­‐valine,	   arachidonic	   acid,	  
PA(36:1)OH,	   PE(36:5),	   PE(P-­‐34:2),	   PE(P-­‐36:2),	   PE(P-­‐36:3),	   1,25-­‐dihydroxyvitamin	   D3	   3-­‐
glycoside,	   glycocholic	   acid	   and	   6	   unknown	  metabolites.	   Features	   that	   were	   significantly	  
higher	   after	   CR	   included	   alanyl-­‐glutamine,	   ketopalmitic	   acid,	   PA(O-­‐42:6),	   PC(28:0),	  
PC(36:4),	   lysoPE(18:0),	   lysoPE(20:1),	   PE(P-­‐38:5),	   PG(34:1),	   PG(P-­‐36:5),	   lactosyl	  
sphingosine(d16:2),	  neuromedin	  N,	  pantothenic	  acid	  and	  6	  unknown	  metabolites.	  
	  
5.3.5	  mtDNA	  profiles	  and	  their	  differences	  between	  groups	  	  
MtDNA	   deletion	   ratio	   and	   mtDNA	   count	   number	   did	   not	   differ	   between	   groups	  
(Table	  5.3)	  and	  did	  not	  change	  with	  CR	  (Table	  5.4).	  
	  
5.3.6	  Skeletal	  muscle	  metabolite	  levels	  and	  mtDNA	  profiles	  change	  with	  age.	  
Among	   the	   NOB	   and	   OB	   groups,	   targeted	   metabolite	   levels	   were	   analyzed	   by	  
ANOVA,	  adjusted	   for	  race,	  sex,	  diabetes	  status	  (yes	  or	  no),	  group	  (NOB	  or	  OB),	  HOMA-­‐IR,	  
BMI	  and	  baseline	  VO2max	  adjusted	  for	  FFM.	  	  We	  found	  that	  age	  was	  negatively	  correlated	  
with	   the	   concentration	   of	   several	   AAs	   (Figure	   5.1a	   and	   Table	   A5.7	   of	   appendices).	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Correlations	  were	  similar	  when	  only	  the	  41	  obese	  subjects	  who	  received	  muscle	  biopsies	  
both	  before	  and	  after	  CR	  were	  evaluated	  (Figure	  5.1b,c	  and	  Table	  A5.8,	  A5.9	  of	  appendices).	  
When	   the	  212	  untargeted	  metabolites	  at	  baseline	  were	   included,	  ANOVA	  adjusted	  
for	  the	  factors	  above,	  we	  found	  that	  1	  unknown	  metabolite	  was	  positively	  correlated	  with	  
age,	   and	   11	   metabolites	   were	   inversely	   correlated	   with	   age,	   including	   lysoPE(22:4),	  
PE(38:2)OH,	   PE(P-­‐36:2),	   PG(36:1),	   PG(P-­‐36:5),	   lysoPS(18:1),	   lysoPS(20:4),	   PS(38:3),	  
dehydroepisterone	   sulfate	   (DHEAS)	   and	   xanthine,	   as	   well	   as	   an	   unknown	   metabolite	  
(Figure	   5.2a	   and	   Table	   A5.10	   of	   appendices).	   When	   only	   the	   41	   obese	   subjects	   who	  
received	   muscle	   biopsies	   both	   before	   and	   after	   CR	   were	   evaluated,	   3	   metabolites	   at	  
baseline	  were	  positively	  correlated	  with	  age,	  which	  were	  lysoPA(16:0),	  PE(38:4)	  and	  PE(O-­‐
44:6),	   and	   6	   metabolites	   at	   baseline	   were	   negatively	   correlated	   with	   age,	   including	  
tryptophyl-­‐valine,	  PA(36:3),	  PS(38:3)	  and	  UDP-­‐n-­‐acetylglucosamine,	  as	  well	  as	  2	  unknown	  
metabolites	   (Figure	   5.2b	   and	   Table	   A5.11	   of	   appendices).	   After	   CR,	   10	  metabolites	  were	  
significantly	   positively	   correlated	   with	   age,	   including	   eicosapentaenoic	   acid,	   PE(38:4),	  
PE(P-­‐38:5),	  PI(38:5),	  11(R)-­‐hydroxyeicosatetraenoic	  acid,	  allopregnanolone,	  calcitroic	  acid	  
and	  urocanic	  acid,	  	  as	  well	  as	  2	  unknown	  metabolites,	  and	  22	  metabolites	  were	  significantly	  
negatively	   correlated	   with	   age,	   including	   cardiolipin(72:8),	   lysoPE(20:0),	   lysoPE(20:2),	  
lysoPE(P-­‐16:0),	   PE(38:4)OH,	   PE(O-­‐34:3),	   PI-­‐ceramide(d28:2),	   lysoPS(20:4),	   PS(40:6),	  
DHEAS,	   lactosyl	  sphingosine(d16:1),	  pregnenolone,	  and	  10	  unknown	  metabolites	  	  (Figure	  
5.2c	  and	  Table	  A5.12	  of	  appendices).	  
ANOVA	  showed	  no	  significant	  correlations	  between	  age	  and	  mtDNA	  profiles	  (Figure	  
5.1a,b,c	  and	  Table	  A5.7,	  A5.8,	  A5.9	  of	  appendices).	  However,	  when	   the	  31	  oldest	   subjects	  
(55-­‐67	  years	  of	  age,	  average	  58)	  were	  compared	  to	  the	  31	  youngest	  subjects	  (26-­‐44	  years	  
of	  age,	  average	  39)	  at	  baseline	  (p-­‐value	  of	  age	  <0.001),	   the	  oldest	  group	  had	  significantly	  
lower	  mtDNA	  count	  number	   (1077±76	  vs.	  1379	  ±104	  counts,	  p-­‐value	  =	  0.023)	  and	  non-­‐
significantly	  trended	  towards	  a	  higher	  mtDNA	  deletion	  ratio	  (69.58±2.09	  vs.	  64.52±2.71%,	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5.3.7	   VO2max	   affects	   skeletal	   muscle	   metabolite	   levels	   and	   mtDNA	   count	   number	  
independently	  of	  age.	  
Because	  VO2max	   is	  highly	   genetically	  determined	   (as	  described	   in	   chapter	  2),	   is	   a	  
function	  of	  FFM	  (29,	  30)	  and	  is	  not	  affected	  by	  fat	  mass	  (30),	  baseline	  VO2max	  adjusted	  for	  
FFM	  (VO2max	  per	  FFM	  at	  baseline)	  was	  used	  for	  the	  analysis.	  	  
Among	   targeted	   metabolomics	   at	   baseline,	   ANOVA	   adjusted	   for	   age,	   race,	   sex,	  
diabetes	  status	  (yes	  or	  no),	  group	  (non-­‐obese	  or	  obese),	  HOMA-­‐IR	  and	  BMI,	  revealed	  that	  
VO2max	   per	   FFM	   at	   baseline	   was	   negatively	   correlated	   with	   most	   AA	   and	   BCAA	  
intermediate	  (C3	  and	  C5	  carnitines)	  levels	  as	  well	  as	  the	  ratios	  of	  C3	  and	  C5	  carnitines	  to	  
their	  substrates	  (Figure	  5.1a	  and	  Table	  A5.7	  of	  appendices).	  Conversely,	  VO2max	  per	  FFM	  
at	   baseline	   was	   positively	   correlated	   with	   short	   even-­‐,	   medium-­‐	   and	   long-­‐chain	   chain	  
acylcarnitines	  as	  well	  as	  C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  (Figure	  5.1a	  and	  Table	  A5.7	  of	  
appendices).	   VO2max	   per	   FFM	   at	   baseline	   was	   positively	   correlated	   with	   TCA	   cycle	  
metabolites	  as	  well	  (Figure	  5.1a	  and	  Table	  A5.7	  of	  appendices).	  Correlations	  were	  similar	  
when	  only	  the	  41	  obese	  subjects	  who	  completed	  muscle	  biopsies	  both	  before	  and	  after	  CR	  
were	   evaluated	   (Figure	   5.1b,c	   and	   Table	   A5.8,	   A5.9	   of	   appendices).	   However,	   the	  
correlations	   of	   VO2max	   per	   FFM	   at	   baseline	   vs.	   medium-­‐	   and	   long-­‐chain	   acylcarnitines	  
were	  more	  significant	  after	  CR	  (Figure	  5.1b,c	  and	  Table	  A5.8,	  A5.9	  of	  appendices).	  
Among	  the	  selected	  212	  untargeted	  metabolites,	  ANOVA	  adjusted	  for	  age,	  race,	  sex,	  
diabetes	   status	   (yes	   or	   no),	   group	   of	   subjects	   (non-­‐obese	   or	   obese),	   HOMA-­‐IR	   and	   BMI	  
revealed	  that	  5	  metabolites	  were	  significantly	  positively	  correlated	  with	  VO2max	  per	  FFM	  
at	  baseline,	  including	  PA(O-­‐42:6),	  PG(34:1),	  PI(38:4),	  reduced	  glutathione	  and	  an	  unknown	  
metabolite,	   and	  11	  metabolites	  were	   significantly	  negatively	   correlated	  with	  VO2max	  per	  
FFM	   at	   baseline,	   including	   3-­‐hydroxypentadecanoic	   acid,	   PC(28:0),	   PE(34:1),	   PE(36:1),	  
PE(36:2),	   PE(P-­‐36:2),	   PE(P-­‐36:3),	   PE(P-­‐40:6)	   and	   lysoPS(18:1),	   as	   well	   as	   2	   unknown	  
metabolites	  (Figure	  5.2a	  and	  Table	  A5.10	  of	  appendices).	  When	  only	  the	  41	  obese	  subjects	  
who	  completed	  muscle	  biopsies	  both	  before	  and	  after	  CR	  were	  evaluated,	  3	  metabolites	  at	  
baseline	  were	  significantly	  positively	  correlated	  with	  VO2max	  per	  FFM	  at	  baseline,	  which	  
were	   UDP-­‐n-­‐acetylglucosamine,	   oxidized	   glutathione	   and	   reduced	   glutathione,	   and	   1	  
baseline	  metabolite,	  beta-­‐citryl-­‐l-­‐glutamic	  acid,	  was	  significantly	  negatively	  correlated	  with	  
VO2max	  per	  FFM	  (Figure	  5.2b	  and	  Table	  A5.11	  of	  appendices).	  After	  CR,	  4	  metabolites	  were	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significantly	   positively	   correlated	   with	   VO2max	   per	   FFM	   at	   baseline,	   including	   DHEAS,	  
urocanic	   acid	   and	   2	   unknown	  metabolites,	   and	   2	  metabolites,	   beta-­‐citryl-­‐l-­‐glutamic	   acid	  
and	  PE(P-­‐36:2),	  were	  significantly	  negatively	  correlated	  with	  VO2max	  per	  FFM	  at	  baseline,	  
(Figure	  5.2c	  and	  Table	  A5.12	  of	  appendices).	  
ANOVA	   also	   revealed	   a	   positive	   correlation	   between	  VO2max	  per	   FFM	  at	   baseline	  
and	   mtDNA	   count	   number	   (Figure	   5.1a,b	   and	   Table	   A5.7,	   A5.8	   of	   appendices),	   but	   the	  
correlation	  disappeared	  after	  CR	  (Figure	  5.1c	  and	  Table	  A5.9	  of	  appendices).	  VO2max	  per	  
FFM	  at	  baseline	  and	  mtDNA	  deletion	  ratio	  were	  not	  correlated.	  When	  the	  31	  least	  fit	  people	  
(VO2max	   per	   FFM	   at	   baseline	   22.62-­‐36.64	  ml/(kg	   x	  min),	   average	   32.92	  ml/(kg	   x	  min))	  
were	  compared	  to	  the	  31	  most	  fit	  people	  (VO2max	  per	  FFM	  at	  baseline	  44.78-­‐77.22	  ml/(kg	  
x	  min),	  50.71	  ml/(kg	  x	  min))	  (p-­‐value	  of	  VO2max	  per	  FFM	  at	  baseline	  <0.001),	   there	  was	  
also	  no	  difference	   in	  mtDNA	  deletion	  ratio	  at	  baseline	  between	  groups	  (60.31±2.69%	  vs.	  
64.96±3.17%,	  p-­‐value	  =	  0.271).	  
	  
5.3.8	  VO2max	  did	  not	  modulate	  age-­‐related	  changes	  in	  skeletal	  muscle	  metabolites.	  
To	   identify	  whether	  VO2max	  alters	   the	  effect	  of	   age	  on	  changes	   in	   skeletal	  muscle	  
metabolite	   levels,	   we	   calculated	   the	   correlations	   between	   [age	   x	   VO2max	   per	   FFM	   at	  
baseline]	   and	  metabolite	   levels	   using	   ANOVA	   adjusted	   for	   age,	   race,	   sex,	   diabetes	   status	  
(yes	  or	  no),	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  HOMA-­‐IR,	  BMI	  and	  VO2max	  per	  FFM	  at	  
baseline.	  If	  VO2max	  alters	  the	  effect	  of	  age	  on	  changes	  in	  metabolite	  levels,	  metabolites	  that	  
were	   significantly	   correlated	   with	   age	   must	   be	   also	   significantly	   correlated	   with	   [age	   x	  
VO2max	  per	   FFM	  at	   baseline].	  However,	   the	   expected	   results	  were	  not	   found,	   suggesting	  
that	  VO2max	  does	  not	  modulate	  age-­‐related	  changes	  in	  skeletal	  muscle	  metabolite	  levels.	  
	  
5.3.9	  The	  effect	  of	  VO2max	  on	  skeletal	  muscle	  metabolite	   levels	   is	  partly	  mediated	  by	  
mtDNA	  count	  number.	  
Because	  VO2max	  was	  positively	  correlated	  with	  mtDNA	  count	  number	  as	  described	  
in	  5.3.7,	  it	  was	  necessary	  to	  determine	  whether	  the	  effect	  of	  VO2max	  on	  metabolite	  levels	  is	  
mediated	  by	  the	  difference	  in	  mtDNA	  count	  number.	  Here	  we	  used	  ANOVA	  adjusted	  for	  age,	  
race,	  sex,	  diabetes	  status	  (yes	  or	  no),	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  HOMA-­‐IR	  and	  
BMI	   to	  evaluate	   the	   relationship	  between	  mtDNA	  count	  number	  and	  metabolite	   levels.	   If	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mtDNA	  count	  number	  mediates	   the	  effect	  of	  VO2max	  on	  metabolite	   levels,	   the	  significant	  
correlation	   between	  mtDNA	   and	  metabolite	   levels	  must	   be	   in	   the	   same	   direction	   as	   the	  
significant	   correlation	   between	   VO2max	   per	   FFM	   at	   baseline	   and	   metabolite	   levels	   as	  
described	   in	   5.3.8.	   The	   results	   suggest	   that	   the	   effect	   of	   VO2max	   on	   9	   metabolites	   is	  
mediated	   by	   the	   difference	   in	   mtDNA	   count	   number,	   including	   asparagine,	   beta-­‐citryl-­‐l-­‐
glutamic	   acid,	   3-­‐hydroxypentadecanoic	   acid,	   PC(28:0),	   PE(36:2),	   PE(P-­‐40:6),	   oxidized	  




Our	   study	   investigated	   the	   effects	   of	   obesity	   and	   CR	   on	  metabolite	   levels,	  mtDNA	  
deletion	  ratio	  and	  mtDNA	  count	  number	  in	  postprandial	  (120	  min)	  skeletal	  muscle	  of	  obese	  
subjects	  at	  baseline	  and	  after	  CR	  as	  well	  as	  non-­‐obese	  controls	  at	  baseline.	  In	  addition,	  we	  
evaluated	   the	  effects	  of	   age	  and	  VO2max	  per	  FFM	  at	  baseline	  on	  metabolites	  and	  mtDNA	  
profiles	  and	  adjusted	  for	  multiple	  covariables	  via	  ANOVA.	  Analysis	  after	  CR	  enabled	  us	  to	  
investigate	  the	  ability	  of	  CR	  to	  mitigate	  aging-­‐induced	  changes,	  its	  relationship	  to	  VO2max	  
and	   its	  effect	  on	  metabolites	  and	  mtDNA	  profiles.	  Additionally,	  we	  sought	   to	  determine	   if	  
the	  effect	  of	  VO2max	  on	  metabolite	  levels	  is	  mediated	  by	  mtDNA.	  To	  our	  knowledge,	  this	  is	  
the	  first	  study	  using	  ANOVA	  to	  document	  the	  effect	  of	  age	  and	  VO2max	  on	  metabolite	  levels	  
in	  human	  skeletal	  muscle.	  
VO2max	   per	   FFM	   was	   lower	   in	   the	   obese	   group.	   This	   is	   consistent	   with	   several	  
previous	  cross-­‐sectional	  and	  longitudinal	  studies,	  all	  of	  which	  found	  that	  higher	  VO2max	  is	  
associated	   with	   lower	   BMI	   in	   both	   non-­‐obese	   and	   obese	   humans	   (31-­‐36).	   CR	   increased	  
VO2max	  per	  FFM,	  which	  was	  previously	  shown	  in	  humans	  (37,	  38).	  The	  increase	  in	  VO2max	  
per	  FFM	  after	  CR	   could	  be	  explained	  by	   improvement	  of	  pulmonary	   (39-­‐42)	   and	   cardiac	  
(39,	  43-­‐45)	  function	  owing	  to	  weight	  loss.	  The	  high	  positive	  correlation	  between	  baseline	  
and	  post-­‐CR	  VO2max	  per	  FFM	  VO2max	  has	  a	  significant	  genetic	  	  determined	  (46-­‐56).	  	  
BCAAs	   (isoleucine,	   leucine	   and	   valine)	   are	   insulin	   resistance-­‐related	   AAs	   (57-­‐64).	  
Therefore,	  it	  is	  not	  surprising	  that	  obese	  subjects	  exhibited	  higher	  levels	  of	  valine,	  or	  that	  
isoleucine+leucine	   decreased	   significantly	   after	   CR	   in	   females.	   Asparagine,	   glutamine,	  
glycine	   and	   serine,	   markers	   of	   insulin	   sensitivity	   (57,	   61,	   65,	   66),	   were	   lower	   in	   obese	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subjects	  and	  increased	  with	  CR,	  consistent	  with	  lower	  insulin	  sensitivity	  in	  obese	  subjects	  
and	  the	  improvement	  after	  CR.	  Glutamine-­‐to-­‐glutamic	  acid	  ratio,	  another	  marker	  of	  insulin	  
sensitivity	  (61),	  was	  lower	  in	  obese	  participants,	  consistent	  with	  lower	  insulin	  sensitivity	  in	  
this	   group.	   Histidine	   was	   lower	   in	   obese	   subjects	   and	   methionine	   was	   lower	   in	   obese	  
females,	  which	   is	   in	  agreement	  with	  a	  previous	   report	   in	  human	  skeletal	  muscle	   (67).	   In	  
that	  study,	  the	  authors	  suggested	  that	  obese	  subjects	  had	  lower	  histidine	  and	  methionine	  
levels	  because	  those	  AAs	  are	  being	  used	  to	  replenish	  TCA	  cycle	  metabolites	  and	  maintain	  
oxidative	   metabolism	   (67).	   The	   C3	   carnitine-­‐to-­‐valine	   ratio	   was	   significantly	   higher	   in	  
obese	  males,	  suggesting	  that	  obesity	  and	  insulin	  resistance	  are	  associated	  with	  decreased	  
mitochondrial	  capacity	  for	  BCAA	  catabolism.	  	  The	  BCAA	  are	  thought	  to	  provide	  anaplerotic	  
intermediates,	  which	  could	  lead	  to	  the	  use	  of	  alternative	  substrates.	  	  (68).	  CR	  decreased	  the	  
C5	   carnitine-­‐to-­‐isoleucine+leucine	   ratio,	   suggesting	   that	   CR	   improves	   mitochondrial	  
capacity	  of	  BCAA	  catabolism.	  This	  effect	  of	  CR	  is	  probably	  not	  only	  due	  to	  improved	  insulin	  
sensitivity,	   but	   also	   increased	   mitochondrial	   protein	   deacetylation	   since	   mitochondrial	  
protein	  deacetylation	  was	  found	  to	  be	  associated	  with	  increased	  mitochondrial	  capacity	  of	  
BCAA	  catabolism	  (69)	  and	  because	  CR	  can	  increase	  mitochondrial	  protein	  deacetylation	  via	  
SIRT1	  (70)	  and	  SIRT3	  (71)	  activation.	  
Long-­‐chain	   acylcarnitine	   reflects	   the	   influx	   of	   FAs	   into	   the	   mitochondria	   via	   the	  
carnitine	   shuttle	   (72).	   In	   this	   study,	   C20:0	   carnitine	   was	   significantly	   lower	   in	   obese	  
subjects	   and	  CR	   increased	   levels	  of	   several	   long-­‐chain	  acylcarnitines.	  Our	   results	   suggest	  
that	   obesity	   is	   associated	   with	   decreased	   FA	   uptake	   into	   the	   mitochondria	   and	   that	   CR	  
attenuates	  this	  pathology.	   	  This	  evidence	  of	  lower	  levels	  is	  consistent	  with	  our	  findings	  in	  
plasma	   (chapter	   4).	   The	   C18:1	   carnitine-­‐to-­‐oleic	   acid	   ratio	   reflects	   influx	   of	   FAs	   into	   the	  
mitochondria.	   	  The	  ratio	  was	  significantly	   lower	   in	  obese	  subjects,	   further	  supporting	  the	  
obesity-­‐associated	  decreased	  FA	  uptake	  into	  the	  mitochondria.	  The	  decrease	  in	  FA	  uptake	  
into	  the	  mitochondria	  may	  be	  explained	  by	  the	  obesity-­‐induced	  reduction	  in	  AMPK	  (73-­‐75)	  
and	  CPT-­‐1	  activity	  (76,	  77).	  
Medium	  (C6-­‐C14)	  and	  short	  even-­‐chain	  (C2	  and	  C4)	  acylcarnitine	  levels	  reflect	  FAO	  
in	  the	  mitochondria	  (72).	  Several	  medium	  and	  short	  even-­‐chain	  acylcarnitines	  were	  lower	  
in	   obese	   participants	   and	   CR	   increased	   C12-­‐OH	   carnitine	   and	   C14-­‐OH	   carnitine	   levels,	  
suggesting	  that	  obesity	  is	  associated	  with	  decreased	  FAO,	  which	  is	  consistent	  with	  previous	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studies	  in	  human	  skeletal	  muscle	  (77-­‐79).	  The	  reduction	  in	  FAO	  is	  probably	  a	  consequence	  
of	   the	   obesity-­‐induced	   decrease	   in	   mitochondrial	   FA	   uptake.	   Similar	   to	   our	   findings,	  
increased	  FAO	  after	  CR	  has	  been	  previously	  observed	  in	  rats	  (80).	  	  
Citrate,	  a	  TCA	  cycle	  metabolite,	  was	  lower	  in	  obese	  subjects	  and	  increased	  after	  CR.	  
This	  may	  be	  due	   to	  decreased	  mitochondrial	   capacity	  of	  BCAA	  catabolism	  and	  decreased	  
FAO	   in	   obesity,	   resulting	   in	   diminished	   acetyl-­‐CoA	   production	   and	   consequently	   lower	  
production	   of	   TCA	   cycle	   metabolites,	   a	   condition	   which	   can	   be	   improved	   by	   CR.	   Lower	  
levels	  of	  TCA	  cycle	  metabolites	  have	  been	  documented	   in	  skeletal	  muscle	  of	  high-­‐fat	  diet	  
(HFD)-­‐induced	  obese	  rats	  (81)	  and	  in	  humans	  with	  insulin	  resistance	  (68).	  	  
The	  TCA	  cycle	  is	  a	  major	  source	  of	  ATP	  production.	  Therefore,	  the	  lower	  ATP	  level	  in	  
obese	   subjects	   was	   consistent	   with	   lower	   citrate	   levels	   and	   could	   be	   explained	   by	  
diminished	   TCA	   cycle	   metabolite	   production	   caused	   by	   an	   obesity-­‐induced	   decrease	   in	  
mitochondrial	   capacity	   for	   BCAA	   catabolism	   and	   decreased	   FAO.	   Oxidative	  
phosphorylation	   (OXPHOS)	  also	  produces	  ATP.	  HFD-­‐induced	  obesity	  has	  been	  associated	  
with	   lower	   expression	   of	   genes	   involved	   in	   OXPHOS	   in	   human	   skeletal	   muscle	   (82),	  
therefore	   decreased	   OXPHOS	   is	   another	   potential	   cause	   of	   the	   lower	   ATP	   level	   in	   obese	  
participants	  (83).	  Lower	  AMP	  and	  ADP	  levels	  in	  obese	  subjects	  may	  be	  associated	  with	  less	  
ATP	   production.	   NADH	   is	   a	   product	   of	   the	   TCA	   cycle,	   whereas	   NAD+	   is	   a	   product	   of	  
OXPHOS.	  Lower	  NADH	  and	  NAD+	  levels	  in	  obese	  subjects	  may	  be	  due	  to	  lower	  production	  
of	  TCA	  cycle	  metabolites	  and	  lower	  OXPHOS,	  respectively.	   Increased	  NAD+-­‐to-­‐NADH	  ratio	  
can	   activate	   SIRT1	   thus	   increasing	   mitochondrial	   protein	   deacetylation,	   resulting	   in	  
decreased	  susceptibility	  to	  metabolic	  syndrome	  (70).	  The	  NAD+-­‐to-­‐NADH	  ratio	  increased	  in	  
skeletal	  muscle	  of	  CR	  mice	  (84).	  Surprisingly,	  the	  NAD+-­‐to-­‐NADH	  ratio	  decreased	  after	  CR	  
in	   this	   study.	   Several	   enzymes	   involving	   FAO	   and	   AA	   catabolism	   are	   FAD-­‐dependent,	  
including	   acetyl-­‐CoA	   dehydrogenases	   (FAO),	   short/branched-­‐chain	   acyl-­‐CoA	  
dehydrogenase	   (isoleucine	   catabolism),	   isovaleryl-­‐CoA	   dehydrogenase	   (leucine	  
catabolism),	   isobutyryl-­‐CoA	   dehydrogenase	   (valine	   catabolism)	   and	   glutaryl-­‐CoA	  
dehydrogenase	  (lysine	  catabolism)	  (85).	  In	  addition,	  FAD	  is	  required	  within	  the	  TCA	  cycle	  
and	  for	  succinate	  dehydrogenase	  (complex	  II	   in	  the	  electron	  transport	  chain	  (ETC),	  which	  
is	  the	  site	  of	  OXPHOS)	  to	  catalyze	  the	  oxidation	  of	  succinate	  to	  fumarate	  (86).	  Thus,	  lower	  
FAD	   levels	   in	  obese	  subjects	  may	  be	  associated	  with	  decreased	  mitochondrial	  capacity	  of	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BCAA	   catabolism,	   decreased	   FAO,	   decreased	   production	   of	   TCA	   cycle	   metabolites	   and	  
lower	  OXPHOS.	  
Untargeted	   metabolomics	   revealed	   that	   glycyl-­‐phenylalanine	   and	   N-­‐(4-­‐
aminobutyryl)-­‐l-­‐histidine	   were	   lower	   in	   obese	   subjects,	   consistent	   with	   lower	   levels	   of	  
glycine	  and	  histidine,	   respectively.	  Conversely,	   tryptophyl-­‐valine	  was	  higher	   in	   the	  obese	  
group,	  consistent	  with	  the	  higher	  valine	  level.	  	  Skeletal	  muscle	  carnosine	  is	  associated	  with	  
cardiometabolic	   risk	   factors	   in	   humans,	   It	   is	   positively	   correlated	   with	   total	   body	   fat	  
percentage	  but	  inversely	  correlated	  with	  insulin	  sensitivity	  and	  HDL	  cholesterol	  level	  (87).	  
.	  CR	  decreased	  tryptophyl-­‐valine,	  which	  was	  consistent	  with	  a	  reduction	  in	  tryptophan	  and	  
valine	   after	   CR.	   	   The	   increase	   in	   alanyl-­‐glutamine	   after	   CR	   was	   consistent	   with	   the	  
increased	   glutamine	   level	   after	   CR	   as	   well.	   3-­‐hydroxypentadecanoic	   acid,	   a	   long-­‐chain	  
hydroxyl	   FA,	   and	   ketooleic	   acid	   were	   significantly	   lower	   in	   the	   obese	   group,	   and	   CR	  
increased	  ketopalmitic	  acid	  level.	  	  These	  oxidized	  FAs	  can	  arise	  from	  microbial	  metabolism	  
of	   FA	   and	   have	   biological	   activity,	   including	   inhibition	   of	   colinesterases	   (88).	   The	   higher	  
level	   of	   FAs	   in	   non-­‐obese	   subjects	   and	   in	   obese	   individuals	   after	   CR	   may	   be	   caused	   by	  
insulin-­‐induced	  FAT/CD36	   translocation	   to	   the	  plasma	  membrane	   to	   facilitate	  FA	  uptake	  
(89).	  However,	  arachidonic	  acid,	  a	  polyunsaturated	  fatty	  acid	  (PUFA),	  was	  lower	  after	  CR.	  
This	  has	  also	  been	  observed	  in	  rat	  liver	  (90)	  and	  various	  mouse	  tissues	  including	  skeletal	  
muscle	   (91),	   consistent	   with	   the	   CR-­‐induced	   decrease	   in	   mitochondrial	   membrane	   lipid	  
unsaturation	  (90-­‐92),	  which	  is	  associated	  with	  decreased	  susceptibility	  to	  age-­‐related	  lipid	  
peroxidative	  damage	  to	  mitochondria	  (6,	  93,	  94),	  i.e.	  it	  delays	  aging.	  	  
Phospholipids,	  which	  are	  major	  components	  of	  cell	  and	  mitochondrial	  membranes	  
(95,	  96),	  were	   lower	   in	   the	  obese	  group.	  Skeletal	  muscle	  PC	  and	  PE	  were	   lower	   in	  obese	  
subjects	   and	   were	   positively	   correlated	   with	   insulin	   sensitivity	   (97),	   and	   the	   authors	  
believed	  that	  these	  findings	  were	  partly	  PGC-­‐1𝛼  dependent	  (97).	   	  Phospholipids	  also	  play	  
various	  important	  roles	  in	  cell	  and	  mitochondrial	  function,	  including	  mitochondrial	  fusion	  
and	  fission	  (PA),	  lipid	  to	  protein	  interactions	  (PC),	  OXPHOS	  (PE),	  lipid	  signaling	  (PI),	  vesicle	  
trafficking	  (PI),	  actin	  rearrangement	  (PI),	  calcium	  regulation	  (PI),	  O2	  transfer	  mechanism	  of	  
complex	   IV	   of	   OXPHOS	   (PG)	   and	   cell	   apoptosis	   (PS)	   (95,	   98-­‐102).	   Therefore,	   lower	  
phospholipid	  levels	  in	  obese	  subjects	  may	  be	  associated	  with	  the	  obesity-­‐related	  decrease	  
in	   cell	   and	   mitochondrial	   function.	   After	   CR,	   changes	   in	   the	   level	   and	   saturation	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composition	   of	   phospholipids	   varied,	   consistent	   with	   previous	   research	   in	   mouse	   liver	  
(103).	   Surprisingly,	   ceramides	   were	   lower	   in	   our	   obese	   participants,	   which	   was	  
inconsistent	  with	  previous	  studies	  that	  found	  higher	  (104)	  or	  similar	  (105)	  ceramide	  level	  
in	  skeletal	  muscle	  of	  obese	  vs.	  non-­‐obese	  humans.	  Nicotinate	  beta-­‐d-­‐ribonucleotide	  is	  part	  
of	  nicotinate	  and	  nicotinamide	  metabolism	  pathways	  (106),	  therefore	  the	  lower	  level	  found	  
in	   obese	   participants	   was	   consistent	   with	   the	   lower	   NAD+	   level	   previously	   discussed	   as	  
well.	   Calcitroic	   acid,	   a	   metabolite	   of	   1,25-­‐dihydroxyvitamin	   D3	   (107),	   was	   lower	   in	   the	  
obese	   group.	   The	   agrees	   with	   previous	   studies	   that	   documented	   lower	   1,25-­‐
dihydroxyvitamin	  D3	  level	  in	  serum	  of	  obese	  subjects	  (108,	  109),	  which	  could	  be	  explained	  
by	   the	   decrease	   in	   25-­‐hydroxyvitamin	   D	   (a	   precursor	   of	   1,25-­‐dihydroxyvitamin	   D3)	   by	  
multiple	   possible	   mechanisms,	   including	   lower	   dietary	   intake,	   reduced	   cutaneous	  
synthesis,	   reduced	   intestinal	   absorption,	   and	   sequestration	   of	   25-­‐hydroxyvitamin	   D	   in	  
adipose	   tissue	   (110).	   Reduced	   glutathione	   is	   the	  most	   abundant	   endogenous	   antioxidant	  
that	  protects	  mitochondria	  against	  oxidative	  stress	  (111);	  its	  level	  decreases	  with	  aging	  in	  
humans	   (112-­‐114).	   In	   this	   study,	   reduced	   glutathione	   was	   lower	   in	   obese	   participants,	  
consistent	  with	  previous	  analysis	  of	  human	  blood	  (115-­‐117)	  and	  rat	  adipose	  tissue	  (118).	  	  
However,	  we	  did	  not	  see	  a	  significant	  relationship	  with	  age	  in	  our	  study,	  after	  adjusting	  for	  
multiple	   clinical	   factors.	   	   Because	   reduced	   glutathione	   deficiency	   is	   associated	   with	  
decreased	  FAO	  and	   insulin	  resistance	  (111),	  our	  results	  suggest	   that	  reduced	  glutathione	  
level	  may	  play	  a	  role	  in	  the	  reduction	  of	  FAO.	  Essentially,	  obesity	  mimics	  aging.	  	  
In	  a	  longitudinal	  study	  in	  humans	  (119),	  several	  bile	  acids	  in	  plasma	  were	  found	  to	  
be	  associated	  with	  lower	  odds	  of	  longevity.	  Lower	  glycocholic	  acid,	  a	  bile	  acid,	  after	  CR	  in	  
this	   study	   is	   consistent	  with	   decreased	  markers	   of	   short	   lifespan,	   again,	   providing	   some	  
indirect	   evidence	   that	   CR	   delays	   metabolic	   aging.	   To	   our	   knowledge,	   the	   increase	   in	  
pantothenic	  acid	  level	  after	  CR	  has	  not	  been	  previously	  documented.	  Obese	  mice	  receiving	  
pantothenic	   acid	   derivatives	   exhibited	   lower	   blood	   glucose	   and	   serum	   insulin	   (120),	  
suggesting	  that	  the	  higher	  level	  of	  pantothenic	  acid	  after	  CR	  observed	  in	  this	  study	  may	  be	  
associated	  with	  improved	  insulin	  sensitivity.	  
MtDNA	   count	   number	   did	   not	   differ	   between	   groups,	   consistent	   with	   a	   previous	  
study	   in	   human	   skeletal	  muscle	   (105).	  However,	   to	   identify	  whether	  CR	   can	  prevent	   the	  
age-­‐related	   decrease	   in	   mtDNA	   count	   number	   in	   human	   skeletal	   muscle,	   like	   previous	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research	  in	  rat	  skeletal	  muscle	  (24),	  a	  study	  with	  long-­‐term	  CR	  and	  long-­‐term	  follow	  up	  is	  
needed.	  This	  type	  of	  study	  may	  also	  demonstrate	  the	  attenuating	  effect	  of	  CR	  on	  age-­‐related	  
mtDNA	  deletion,	  as	  previous	  research	   in	  mouse	  skeletal	  muscle	   found	   that	  CR	  prevented	  
aging-­‐induced	  oxidative	  damage	  to	  mitochondria	  (21).	  
ANOVA	   from	  targeted	  metabolomics	  demonstrated	   that	  aging	  was	  associated	  with	  
lower	   AA	   levels	   in	   skeletal	   muscle.	   This	   was	   not	   caused	   by	   sarcopenia	   of	   aging	   since	  
metabolite	  levels	  were	  adjusted	  by	  skeletal	  muscle	  tissue	  mass.	  Rather,	  it	  may	  be	  explained	  
by	  an	  aging-­‐induced	  impairment	  of	  dietary	  AA	  delivery	  to	  skeletal	  muscle	  (121)	  caused	  by	  
several	  mechanisms,	  including	  diminished	  response	  to	  protein	  ingestion	  (122-­‐124),	  as	  well	  
as	   impaired	   skeletal	  muscle	   protein	   anabolic	   response	   to	   insulin	   and	  muscle	   contraction	  
(125-­‐129).	  However,	  the	  impairment	  of	  dietary	  AA	  delivery	  to	  skeletal	  muscle	  likely	  plays	  a	  
role	  in	  the	  sarcopenia	  of	  aging	  (130-­‐132).	  
ANOVA	  of	  untargeted	  metabolomics	  demonstrated	   that	   aging	  was	   associated	  with	  
lower	   tryptophyl-­‐valine	   levels	   in	   skeletal	   muscle,	   which	   agrees	   with	   the	   previously	  
discussed	   lower	   AA	   levels	   with	   age.	   11(R)-­‐hydroxyeicosatetraenoic	   acid	   is	   a	   pro-­‐
inflammatory	  substance	  (133).	  Similar	  to	  this	  study,	  a	  previous	  research	  in	  human	  plasma	  
found	   that	   several	   pro-­‐inflammatory	   hydroxyeicosatetraenoic	   acids	   increase	   with	   age	  
(134),	   consistent	   with	   age-­‐related	   inflammation.	   Eicosapentaenoic	   acid,	   an	   omega-­‐3	   FA,	  
was	  higher	  with	  age,	  consistent	  previous	  studies	  of	  human	  plasma	  and	  erythrocytes	  (135-­‐
144).	  However,	  mechanisms	  responsible	  for	  the	  correlation	  are	  still	  unclear;	  some	  studies	  
suggest	   that	   this	   is	  caused	  by	  higher	   intake	  of	   fish	  and	  omega-­‐3	  FA	  supplements	   in	  older	  
people	   (143,	   144).	   Our	   study	   did	   not	   include	   dietary	   records	   and	   therefore	   did	   not	  
document	   habitual	   fish	   intake.	   Omega-­‐3	   FA	   supplement	   did	   not	   explain	   the	   correlation	  
because	  the	  age	  range	  (40	  -­‐	  62	  years	  of	  age,	  average	  49	  years)	  of	  participants	  who	  reported	  
fish	  oil	  supplement	  usage	  (n	  =	  11)	  was	  narrow.	  	  
As	  previously	  discussed,	  PA,	  PC,	  PE,	  PG,	  PI	  and	  PS	  are	  phospholipids	  that	  are	  major	  
components	  of	  cell	  and	  mitochondrial	  membranes;	  they	  play	  various	  important	  roles	  in	  cell	  
and	  mitochondrial	  function.	  Cardiolipins	  are	  also	  phospholipids	  and	  are	  exclusively	  located	  
in	   the	   inner	   mitochondrial	   membrane	   (145-­‐147).	   They	   are	   involved	   in	   several	  
mitochondrial	   bioenergetic	   processes	   and	   optimize	   the	   activity	   of	   proteins	   involved	   in	  
OXPHOS	  (148-­‐151).	  Thus,	   the	  age-­‐associated	  decrease	  of	  most	  phospholipids	  observed	  in	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our	  study	  may	  be	  associated	  with	  age-­‐related	  decrease	  in	  cell	  and	  mitochondrial	  function.	  
However,	  we	  found	  that	  several	  polyunsaturated	  phospholipids	  were	  positivity	  correlated	  
with	   age,	   suggesting	   that	   aging	   is	   also	   associated	   with	   higher	   lipid	   unsaturation	   of	   the	  
mitochondrial	   membrane,	   which	   is	   associated	   with	   increased	   susceptibility	   to	   lipid	  
peroxidation,	   consistent	   with	   the	   age-­‐related	   increase	   in	   lipid	   peroxidative	   damage	   to	  
mitochondria	   (6,	   93,	   94).	   Because	   phospholipid	   levels	  were	   lower	   in	   obese	   subjects,	   the	  
effect	  of	  obesity	  on	  phospholipids	  is	  similar	  to	  the	  effect	  of	  aging,	  i.e.	  obesity	  mimics	  aging.	  
UDP-­‐n-­‐acetylglucosamine	   plays	   a	   crucial	   role	   in	   intracellular	   signaling	   (152).	   Thus,	   the	  
reduction	  in	  UDP-­‐n-­‐acetylglucosamine	  with	  age	  documented	  in	  this	  study	  may	  link	  to	  age-­‐
related	  decreased	  in	  cellular	  function.	  However,	  further	  studies	  are	  needed	  to	  identify	  how	  
UDP-­‐n-­‐acetylglucosamine	   decreases	   with	   age.	   It	   is	   widely	   accepted	   that	   the	   adrenal	  
production	  of	  DHEAS	  and	  pregnenolone,	  which	  are	  a	  steroid	  hormone	  and	  steroid	  hormone	  
precursor,	  respectively,	  declines	  with	  age	  (153-­‐158).	  Therefore,	  it	  is	  not	  surprising	  that	  age	  
and	  DHEAS	  as	  well	  as	  age	  and	  pregnenolone	  were	  negatively	  correlated	  in	  this	  study.	  	  
Xanthine	   is	   catalyzed	   by	   the	   enzyme	   xanthine	   oxidase	   (159).	   Previous	   research	  
demonstrated	  that	  xanthine	  oxidase	  expression	  and	  activity	  increased	  with	  age	  in	  several	  
mouse	   tissues	   (160),	   in	   skeletal	   muscle	   and	   plasma	   of	   rats	   (161),	   as	   well	   as	   in	   human	  
plasma	  (161),	   resulting	   in	  age-­‐related	  oxidative	  stress	  caused	  by	  production	  of	  hydrogen	  
peroxide	   and	   superoxide	   anion	   from	   xanthine	   catabolism	   (162).	   Thus,	   the	   negative	  
correlation	  between	  age	  and	  xanthine	  found	  in	  our	  study	  may	  be	  associated	  with	  the	  age-­‐
related	  increase	  in	  xanthine	  catabolism	  due	  to	  increased	  xanthine	  oxidase	  activity.	  
ANOVA	   showed	   no	   significant	   correlation	   between	   age	   and	   mtDNA	   profiles.	  
However,	   there	   were	   baseline	  mtDNA	   deletion	   ratio	   and	  mtDNA	   count	   number	   differed	  
between	   the	   31	   oldest	   and	   31	   youngest	   subjects.	   Previous	   research	   in	   human	   skeletal	  
muscle	   (16)	   reported	   significantly	   higher	   mtDNA	   deletion	   in	   older	   individuals	   when	  
compared	   to	   their	   younger	   counterparts,	   but	   the	   difference	   between	   age	   groups	   in	   our	  
study	  did	  not	   reach	   statistical	   significance.	  This	  may	  be	  due	   to	   a	   larger	   age	  difference	  of	  
between	   groups	   in	   the	   previous	   study	   (54-­‐78	   years	   of	   age,	   average	   69	   years	   vs.	   19-­‐40	  
years,	  average	  29	  years)	  compared	  with	  our	  study	  (55-­‐67	  years	  of	  age,	  average	  58	  years	  vs.	  
26-­‐44	   years	   of	   age,	   average	   39	   years),	   we	   just	  may	   not	   have	   the	   power	   to	   detect	   small	  
differences	   across	   the	   groups.	  mtDNA	  deletion	   analysis	   suggests	   that	   the	   pattern	   of	   age-­‐
	   154	  
related	   mtDNA	   deletion	   is	   not	   linear	   and	   may	   be	   mediated	   by	   other	   factors.	   Previous	  
research	   in	   human	   skeletal	   muscle	   (23)	   demonstrated	   significant	   negative	   correlation	  
between	  age	  and	  mtDNA	  count	  number,	  which	  was	  not	  documented	  in	  this	  study.	  However,	  
that	   study	   did	   not	   adjust	   for	   any	   other	   covariables,	   suggesting	   that	   the	   effect	   of	   age	   on	  
mtDNA	  count	  number	  may	  be	  mediated	  by	  other	  factors.	  Further	  research	  is	  necessary	  to	  
identify	  mediators	  of	  the	  effects	  of	  age	  on	  mtDNA	  profiles.	  
ANOVA	  from	  targeted	  metabolomics	  revealed	  that	  high	  VO2max	  was	  associated	  with	  
lower	   AA	   and	   BCAA	   intermediate	   levels	   at	   120	   min	   after	   high-­‐protein	   liquid	   ingestion	  
(MMTT).	  Although	  several	  AAs	  are	  associated	  with	   insulin	  sensitivity	  status,	   the	  negative	  
correlations	  between	  VO2max	  and	  AAs	  are	  not	  due	  to	  insulin	  sensitivity	  status	  as	  ANOVAs	  
were	   adjusted	   by	   HOMA-­‐IR.	   Rather,	   the	   negative	   correlations	   may	   be	   explained	   by	   the	  
higher	  mitochondrial	   capacity	   for	  AA	  catabolism	   in	  people	  with	  high	  VO2max,	  which	  was	  
confirmed	   by	   the	   negative	   correlations	   between	   VO2max	   and	   BCAA	   intermediate-­‐to-­‐
substrate	   ratios,	   consistent	   with	   previous	   work	   in	   rats	   (69).	   Because	   CR	   was	   also	  
associated	  with	   increased	  mitochondrial	   capacity	   for	  BCAA	  catabolism,	   this	  effect	  of	  high	  
VO2max	   is	   comparable	   to	   the	   effect	   of	   CR.	  Unlike	  AAs,	   high	  VO2max	  was	   associated	  with	  
higher	   long-­‐chain	   acylcarnitines	   and	   C18:1	   carnitine-­‐to-­‐oleic	   acid	   ratio,	   suggesting	   that	  
people	  with	  high	  VO2	  max	  have	  higher	  FA	  uptake	  into	  the	  mitochondria	  for	  FAO.	  Since	  CR	  
also	   increased	   the	   levels	   of	   long-­‐chain	   acylcarnitines,	   the	   effect	   of	   high	   VO2max	   on	  
increased	   FA	   uptake	   into	   the	   mitochondria	   for	   FAO	   is	   comparable	   to	   the	   effect	   of	   CR.	  	  
Positive	   correlations	   between	   VO2max	   and	   short-­‐even	   chain	   acylcarnitines	   as	   well	   as	  
medium-­‐chain	   acylcarnitines	   suggest	   that	   high	   VO2max	   is	   associated	   with	   higher	   FAO,	  
which	   agrees	   with	   previous	   research	   in	   rats	   (25,	   69,	   163-­‐166)	   and	   humans	   (167-­‐169).	  
Because	  CR	  also	  increased	  medium-­‐chain	  acylcarnitine	  levels,	  the	  effect	  of	  high	  VO2max	  on	  
increased	  FAO	  is	  comparable	  to	  the	  effect	  of	  CR	  as	  well.	  	  Moreover,	  the	  positive	  correlations	  
were	  more	  significant	  after	  CR,	  suggesting	  that	  obesity	  overwhelms	  the	  effect	  of	  VO2max	  on	  
FAO.	  Higher	  mitochondrial	  capacity	  for	  AA	  catabolism	  and	  FAO	  in	  people	  with	  high	  VO2max	  
resulted	  in	  increased	  TCA	  cycle	  production,	  consistent	  with	  positive	  correlations	  between	  
VO2max	  and	  TCA	  cycle	  metabolites	  found	  in	  this	  study	  as	  well	  as	  previous	  work	  in	  mouse	  
skeletal	  muscle	  (170),	  which	  is	  again	  comparable	  with	  the	  effect	  of	  CR.	  	  
To	  our	  knowledge,	  human	  studies	  that	  identify	  mechanisms	  by	  which	  high	  VO2max	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is	   associated	   with	   higher	   mitochondrial	   capacity	   for	   AA	   catabolism	   and	   FA	   metabolism	  
have	  not	  yet	  been	  published.	  However,	  studies	  in	  the	  rat	  genetic	  model	  of	  aerobic	  treadmill	  
running	   capacity	   demonstrated	   that	   higher	   mitochondrial	   capacity	   for	   AA	   catabolism	   in	  
high	   capacity	   running	   (HCR)	   rats	   was	   associated	   with	   higher	   mitochondrial	   protein	  
deacetylation	  (69)	  and	  higher	  mitochondrial	  capacity	   for	  FA	  metabolism	  in	  HCR	  rats	  was	  
associated	   with	   higher	   mitochondrial	   protein	   deacetylation	   (69)	   as	   well	   as	   higher	  
expression	  of	  genes	  and	  proteins	  responsible	  for	  FA	  metabolism	  as	  described	  in	  chapter	  2.	  
Unlike	  this	  skeletal	  muscle	  study,	  the	  study	  in	  fasting	  plasma	  described	  in	  chapter	  4	  
demonstrated	  that	  VO2max	  was	  negatively	  correlated	  with	  short	  even-­‐,	  medium-­‐	  and	  long-­‐
chain	   acylcarnitine	   levels.	   Therefore,	   we	   calculated	   correlations	   between	   fasting	   plasma	  
acylcarnitines	  and	  acylcarnitines	  in	  skeletal	  muscle	  at	  120	  min	  of	  MMTT	  from	  61	  (14	  non-­‐
obese	  and	  47	  obese)	   subjects	  who	  enrolled	   in	  both	   fasting	  plasma	  study	   (chapter	  4)	  and	  
this	   skeletal	   muscle	   study.	   There	   were	   not	   any	   highly	   positive	   correlations	   between	  
acylcarnitines	  in	  fasting	  plasma	  and	  postprandial	  skeletal	  muscle	  (r	  =	  -­‐0.143	  to	  0.320).	  We	  
also	  calculated	  correlations	  between	  acylcarnitines	  in	  plasma	  and	  skeletal	  muscle	  collected	  
at	  120	  min	  of	  MMTT	   from	  36	   (11	  non-­‐obese	  and	  25	  obese)	   subjects	  who	  participated	   in	  
both	  study	  in	  plasma	  over	  MMTT	  (described	  in	  chapter	  6)	  and	  this	  skeletal	  muscle	  study.	  
Like	  fasting	  plasma,	  there	  were	  no	  highly	  positive	  correlations	  between	  any	  acylcarnitines	  
in	   plasma	   and	   skeletal	   muscle	   at	   120	   min	   of	   MMTT	   (r	   =	   -­‐0.313	   to	   0.382).	   The	   poor	  
correlations	  between	   fasting	  acylcarnitines	   in	  plasma	  and	   skeletal	  muscle	  of	  humans	  has	  
been	  previously	  documented	  (171)	  though	  a	  separate	  study	  in	  humans	  demonstrated	  that	  
most	   acylcarnitines	   in	   fasting	   plasma	   originated	   from	   skeletal	   muscle	   (172).	   A	   possible	  
explanation	  for	  the	  poor	  correlations	  is	  that	  acylcarnitines	  produced	  during	  FAO	  are	  only	  
briefly	   present	   in	   skeletal	  muscle;	   incomplete	   FAO	   associated	  with	   low	  VO2max	   leads	   to	  
accumulation	   of	   acylcarnitines	   in	   plasma,	   and	   thus	   there	   were	   negative	   correlations	  
between	  VO2max	  and	  FA-­‐derived	  plasma	  acylcarnitines.	  
ANOVA	   in	   untargeted	   metabolomics	   demonstrated	   that	   PE	   and	   VO2max	   were	  
negatively	  correlated.	  This	  is	  at	  odds	  with	  previous	  research	  in	  human	  skeletal	  muscle	  that	  
observed	   higher	   PE	   in	   the	   group	   of	   people	   with	   high	   VO2max	   who	   had	   higher	   insulin	  
sensitivity	   and	   lower	   BMI	   (97).	   However,	   the	   results	   from	   that	   previous	   study	  were	   not	  
adjusted	   by	   insulin	   sensitivity	   status	   or	   BMI,	   thus	   the	   higher	   level	   of	   PE	  may	   instead	   be	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caused	  by	  higher	  insulin	  sensitivity	  and	  lower	  BMI.	  Further	  in-­‐depth	  research	  is	  necessary	  
to	   identify	   the	   interaction	   among	   skeletal	   muscle	   PE,	   obesity,	   insulin	   resistance,	   and	  
VO2max.	   We	   found	   that	   levels	   of	   PA,	   PG	   and	   PI	   were	   positively	   correlated	   with	   high	  
VO2max;	   the	   results	   suggest	   that	   high	   VO2max	   is	   associated	   with	   better	   cell	   and	  
mitochondrial	   function	   since	   these	   metabolites	   play	   various	   important	   roles	   in	   cell	   and	  
mitochondrial	  function.	  	  
As	  previously	  discussed,	  UDP-­‐n-­‐acetylglucosamine	  has	  a	  crucial	  role	  in	  intracellular	  
signaling.	   Therefore,	   the	   positive	   correlation	   between	   VO2max	   and	   UDP-­‐n-­‐
acetylglucosamine	   observed	   in	   this	   study	   may	   be	   related	   to	   high	   VO2max-­‐associated	  
improved	   cellular	   function.	   Because	   aging	   was	   associated	   with	   lower	   UDP-­‐n-­‐
acetylglucosamine	   level,	   the	   age	   independent	   positive	   correlation	   between	   VO2max	   and	  
UDP-­‐n-­‐acetylglucosamine	   suggests	   that	   VO2max	   is	   associated	   with	   delay	   aging.	   We	   also	  
found	   that	   DHEAS	   was	   positively	   correlated	   with	   VO2max,	   which	   agrees	   with	   previous	  
findings	   in	   human	   serum	   (158,	   173).	   However,	   the	   mechanisms	   responsible	   for	   this	  
positive	   correlation	   remain	   unclear	   (173).	   Interestingly,	   several	   observational	   studies	   in	  
humans	   have	   demonstrated	   that	   low	   serum	   DHEAS	   is	   associated	   with	   cardiovascular	  
diseases	  (CVD)	  (174-­‐182).	  Thus,	  the	  protective	  effect	  of	  high	  VO2max	  against	  CVD	  may	  in	  
part	   be	  mediated	   by	  DHEAS.	   Since	   aging	  was	   associated	  with	   lower	  DHEAS,	   the	   positive	  
correlation	  between	  VO2max	  and	  DHEAS	  independent	  of	  age	  further	  suggests	  that	  VO2max	  
is	   associated	  with	  delayed	  aging.	   It	  has	  been	  previously	  documented	  antioxidant	  enzyme	  
glutathione	  peroxidase	  activity	  was	  higher	  in	  plasma	  (18)	  of	  people	  with	  higher	  VO2max.	  In	  
addition,	  the	  increased	  antioxidant	  enzyme	  glutathione	  reductase	  activity	  in	  human	  plasma	  
was	   associated	  with	   increased	   VO2max	   after	   training	   (183,	   184).	   Therefore,	   the	   positive	  
correlations	   between	   VO2max	   and	   oxidized	   glutathione	   as	   well	   as	   VO2max	   and	   reduced	  
glutathione	   found	   in	  our	   study	  may	  be	  associated	  with	  activity	  of	  glutathione	  peroxidase	  
and	   glutathione	   reductase,	   respectively,	   suggesting	   that	   high	   VO2max	   is	   associated	   with	  
lower	  oxidative	  stress,	  consistent	  with	  previous	  studies	  in	  the	  rat	  genetic	  model	  of	  aerobic	  
treadmill	  running	  capacity	  and	  humans	  as	  described	  in	  chapter	  2.	  
ANOVA	   also	   demonstrated	   a	   positive	   correlation	   between	   VO2max	   and	   mtDNA	  
count	  number,	  consistent	  with	  previous	  skeletal	  muscle	  research	  in	  humans	  (23)	  and	  rats	  
(25).	   This	   positive	   correlation	   disappeared	   after	   CR,	   suggesting	   that	   CR	   diminishes	   the	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effect	  of	  VO2max	  on	  mtDNA	  count	  number.	  
In	   contrast	   to	   fasting	  plasma	  (described	   in	  chapter	  4),	  VO2max	  does	  not	  modulate	  
age-­‐related	   changes	   in	   skeletal	   muscle	   metabolite	   levels.	   Rather,	   it	   directly	   affects	  
metabolite	  levels	  in	  skeletal	  muscle.	  The	  agrees	  with	  the	  fact	  that	  skeletal	  muscle	  is	  a	  major	  
determinant	  of	  VO2max	  (185).	  Moreover,	   the	  modulating	  effect	  of	  VO2max	  on	  age-­‐related	  
changes	   in	   plasma	  metabolite	   levels	   does	   not	   reflect	   current	   skeletal	   muscle	  metabolite	  
levels.	  
Our	  study	  revealed	  that	  the	  effect	  of	  VO2max	  on	  a	  few	  metabolites	  in	  skeletal	  muscle	  
is	   mediated	   by	   mtDNA	   count	   number,	   suggesting	   that	   the	   effect	   of	   VO2max	   on	   skeletal	  
muscle	  metabolite	  levels	  is	  in	  part	  mediated	  by	  mtDNA.	  	  Other	  possible	  mediators	  include	  
mitophagy,	   mitochondrial	   proteostasis,	   mitochondrial	   membrane	   lipid	   composition	   and	  
ETC	  efficiency	  (6).	  Further	  research	  is	  necessary	  to	  identify	  related	  mediators.	  	  
Our	  study	  has	  some	   limitations,	   including	   the	  small	  number	  of	  non-­‐obese	  subjects	  
and	  limited	  amount	  of	  skeletal	  muscle	  tissue	  available	  for	  mitochondrial	  isolation.	  Further	  
research	  on	  isolated	  skeletal	  muscle	  from	  non-­‐obese	  subjects	  would	  determine	  the	  effects	  
of	   age	   and	   VO2max	   on	   mitochondria-­‐specific	   metabolites	   in	   skeletal	   muscle	   under	  
physiological	  condition.	  Additionally,	  the	  duration	  of	  CR	  in	  this	  study	  was	  not	  long	  enough	  
to	  identify	  the	  changes	  in	  metabolite	  levels	  and	  mtDNA	  profiles	  in	  older	  individuals.	  Future	  
research	  that	  includes	  a	  longer	  duration	  of	  CR	  may	  reveal	  the	  dynamic	  effect	  of	  CR	  on	  age-­‐
related	  changes	  in	  metabolite	  levels	  and	  mtDNA	  profiles.	  	  
	  
5.5	  Summary	  
Analysis	   of	   human	   skeletal	   muscle	   via	   targeted	   and	   untargeted	   metabolomics	  
approaches	  revealed	  that	  metabolism	  changes	  with	  age.	  Obesity	  was	  associated	  with	  lower	  
levels	  of	  reduced	  glutathione	  and	  phospholipids,	  conditions	   that	  also	  decreased	  with	  age,	  
suggesting	   that	   obesity	   mimics	   aging.	   CR	   decreased	   mitochondrial	   membrane	   lipid	  
unsaturation	   by	   reducing	   the	   levels	   of	   PUFAs,	   which	   is	   associated	   with	   decreased	  
susceptibility	   to	   age-­‐related	   lipid	   peroxidative	   damage	   to	   mitochondria,	   consistent	   with	  
delayed	  metabolic	  aging.	  CR	  also	  delays	  aging	  by	  decreasing	  the	  level	  of	  glycocholic	  acid,	  a	  
marker	  of	  short	  lifespan.	  Unlike	  plasma	  metabolites,	  VO2max	  did	  not	  modulate	  the	  effect	  of	  
age-­‐related	  changes	  in	  skeletal	  muscle	  metabolite	  levels.	  Rather,	  it	  was	  directly	  associated	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with	  changes	  in	  metabolite	  levels	  in	  skeletal	  muscle,	  and	  this	  effect	  of	  VO2max	  at	  baseline	  
was	   partly	   mediated	   by	   mtDNA	   count	   number.	   However,	   CR	   diminished	   the	   effect	   of	  
VO2max	  on	  mtDNA	  count	  number.	  High	  VO2max	  was	  associated	  with	  higher	  levels	  of	  UDP-­‐
n-­‐acetyl	  glucosamine,	  glutathione,	  and	  DHEAS,	  all	  of	  which	  decrease	  with	  age,	   suggesting	  
that	   high	   VO2max	   delays	   metabolic	   aging	   as	   well.	   Moreover,	   CR	   and	   high	   VO2max	   were	  
associated	   with	   improved	  mitochondrial	   capacity	   for	   AA	   and	   FA	   utilization,	   resulting	   in	  
increased	  TCA	  cycle	  metabolite	  production.	  Because	  both	  CR	  and	  high	  VO2max	  can	  delay	  
metabolic	  aging	  and	  improve	  mitochondrial	  substrate	  utilization,	  the	  effects	  of	  CR	  and	  high	  
VO2max	   are	   comparable	   with	   each	   other.	   These	   benefits	   of	   CR	   and	   high	   VO2max	   are	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Table	   5.1	   Characteristics	   and	   non-­‐metabolite	   parameters	   of	   all	   participants	   at	   baseline	   and	   41	   obese	  
participants	   after	   CR.	   Data	   reported	   as	   mean	   (minimum-­‐maximum)	   unless	   otherwise	   noted.	   $	   =	   p-­‐value	  
<0.050;	  NA	  =	  not	  available	  
	  












subjects	   15	   99	   41	   NA	   NA	  
Male/female	   7/8	   40/59	   21/20	   NA	   NA	  
Race	  (n)	  
	  	  Caucasian	  
	  	  African	  	  	  	  
	  	  American	  



























	  	  	  Male	  
	  	  	  Female	  






















	  	  	  Male	  
	  	  	  Female	  





















Type	  2	  DM	  (n)	  
	  	  	  Male	  
	  	  	  Female	  




















	  	  	  Male	  
	  	  	  Female	  































Lean	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  






















free)	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  


























Fat	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  





















Total	  body	  fat	  
(%)	  
	  	  	  Male	  
	  	  	  Female	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  Male	  
	  	  	  Female	  


















	  	  	  Male	  
	  	  	  Female	  




























glucose	  x	  fasting	  
plasma	  insulin)	  
/405)	  
	  	  	  Male	  
	  	  	  Female	  












































	  	  	  Male	  
	  	  	  Female	  































REE	  per	  fat-­‐free	  
mass	  (kCal/kg)	  
	  	  	  Male	  
	  	  	  Female	  



























quotient	  at	  rest	  
(RQR)	  
	  	  	  Male	  
	  	  	  Female	  


































	  	  	  Male	  
	  	  	  Female	  
































	  	  	  Male	  
	  	  	  Female	  























(ml/(kg	  x	  min))	  
	  	  	  Male	  
	  	  	  	  
	  	  	  Female	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Table	   5.2	   Characteristics	   and	   non-­‐metabolite	   parameters	   of	   41	   obese	   participants	  who	   completed	  muscle	  
biopsies	  both	  before	  and	  after	  CR.	  Data	  were	  reported	  as	  “average	  (minimum-­‐maximum)”.	  $	  =	  p-­‐value	  <0.050;	  
NA	  =	  not	  available	  
	  	  	  Characteristics	   	  	  	  Obese	  at	  baseline	   	  	  Obese	  after	  CR	  
p-­‐value	  of	  
obese	  at	  baseline	  
vs.	  
obese	  after	  CR	  
Number	  of	  subjects	   41	   NA	  
Male/female	   21/20	   NA	  
Race	  
	  	  Caucasian	  
	  	  African	  American	  










	  	  	  Male	  
	  	  	  Female	  










	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  	  	  38.8	  (30.0-­‐32.0)	  
	  	  	  40.0	  (30.9-­‐48.5)	  
	  	  	  39.5	  (30.0-­‐48.5)	  
	  
	  	  	  	  	  	  31.9	  (26.1-­‐44.4)	  
	  	  	  	  	  	  32.8	  (26.0-­‐39.3)	  





%	  of	  weight	  loss	  after	  CR	  
	  	  	  Male	  
	  	  	  Female	  









Number	  of	  type	  2	  DM	  
	  	  	  Male	  
	  	  	  Female	  






	  	  	  	  7	  
	  	  	  	  6	  





Number	  of	  subjects	  who	  
received	  anti-­‐diabetic	  drugs	  
	  	  	  Male	  
	  	  	  Female	  








	  	  	  	  5	  
	  	  	  	  5	  






Lean	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  70.0	  (51.7-­‐82.6)	  
	  	  52.9	  (46.9-­‐60.1)	  
	  	  61.2	  (46.9-­‐82.6)	  
	  
	  	  	  	  67.3	  (49.9-­‐78.0)	  
	  	  	  	  50.3	  (43.1-­‐60.1)	  





Lean+bone	  (fat-­‐free)	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  73.5	  (54.6-­‐86.5)	  
	  	  55.6	  (49.4-­‐63.7)	  
	  	  64.8	  (49.4-­‐86.5)	  
	  
	  	  	  70.8	  (52.9-­‐82.0)	  
	  	  	  53.0	  (45.7-­‐63.3)	  





Fat	  mass	  (kg)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  49.9	  (33.4-­‐70.8)	  
	  	  52.0	  (33.0-­‐73.8)	  
	  	  50.9	  (33.0-­‐73.8)	  
	  
	  	  	  	  33.3	  (18.7-­‐61.5)	  
	  	  	  	  37.9	  (19.8-­‐58.4)	  





Total	  body	  fat	  percentage	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  41.4	  (31.3-­‐50.5)	  
	  	  49.0	  (37.5-­‐58.3)	  
	  	  45.1	  (31.3-­‐58.3)	  
	  	  	  
	  	  	  	  32.5	  (22.3-­‐44.7)	  
	  	  	  	  42.4	  (30.1-­‐50.6)	  





Fasting	  plasma	  glucose	  (mg/dl)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  100	  (73-­‐137)	  
	  	  105	  (80-­‐146)	  
	  	  102	  (73-­‐146)	  
	  
	  	  	  	  95	  (69-­‐131)	  
	  	  	  	  97	  (83-­‐148)	  















Fasting	  plasma	  insulin	  (mIU/l)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  22.5	  (11.0-­‐33.2)	  
	  	  	  	  21.0	  (9.9-­‐38.1)	  
	  	  	  	  21.7	  (9.9-­‐38.1)	  
	  
	  	  	  	  13.6	  (5.7-­‐24.8)	  
	  	  	  	  14.1	  (7.7-­‐22.5)	  






((Fasting	  plasma	  glucose	  x	  
Fasting	  plasma	  insulin)/405)	  
	  	  	  Male	  
	  	  	  Female	  




	  	  	  	  5.7	  (2.1-­‐10.7)	  
	  	  	  	  5.6	  (2.2-­‐11.0)	  




	  	  	  	  3.3	  (1.4-­‐7.1)	  
	  	  	  	  3.4	  (1.6-­‐5.2)	  







Resting	  energy	  expenditure	  
(REE)	  (kCal)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  
	  	  	  2237	  (1573-­‐2886)	  
	  	  	  1773	  (1304-­‐2293)	  
	  	  	  2005	  (1304-­‐2886)	  
	  
	  
	  	  	  	  	  2004	  (1246-­‐2578)	  
	  	  	  	  	  1605	  (1144-­‐2031)	  






REE	  per	  fat-­‐free	  mass	  	  
(kCal/kg)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  
	  	  	  	  30.3	  (25.9-­‐35.1)	  
	  	  	  	  31.9	  (25.5-­‐37.1)	  
	  	  	  	  31.1	  (25.5-­‐37.1)	  
	  
	  
	  	  	  	  28.2	  (23.2-­‐35.6)	  
	  	  	  	  30.1	  (23.2-­‐36.7)	  






Respiratory	  quotient	  at	  rest	  
(RQR)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  
	  	  	  	  0.80	  (0.74-­‐0.93)	  
	  	  	  	  0.82	  (0.77-­‐0.93)	  
	  	  	  0.81	  (0.74-­‐0.93)	  
	  
	  
	  	  	  	  0.79	  (0.68-­‐1.06)	  
	  	  	  	  0.80	  (0.70-­‐0.91)	  






Respiratory	  quotient	  at	  VO2max	  
(RQE)	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  
	  	  	  	  1.17	  (1.02-­‐1.37)	  
	  	  	  	  1.11	  (0.97-­‐1.25)	  
	  	  	  	  1.14	  (0.97-­‐1.37)	  
	  
	  
	  	  	  1.15	  (0.85-­‐1.37)	  
	  	  	  1.14	  (0.96-­‐1.35)	  







	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  	  	  3.19	  (1.69-­‐4.30)	  
	  	  	  2.18	  (1.69-­‐2.91)	  
	  	  	  2.70	  (1.69-­‐4.30)	  
	  
	  	  	  	  3.23	  (1.77-­‐4.69)	  
	  	  	  	  2.25	  (1.57-­‐3.64)	  





VO2max	  per	  fat-­‐free	  mass	  
(ml/(kg	  x	  min))	  
	  	  	  Male	  
	  	  	  Female	  
	  	  	  All	  	  	  
	  
	  
	  	  	  43.20	  (30.94-­‐53.98)	  
	  	  	  39.40	  (27.96-­‐43.84)	  
	  	  	  41.35	  (27.96-­‐53.98)	  
	  
	  
	  	  	  45.32	  (30.52-­‐58.83)	  
	  	  	  42.79	  (27.08-­‐70.71)	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Table	  5.3	  Concentrations	  and	  ratios	  of	  targeted	  metabolites	  and	  mtDNA	  profiles	  of	  all	  participants	  at	  baseline	  
and	  41	  obese	  participants	  after	  CR.	  Data	  were	  reported	  as	  average±SEM.	  $	  =	  p-­‐value	  <0.050	  












	  	  Male	  
	  	  Female	  























	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  



























(pmol/mg)	   	  
	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  



























glutamic	  acid	  ratio	  
	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  























	  	  Male	  
	  	  Female	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  Female	  












	  	  Male	  
	  	  Female	  























	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  






















	  	  Male	  
	  	  Female	  























	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  






















metabolites	  	   Non-­‐obese	  
Obese	  at	  












	  	  Male	  
	  	  Female	  





















Glucose-­‐6-­‐ 	   	   	   	   	  




	  	  Male	  
	  	  Female	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  Female	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  Male	  
	  	  Female	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  Female	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  Female	  













	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	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  Male	  
	  	  Female	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  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	  



























metabolites	   Non-­‐obese	  
Obese	  at	  












	  	  Male	  
	  	  Female	  





















Succinate	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(pmol/mg)	  
	  	  Male	  
	  	  Female	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  Male	  
	  	  Female	  






















	  	  Male	  
	  	  Female	  























	  	  Male	  
	  	  Female	  



























	  	  Male	  
	  	  Female	  






















	  	  Male	  
	  	  Female	  



































C18:1	  carnitine-­‐to-­‐ 	   	   	   	   	  










oleic	  acid	  ratio	  	  
(x10-­‐1)	  
	  	  Male	  
	  	  Female	  


























C3	  and	  C5	  carnitine-­‐
to-­‐substrate	  ratios	   Non-­‐obese	  
Obese	  at	  












valine	  ratio	  (x10-­‐2)	  
	  	  Male	  
	  	  Female	  





























	  	  Male	  
	  	  Female	  












































	  	  Male	  
	  	  Female	  




























	  	  Male	  
	  	  Female	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Table	   5.4	   Concentrations	   and	   ratios	   of	   targeted	  metabolites	   and	  mtDNA	  profiles	   of	   41	   obese	   participants	  
who	  completed	  muscle	  biopsies	  both	  before	  and	  after	  CR.	  Data	  were	  reported	  as	  average±SEM.	   $	  =	  p-­‐value	  
<0.050	  
AAs	   Obese	  at	  baseline	   Obese	  after	  CR	  






	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  













Aspartic	  acid	  (pmol/mg)	  	  
	  	  Male	  
	  	  Female	  













Glutamic	  acid	  (nmol/mg)	  
	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  













Glutamine-­‐to-­‐glutamic	  acid	  ratio	  
	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	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  Female	  








	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  













Glycolysis	  metabolites	  	   Obese	  at	  baseline	   Obese	  after	  CR	  






	  	  Male	  
	  	  Female	  















	  	  Male	  
	  	  Female	  
















Fructose	  1,6-­‐bisphosphate	  	  (nmol/mg)	  
	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  













Dihydroxyacetone	  phosphate	  	  (nmol/mg)	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  Female	  








3-­‐phosphoglyceric	  acid	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  

















	  	  Male	  
	  	  Female	  















	  	  Male	  
	  	  Female	  
















FA	   Obese	  at	  baseline	   Obese	  after	  CR	  





Oleic	  acid	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













Acylcarnitines	   Obese	  at	  baseline	   Obese	  after	  CR	  






	  	  Male	  
	  	  Female	  













C2	  carnitine	  (nmol/mg)	  
	  	  Male	  
	  	  Female	  













C3	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C4	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C5	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C5-­‐DC	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	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C6	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C8:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C8:1	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C10:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C10:1	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C12:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C12:1	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C12-­‐OH	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C14:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C14:1	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C14:2	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C14-­‐OH	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C16:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C16:1	  carnitine	  (pmol/mg)	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  Female	  







C16-­‐OH	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C18:0	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C18:1	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C18:2	  carnitine	  (pmol/mg)	  
	  	  Male	  
	  	  Female	  













C20:0	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C20:1	  carnitine	  (fmol/mg)	  
	  	  Male	  
	  	  Female	  













C20:2	  carnitine	  (fmol/mg	  )	  
	  	  Male	  
	  	  Female	  













C20:3	  carnitine	  (fmol/mg	  )	  
	  	  Male	  
	  	  Female	  













C20:4	  carnitine	  (fmol/mg	  )	  
	  	  Male	  
	  	  Female	  













TCA	  cycle	  metabolites	   Obese	  at	  baseline	   Obese	  after	  CR	  






	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  










	   176	  
	  	  All	   1005.93±170.31	   1286.36±238.75	   0.191	  
Nucleotides	   Obese	  at	  baseline	   Obese	  after	  CR	  






	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  














	  	  Male	  
	  	  Female	  













Long-­‐chain	  acylcarnitine-­‐to-­‐FA	  ratio	   Obese	  at	  baseline	   Obese	  after	  CR	  





C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  	  
(x10-­‐1)	  
	  	  Male	  
	  	  Female	  
















C3	  and	  C5	  carnitine-­‐to-­‐substrate	  ratios	   Obese	  at	  baseline	   Obese	  after	  CR	  





C3	  carnitine-­‐to-­‐valine	  ratio	  (x10-­‐2)	   	   	   	  




























	  	  Male	  
	  	  Female	  










C5	  carnitine-­‐to-­‐isoleucine+leucine	  ratio	  
(x10-­‐2)	  
	  	  Male	  
	  	  Female	  
















mtDNA	  profiles	   Obese	  at	  baseline	   Obese	  after	  CR	  





mtDNA	  deletion	  ratio	  (%)	  
	  	  Male	  
	  	  Female	  













mtDNA	  count	  number	  	  
	  	  Male	  
	  	  Female	  













	   178	  
Table	  5.5	  Normalized	  peak	  areas	  of	  untargeted	  metabolites	  that	  were	  different	  between	  non-­‐obese	  and	  all	  
obese	   participants	   after	   CR.	   Data	   were	   reported	   as	   average±SEM.	   Neutral	   mass	   and	   retention	   time	   were	  
reported	  as	  Da	  and	  min,	  respectively.	  $	  =	  p-­‐value	  <0.050	  
Dipeptides	  







	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  
























	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  
























	  	  Male	  
	  	  Female	  


















	  	  Male	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  All	   5.64±0.74	   3.94±0.15	   <0.001$	  
LysoPA(18:2)	  
(434.2439_8.54)	  (x105)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	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  Female	  









	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	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  Male	  
	  	  Female	  












	  	  Male	  
	  	  Female	  
















TCA	  cycle	  metabolites	  







	  	  Male	  
	  	  Female	  
























	  	  Male	  
	  	  Female	  
























	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  













	   182	  
	  	  All	   2.86±0.33	   2.23±0.08	   0.014$	  
Phosphocreatine	  
(477.0836_1.20)	  (x106)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  
























	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	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  All	   1.89±0.43	   1.28±0.08	   0.020$	  
Unknown	  
(633.0985_1.21)	  (x106)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  







































































	  	  Female	  









	  	  Male	  
	  	  Female	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Table	   5.6	  Normalized	  peak	  areas	  of	  untargeted	  metabolites	   that	  were	  significantly	   changed	  after	  CR	   in	  41	  
obese	  participants.	  Data	  were	  reported	  as	  average±SEM.	  Neutral	  mass	  and	  retention	  time	  were	  reported	  as	  
Da	  and	  min,	  respectively.	  $	  =	  p-­‐value	  <0.050	  
Dipeptides	  	  
(neutral	  mass_retention	  time)	   Obese	  at	  baseline	   Obese	  after	  CR	  
p-­‐value	  of	  	  
obese	  at	  baseline	  	  
vs.	  obese	  after	  CR	  
Alanyl-­‐glutamine	  
(217.0934_2.83)	  (x105)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  

















(neutral	  mass_retention	  time)	   Obese	  at	  baseline	   Obese	  after	  CR	  
p-­‐value	  of	  	  
obese	  at	  baseline	  	  
vs.	  obese	  after	  CR	  
Arachidonic	  acid	  
(446.3331_9.05)	  (x105)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  

















(neutral	  mass_retention	  time)	   Obese	  at	  baseline	   Obese	  after	  CR	  
p-­‐value	  of	  	  
obese	  at	  baseline	  	  
vs.	  obese	  after	  CR	  
PA(O-­‐42:6)	  
(762.5422_10.77)	  (x105)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	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  Male	  
	  	  Female	  












	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  

















(neutral	  mass_retention	  time)	   Obese	  at	  baseline	   Obese	  after	  CR	  
p-­‐value	  of	  	  
obese	  at	  baseline	  	  
vs.	  obese	  after	  CR	  
1,25-­‐dihydroxyvitamin	  D3	  3-­‐glycoside	  
(578.3776_9.31)	  (x105)	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  Female	  









	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  

















(neutral	  mass_retention	  time)	   Obese	  at	  baseline	   Obese	  after	  CR	  
p-­‐value	  of	  	  
obese	  at	  baseline	  	  
vs.	  obese	  after	  CR	  
Unknown	  
(287.9841_1.07)	  (x106)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  






























	  	  All	   1.34±0.11	   1.92±0.27	   0.045$	  
Unknown	  
(664.0899_0.98)	  (x106)	  
	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	  


















	  	  Male	  
	  	  Female	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Figure	  5.1	  Correlations	  of	  targeted	  metabolites	  and	  mtDNA	  profiles	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  

























































































































	   192	  
Figure	  5.2	  Correlations	  of	  untargeted	  metabolites	  and	  mtDNA	  profiles	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	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Figure	  5.3	  Correlations	  of	  targeted	  metabolites	  and	  mtDNA	  profiles	  vs.	  VO2max	  per	  FFM	  at	  baseline,	  as	  well	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Figure	  5.4	  Correlations	  of	  untargeted	  metabolites	  and	  mtDNA	  profiles	  vs.	  VO2max	  per	  FFM	  at	  baseline,	  as	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A	  drift	  correction	  and	  batch	  combination	  tool	  for	  	  
mass	  spectrometry-­‐based	  metabolomics	  data	  
	  
6.1	  Introduction	  
As	  metabolomics	  has	  matured	  as	  a	  member	  of	  the	  ‘omics’	  sciences,	  its	  application	  to	  
large-­‐scale	   epidemiological	   studies	  of	  human	   subjects	  has	  undergone	   substantial	   growth.	  
Unlike	   experiments	   using	   cell	   culture	   or	   animal	   models	   in	   which	   carefully	   controlled	  
conditions	   allow	   studies	   with	   modest	   sample	   numbers	   to	   achieve	   sufficient	   statistical	  
power,	  studies	  of	  human	  subjects	  require	  analysis	  of	  hundreds	  or	  thousands	  of	  samples	  to	  
overcome	   natural	   variability	   and	   detect	   subtle	   biological	   effects.	   However,	   due	   to	   the	  
extended	  nature	  of	  some	  protocols	  in	  clinical	  research,	  metabolomics	  data	  may	  be	  acquired	  
in	  multiple	  batches	  over	  the	  course	  of	  weeks,	  months	  or	  years.	  In	  mass	  spectrometry	  (MS)-­‐
based	   metabolomics	   studies,	   both	   short-­‐	   and	   long-­‐term	   instrument	   sensitivity	   drift	   add	  
variability	  to	  the	  data	  and	  may	  limit	  the	  ability	  to	  detect	  biologically	  significant	  effects	  (1).	  
Thus,	   the	  difficulty	  of	   achieving	   reproducible	  quantitation	   is	   a	  great	  barrier	   to	   successful	  
completion	  of	  large-­‐scale	  metabolomics	  studies.	  
The	   need	   for	   robust	   normalization	   techniques	   for	   large	   sets	   of	   MS-­‐based	  
metabolomics	   data	   has	   long	   been	   apparent	   and	   various	   approaches	   have	   been	  
implemented	  previously.	  The	  simplest	  option	  is	  to	  normalize	  data	  to	  total	  metabolite	  signal	  
intensity	   or	   median	   signal	   intensity	   (2,	   3).	   However,	   this	   approach	   assumes	   that	   all	  
metabolites	   experience	   the	   same	   pattern	   of	   drift	   over	   and	   that	   the	   sum	   or	   median	  
metabolite	  abundance	  is	  approximately	  the	  same	  in	  all	  samples,	  which	  is	  often	  not	  the	  case	  
(4).	  A	  second	  option	  is	  to	  use	  internal	  standards	  (IS),	  added	  at	  a	  uniform	  concentration	  to	  
all	  samples,	  to	  monitor	  or	  correct	  for	  quantitative	  drift.	  This	  is	  most	  effective	  when	  stable	  




dilution	   mass	   spectrometry)	   (5,	   6),	   but	   in	   most	   cases	   it	   is	   impractical	   or	   impossible	   to	  
include	  an	  isotope-­‐labeled	  IS	  for	  all	  metabolites	  of	  interest.	  To	  enable	  more	  comprehensive	  
metabolomics	   profiling	   with	   IS	   normalization,	   computational	   techniques	   have	   been	  
proposed	   to	   aid	   in	   selection	   of	   an	   internal	   standard	   from	   the	   available	   subset	   that	  most	  
optimally	  corrects	   for	  drift	  or	  matrix	  effects	   in	  each	  metabolite	  (4).	  While	  superior	  to	  ad-­‐
hoc	  internal	  standard	  selection,	  it	  is	  not	  possible	  to	  ensure	  the	  drift	  correction	  is	  valid	  for	  
each	  compound,	  as	  the	  pattern	  of	  intensity	  drift	  often	  varies	  significantly	  from	  metabolite	  
to	  metabolite,	  even	  within	  a	  class	  of	  compounds.	  
The	  other	  major	  drift	  correction	  strategy,	  which	  has	  become	  the	  most	  widely	  cited	  
approach	   in	   recent	   metabolomics	   literature,	   is	   to	   use	   a	   quality	   control	   (QC)	   sample	  
analyzed	  once	  or	  repeatedly	  with	  each	  batch	  of	  samples	  as	   the	  basis	   for	  performing	  drift	  
correction	  (1,	  7-­‐12).	  This	  technique	  requires	  an	  ample	  supply	  of	  a	  suitable	  QC	  sample	  to	  be	  
prepared	  in	  advance	  for	  use	  as	  long	  as	  sample	  analysis	  is	  being	  performed,	  and	  increases	  
the	   number	   of	   samples	   to	   be	   analyzed.	   However,	   the	   strategy	   allows	   correction	   for	  
quantitative	   drift	   in	   each	   individual	   metabolite,	   regardless	   of	   whether	   an	   appropriate	  
internal	   standard	   is	   available,	   making	   it	   suited	   for	   both	   targeted	   and	   untargeted	  
metabolomics	  studies.	  One	  of	  the	  most	  widely	  cited	  variants	  of	  this	  strategy	  was	  described	  
by	   Dunn	   et	   al.,	   who	   used	   locally	   estimated	   scatterplot	   smoothing	   (LOESS)	   to	   correct	   for	  
peak	   area	   drift	   based	   upon	   observed	   intensity	   drift	   in	   a	   QC	   sample	   (7),	   although	   other	  
curve-­‐fitting	  strategies	  have	  also	  been	  proposed	  (13).	  	  
Existing	   tools	   for	   metabolomics	   data	   analysis	   such	   as	   XCMS	   Online	   and	  
MetaboAnalyst	  offer	  basic	  methods	  for	  automated	  normalization	  of	  metabolomics	  data	  (14,	  
15),	   but	   no	   currently	   available	   software	   offers	   an	   automated	   workflow	   for	   combining	  
batches	   and	   performing	   QC-­‐sample	   based	   drift	   correction	   with	   visualization.	   In	   this	  
manuscript,	  we	  present	  a	  Microsoft	  Excel	  (2013)	  based	  tool	  which	  allows	  data	  acquired	  on	  
any	  platform	  to	  be	  easily	  visualized	  and	  assessed	  for	  within	  and	  between-­‐batch	  drift.	  The	  
tool	   performs	   automatic	   drift	   correction	   based	   on	   QC	   sample	   data	   using	   a	   quadratic	  
regression	  or	  LOESS	  smoothing.	  We	  demonstrate	  the	  use	  of	  the	  tool	  on	  archived	  data	  and	  
an	   original	   set	   of	   LC-­‐MS-­‐based	   metabolomics	   data:	   a	   study	   of	   metabolic	   response	   to	   a	  





6.2	  Materials	  and	  methods	  
Enrollment	   criteria,	   CR	   protocol	   and	   mixed	   meal	   tolerance	   test	   (MMTT)	   were	  
described	  in	  chapter	  4.	  
	  
6.2.1	  Plasma	  extraction	  and	  LC-­‐MS	  metabolomics	  analysis	  
Targeted	   metabolomics	   was	   used	   to	   quantitate	   122	   plasma	   metabolites	   from	   a	  
variety	  of	  classes;	  all	  species	  measured	  are	  listed	  in	  Table	  A6.1	  of	  appendices.	  To	  serve	  as	  a	  
QC	   sample,	   a	   pooled	   human	   plasma	   sample	   obtained	   from	   the	   American	   Red	   Cross	  was	  
separated	  into	  50	  μl	  aliquots	  in	  microcentrifuge	  tubes	  and	  stored	  at	  -­‐80	  °C	  until	  individual	  
aliquots	   were	   thawed	   and	   extracted	   along	   with	   each	   analytical	   batch.	   To	   precipitate	  
proteins	  and	  extract	  metabolites,	  200	  μl	  of	  extraction	  solvent	  (1:1:1	  methanol:	  acetonitrile:	  
acetone)	   containing	   a	   mixture	   of	   isotope-­‐labeled	   internal	   standards	   (Table	   A6.2	   of	  
appendices)	  was	  added	  to	  50	  μl	  of	  plasma.	  The	  samples	  were	  vortexed	  for	  10	  sec,	  allowed	  
to	   rest	   on	   ice	   for	   5	   min,	   and	   then	   centrifuged	   at	   16,000	   g	   for	   10	   min	   at	   4	  °C.	   The	  
supernatant	   was	   transferred	   to	   an	   autosampler	   vial	   for	   liquid	   chromatography-­‐mass	  
spectrometry	   (LC-­‐MS)	   analysis	   using	   an	   Agilent	   1200	   LC	   with	   an	   Agilent	   6220	   time-­‐of-­‐
flight	  MS	   (Santa	   Clara,	   CA).	   All	   solvents	   and	   reagents	   used	  were	   LC-­‐MS	   grade	   and	  were	  
obtained	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   MO).	   Hydrophilic	   interaction	   chromatography	  
(HILIC)	   in	   negative	   ion	   mode	   was	   performed	  using	   a	   method	   similar	   to	   that	   described	  
previously	  (16)	  using	  a	  Phenomenex	  Luna	  NH2	  column,	  3	  μm	  particle	  size,	  150	  mm	  x	  1	  mm	  
inner	  diameter	  (i.d.)	  (Torrance,	  CA).	  Mobile	  phase	  A	  was	  5	  mM	  ammonium	  acetate	  in	  water	  
adjusted	  to	  pH	  9.9	  using	  ammonium	  hydroxide,	  and	  mobile	  phase	  B	  was	  acetonitrile.	  The	  
gradient	  consisted	  of	  a	  15-­‐min	  linear	  ramp	  from	  80	  to	  0%	  B,	  5	  min	  at	  0%	  B,	  and	  15	  min	  of	  
re-­‐equilibration	  at	  80%	  B.	  The	  flow	  rate	  was	  0.07	  ml/min	  from	  0-­‐27min,	  0.08	  ml/min	  from	  
27-­‐32	   min	   and	   0.09	   ml/min	   from	   32-­‐35	   min.	   MS	   parameters	   were	   as	   follows:	   full-­‐
scanmode	  (m/z	  50	  to	  1,200),	  acquisition	  rate	  1	  spectrum/sec,	  capillary	  voltage	  3500	  V,	  gas	  
temperature	  350	  °C,	  drying	  gas	  10	   l/min,	  nebulizer	  pressure	  20	  psig,	  and	  reference	  mass	  
correction	   enabled.	   Reversed-­‐phase	   liquid	   chromatography	   (RPLC)	   in	   both	   negative	   and	  
positive	  ion	  modes	  was	  performed	  a	  method	  similar	  to	  that	  described	  previously	  (17)	  using	  
a	  Waters	  Acquity	  HSS	  T3column,	  1.8	  μm	  particle	  size,	  2.1	  x	  100	  mm	  i.d.,	  with	  a	  flow	  rate	  of	  




hydroxide	   in	   water	   and	   mobile	   phase	   B	   was	   0.1%	   formic	   acid	   and	   0.028%	   ammonium	  
hydroxide	  in	  8:2	  isopropanol:methanol.	  The	  gradient	  consisted	  of	  6-­‐min	  linear	  ramp	  from	  0	  
to	  100%	  B,	  4	  min	  at	  100%	  B,	  and	  5	  min	  of	  re-­‐equilibration	  at	  0%	  B.	  MS	  parameters	  were	  
the	  same	  as	  HILIC	  except	  the	  acquisition	  rate	  was	  2	  spectra/sec	  and	  the	  nebulizer	  pressure	  
was	  40	  psig.	  A	   total	  of	  418	  test	  samples	  and	  66	  QC	  samples	  were	  analyzed	   in	  14	  batches	  
using	   both	  HILIC	   and	   RPLC	  methods.	   The	  QC	   sample	  was	   analyzed	   approximately	   every	  
8th	  run	  within	  each	  batch.	  To	  improve	  data	  quality	  and	  eliminate	  the	  runs	  prone	  to	  the	  most	  
extreme	  drift,	  the	  QC	  sample	  prepared	  with	  each	  batch	  was	  injected	  and	  analyzed	  3	  times	  
(for	  HILIC)	  or	  5	  times	  (for	  RPLC)	  before	  starting	  analysis	  of	  each	  new	  batch,	  and	  data	  from	  
all	   these	   QC	   pre-­‐injections	   were	   disregarded	   in	   subsequent	   data	   analysis	   and	   drift	  
correction.	  Targeted	  metabolomics	  data	  analysis	  was	  performed	  using	  Agilent	  Masshunter	  
Quantitative	   Analysis	   software	   version	   B.07.00.	   Peaks	   were	   identified	   by	   comparison	   of	  
accurate	   mass	   and	   retention	   time	   with	   those	   of	   authentic	   standards	   analyzed	   using	   the	  
same	  method.	  Peaks	  were	  quantitated	  by	  peak	  area	  using	  the	  ‘Agile2’	  peak	  integrator	  and	  
these	  data	  were	  exported	  into	  a	  spreadsheet	  (comma-­‐separated	  values	  file).	  A	  second	  set	  of	  
metabolomics	  data,	   generated	  by	   the	  West	  Coast	  Metabolomics	  Core	   at	   the	  University	   of	  
California,	   Davis,	   was	   obtained	   from	   the	   NIH	   Common	   Fund's	   Data	   Repository	   and	  
Coordinating	   Center	   (Metabolomics	   Workbench	   Project	   ID:	   PR000303,	   accessible	   at	  
http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Project&Projec
tID=PR000303.	  These	  data	  consisted	  of	  250	  test	  samples	  and	  26	  QC	  samples	  analyzed	  by	  
RPLC	  in	  both	  positive	  and	  negative	  ion	  mode.	  Based	  on	  run	  timestamp	  data,	  positive	  mode	  
data	   were	   acquired	   in	   a	   single	   batch	   of	   consecutive	   runs;	   negative	   ion	  mode	   data	   were	  
broken	   into	   two	   batches.	   Raw	   data	  were	   confirmed	   to	   have	   no	   prior	   drift	   correction	   or	  
other	  normalization	  applied.	  
	  
6.2.2	  Peak	  area	  drift	  correction,	  calculations	  and	  statistics	  
To	  correct	  for	  peak	  area	  drift	  within	  and	  between	  each	  sample	  batch,	  we	  developed	  
a	  custom	  macro-­‐enabled	  Excel	  spreadsheet	  called	  MetaboDrift	  (attached	  separately	  as	  the	  
Microsoft	   Excel	   file).	  Detailed	   instructions	   for	  using	  MetaboDrift	   are	  provided	  within	   the	  
Excel	  file;	  the	  general	  workflow	  for	  the	  software	  is	  as	  follows.	  Peak	  area	  data	  are	  inserted	  




number.	  Quality	  control	  samples	  are	   flagged	  to	  enable	   their	  use	   for	  drift	  correction.	  Peak	  
intensity	  profiles	  for	  each	  metabolite	  are	  then	  automatically	  visualized	  for	  QC	  and	  all	  other	  
samples.	   Two	   options	   are	   available	   for	   correction	   of	   within-­‐batch	   drift:	   quadratic	   fit	  
(QUAD)	  and	  LOESS.	  QUAD	  applies	  a	  standard	  least-­‐squares	  quadratic	  regression	  to	  the	  QC	  
sample	  data.	  For	  the	  purpose	  of	  curve	  fitting,	  y-­‐values	  are	  metabolite	  peak	  areas	  from	  the	  
QC	  samples	  and	  x-­‐values	  are	  the	  run	  number.	  The	  output	  of	  the	  regression	  is	  an	  equation	  in	  
the	  format	  of	  y=ax2+bx+c;	  the	  polynomial	  coefficients	  are	  used	  to	  estimate	  a	  predicted	  peak	  
area	  (y)	  on	  the	  quadratic	  curve	  given	  any	  run	  number	  (x)	  (Figure	  6.1).	  LOESS	  uses	  a	  locally-­‐
estimated	   polynomial	   smoothing	   procedure,	   as	   described	   by	   Dunn	   et	   al.,	   to	   generate	   a	  
predicted	   peak	   area	   at	   each	   point	   along	   the	   smoothed	   curve	   (7).	   Our	   implementation	   of	  
LOESS	  drift	  correction	  in	  Excel	  uses	  a	  publically	  available	  Excel	  add-­‐on	  function,	  accessible	  
at	  (http://peltiertech.com/loess-­‐smoothing-­‐in-­‐excel).	  It	  accepts	  the	  same	  x	  and	  y	  inputs	  as	  
QUAD,	   plus	   a	   parameter	   (n)	   for	   the	   number	   of	   points	   to	   use	   in	   the	   moving	   smoothing	  
function.	   Optimal	   setting	   for	   this	   parameter	   can	   be	   adjusted	   to	   optimize	   LOESS	   fit	   as	  
described	  previously	  (7).	  After	  predicted	  peak	  areas	  are	  calculated	  for	  all	  samples	  in	  a	  data	  
set,	  peak	  area	  correction	  is	  applied	  to	  each	  data	  point	  in	  the	  raw	  data	  using	  the	  following	  
formula:	  
Peak	  area	  corrected	  =	  Peak	  area	  raw	  ×	  (Peak	  area	  first	  run	  in	  data	  set	  /	  Peak	  area	  predicted)	  
This	   normalization	   has	   the	   effect	   of	   setting	   the	   peak	   area	   in	   the	   first	   QC	   sample	   of	   each	  
batch	   to	   the	   same	  value,	   and	  applying	   individual	  drift	   correction	   to	  each	  batch.	  The	  data	  
resulting	   from	   quadratic	   or	   LOESS	   drift-­‐correction	   are	   placed	   in	   new	  worksheets,	  which	  
allows	  comparison	  of	  the	  drift-­‐corrected	  data	  with	  the	  raw	  data.	  If	  the	  drift-­‐corrected	  data	  
does	  not	  meet	  acceptable	  criteria	  (e.g.,	  <10%	  RSD	  for	  corrected	  peak	  area	  in	  QC	  samples),	  
the	   metabolite	   can	   be	   dropped	   from	   further	   analysis	   or	   an	   alternate	   drift	   correction	  
strategy	  can	  be	  considered.	  
Drift-­‐corrected	  area	  under	  the	  curve	  (AUC)	  values	  were	  calculated	  by	  summing	  the	  
trapezoidal	   areas	   between	   the	   0,	   15,	   30,	   60,	   and	   120	  minute	   timepoints.	   Comparison	   of	  
metabolite	  levels	  between	  non-­‐obese	  and	  obese	  groups	  were	  performed	  using	  an	  unpaired-­‐
two-­‐tailed	  student’s	  t	  test.	  For	  the	  comparison	  between	  obese	  subjects	  at	  baseline	  and	  after	  




average±standard	   error	   of	   mean	   (SEM);	   p-­‐value	   <0.050	   were	   considered	   statistically	  
significant.	  
	  
6.3	  Results	  and	  discussion	  
	  
6.3.1	  Participant	  characteristics	  and	  non-­‐metabolite	  parameters	  
Participant	  characteristics	  were	  listed	  in	  Table	  6.1.	  Samples	  were	  obtained	  from	  35	  
obese	  (20	  males	  and	  15	  females)	  and	  16	  non-­‐obese	  (6	  males	  and	  10	  females)	  subjects.	  Age	  
was	  not	  significantly	  different	  between	  groups.	  Obese	  individuals	  were	  heavier	  (39.8±0.5	  
vs.	  23.1±0.8	  kg/m2).	  Body	  weight	  of	  obese	  individuals	  was	  decreased	  by	  17.7±1.3%	  with	  
CR	  (range	  4.1-­‐35.8%).	  The	  obese	  group	  had	  higher	   fasting	  plasma	  glucose	  and	   insulin,	  as	  
well	  as	  HOMA-­‐IR.	  All	  of	  these	  parameters	  altered	  significantly	  after	  CR	  and	  values	  became	  
closer	  to	  those	  of	  non-­‐obese	  subjects.	  
	  
6.3.2	  Peak	  area	  drift	  within	  and	  between	  batches	  	  
Substantial	  within-­‐batch	  metabolite	  peak	  area	  drift	  was	  observed	  in	  the	  raw	  MMTT	  
and	  Fiehn	  metabolomics	  data	  (Figure	  6.1a-­‐c).	  IS	  compounds	  also	  showed	  similar	  patterns	  
of	  drift	  (Figure	  6.1d).	  For	  many	  metabolites,	  the	  trend	  was	  for	  declining	  peak	  area	  over	  the	  
course	   of	   the	   runs;	   however,	   for	   some	   metabolites,	   drift	   was	   random	   or	   the	   peak	   area	  
increased.	  Between-­‐batch	  intensity	  shifts	  were	  also	  prominent,	  reflected	  as	  abrupt	  changes	  
in	   peak	   area	   in	   the	  QC	   sample	  data	   (Figure	  6.3a,c).	   In	   contrast	   to	   the	   observed	   intensity	  
drift,	  there	  was	  little	  retention	  time	  drift	  nor	  alteration	  in	  peak	  shape	  for	  the	  vast	  majority	  
of	   metabolites	   (average	   retention	   time	   RSDs	   were	   0.28%,	   0.26%	   and	   1.22%	   for	   RPLC+,	  
RPLC-­‐,	   and	   HILIC-­‐,	   respectively),	   suggesting	   that	   deterioration	   in	   chromatographic	  
performance	  was	  not	  responsible	  for	  the	  observed	  intensity	  drift.	  Possible	  causes	  for	  peak	  
area	   drift	   include	   fouling	   of	   the	   instrument	   ion	   source,	   charging	   of	   ion	   optics,	   and	  
degradation	  or	  interconversion	  of	  labile	  metabolites	  in	  solution,	  but	  detailed	  assessment	  of	  
the	  origin	  of	  the	  drift	  was	  beyond	  the	  scope	  of	  this	  manuscript.	  Peak	  area	  drift	  is	  a	  common	  
occurrence	   (7,	   8)	   and	   frequently	   interferes	   with	   metabolite	   quantification.	   Although	  
cleaning	   the	   source	   and	   ion	   optics	   of	   the	   mass	   spectrometer	   can	   sometimes	   restore	  




practical	   to	   perform	   such	  maintenance	   frequently	   enough	   to	   eliminate	   its	   impact	   on	   the	  
data.	  Therefore,	  unless	  a	  validated	  internal	  standard	  is	  available	  for	  each	  metabolite	  to	  be	  
quantitated,	  it	  is	  essential	  to	  correct	  large	  metabolomics	  data	  sets	  for	  peak	  area	  drift.	  
	  
6.3.3	  Peak	  area	  drift	  correction	  using	  MetaboDrift	  
We	   evaluated	   two	   curve	   fitting	   approaches	   to	   model	   peak	   area	   drift:	   QUAD	   and	  
LOESS	  (Figure	  6.2).	  In	  many	  cases,	  both	  methods	  fit	  within-­‐batch	  drift	  nearly	  equally	  well,	  
particularly	  when	  the	  drift	  had	  a	  trend	  toward	  higher	  or	  lower	  abundance.	  QUAD	  has	  the	  
advantage	  of	  using	  a	  simple	  curve	  which	  is	  unlikely	  to	  suffer	  from	  issues	  of	  ‘overfitting’,	  in	  
which	  random	  variation	  in	  pooled	  sample	  peak	  caused	  by	  measurement	  error	  may	  have	  an	  
undue	   influence	   on	   curve	   shape	   (18).	   This	  may	  be	   particularly	   relevant	  when	  batch	   size	  
and	  the	  number	  of	  QC	  samples	  per	  batch	  is	  small,	  as	  was	  the	  case	  in	  the	  MMTT	  data	  (Figure	  
6.2a-­‐c).	  LOESS	  was	  unable	  to	  fit	  data	  from	  one	  sample	  batch	  in	  which	  only	  two	  QC	  samples	  
were	   used.	   On	   the	   other	   hand,	   LOESS	   has	   advantages	   over	   QUAD	   in	   that,	   as	   a	   non-­‐
parametric	   fitting	  method,	   it	   is	   not	   constrained	   to	   a	   specific	   curve	   shape.	   In	   the	   case	   of	  
metabolomics	  data	  with	  large	  batch	  size	  and	  a	  more	  random	  trend	  in	  peak	  area	  drift,	  such	  
as	  the	  Fiehn	  lab	  data,	  LOESS	  produced	  a	  superior	  curve	  fit	  and	  resulted	  in	  lower	  peak	  area	  
RSD	  values	  (Figure	  6.2d-­‐f).	  We	  also	  evaluated	  the	  use	  of	  higher-­‐order	  polynomials	  for	  drift	  
correction,	   but	   found	   these	   methods	   to	   be	   more	   prone	   to	   overfitting	   than	   QUAD,	   while	  
showing	  no	  clear	  advantages	  over	  LOESS	  for	  large	  batches	  or	  irregular	  peak	  drift	  patterns.	  
Therefore,	   no	   polynomial	   drift	   correction	   options	   other	   than	   QUAD	   were	   included	   in	  
MetaboDrift.	  	  
We	  selected	  QUAD	  for	  further	  examination	  of	  the	  MMTT	  data	  and	  applied	  the	  peak	  
area	   drift	   correction	   procedure	   to	   all	   metabolites	   as	   described	   in	   the	   methods	   section.	  
Variability	  between	  metabolite	  peak	  area	  before	  and	  after	  drift	   correction	  were	  assessed	  
by	  percent	  relative	  standard	  deviation	  (%RSD).	  As	  expected,	  drift	  correction	  compensated	  
for	  most	  of	  the	  peak	  area	  drift	  in	  the	  QC	  samples,	  as	  illustrated	  in	  Figure	  6.3.	  Average	  %RSD	  
for	  all	  metabolites	   in	   the	  QC	  samples	  of	   the	  MMTT	  data	  was	  50.7%	  and	  6.6%	  before	  and	  
after	  QUAD	  drift	  correction,	  respectively.	  Internal	  standard	  compounds,	  which	  were	  added	  
at	  the	  same	  concentration	  to	  all	  samples,	  also	  showed	  improved	  reproducibility	  in	  both	  QC	  




of	  the	  drift	  correction	  strategy,	  metabolites	  with	  an	  exact-­‐matching	  internal	  standard	  were	  
quantitated	   by	   isotope	   dilution	   MS.	   After	   QC	   sample	   drift	   correction,	   the	   correlation	  
between	  peak	  area	  vs.	   concentration	   increased	  (Figure	  6.4),	   indicating	   that	   the	  corrected	  
peak	   areas	  more	   accurately	   reflect	   true	  metabolite	   concentrations	   than	   the	   uncorrected	  
data.	   Further	   comparison	   between	   the	   raw	   and	   drift-­‐corrected	   data	   are	   included	   as	  
Supporting	   Information	  as	  copies	  of	   the	  MetaboDrift	  worksheet	  pre-­‐loaded	  with	   the	  data	  
sets	  from	  this	  study.	  
	  
6.3.4	  Drift-­‐correction	  enhances	  interpretation	  of	  MMTT	  data	  
An	   important	   measure	   of	   the	   utility	   of	   drift	   correction	   is	   whether	   it	   enables	  
interpretation	   of	   biological	   phenomena	   in	   data	   sets	   which	   experienced	   substantial	  
instrumental	  drift	  over	  the	  course	  of	  data	  acquisition.	  To	  this	  end,	  we	  used	  the	  entire	  drift-­‐
corrected	  data	  set	  described	  above	  to	  examine	  the	  dynamics	  of	  metabolite	  levels	  the	  MMTT	  
in	   non-­‐obese	   and	   obese	   individuals.	   The	   time-­‐resolved	   profiles	   of	   select	  metabolites	   are	  
highlighted	   in	   Figure	   6.5,	   and	   all	   metabolites	   are	   visualized	   as	   a	   heatmap	   in	   Figure	   6.6.	  
Plasma	  glucose	  and	  most	  amino	  acids	  (AAs)	  increased	  and	  reached	  a	  maximum	  at	  30	  and	  
60	  min	   postprandial,	   respectively,	   consistent	   with	   the	   typical	   timecourse	   of	   appearance	  
and	  clearance	  of	  these	  nutrients	  from	  the	  bloodstream	  following	  a	  meal	  (Figure	  6.5a,b)	  (19,	  
20).	  Lactate,	   the	  downstream	  product	  of	  non-­‐oxidative	  glucose	  metabolism,	  peaked	  at	  60	  
min	   (Figure	   6.5c)	   and	   was	   elevated	   in	   obese	   subjects	   throughout	   the	   timecourse.	   Fatty	  
acids	   (FAs)	   and	   their	   metabolic	   byproducts,	   medium-­‐chain	   acylcarnitines,	   decreased	  
postprandially	  and	  reached	  a	  minimum	  at	  60	  min,	  suggesting	  insulin-­‐induced	  suppression	  
of	   lipolysis	   (Figure	   6.5d,e).	   Small	   to	   no	   changes	   were	   observed	   in	   triglycerides,	  
phospholipids,	  acetyl-­‐CoA	  or	  TCA	  cycle	  metabolites	  during	  the	  2-­‐hour	  time	  course,	  which	  is	  
expected	  given	  the	  relatively	  short	  duration	  and	  moderate	  caloric	   load	  of	   the	  MMTT.	  The	  
bile	   acid	   chenodeoxyglycholic	   acid,	   which	   facilitates	   lipid	   digestion	   in	   the	   intestine,	  
increased	   over	   the	   time	   course	   of	   the	  MMTT,	   consistent	  with	   the	  metabolic	   response	   to	  
food	  consumption	  (Figure	  6.5f).	  	  
To	   investigate	   differences	   in	  metabolite	   clearance	   post-­‐meal	   between	   the	   groups,	  
we	   calculated	   AUC	   values	   as	   described	   in	   the	   methods.	   Glucose	   AUC	   was	   significantly	  




significantly	  after	  CR	  (Figure	  6.7a).	  Isoleucine+leucine	  AUC,	  which	  have	  been	  described	  as	  
metabolic	  markers	  of	  insulin	  resistance	  (21,	  22),	  were	  significantly	  higher	  in	  obese	  subjects	  
and	  weight	  loss	  decreased	  their	  levels	  (Figure	  6.7b).	  Free	  fatty	  acid	  (FFA)	  AUC	  values	  were	  
significantly	   lower	   in	   non-­‐obese	   subjects,	   and	  were	   reduced	   by	  weight	   loss	   in	   the	   obese	  
group	   (Figure	   6.7c).	   AUC	   of	   certain	  medium-­‐chain	   (C6	   to	   C14)	   acylcarnitines,	   which	   are	  
metabolic	   intermediates	   of	   incomplete	   lipid	   oxidation,	  were	   significantly	   higher	   in	   obese	  
subjects	  and	  were	  reduced	  by	  weight	  loss,	  suggesting	  incomplete	  fatty	  acid	  oxidation	  (FAO)	  
associated	  with	  obesity	  (Figure	  6.7d)	  (23-­‐25).	  Likewise,	  the	  postprandial	  reduction	  in	  FFAs	  
and	  acylcarnitines	   (expressed	  as	   change	   in	  drift-­‐corrected	  peak	  area	   from	  baseline	   to	  60	  
min)	   was	   significantly	   smaller	   in	   obese	   than	   non-­‐obese	   subjects	   (Figure	   6.7e	   and	   6.7f),	  
suggesting	   lesser	   reduction	   in	   lipolysis	   in	   response	   to	   food	   consumption.	   To	   evaluate	  
whether	   drift	   correction	   was	   essential	   to	   interpretation	   of	   results	   from	   the	   MMTT,	   we	  
attempted	  the	  comparisons	  described	  above	  using	  uncorrected	  data.	  Greater	  variability	  in	  
the	   uncorrected	   data	   resulted	   in	   the	   loss	   of	   statistical	   significance	   of	   most	   of	   the	  
comparisons	   described	   above	   (Figure	   6.8),	   confirming	   that	   drift	   correction	   allowed	  
improved	  biological	  insight	  into	  this	  multi-­‐batch	  metabolomics	  data.	  
	  
6.4	  Summary	  
Our	  strategy	  allows	  metabolomics	  data	  drift	  correction	  and	  batch	  combination	  to	  be	  
implemented	  with	  a	  minimum	  of	  prior	  data	  manipulation	  using	  a	  simple	  Excel	  worksheet.	  
Selection	   of	   Excel	   as	   the	   platform	   for	   MetaboDrift	   has	   distinct	   advantages	   and	  
disadvantages.	   On	   one	   hand,	   Excel	   is	   a	   familiar	   data	   analysis	   environment	   with	   a	   small	  
learning	  curve,	  and	  thus	  should	  be	  accessible	  to	  novice	  users	  interested	  in	  evaluating	  and	  
correcting	  intensity	  drift	  in	  metabolomics	  data	  obtained	  from	  a	  core	  facility	  or	  downloaded	  
from	   a	   publically-­‐accessible	   data	   repository.	   Additionally,	   the	   spreadsheet-­‐based	  
environment	   with	   integrated	   graphics	   allows	   rapid	   visualization	   of	   the	   entire	   data	   set,	  
allowing	  trends	  to	  be	  observed	  and/or	  specific	  abnormalities	   in	   individual	  metabolites	  to	  
be	   detected	   and	   flagged	   for	   further	   assessment.	   However,	   Excel	   is	   generally	   less	  
computationally	   efficient	   than	   environments	   such	   as	   R	   or	   Matlab,	   which	   may	   increase	  
analysis	   time	   for	   large	   data	   sets,	   and	   may	   not	   be	   as	   versatile	   for	   automation	   or	  




statisticians	  and	  bioinformaticians	  may	  already	  be	  comfortable	  with	  LOESS	  or	  other	  drift-­‐
correction	   techniques	   and	   may	   not	   require	   software	   tools	   such	   as	   MetaboDrift,	   as	   the	  
metabolomics	   community	   continues	   to	   expand	   to	   a	   wider	   diversity	   of	   researchers,	  
approachable	   tools	   for	   data	   analysis	   become	   increasingly	   necessary,	   and	   solutions	   for	  
common	   challenges	   such	   as	   intensity	   drift	   have	   an	   important	   role	   to	   play	   in	  maximizing	  





























Table	  6.1	  Participants’	  characteristics.	  Data	  are	  shown	  as	  average	  (minimum-­‐maximum).	  $	  =	  p-­‐value	  <0.050;	  	  
NA	  =	  not	  applicable	  
	  
Figure	  6.1	  Scatter	  plots	  of	  QC	  and	  internal	  standard	  metabolite	  peak	  areas	  vs.	  run	  number.	  	  Figure	  6.1a,	  6.1b	  































Number	  (n)	  	  
of	  subjects	   16	   35	   NA	   NA	   NA	  
Male/female	  (n)	   6/10	   20/15	   NA	   NA	   NA	  
Age	  (years)	   48	  (27-­‐60)	  
50	  
(30-­‐63)	   0.412	   0.412	   NA	  





$	   <0.001$	   <0.001$	  
%	  Weight	  loss	  
after	  CR	   NA	   NA	  
17.7	  


















$	   <0.001$	   <0.001$	  
HOMA-­‐IR	  
((fasting	  plasma	  













Figure	  6.2	  Comparison	  between	  quadratic	  and	  LOESS	  drift-­‐correction	  for	  LC-­‐MS	  metabolomics	  data.	  	  Figure	  
























































Figure	  6.3	  Peak	  area	  of	  metabolites	  and	  internal	  standards	  before	  (Figure	  6.3a,	  6.3c,	  6.3e	  and	  6.3g)	  vs.	  after	  
(Figure	  6.3b,	  6.3d,	  6.3f	  and	  6.3h)	  quadratic	  drift-­‐correction.	  Figure	  6.3a-­‐f	  were	  generated	   from	  MMTT	  data;	  
























































Figure	   6.4	   Peak	   area	   vs.	   concentrations	   of	  metabolites	   in	   all	   test	   and	  QC	   samples	   before	   (Figure	   6.4a	   and	  















































Figure	   6.5	   Corrected	   peak	   areas	   of	   selected	  metabolites	   during	  MMTT.	   Data	   are	   shown	   as	   average±SEM.	  

































































































Figure	  6.7	  Corrected	  area	  under	  the	  curve	  (AUC)	  values	  for	  select	  metabolites	  during	  the	  MMTT	  (Figure	  6.7a-­‐
d).	  	  Change	  in	  corrected	  peak	  area	  from	  fasting	  to	  60	  min	  by	  subject	  group	  (Figure	  6.7e-­‐f).	  Data	  are	  shown	  as	  
average±SEM.	  	  $	  =	  p-­‐value	  <0.050	  vs.	  non-­‐obese	  subjects;	  *	  =	  p-­‐value	  <0.050	  vs.	  obese	  at	  baseline.	  Non-­‐OB	  =	  

































Figure	  6.8	  Non-­‐corrected	  area	  under	  the	  curve	  (AUC)	  values	  for	  select	  metabolites	  during	  the	  MMTT	  (Figure	  
6.8a-­‐d).	  	  Change	  in	  non-­‐corrected	  peak	  area	  from	  fasting	  to	  60	  min	  by	  subject	  group	  (Figure	  6.8e-­‐f).	  Data	  are	  
shown	  as	  average±SEM.	  	  $	  =	  p-­‐value	  <0.050	  vs.	  non-­‐obese	  subjects;	  *	  =	  p-­‐value	  <0.050	  vs.	  obese	  at	  baseline.	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Implications	  and	  future	  directions	  
	  
7.1	  Implications	  to	  health	  and	  longevity	  
In	   fasting	   plasma	   (Chapter	   4)	   and	   postprandial	   skeletal	   muscle	   (Chapter	   5),	   we	  
found	   that	   several	   metabolites	   change	   with	   VO2max,	   suggesting	   that	   cardiorespiratory	  
fitness	   (CRF)	   impacts	   metabolism.	   Not	   surprisingly,	   the	   affected	   metabolites	   were	  
primarily	  associated	  with	  mitochondrial	  metabolism	  and	  supports	  the	  hypothesis	  that	  it	  is	  
through	  effects	  on	  mitochondrial	  metabolism	  that	  CRF	  is	  correlated	  with	  beneficial	  effect	  of	  
on	  health	  and	  longevity.	  As	  in	  previous	  studies	  from	  our	  laboratory	  in	  a	  rat	  model,	  CRF	  was	  
associated	  with	   increased	  and	  more	  complete	   fatty	  acid	  oxidation	   (FAO).	   In	  other	  words,	  
high	  CRF	  was	  associated	  with	  higher	  mitochondrial	  capacity	  to	  use	  fat	  as	  fuel,	  but,	  given	  its	  
relationship	  with	  decreased	  weight	  in	  animals	  with	  high	  CRF,	  it	  is	  associated	  with	  reduced	  
mitochondrial	   efficiency.	   	   This	   hypothesized	   pathway	   would	   be	   consistent	   with	  
observational	   longitudinal	   studies	   which	   indicate	   that	   high	   CRF	   is	   protective	   against	  
incident	  obesity,	  weight	  gain	  and	  increased	  adiposity	  and	  risk	  of	  type	  2	  diabetes	  (Chapter	  
2).	  	  
In	   postprandial	   skeletal	   muscle	   (Chapter	   5),	   people	   with	   higher	   CRF	   had	   lower	  
levels	   of	   branched-­‐chain	   amino	   acids	   (BCAAs)	   and	   aromatic	   amino	   acids	   (phenylalanine	  
and	  tyrosine),	  suggesting	  that,	   in	  parallel	  with	  fatty	  acid	  oxidation,	  high	  CRF	  is	  associated	  
with	  higher	  capacity	  for	  BCAA	  and	  aromatic	  amino	  acid	  (AA)	  catabolism.	  Given	  that	  BCAAs	  
and	  aromatic	  AAs	  are	  associated	  with	  insulin	  resistance	  (1-­‐8),	  increased	  utilization	  of	  those	  
AAs	  due	   to	  higher	  CRF	   is	   consistent	  with	  observational	   longitudinal	   studies	  which	   found	  
that	   high	   CRF	   is	   protective	   against	   impaired	   fasting	   glucose	   (IFG)	   and	   diabetes	  mellitus	  
(DM)	   as	   reviewed	   in	   Chapter	   2.	   	  Moreover,	   since	   obesity	   and	   insulin	   resistance	   are	   also	  
associated	  with	  increased	  risk	  of	  cancer	  (9-­‐16)	  and	  cardiovascular	  diseases	  (CVD)	  (17-­‐25),	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our	   findings	  are	  consistent	  with	  the	  hypothesis	   that	   it	   is	  a	  higher	  CRF	  which	   is	  providing	  
protection	  against	  incident	  cancer,	  incident	  CVD,	  as	  well	  as	  mortality	  from	  these	  diseases.	  
We	  also	  observed	  that	  higher	  CRF	  was	  associated	  with	  higher	  skeletal	  muscle	  glutathione,	  
which	   is	   the	  most	   abundant	   endogenous	   antioxidant	   that	   protects	  mitochondria	   against	  
oxidative	   stress	   (26).	   This	   agrees	   with	   previous	   research	   which	   found	   that	   high	   CRF	   is	  
protective	  against	  oxidative	  stress	   (Chapter	  2).	  Additionally,	  we	   found	   that	  high	  CRF	  was	  
associated	  with	  higher	  levels	  of	  UDP-­‐n-­‐acetyl	  glucosamine	  and	  DHEAs	  and	  decreased	  levels	  
of	  glycocholic	  acid	  (Chapter	  5),	  each	  reversing	  the	  trends	  of	  each	  metabolite	  in	  ageing,	  also	  
suggesting	  that	  high	  CRF	  is	  consistent	  with	  a	  ‘younger’	  metabolic	  state.	  
Because	  CRF	  has	  a	  high	  genetic	  underpinning,	  a	  strategy	  to	  target	  efforts	  to	  promote	  
good	  health	  would	  be	  more	  impactful	  in	  individuals	  who	  are	  born	  ‘unfit’.	  	  	  However,	  given	  
that	   there	   are	   diminishing	   returns	   from	   increasing	   exercise	   in	   low	   CRF	   individuals,	   and	  
maintaining	  an	  elevated	  CRF	   is	  difficult	   to	  maintain,	  alternative	  strategies	  are	  needed.	  As	  
reviewed	   in	   Chapter	   3,	   caloric	   restriction	   (CR)	   can	   extend	   life	   span	   and	   attenuate	   age-­‐
related	  pathology.	   	  Our	  results	  suggest	   that	  those	   individuals	  with	   lower	  CRF	  may	  have	  a	  
greater	  impact	  on	  their	  metabolism	  from	  CR.	  Indeed,	  we	  found	  that	  CR	  is	  associated	  with	  
more	  complete	  FAO	  as	  well	  as	  higher	  mitochondrial	  capacity	  for	  BCAA	  catabolism,	  that	   is	  
also	  seen	  in	  CRF.	  In	  addition,	  we	  demonstrated	  that	  CR	  decreased	  muscle	  membrane	  lipid	  
unsaturation,	   which	   is	   associated	   with	   decreased	   susceptibility	   to	   age-­‐related	   lipid	  
peroxidative	  damage	  in	  mitochondria.	  	  	  	  	  
Our	   results	   suggest	   that	   CR	   can	   make	   people	   who	   were	   born	   ‘unfit’	   attain	   a	  
metabolism	   that	   is	  more	   akin	   to	   those	  who	  were	   born	   ‘fit’.	   	   In	   contrast,	   our	   results	   also	  
suggest	  that	  people	  who	  were	  born	  ‘fit’	  may	  not	  appreciably	  benefit	  from	  CR.	  We	  found	  that	  
CR	  minimized	  the	  beneficial	  effects	  of	  high	  CRF	  on	  improved	  FAO	  and	  mitochondrial	  DNA	  
(mtDNA)	  count	  number	  that	  mediates	  the	  effects	  of	  CRF	  on	  some	  metabolites.	  	  	  	  
	  
7.2	  Future	  directions	  
As	  mentioned	  in	  Chapter	  1,	  lifelong	  CR	  is	  rarely	  possible	  and	  obesity	  is	  becoming	  the	  
‘normal	  state’.	  	  And,	  as	  mentioned	  earlier,	  lifelong	  aerobic	  training	  to	  maintain	  a	  higher	  CRF	  
is	  difficult	  as	  we	  age	  and	  there	  are	  data	  that	  suggests	  that	  once	  one	  adjusts	  for	  basal	  CRF,	  
only	  those	  with	  the	  lowest	  levels	  of	  CRF	  attain	  any	  health	  benefit	  from	  exercise.	  There	  are	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emerging	  strategies	  that	  alter	  mitochondrial	  metabolism,	  such	  as	  timed	  eating	  (27,	  28)	  and	  
intermittent	   fasting	   (29,	  30),	   that	  may	  have	   the	  beneficial	   effect	  of	   caloric	   restriction	  but	  
potentially	  easier	  to	  put	  into	  clinical	  use.	  	  
Development	   of	   drugs	   or	   specific	   diets	   that	  would	   induce	   a	   high	   CRF	   or	   CR	   state	  
obviously	  would	  be	  a	  boon	  in	  the	  quest	  to	  achieve	  better	  health	  and	  maximize	  life	  span.	  	  We	  
found	  that	   the	  beneficial	  effects	  of	  high	  CRF	  and	  CR	   involve	  multiple	  metabolic	  pathways	  
within	   the	  mitochondria.	  Therefore,	  metabolic	  pathway-­‐targeted	   therapy	  may	  be	  helpful.	  	  
Indeed,	  the	  suggestion	  that	  the	  mitochondria	  of	  individuals	  with	  higher	  CRF	  have	  a	  capacity	  
for	  fatty	  acid	  oxidation,	  but	  may	  also	  so	  a	  degree	  of	  uncoupling,	  identification	  of	  the	  site	  of	  
potential	   energy	   leak	  may	  provide	   a	   target	   for	   investigation.	   It	  will	   also	   be	   important	   to	  
understand	  if	  the	  mitochondria	  from	  heart	  or	  other	  tissues	  have	  similar	  properties	  that	  are	  
seen	   in	   skeletal	   muscle.	   Future	   ‘fluxomic’	   studies,	   using	   heavy	   isotopes	   (31)	   could	   be	  
employed	  to	  identify	  the	  rate-­‐limiting	  steps	  of	  metabolic	  pathways	  within	  the	  mitochondria	  
may	  provide	  insights	  into	  potentially	  druggable	  targets.	  	  	  
These	   targets	  would	  have	  an	  advantage	   in	   that	  one	  would	  not	  have	   to	  necessarily	  
lose	  weight	   if	   the	   intervention	  can	   induce	  or	  mimic	   the	  metabolism	  associated	  with	  high	  
CRF.	   As	   outlined	   in	   the	   discussions	   in	   Chapters	   4	   and	   5,	   the	  molecular	  mechanisms	   that	  
underlie	  the	  beneficial	  effects	  of	  high	  CRF	  are	  still	  unclear.	  	  It	  is	  tempting	  to	  speculate	  that	  
the	   measurable	   inefficiency	   of	   mitochondria	   with	   higher	   oxidative/fatty	   acid	   oxidative	  
capacity,	  seen	  in	  human	  studies	  (32)	  as	  well	  as	  the	  rat	  model	  of	  divergent	  CRF	  (31),	  results	  
in	  signals	  to	  the	  nucleus	  to	  increase	  cassettes	  of	  genes	  to	  enhance	  fatty	  acid	  (FA)	  and	  BCAA,	  
as	   the	   latter	   is	   seen	   in	   the	   HCR/LCR	   rat	   model	   and	   in	   humans	   with	   higher	   CRG	   (33).	  
Additional	   metabolomics	   studies,	   focusing	   on	  metabolites	   generated	   from	   FA	   and	   BCAA	  
metabolism	  may	  be	  fruitful.	  	  	  
An	   intriguing	   set	   of	   studies	   in	   C.	   elegans	   may	   provide	   a	   clue	   to	   candidate	  
metabolites.	   	   	   In	   these	   studies	   (34-­‐36),	   diets	   deficient	   in	   B12,	   which	   increases	   flux	   of	   l-­‐
methylmalonyl-­‐CoA	  to	  succinyl-­‐CoA	  and	  TCA	  cycle	  metabolites,	  have	  a	  life	  extending	  effect	  
and	  are	  associated	  with	  an	  up-­‐regulation	  of	  the	  cassette	  of	  mitochondrial	  genes	  involved	  in	  
FA	  and	  BCAA	  metabolism	  that	  parallel	   that	   found	   in	  HCR	  rats	   (37).	  Treating	  worms	  with	  
some	  metabolites,	  such	  as	  BCAAs,	  branched-­‐chain	  FAs,	  odd-­‐chain	  FAs,	  propionic	  acid	  and	  
α-­‐ketobutyric	  acid,	  activates	  FA	  and	  BCAA	  catabolizing	  genes	  as	  found	  in	  HCR	  rats	  (37)	  and	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extends	   lifespan	   even	   in	   the	   presence	   of	   B12.	   Thus,	   if	  we	   can	   identify	   the	   pathways	   and	  
probe	  metabolites	  within	  these	  pathways,	  we	  may	  be	  able	  to	  find	  a	  metabolite,	  or	  create	  a	  
mimetic	  that	  could	  convey	  the	  salutary	  effects	  of	  high	  CRF.	  The	  candidate	  metabolites	  are	  
downstream	  metabolites	   of	   treated	  metabolites	   and	  upstream	  metabolites	   of	  B12	  action,	  
including	  propionyl-­‐CoA,	  d-­‐methylmalonyl-­‐CoA	  and	  l-­‐methylmalonyl-­‐CoA.	  
Finally,	   the	   above	   studies	   could	   be	   complemented	   with	   genetic	   studies.	   Only	  
association	  studies	  have	  been	  done,	  but	  no	  publications	  on	  localization	  of	  genes	  associated	  
with	   intrinsically	   high	   CRF	   have	   been	   published.	   An	   ongoing	   NIH	   study	   ‘Molecular	  
Transducers	  of	  Physical	  Activity’	  will	  be	  a	  step	  towards	  this	  goal	  as	  it	  will	  collect	  baseline	  
and	   exercise-­‐trained	   measures	   of	   CRF	   as	   well	   as	   genetic	   information	   in	   up	   to	   3000	  
individuals,	  which	  may	  be	  the	  first	  step	  into	  dissecting	  the	  underlying	  genes	  responsible	  for	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Appendices	  of	  chapter	  4	  
	  
Table	  A4.1	  All	  metabolites	  identified	  in	  this	  study	  
Identified	  metabolites	  
AAs	  
	  	  	  	  Alanine	  	  
	  	  	  	  Arginine	  
	  	  	  	  Asparagine	  	  
	  	  	  	  Aspartic	  acid	  
	  	  	  	  Glutamic	  acid	  	  
	  	  	  	  Glutamine	  	  
	  	  	  	  Glycine	  
	  	  	  	  Histidine	  	  
	  	  	  	  Isoleucine+leucine	  	  
	  	  	  	  Lysine	  	  
	  	  	  	  Methionine	  	  
	  	  	  	  Phenylalanine	  	  
	  	  	  	  Proline	  	  
	  	  	  	  Serine	  	  
	  	  	  	  Threonine	  	  
	  	  	  	  Tryptophan	  	  
	  	  	  	  Tyrosine	  	  
	  	  	  	  Valine	  
Acylcarnitines	  
	  	  	  	  L-­‐carnitine	  
	  	  	  	  C2	  carnitine	  	  
	  	  	  	  C3	  carnitine	  
	  	  	  	  C4	  carnitine	  
	  	  	  	  C5	  carnitine	  
	  	  	  	  C5-­‐DC	  carnitine	  
	  	  	  	  C6	  carnitine	  	  
	  	  	  	  C8:0	  carnitine	  
	  	  	  	  C8:1	  carnitine	  
	  	  	  	  C10:0	  carnitine	  
	  	  	  	  C10:1	  carnitine	  
	  	  	  	  C12:0	  carnitine	  
	  	  	  	  C12:1	  carnitine	  
	  	  	  	  C12-­‐OH	  carnitine	  
	  	  	  	  C14:0	  carnitine	  
	  	  	  	  C14:1	  carnitine	  
	  	  	  	  C14:2	  carnitine	  
	  	  	  	  C14-­‐OH	  carnitine	  
	  	  	  	  C16:0	  carnitine	  
	  	  	  	  C16:1	  carnitine	  
	  	  	  	  C16-­‐OH	  carnitine	  
	  	  	  	  C18:0	  carnitine	  
	  	  	  	  C18:1	  carnitine	  
	  	  	  	  C18:2	  carnitine	  
	  	  	  	  C18:2-­‐OH	  carnitine	  
	  	  	  	  C20:0	  carnitine	  
	  	  	  	  C20:1	  carnitine	  
	  	  	  	  C20:2	  carnitine	  
	  	  	  	  C20:3	  carnitine	  
	  	  	  	  C20:4	  carnitine	  
BCKAs	  
	  	  	  	  Ketosoleucine+ketoleucine	  	  
	  	  	  	  Ketovaline	  
FFAs	  
	  	  	  	  Oleic	  acid	  





Table	  A4.2	   Internal	  standards	  used	  for	  quantitation	  of	  metabolites	   in	  plasma.	  NSK-­‐B	  internal	  standard	  mix	  
was	  purchased	  from	  Cambridge	  Isotope	  (Andover,	  MA).	  All	  other	  carbon-­‐13	  stable	  isotope	  internal	  standards	  
were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  	  
Internal	  Standards	  
Internal	  standard	  concentration	  
added	  to	  extraction	  solvent	  
Algal	  AA	  mixture_13C	   20	  μg/ml	  
2-­‐keto-­‐3-­‐methylbutyric	  acid	  (ketovaline)_13C5,	  3-­‐d	  sodium	  salt	   3	  μM	  
Oleic	  acid_13C18	   15	  μM	  
Palmitic	  acid_13C16	   15	  μM	  
NSK-­‐B	  internal	  standard	  mix	  
	  	  	  	  	  	  	  	  2H9-­‐Carnitine	  (L-­‐carnitine)	  
	  	  	  	  	  	  	  	  2H3-­‐Acetylcarnitine	  (C2)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Propionylcarnitine	  (C3)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Butyrylcarnitine	  (C4)	  
	  	  	  	  	  	  	  	  2H9-­‐Isovalerylcarnitine	  (C5)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Octanoylcarnitine	  (C8)	  	  
	  	  	  	  	  	  	  	  2H9-­‐Myristoylcarnitine	  (C14)	  	  















































Table	  A4.3	  MRM	  for	  AA	  detection.	  Dwell	  time	  of	  50	  ms	  was	  used	  for	  all	  AAs.	  
Metabolites	   Precursor	  Ion	   Product	  Ion	   Fragmentor	   Collision	  Energy	  
Alanine	   90.05	   44.1	   44	   8	  
Alanine_13C3	   93.05	   46.1	   44	   8	  
Arginine	   175.11	   70	   100	   24	  
Arginine_13C6	   181.11	   74	   100	   24	  
Asparagine	   133.05	   74.02	   86	   8	  
Aspartic	  acid	   134.04	   74.02	   72	   4	  
Aspartic	  acid_13C4	   138.04	   76.02	   72	   4	  
Glutamic	  acid	   148.05	   84.1	   72	   12	  
Glutamic	  acid_13C5	   153.05	   88.1	   72	   12	  
Glutamine	   147.07	   84.1	   72	   16	  
Glycine	   76.03	   30	   30	   4	  
Glycine_13C2	   78.03	   31	   30	   4	  
Histidine	   156.07	   110.1	   86	   16	  
Histidine_13C6	   162.07	   115.1	   86	   16	  
Isoleucine+leucine	   132.09	   86.1	   72	   8	  
Isoleucine+leucine_13C6	   138.09	   91.1	   72	   8	  
Lysine	   147.11	   84.1	   72	   20	  
Lysine_13C6	   153.11	   89.1	   72	   20	  
Methionine	   150.05	   55.8	   72	   16	  
Methionine_13C5	   155.05	   58.8	   72	   16	  
Phenylalanine	   166.08	   119.9	   72	   12	  
Phenylalanine_13C9	   175.08	   127.9	   72	   12	  
Proline	   116.06	   70.1	   86	   20	  
Proline_13C5	   121.06	   74.1	   86	   20	  
Serine	   106.04	   60.1	   58	   8	  
Serine_13C3	   109.04	   62.1	   58	   8	  
Threonine	   120.06	   74.06	   100	   10	  
Threonine_13C4	   124.06	   77.06	   100	   10	  
Tryptophan	   205.09	   118.1	   72	   28	  
Tyrosine	   182.07	   91.1	   72	   32	  
Tyrosine_13C9	   191.07	   98.1	   72	   32	  
Valine	   118.08	   72.1	   58	   8	  













	  	  	  	  	  	  	  	  Table	  A4.4	  SIM	  for	  BCKA	  and	  FFA	  detection.	  Dwell	  time	  of	  200	  ms	  was	  used	  for	  all	  BCKAs	  and	  FFAs.	  
Metabolites	   Precursor	  Ion	   Fragmentor	  
BCKAs	  	  	  	  	  





	  	  	  	  Ketovaline	   115.05	   60	  
	  	  	  	  Ketovaline_13C6	   121.05	   60	  
FFAs	  	  	  





	  	  	  	  Oleic	  acid	  _13C18	   299.26	   90	  
	  	  	  	  Palmitic	  acid	   255.24	   90	  
	  	  	  	  Palmitic	  acid_13C16	   271.24	   90	  
	  
	  
Table	  A4.5	  Calibration	  parameters	  used	  for	  quantitation	  of	  metabolites	   in	  plasma.	  All	  calibration	  curve	  fits	  




R2	   IS	  isotope	  chosen	  
Amino	  acids	  	  	  	  	  
	  	  	  	  Alanine	  
	  





	  	  	  	  Arginine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9994	   Arginine	  
	  	  	  	  Asparagine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9988	   Threonine	  
	  	  	  	  Aspartic	  acid	   0,	  7.5,	  25,	  75,	  250	   0.9994	   Aspartic	  acid	  
	  	  	  	  Glutamic	  acid	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9996	   Glutamic	  acid	  
	  	  	  	  Glutamine	   0,	  15,	  50,	  150,	  500,	  1500	   0.9946	   Threonine	  
	  	  	  	  Glycine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9989	   Glycine	  
	  	  	  	  Histidine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9993	   Histidine	  
	  	  	  	  Isoleucine+leucine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9995	   Isoleucine+leucine	  
	  	  	  	  Lysine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9994	   Lysine	  
	  	  	  	  Methionine	   0,	  7.5,	  25,	  75,	  250	   0.9955	   Methionine	  
	  	  	  	  Phenylalanine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9994	   Phenylalanine	  
	  	  	  	  Proline	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9990	   Proline	  
	  	  	  	  Serine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9995	   Serine	  
	  	  	  	  Threonine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9997	   Threonine	  
	  	  	  	  Tryptophan	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9992	   Tyrosine	  
	  	  	  	  Tyrosine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9995	   Tyrosine	  
	  	  	  	  Valine	   0,	  7.5,	  25,	  75,	  250,	  750	   0.9995	   Valine	  
BCKAs	  
	  	  	  	  Ketoisoleucine+ketoleucine	  
	  





	  	  	  	  Ketovaline	   0,	  1.5,	  5,	  15,	  50	   0.9933	   Ketovaline	  
FFAs	  
	  	  	  	  	  Oleic	  acid	  
	  











Table	  A4.6	  Age	  and	  VO2max	  per	  FFM	  in	  non-­‐obese	  vs.	  obese	  subjects	  at	  baseline	  whose	  age	  35	  years	  or	  more.	  
Data	  were	  reported	  as	  average	  (minimum-­‐maximum).	  n	  =	  8	  non-­‐obese	  males,	  n	  =	  11	  non-­‐obese	  females,	  n	  =	  
54	  obese	  males	  and	  n	  =	  63	  obese	  females;	  $	  =	  p-­‐value	  <0.050	  
 
Characteristics	   Non-­‐obese	   Obese	  at	  baseline	  
p-­‐value	  of	  
non-­‐obese	  vs.	  
obese	  at	  baseline	  
Age	  (years)	  
	  	  	  Male	  
	  	  	  Female	  













VO2max	  per	  fat-­‐free	  mass	  (ml/(kg	  x	  
min))	  
	  	  	  Male	  
	  	  	  Female	  

















Table	  A4.7	  Correlations	  of	  metabolites	  and	  insulin	  resistance	  profiles	  at	  baseline	  (non-­‐obese	  and	  obese	  subjects)	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  
and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline]	  
Group	  I	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  





























C16:0	  carnitine-­‐to-­‐palmitic	  acid	  	  
ratio	  
C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  
	  	  
-­‐1.42	  x	  10-­‐1	  
-­‐9.24	  x	  10-­‐2	  
3.17	  x	  10-­‐1	  
-­‐5.25	  x	  10-­‐2	  
3.77	  
-­‐3.03	  x	  10-­‐1	  
-­‐9.31	  x	  10-­‐2	  
-­‐5.81	  x	  10-­‐1	  
2.72	  x	  10-­‐4	  
3.03	  x	  10-­‐5	  
3.40	  x	  10-­‐6	  
	  

















-­‐9.71	  x	  10-­‐2	  
-­‐2.29	  x	  10-­‐2	  
1.87	  x	  10-­‐1	  
-­‐5.24	  x	  10-­‐2	  
2.76	  
-­‐1.20	  x	  10-­‐1	  
1.10	  x	  10-­‐1	  
-­‐7.74	  x	  10-­‐1	  
-­‐7.18	  x	  10-­‐5	  
-­‐2.50	  x	  10-­‐6	  
5.00	  x	  10-­‐7	  
	  
















9.14	  x	  10-­‐3	  
-­‐9.26	  x	  10-­‐5	  
-­‐3.11	  x	  10-­‐2	  
-­‐9.84	  x	  10-­‐3	  
-­‐1.83	  x	  10-­‐1	  
4.27	  x	  10-­‐3	  
-­‐1.15	  x	  10-­‐2	  
7.33	  x	  10-­‐3	  
7.70	  x	  10-­‐6	  
8.00	  x	  10-­‐7	  
<1.00	  x	  10-­‐7	  
	  

















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  




























	  	  	  3.01	  x	  10-­‐1	  
-­‐1.34	  x	  10-­‐1	  
-­‐3.51	  x	  10-­‐2	  
4.18	  x	  10-­‐2	  
8.20	  x	  10-­‐3	  
3.39	  x	  10-­‐1	  
-­‐6.82	  x	  10-­‐1	  
-­‐4.19	  x	  10-­‐2	  










-­‐1.00	  x	  10-­‐1	  
-­‐2.90	  x	  10-­‐1	  
-­‐9.91	  x	  10-­‐2	  
-­‐9.07	  x	  10-­‐1	  
2.06	  x	  10-­‐4	  
-­‐3.72	  x	  10-­‐1	  
-­‐4.66	  x	  10-­‐1	  
-­‐2.71	  x	  10-­‐1	  










1.20	  x	  10-­‐2	  
5.90	  x	  10-­‐3	  
2.99	  x	  10-­‐3	  
-­‐2.87	  x	  10-­‐2	  
1.20	  x	  10-­‐3	  
2.53	  x	  10-­‐2	  
4.38	  x	  10-­‐3	  
4.93	  x	  10-­‐3	  



















C8:0	  carnitine-­‐to-­‐C10:0	  carnitine	  
ratio	  
	  	  
-­‐3.90	  x	  10-­‐3	  
-­‐8.11	  x	  10-­‐1	  
-­‐5.26	  x	  10-­‐2	  
4.59	  x	  10-­‐3	  
-­‐2.02	  x	  10-­‐1	  
-­‐3.04	  x	  10-­‐1	  
-­‐2.22	  x	  10-­‐2	  
8.10	  x	  10-­‐6	  














-­‐3.87	  x	  10-­‐2	  
-­‐2.14	  
1.92	  x	  10-­‐1	  
-­‐5.56	  x	  10-­‐2	  
-­‐2.40	  x	  10-­‐1	  
-­‐2.00	  x	  10-­‐1	  
-­‐5.17	  x	  10-­‐2	  
-­‐7.83	  x	  10-­‐5	  












-­‐4.88	  x	  10-­‐3	  
-­‐2.08	  x	  10-­‐2	  
-­‐1.09	  x	  10-­‐3	  
9.29	  x	  10-­‐3	  
1.60	  x	  10-­‐2	  
6.88	  x	  10-­‐4	  
2.10	  x	  10-­‐4	  
-­‐1.07	  x	  10-­‐5	  













Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
























C3	  carnitine-­‐to-­‐ketovaline	  ratio	  
C3	  carnitine-­‐to-­‐valine	  ratio	  
C5	  carnitine-­‐to-­‐
ketoisoleucine+ketoleucine	  ratio	  
C5	  carnitine-­‐to-­‐isoleucine+leucine	  	  
ratio	  
	  	  
3.16	  x	  10-­‐1	  
2.00	  x	  10-­‐3	  
1.74	  x	  10-­‐3	  
4.38	  x	  10-­‐4	  
2.08	  x	  10-­‐3	  
9.10	  x	  10-­‐6	  
2.03	  x	  10-­‐4	  
4.50	  x	  10-­‐6	  
	  














-­‐1.04	  x	  10-­‐1	  
-­‐1.46	  x	  10-­‐3	  
1.75	  x	  10-­‐4	  
-­‐3.77	  x	  10-­‐4	  
-­‐2.59	  x	  10-­‐3	  
-­‐3.10	  x	  10-­‐6	  
2.49	  x	  10-­‐5	  
-­‐4.00	  x	  10-­‐7	  
	  














3.60	  x	  10-­‐3	  
-­‐3.82	  x	  10-­‐5	  
-­‐2.11	  x	  10-­‐4	  
1.50	  x	  10-­‐6	  
-­‐8.30	  x	  10-­‐6	  
-­‐4.00	  x	  10-­‐7	  
-­‐3.90	  x	  10-­‐6	  
-­‐1.00	  x	  10-­‐7	  
	  















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  






















1.03	  x	  10-­‐1	  
1.03	  




-­‐9.31	  x	  10-­‐1	  
-­‐3.25	  x	  10-­‐2	  




-­‐7.09	  x	  10-­‐2	  
-­‐1.64	  x	  10-­‐1	  



























8.87	  x	  10-­‐4	  
2.73	  x	  10-­‐3	  
4.98	  x	  10-­‐3	  
3.03	  x	  10-­‐3	  
3.27	  x	  10-­‐4	  
6.66	  x	  10-­‐4	  
5.72	  x	  10-­‐5	  
1.85	  x	  10-­‐4	  
5.59	  x	  10-­‐4	  
3.42	  x	  10-­‐4	  
2.56	  x	  10-­‐5	  
3.86	  x	  10-­‐4	  
3.88	  x	  10-­‐4	  
7.40	  x	  10-­‐6	  
1.32	  x	  10-­‐3	  
4.32	  x	  10-­‐4	  
3.77	  x	  10-­‐5	  
1.08	  x	  10-­‐4	  
4.54	  x	  10-­‐5	  
2.68	  x	  10-­‐5	  
























-­‐6.80	  x	  10-­‐4	  
-­‐1.51	  x	  10-­‐3	  
-­‐3.87	  x	  10-­‐3	  
-­‐1.67	  x	  10-­‐3	  
-­‐7.78	  x	  10-­‐4	  
-­‐6.24	  x	  10-­‐4	  
-­‐7.59	  x	  10-­‐5	  
-­‐2.78	  x	  10-­‐4	  
-­‐9.15	  x	  10-­‐4	  
-­‐4.39	  x	  10-­‐4	  
-­‐5.00	  x	  10-­‐5	  
-­‐2.05	  x	  10-­‐4	  
-­‐2.02	  x	  10-­‐4	  
-­‐5.50	  x	  10-­‐5	  
1.14	  x	  10-­‐4	  
4.00	  x	  10-­‐5	  
-­‐3.09	  x	  10-­‐5	  
3.03	  x	  10-­‐5	  
1.43	  x	  10-­‐5	  
6.60	  x	  10-­‐6	  
























-­‐4.21	  x	  10-­‐5	  
-­‐1.27	  x	  10-­‐4	  
-­‐2.50	  x	  10-­‐4	  
-­‐1.63	  x	  10-­‐4	  
-­‐4.89	  x	  10-­‐5	  
-­‐7.64	  x	  10-­‐5	  
-­‐1.02	  x	  10-­‐5	  
-­‐1.82	  x	  10-­‐5	  
-­‐1.06	  x	  10-­‐4	  
-­‐5.00	  x	  10-­‐5	  
-­‐4.30	  x	  10-­‐6	  
-­‐2.29	  x	  10-­‐5	  
-­‐3.27	  x	  10-­‐5	  
-­‐4.00	  x	  10-­‐6	  
-­‐6.40	  x	  10-­‐5	  
-­‐1.63	  x	  10-­‐5	  
-­‐5.30	  x	  10-­‐6	  
-­‐1.80	  x	  10-­‐6	  
-­‐1.00	  x	  10-­‐6	  
-­‐2.00	  x	  10-­‐7	  
























1Data	  were	  adjusted	  for	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI	  and	  diabetes	  status	  (yes	  or	  no).	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
$	  =	  p-­‐value	  <0.050	  












Table	  A4.8	   Correlations	  of	  metabolites	   and	   insulin	   resistance	  profiles	   in	  obese	   subjects	   at	  baseline	  vs.	   age,	  VO2max	  per	  FFM	  at	  baseline	  and	   [age	  x	  
VO2max	  per	  FFM	  at	  baseline]	  
Group	  I	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  





























C16:0	  carnitine-­‐to-­‐palmitic	  acid	  	  
ratio	  
C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  
	  	  
-­‐2.53	  x	  10-­‐1	  
-­‐1.21	  x	  10-­‐1	  
4.88	  x	  10-­‐1	  
4.98	  x	  10-­‐3	  
5.36	  
-­‐2.91	  x	  10-­‐1	  
1.54	  x	  10-­‐1	  
-­‐6.42	  x	  10-­‐1	  
1.65	  x	  10-­‐4	  
2.33	  x	  10-­‐5	  
5.00	  x	  10-­‐6	  
	  

















-­‐6.55	  x	  10-­‐2	  
-­‐3.61	  x	  10-­‐2	  
1.31	  x	  10-­‐1	  
-­‐9.54	  x	  10-­‐3	  
4.08	  
-­‐1.05	  x	  10-­‐1	  
2.01	  x	  10-­‐1	  
-­‐8.13	  x	  10-­‐1	  
-­‐8.92	  x	  10-­‐5	  
-­‐9.00	  x	  10-­‐7	  
2.60	  x	  10-­‐6	  
	  

















-­‐1.27	  x	  10-­‐2	   X	  10	  
-­‐4.71	  x	  10-­‐3	   X	  10	  
-­‐4.23	  x	  10-­‐2	   X	  10	  
-­‐6.98	  x	  10-­‐3	   X	  10	  
-­‐2.07	  x	  10-­‐1	   X	  10	  
-­‐2.79	  x	  10-­‐3	   X	  10	  
-­‐4.47	  x	  10-­‐3	   X	  10	  
-­‐1.09	  x	  10-­‐3	   X	  10	  
-­‐3.30	  x	  10-­‐6	   X	  10	  
<1.00	  x	  10-­‐7	   X	  10	  




-­‐1.00	  x	  10-­‐7	   X	  10	  
	  















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  




























3.01	  x	  10-­‐1	  
-­‐1.91	  x	  10-­‐1	  
-­‐5.27	  x	  10-­‐2	  
-­‐2.87	  x	  10-­‐1	  
5.45	  x	  10-­‐3	  
3.48	  x	  10-­‐1	  
-­‐8.93	  x	  10-­‐1	  
-­‐2.28	  x	  10-­‐1	  










-­‐1.73	  x	  10-­‐1	  
-­‐3.60	  x	  10-­‐1	  
-­‐1.26	  x	  10-­‐1	  
-­‐1.22	  
-­‐1.73	  x	  10-­‐2	  
-­‐5.27	  x	  10-­‐1	  
-­‐5.73	  x	  10-­‐1	  
-­‐3.71	  x	  10-­‐1	  










1.76	  x	  10-­‐2	  
6.34	  x	  10-­‐3	  
4.10	  x	  10-­‐3	  
-­‐6.55	  x	  10-­‐2	  
2.62	  x	  10-­‐3	  
5.59	  x	  10-­‐2	  
5.66	  x	  10-­‐3	  
-­‐1.82	  x	  10-­‐2	  



















C8:0	  carnitine-­‐to-­‐C10:0	  carnitine	  
ratio	  
	  	  
-­‐7.01	  x	  10-­‐2	  
-­‐7.50	  x	  10-­‐1	  
-­‐5.32	  x	  10-­‐2	  
-­‐2.24	  x	  10-­‐2	  
-­‐2.51	  x	  10-­‐1	  
-­‐3.56	  x	  10-­‐1	  
-­‐3.23	  x	  10-­‐2	  
9.00	  x	  10-­‐6	  












-­‐1.28	  x	  10-­‐1	  
-­‐1.92	  
1.82	  x	  10-­‐1	  
-­‐6.99	  x	  10-­‐2	  
-­‐2.21	  x	  10-­‐1	  
-­‐2.21	  x	  10-­‐1	  
-­‐5.73	  x	  10-­‐2	  
-­‐1.16	  x	  10-­‐4	  












-­‐1.11	  x	  10-­‐2	  
-­‐5.01	  x	  10-­‐2	  
-­‐5.75	  x	  10-­‐3	  
7.16	  x	  10-­‐3	  
3.72	  x	  10-­‐2	  
4.42	  x	  10-­‐4	  
6.76	  x	  10-­‐4	  
-­‐1.20	  x	  10-­‐5	  













Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
























C3	  carnitine-­‐to-­‐ketovaline	  ratio	  
C3	  carnitine-­‐to-­‐valine	  ratio	  
C5	  carnitine-­‐to-­‐
ketoisoleucine+ketoleucine	  ratio	  
C5	  carnitine-­‐to-­‐isoleucine+leucine	  	  
ratio	  
	  	  
3.00	  x	  10-­‐1	  
1.91	  x	  10-­‐3	  
2.05	  x	  10-­‐3	  
6.36	  x	  10-­‐4	  
2.36	  x	  10-­‐3	  
9.80	  x	  10-­‐6	  
2.39	  x	  10-­‐4	  
6.30	  x	  10-­‐6	  
	  














-­‐1.25	  x	  10-­‐1	  
	  -­‐1.63	  x	  10-­‐3	   	  
-­‐8.04	  x	  10-­‐4	   	  
-­‐2.61	  x	  10-­‐4	   	  
-­‐2.77	  x	  10-­‐3	   	  
-­‐3.00	  x	  10-­‐6	   	  
3.85	  x	  10-­‐5	   	  


















6.54	  x	  10-­‐3	  
-­‐5.73	  x	  10-­‐5	  
-­‐8.91	  x	  10-­‐5	  
3.81	  x	  10-­‐5	  
4.77	  x	  10-­‐5	  
-­‐6.00	  x	  10-­‐7	  
-­‐5.60	  x	  10-­‐6	  
1.00	  x	  10-­‐7	  
	  















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  






















-­‐9.34	  x	  10-­‐2	  
1.68	  





-­‐1.89	  x	  10-­‐1	  




-­‐5.14	  x	  10-­‐2	  
-­‐7.82	  x	  10-­‐2	  



























8.26	  x	  10-­‐4	  
2.19	  x	  10-­‐3	  
3.78	  x	  10-­‐3	  
2.47	  x	  10-­‐3	  
2.54	  x	  10-­‐4	  
6.93	  x	  10-­‐4	  
3.37	  x	  10-­‐5	  
2.08	  x	  10-­‐4	  
7.37	  x	  10-­‐4	  
3.46	  x	  10-­‐4	  
2.34	  x	  10-­‐5	  
3.42	  x	  10-­‐4	  
4.70	  x	  10-­‐4	  
1.39	  x	  10-­‐5	  
1.45	  x	  10-­‐3	  
4.22	  x	  10-­‐4	  
5.02	  x	  10-­‐5	  
1.12	  x	  10-­‐4	  
4.90	  x	  10-­‐5	  
2.47	  x	  10-­‐5	  
























-­‐8.33	  x	  10-­‐4	  
-­‐1.83	  x	  10-­‐3	  
-­‐4.30	  x	  10-­‐3	  
-­‐2.19	  x	  10-­‐3	  
-­‐8.60	  x	  10-­‐4	  
-­‐7.59	  x	  10-­‐4	  
-­‐1.30	  x	  10-­‐4	  
-­‐2.85	  x	  10-­‐4	  
-­‐1.07	  x	  10-­‐3	  
-­‐5.12	  x	  10-­‐4	  
-­‐7.49	  x	  10-­‐5	  
-­‐2.51	  x	  10-­‐4	  
-­‐2.11	  x	  10-­‐4	  
-­‐6.48	  x	  10-­‐5	  
-­‐2.25	  x	  10-­‐5	  
1.54	  x	  10-­‐5	  
-­‐3.77	  x	  10-­‐5	  
2.29	  x	  10-­‐5	  
1.48	  x	  10-­‐5	  
4.20	  x	  10-­‐6	  
























-­‐5.46	  x	  10-­‐5	  
-­‐2.27	  x	  10-­‐4	  
-­‐4.76	  x	  10-­‐4	  
-­‐2.59	  x	  10-­‐4	  
-­‐6.65	  x	  10-­‐5	  
-­‐9.15	  x	  10-­‐5	  
-­‐1.04	  x	  10-­‐5	  
-­‐2.13	  x	  10-­‐5	  
-­‐9.87	  x	  10-­‐5	  
-­‐5.46	  x	  10-­‐5	  
-­‐3.80	  x	  10-­‐6	  
-­‐3.82	  x	  10-­‐5	  
-­‐3.31	  x	  10-­‐5	  
-­‐3.70	  x	  10-­‐6	  
-­‐5.85	  x	  10-­‐5	  
-­‐1.40	  x	  10-­‐5	  
-­‐5.00	  x	  10-­‐6	  
-­‐2.00	  x	  10-­‐6	  
-­‐1.10	  x	  10-­‐6	  
-­‐5.00	  x	  10-­‐7	  
























1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no).	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
$	  =	  p-­‐value	  <0.050	  












Table	  A4.9	  Correlations	  of	  metabolites	  and	  insulin	  resistance	  profiles	  in	  obese	  subjects	  after	  CR	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  
per	  FFM	  at	  baseline]	  
Group	  I	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  





























C16:0	  carnitine-­‐to-­‐palmitic	  acid	  	  
ratio	  
C18:1	  carnitine-­‐to-­‐oleic	  acid	  ratio	  
	  	  
1.70	  x	  10-­‐1	  
-­‐3.28	  x	  10-­‐2	  
2.07	  
1.28	  x	  10-­‐1	  
6.07	  
-­‐8.72	  x	  10-­‐2	  
2.17	  x	  10-­‐1	  
4.40	  x	  10-­‐1	  
2.22	  x	  10-­‐4	  
2.97	  x	  10-­‐5	  
3.90	  x	  10-­‐6	  
	  

















1.37	  x	  10-­‐1	  
1.02	  x	  10-­‐1	  
1.37	  
1.03	  x	  10-­‐2	  
3.20	  
1.50	  x	  10-­‐1	  
7.21	  x	  10-­‐1	  
4.61	  x	  10-­‐1	  
1.12	  X	  10-­‐5	  
6.70	  x	  10-­‐6	  
-­‐4.00	  x	  10-­‐7	  
	  

















-­‐1.04	  x	  10-­‐2	  
-­‐2.09	  x	  10-­‐3	  
-­‐1.02	  x	  10-­‐2	  
-­‐1.44	  x	  10-­‐2	  
-­‐3.87	  x	  10-­‐1	  
8.58	  x	  10-­‐3	  
-­‐2.80	  x	  10-­‐4	  
1.41	  x	  10-­‐4	  
-­‐8.00	  x	  10-­‐6	  
-­‐1.10	  x	  10-­‐6	  
3.00	  x	  10-­‐7	  
	  


















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  




























4.06	  x	  10-­‐1	  
8.18	  x	  10-­‐3	  
1.41	  x	  10-­‐2	  
7.02	  x	  10-­‐1	  
1.76	  x	  10-­‐2	  
3.87	  x	  10-­‐1	  
-­‐9.30	  x	  10-­‐1	  
2.84	  x	  10-­‐1	  










3.49	  x	  10-­‐2	  
-­‐1.31	  x	  10-­‐1	  
-­‐3.56	  x	  10-­‐2	  
-­‐2.28	  x	  10-­‐1	  
-­‐2.51	  x	  10-­‐3	  
-­‐4.21	  x	  10-­‐2	  
-­‐2.84	  x	  10-­‐1	  
7.22	  x	  10-­‐1	  










5.88	  x	  10-­‐3	  
1.70	  x	  10-­‐3	  
4.87	  x	  10-­‐4	  
1.05	  x	  10-­‐2	  
-­‐2.81	  x	  10-­‐4	  
3.81	  x	  10-­‐2	  
-­‐4.42	  x	  10-­‐3	  
-­‐3.75	  x	  10-­‐2	  



















C8:0	  carnitine-­‐to-­‐C10:0	  carnitine	  
ratio	  
	  	  
-­‐1.64	  x	  10-­‐2	  
9.21	  x	  10-­‐2	  
-­‐9.23	  x	  10-­‐2	  
2.61	  x	  10-­‐1	  
2.30	  x	  10-­‐2	  
-­‐3.77	  x	  10-­‐1	  
-­‐1.62	  x	  10-­‐2	  
-­‐6.06	  x	  10-­‐5	  












-­‐1.33	  x	  10-­‐3	  
-­‐6.27	  x	  10-­‐1	  
7.92	  x	  10-­‐2	  
2.08	  x	  10-­‐1	  
3.09	  x	  10-­‐1	  
-­‐2.43	  x	  10-­‐1	  
-­‐4.52	  x	  10-­‐2	  
-­‐4.58	  x	  10-­‐5	  












-­‐2.27	  x	  10-­‐2	  
4.41	  x	  10-­‐2	  
-­‐1.93	  x	  10-­‐3	  
3.92	  x	  10-­‐3	  
-­‐2.15	  x	  10-­‐3	  
6.53	  x	  10-­‐3	  
9.09	  x	  10-­‐4	  
-­‐1.98	  x	  10-­‐5	  













Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
























C3	  carnitine-­‐to-­‐ketovaline	  ratio	  
C3	  carnitine-­‐to-­‐valine	  ratio	  
C5	  carnitine-­‐to-­‐
ketoisoleucine+ketoleucine	  ratio	  
C5	  carnitine-­‐to-­‐isoleucine+leucine	  	  
ratio	  
	  	  
2.18	  x	  10-­‐1	  
3.11	  x	  10-­‐3	  
2.76	  x	  10-­‐3	  
4.29	  x	  10-­‐4	  
7.48	  x	  10-­‐4	  
1.53	  x	  10-­‐5	  
3.09	  x	  10-­‐4	  
6.00	  x	  10-­‐6	  
	  














-­‐1.79	  x	  10-­‐1	  
-­‐2.26	  x	  10-­‐3	  
-­‐1.18	  x	  10-­‐4	  
-­‐5.76	  x	  10-­‐4	  
-­‐1.68	  x	  10-­‐3	  
-­‐8.00	  x	  10-­‐6	  
3.70	  x	  10-­‐6	  
-­‐1.90	  x	  10-­‐6	  
	  














2.06	  x	  10-­‐3	  
-­‐1.77	  x	  10-­‐4	  
-­‐1.28	  x	  10-­‐4	  
-­‐5.94	  x	  10-­‐5	  
1.13	  x	  10-­‐5	  
-­‐1.00	  x	  10-­‐6	  
-­‐1.93	  x	  10-­‐5	  
-­‐4.00	  x	  10-­‐7	  
	  















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  






















4.85	  x	  10-­‐2	  
2.41	  










-­‐1.53	  x	  10-­‐1	  
-­‐1.20	  x	  10-­‐1	  



























1.13	  x	  10-­‐3	  
3.97	  x	  10-­‐3	  
8.36	  x	  10-­‐3	  
3.87	  x	  10-­‐3	  
8.90	  x	  10-­‐4	  
1.08	  x	  10-­‐3	  
8.57	  x	  10-­‐5	  
3.25	  x	  10-­‐4	  
1.40	  x	  10-­‐3	  
6.18	  x	  10-­‐4	  
4.25	  x	  10-­‐5	  
5.12	  x	  10-­‐4	  
6.21	  x	  10-­‐4	  
1.61	  x	  10-­‐5	  
1.82	  x	  10-­‐3	  
5.43	  x	  10-­‐4	  
6.59	  x	  10-­‐5	  
1.72	  x	  10-­‐4	  
6.83	  x	  10-­‐5	  
2.94	  x	  10-­‐5	  
























-­‐2.19	  x	  10-­‐4	  
2.16	  x	  10-­‐5	  
3.03	  x	  10-­‐4	  
2.56	  x	  10-­‐5	  
6.78	  x	  10-­‐5	  
1.86	  x	  10-­‐4	  
-­‐2.00x	  10-­‐7	  
4.15	  x	  10-­‐5	  
2.85	  x	  10-­‐4	  
1.55	  x	  10-­‐4	  
-­‐5.30	  x	  10-­‐6	  
2.36	  x	  10-­‐4	  
2.17	  x	  10-­‐4	  
-­‐3.14	  x	  10-­‐5	  
7.77	  x	  10-­‐4	  
2.53	  x	  10-­‐4	  
1.68	  x	  10-­‐5	  
4.80	  x	  10-­‐5	  
1.83	  x	  10-­‐5	  
3.40	  x	  10-­‐6	  
























-­‐4.76	  x	  10-­‐5	  
-­‐1.59	  x	  10-­‐4	  
-­‐3.22	  x	  10-­‐4	  
-­‐2.06	  x	  10-­‐4	  
-­‐4.19	  x	  10-­‐5	  
-­‐5.84	  x	  10-­‐5	  
-­‐8.40	  x	  10-­‐6	  
-­‐1.43	  x	  10-­‐5	  
-­‐6.22	  x	  10-­‐5	  
-­‐3.90	  x	  10-­‐5	  
-­‐4.60	  x	  10-­‐6	  
-­‐3.51	  x	  10-­‐5	  
-­‐2.46	  x	  10-­‐5	  
-­‐2.10	  x	  10-­‐6	  
-­‐4.91	  x	  10-­‐5	  
-­‐1.56	  x	  10-­‐5	  
-­‐3.50	  x	  10-­‐6	  
-­‐5.10	  x	  10-­‐6	  
-­‐1.60	  x	  10-­‐6	  
-­‐7.00	  x	  10-­‐7	  
























1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no).	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  VO2max	  per	  FFM	  at	  baseline.	  
$	  =	  p-­‐value	  <0.050	  












Appendices	  of	  chapter	  5	  
	  
Method	  of	  external	  calibration	  
When	   exact-­‐matching	   stable	   isotope	   internal	   standards	   were	   not	   available,	  
metabolite	  concentrations	  were	  estimated	  by	  external	  calibration	  in	  the	  presence	  of	  sample	  
matrix	   as	   follows.	   A	   pooled	   sample	   was	   generated	   by	   combining	   aliquots	   of	   extracted	  
human	  subject	  samples.	  The	  pooled	  sample	  was	  divided	  into	  4	  aliquots,	  which	  were	  spiked	  
with	  the	  concentrations	  of	  metabolite	  standards	  listed	  in	  table	  A5.4,	  such	  that	  the	  volume	  
ratio	  of	  pooled	  sample-­‐to-­‐spiked	  standard	  was	  9:1.	  The	  slopes	  of	  the	  resulting	  calibration	  
curves	  were	  used	  to	  calculate	  metabolite	  concentrations	  from	  measured	  peak	  areas	  (the	  y-­‐
intercept	  was	  set	  as	  the	  average	  peak	  area	  from	  replicate	  runs	  of	  a	  blank	  sample).	  
	  
Table	  A5.1	   Internal	   standards	   used	   for	   quantitation	   of	   targeted	  metabolites.	   NSK-­‐B	   internal	   standard	  mix	  
was	  purchased	  from	  Cambridge	  Isotope	  (Andover,	  MA).	  All	  other	  carbon-­‐13	  stable	  isotope	  internal	  standards	  
were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  	  
Internal	  Standards	   Internal	  standard	  concentration	  added	  to	  extraction	  solvent	  
Algal	  AA	  mixture_13C	   10	  μg/ml	  
AMP_13C10_15N5	   800	  nM	  
ATP_13C10_15N5	   20	  μM	  
Citrate_13C6	   2	  μM	  
Fructose	  1,6-­‐bisphosphate_13C6	  	   16	  μM	  
Frucose-­‐6-­‐phosphate_13C6	   20	  μM	  
Glutamine_13C5	   4	  μM	  
Glucose_13C6	   40	  μM	  
Lactate_13C3	   40	  μM	  
Malate_13C4	   4	  μM	  
NSK-­‐B	  internal	  standard	  mix	  
	  	  	  	  	  	  	  	  2H9-­‐Carnitine	  (L-­‐carnitine)	  
	  	  	  	  	  	  	  	  2H3-­‐Acetylcarnitine	  (C2)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Propionylcarnitine	  (C3)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Butyrylcarnitine	  (C4)	  
	  	  	  	  	  	  	  	  2H9-­‐Isovalerylcarnitine	  (C5)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Octanoylcarnitine	  (C8)	  	  
	  	  	  	  	  	  	  	  2H9-­‐Myristoylcarnitine	  (C14)	  	  










Oleic	  acid_13C18	   10	  μM	  
Succinate-­‐13C4	   4	  μM	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Table	  A5.2	  All	  targeted	  metabolites	  identified	  in	  this	  study	  
Identified	  targeted	  metabolites	  
AAs	  
	  	  	  Alanine	  	  
	  	  	  Arginine	  
	  	  	  Asparagine	  	  
	  	  	  Aspartic	  acid	  
	  	  	  Glutamic	  acid	  	  
	  	  	  Glutamine	  	  
	  	  	  Glycine	  
	  	  	  Histidine	  	  
	  	  	  Isoleucine+leucine	  	  
	  	  	  Lysine	  	  
	  	  	  Methionine	  	  
	  	  	  Phenylalanine	  	  
	  	  	  Proline	  	  
	  	  	  Serine	  	  
	  	  	  Threonine	  	  
	  	  	  Tryptophan	  	  
	  	  	  Tyrosine	  	  
	  	  	  Valine	  
Acylcarnitines	  
	  	  	  L-­‐carnitine	  
	  	  	  C2	  carnitine	  	  
	  	  	  C3	  carnitine	  
	  	  	  C4	  carnitine	  
	  	  	  C5	  carnitine	  
	  	  	  C5-­‐DC	  carnitine	  
	  	  	  C6	  carnitine	  	  
	  	  	  C8:0	  carnitine	  
	  	  	  C8:1	  carnitine	  
	  	  	  C10:0	  carnitine	  
	  	  	  C10:1	  carnitine	  
	  	  	  C12:0	  carnitine	  
	  	  	  C12:1	  carnitine	  
	  	  	  C12-­‐OH	  carnitine	  
	  	  	  C14:0	  carnitine	  
	  	  	  C14:1	  carnitine	  
	  	  	  C14:2	  carnitine	  
	  	  	  C14-­‐OH	  carnitine	  
	  	  	  C16:0	  carnitine	  
	  	  	  C16:1	  carnitine	  
	  	  	  C16-­‐OH	  carnitine	  
	  	  	  C18:0	  carnitine	  
	  	  	  C18:1	  carnitine	  
	  	  	  C18:2	  carnitine	  
	  	  	  C18:2-­‐OH	  carnitine	  
	  	  	  C20:0	  carnitine	  
	  	  	  C20:1	  carnitine	  
	  	  	  C20:2	  carnitine	  
	  	  	  C20:3	  carnitine	  
	  	  	  C20:4	  carnitine	  
Glycolysis	  metabolites	  
	  	  	  Glucose	  
	  	  	  Glucose-­‐6-­‐phosphate+fructose-­‐6-­‐phosphate	  
	  	  	  Fructose	  1,6-­‐bisphosphate	  
	  	  	  Dihydroxyacetone	  phosphate	  
	  	  	  2-­‐phosphoglyceric	  acid+3-­‐phosphoglyceric	  acid	  
	  	  	  Glycerol-­‐3-­‐phosphate	  
	  	  	  Lactate	  
FFA	  
	  	  	  Oleic	  acid	  
TCA	  cycle	  metabolites	  
	  	  	  Citrate	  
	  	  	  Succinate	  	  
	  	  	  Malate	  
	  	  	  	  
Nucleotides	  
	  	  	  AMP	  
	  	  	  ADP	  
	  	  	  ATP	  
	  	  	  NAD	  
	  	  	  NADH	  
	  	  	  NADP	  














Table	  A5.3	  MRM	  for	  detection	  of	  AAs,	  oleic	  acids,	  glycolysis	  metabolites,	  TCA	  metabolites	  and	  nucleotides.	  
Dwell	  time	  of	  10	  ms	  was	  used	  for	  all	  metabolites.	  
Metabolites	   Precursor	  Ion	   Product	  Ion	   Fragmentor	   Collision	  Energy	  
2-­‐phosphoglyceric	  acid+	  
3-­‐phosphoglyceric	  acid	   185	   79	   100	   45	  
ADP	   426	   79	   70	   55	  
Alanine	   88.05	   88.05	   50	   0	  
Alanine_13C3	   91.05	   91.05	   50	   0	  
AMP	   346.1	   79	   155	   60	  
AMP_13C10_15N5	   361.1	   79	   155	   60	  
Arginine	   173.11	   131.1	   110	   10	  
Arginine_13C6	   179.11	   136.1	   110	   10	  
Asparagine	   131.05	   113	   80	   6	  
Aspartic	  acid	   132	   88	   60	   7	  
Aspartic	  acid_13C4	   136	   91	   60	   7	  
ATP	   506	   79	   90	   100	  
ATP_13C10_15N5	   521	   79	   90	   100	  
Citrate	   191	   87	   95	   13	  
Citrate_13C6	   197	   116.1	   80	   7	  
Dihydroxyacetone	  
phosphate	  
169	   79	   50	   34	  
FAD	   784	   79	   170	   165	  
Fructose	  1,6-­‐bisphosphate	   339	   97	   85	   18	  
Fructose	  1,6-­‐
bisphosphate_13C6	  
345	   79	   85	   18	  
Glucose	   179.1	   59	   80	   15	  
Glucose_13C6	   185.1	   61	   80	   15	  
Glucose-­‐6-­‐phosphate+	  
fructose-­‐6-­‐phosphate	  
259	   97	   75	   10	  
Fructose-­‐6-­‐phosphate_13C6	   265	   79	   75	   10	  
Glutamic	  acid	   146	   102	   60	   7	  
Glutamic	  acid_13C5	   151	   106	   60	   7	  
Glutamine	   145.07	   127.1	   80	   6	  
Glutamine_13C5	   150.07	   132.1	   80	   6	  
Glyceraldehyde-­‐3-­‐
phosphate	  	  	  	  
171.01	   79	   80	   30	  
Glycine	   74.03	   74.03	   30	   0	  
Glycine_13C2	   76.03	   76.03	   30	   0	  
Histidine	   154.07	   93	   80	   14	  
Isoleucine+leucine	   130.09	   130.09	   72	   0	  
Isoleucine+leucine_13C6	   136.09	   136.09	   72	   0	  
Lactate	   89	   43	   65	   9	  
Lactate_13C3	   92	   45	   65	   9	  
Lysine	   145.11	   145.11	   72	   0	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Malate	   133	   115	   50	   5	  
Malate_13C4	   137	   119	   50	   5	  
Methionine	   148.05	   47.1	   80	   10	  
Methionine_13C5	   153.05	   48.1	   80	   10	  
NAD	   662	   540	   150	   15	  
NADH	   664	   408	   140	   40	  
NADP	   742	   620	   140	   20	  
Oleic	  acid	   281.26	   281.26	   50	   0	  
Oleic	  acid_13C18	   299.26	   299.26	   50	   0	  
Phenylalanine	   164.08	   147.1	   80	   10	  
Phenylalanine_13C9	   173.08	   156.1	   80	   10	  
Proline	   114.06	   114.06	   86	   0	  
Proline_13C5	   119.06	   119.06	   86	   0	  
Serine	   104.04	   74.1	   80	   6	  
Serine_13C3	   107.04	   76.1	   80	   6	  
Succinate	   117	   73	   55	   7	  
Succinate_13C4	   121	   76	   55	   7	  
Threonine	   118.06	   74.1	   80	   6	  
Threonine_13C4	   122.06	   76.1	   80	   6	  
Tryptophan	   203.09	   159.1	   80	   6	  
Tyrosine	   180.07	   163	   80	   10	  
Tyrosine_13C9	   189.07	   172	   80	   10	  
Valine	   116.08	   116.08	   58	   0	  



























Table	  A5.4	   Calibration	   parameters	   used	   for	   quantitation	   of	   targeted	  metabolites.	   All	   calibration	   curve	   fits	  
were	  linear.	  All	  metabolite	  standards	  were	  purchased	  from	  Sigma-­‐Aldrich.	  
Metabolites	  
Calibration	  curve	  concentrations	  	  
(µM)	  
R2	  
Metabolites	  with	  exact-­‐matching	  stable	  isotope	  
internal	  standards	  
	  	  	  AAs	  
	  	  	  	  	  	  Alanine	  
	  	  	  	  	  	  Arginine	  
	  	  	  	  	  	  Aspartic	  acid	  
	  	  	  	  	  	  Glutamic	  acid	  
	  	  	  	  	  	  Glutamine	  
	  	  	  	  	  	  Glycine	  
	  	  	  	  	  	  Isoleucine+leucine	  
	  	  	  	  	  	  Methionine	  
	  	  	  	  	  	  Phenylalanine	  
	  	  	  	  	  	  Proline	  
	  	  	  	  	  	  Serine	  
	  	  	  	  	  	  Threonine	  
	  	  	  	  	  	  Tyrosine	  
	  	  	  	  	  	  Valine	  
	  	  Glycolysis	  metabolites	  
	  	  	  	  	  	  Glucose	  
	  	  	  	  	  	  Glucose-­‐6-­‐phosphate+fructose-­‐6-­‐phosphate	  
	  	  	  	  	  	  Fructose	  1,6-­‐bisphosphate	  
	  	  	  	  	  	  Lactate	  
	  	  FFA	  	  	  	  
	  	  	  	  	  	  Oleic	  acid	  
	  	  TCA	  cycle	  metabolites	  
	  	  	  	  	  	  Citrate	  
	  	  	  	  	  	  Succinate	  	  
	  	  	  	  	  	  Malate	  
	  	  Nucleotides	  
	  	  	  	  	  	  AMP	  




0,	  25,	  83.33,	  250,	  833.33,	  2500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  25,	  83.33,	  250,	  833.33,	  2500	  
0,	  75,	  250,	  750,	  2500,	  7500	  	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  10,	  33.33,	  100,	  333.33	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
	  
0,	  200,	  666.67,	  2000,	  6666.67,	  20000	  
0,	  45,	  150,	  450,	  1500,	  4500	  
0,	  45,	  150,	  450,	  1500,	  4500	  
0,	  480,	  1600,	  4800,	  16000,	  48000	  
	  
0,	  2,	  6.67,	  20,	  66.67,	  200	  
	  
0,	  5,	  16.67,	  50,	  166.67,	  500	  
0,	  10,	  33.33,	  100,	  333.33,	  1000	  
0,	  10,	  33.33,	  100,	  333.33,	  1000	  
	  
0,	  10,	  33.33,	  100,	  333.33	  
































Metabolites	  without	  exact-­‐matching	  stable	  
isotope	  internal	  standards	  
	  	  	  AAs	  
	  	  	  	  	  	  Asparagine	  
	  	  	  	  	  	  Histidine	  
	  	  	  	  	  	  Lysine	  
	  	  	  	  	  	  Tryptophan	  
	  	  	  Glycolysis	  metabolites	  
	  	  	  	  	  	  Dihydroxyacetone	  phosphate	  
	  	  	  	  	  	  2-­‐phosphoglyceric	  acid+3-­‐phosphoglyceric	  acid	  
	  	  	  	  	  	  Glycerol-­‐3-­‐phosphate	  	  	  	  
	  	  	  Nucleotides	  
	  	  	  	  	  	  ADP	  
	  	  	  	  	  	  NAD	  
	  	  	  	  	  	  NADH	  
	  	  	  	  	  	  NADP	  




0,	  9.6,	  32,	  96	  
0,	  21,	  70,	  210	  
0,	  50,	  166.67,	  500	  
0,	  0.9,	  3,	  9	  
	  
0,	  6,	  20,	  60	  
0,	  6.9,	  23,	  69	  
0,	  30,	  100,	  300	  
	  
0,	  18,	  60,	  180	  
0,	  10.05,	  33.5,	  100.5	  
0,	  1,	  3.33,	  10	  
0,	  1.05,	  3.5,	  10.5	  





















Table	  A5.5	  Primers	  used	  for	  DNA	  analysis.	  All	  primers	  were	  purchased	  from	  Invitrogen.	  
Primers	   Binding	  site	  position	   Sequence	  (5′-­‐3′)	  
mtDNA	  at	  the	  major	  arc	  
(Forward	  sequence)	  
mtDNA	  at	  the	  major	  arc	  
(Reverse	  sequence)	  
mtDNA	  at	  the	  minor	  arc	  
(Forward	  sequence)	  
mtDNA	  at	  the	  minor	  arc	  
(Reverse	  sequence)	  
DNA	  at	  β2M	  gene	  of	  nucleus	  	  
(Forward	  sequence)	  
DNA	  at	  β2M	  gene	  of	  nucleus	  	  
(Reverse	  sequence)	  
mt	  10,912	  –	  10,931	  
	  
mt	  10,975	  –	  10,994	  
	  
mt	  16,528	  –	  16,548	  
	  
mt	  23	  –	  42	  
	  
Chr15	  15,798,932	  –	  15,798,958	  
	  






















































Table	  A5.6	  All	  212	  selected	  untargeted	  metabolites	  for	  final	  analysis	  





























































































































































































































































































































































































































































































































































































































































Table	  A5.7	  Correlations	  of	  targeted	  metabolites	  and	  mtDNA	  profiles	  at	  baseline	  (non-­‐obese	  and	  all	  obese	  subjects)	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  
and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  at	  baseline	  vs.	  mtDNA	  count	  number	  at	  baseline	  
AAs	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






















7.30	  x	  10-­‐1	  
-­‐44.99	  
2.07	  
7.91	  x	  10-­‐1	  
36.08	  




-­‐2.16	  x	  10-­‐1	  
1.24	  x	  102	  
-­‐4.75	  x	  10-­‐1	  
































-­‐1.70	  x	  102	  




-­‐4.33	  x	  10-­‐1	  
-­‐3.14	  x	  102	  
-­‐1.03	  




























1.16	  x	  10-­‐1	  
2.74	  
-­‐6.61	  x	  10-­‐1	  
-­‐4.37	  
11.12	  




3.36	  x	  10-­‐4	  
-­‐4.93	  
2.48	  x	  10-­‐2	  
5.10	  x	  10-­‐3	  
-­‐2.34	  x	  10-­‐1	  
1.78	  x	  10-­‐1	  
5.05	  x	  10-­‐1	  
1.44	  x	  10-­‐1	  
7.84	  x	  10-­‐2	  





















-­‐6.21	  x	  10-­‐1	  
-­‐1.31	  x	  10-­‐2	  
-­‐5.83	  x	  10-­‐1	  
1.28	  x	  10-­‐1	  
1.16	  
-­‐1.38	  x	  10-­‐1	  
-­‐7.48	  x	  10-­‐4	  
	  
-­‐2.87	  x	  10-­‐1	  
1.14	  x	  10-­‐1	  
-­‐6.58	  x	  10-­‐4	  
-­‐3.28	  
-­‐5.93	  x	  10-­‐3	  
-­‐6.44	  x	  10-­‐3	  
-­‐1.83	  x	  10-­‐1	  
-­‐5.43	  x	  10-­‐2	  
-­‐7.01	  x	  10-­‐2	  
2.95	  x	  10-­‐2	  
-­‐1.28	  x	  10-­‐2	  























Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  











-­‐2.30	  x	  102	  
	  
	  















1.42	  x	  102	  
	  
	  
-­‐1.11	  x	  102	  
	  



















































































1.09	  x	  103	  









































Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Oleic	  acid	   -­‐2.81	  x	  10-­‐1	   0.965	   -­‐4.30	   0.621	   -­‐3.32	  x	  10-­‐1	   0.562	   3.33	  x	  10-­‐2	   0.646	  
Acylcarnitines	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






















1.09	  x	  10-­‐1	  
-­‐4.26	  x	  10-­‐1	  
-­‐5.90	  x	  10-­‐2	  
-­‐7.45	  x	  10-­‐3	  
-­‐1.88	  x	  10-­‐1	  
-­‐5.30	  x	  10-­‐2	  
1.11	  x	  10-­‐2	  
-­‐4.72	  x	  10-­‐2	  
-­‐1.39	  x	  10-­‐2	  
-­‐9.91	  x	  10-­‐2	  
-­‐9.29	  x	  10-­‐3	  
-­‐5.12	  x	  10-­‐2	  
2.46	  x	  10-­‐2	  
3.28	  x	  10-­‐2	  
1.13	  x	  10-­‐2	  
-­‐7.13	  x	  10-­‐3	  






















-­‐7.62	  x	  10-­‐1	  
4.15	  x	  10-­‐1	  
-­‐7.24	  x	  10-­‐2	  
3.40	  x	  10-­‐2	  
9.69	  x	  10-­‐2	  
5.37	  x	  10-­‐2	  
7.81	  x	  10-­‐3	  
6.17	  x	  10-­‐2	  
1.73	  x	  10-­‐2	  
1.09	  x	  10-­‐1	  
3.30	  x	  10-­‐2	  
1.11	  x	  10-­‐2	  
3.34	  x	  10-­‐1	  
3.23	  x	  10-­‐1	  
9.97	  x	  10-­‐2	  
9.42	  x	  10-­‐3	  






















-­‐9.39	  x	  10-­‐3	  
-­‐1.15	  x	  10-­‐1	  
7.45	  x	  10-­‐3	  
-­‐4.91	  x	  10-­‐3	  
-­‐1.24	  x	  10-­‐2	  
-­‐2.35	  x	  10-­‐3	  
4.23	  x	  10-­‐4	  
-­‐2.67	  x	  10-­‐3	  
-­‐3.74	  x	  10-­‐4	  
6.13	  x	  10-­‐4	  
-­‐3.53	  x	  10-­‐4	  
-­‐4.48	  x	  10-­‐4	  
2.94	  x	  10-­‐3	  
3.66	  x	  10-­‐3	  
2.76	  x	  10-­‐3	  
-­‐4.71	  x	  10-­‐4	  




















5.81	  x	  10-­‐2	  
2.14	  x	  10-­‐1	  
-­‐2.28	  x	  10-­‐3	  
1.12	  x	  10-­‐3	  
-­‐3.29	  x	  10-­‐4	  
1.56	  x	  10-­‐4	  
-­‐4.63	  x	  10-­‐4	  
-­‐5.04	  x	  10-­‐4	  
3.43	  x	  10-­‐3	  
-­‐5.43	  x	  10-­‐4	  
-­‐1.21	  x	  10-­‐4	  
-­‐1.82	  x	  10-­‐3	  
-­‐1.12	  x	  10-­‐4	  
-­‐5.06	  x	  10-­‐4	  
-­‐1.53	  x	  10-­‐3	  
-­‐6.02	  x	  10-­‐4	  
-­‐2.11	  x	  10-­‐4	  
-­‐5.79	  x	  10-­‐5	  































4.01	  x	  10-­‐1	  
-­‐1.77	  x	  10-­‐2	  
3.28	  x	  10-­‐1	  
1.84	  
6.21	  x	  10-­‐1	  
5.05	  x	  10-­‐3	  
3.52	  x	  10-­‐2	  
1.26	  x	  10-­‐2	  
1.30	  x	  10-­‐2	  











9.63	  x	  10-­‐1	  
2.44	  x	  10-­‐2	  
7.24	  x	  10-­‐1	  
2.32	  
9.34	  x	  10-­‐1	  
9.17	  x	  10-­‐3	  
6.20	  x	  10-­‐2	  
1.86	  x	  10-­‐2	  
1.63	  x	  10-­‐2	  	  











7.49	  x	  10-­‐3	  
2.46	  x	  10-­‐3	  
1.83	  x	  10-­‐2	  
-­‐7.48	  x	  10-­‐3	  
1.24	  x	  10-­‐2	  
2.42	  x	  10-­‐5	  
3.07	  x	  10-­‐4	  
5.82	  x	  10-­‐5	  
8.36	  x	  10-­‐5	  











-­‐1.83	  x	  10-­‐3	  
-­‐2.59	  x	  10-­‐4	  
-­‐2.65	  x	  10-­‐3	  
-­‐1.18	  x	  10-­‐2	  
-­‐1.88	  x	  10-­‐3	  
1.83	  x	  10-­‐5	  
-­‐1.44	  x	  10-­‐4	  
-­‐4.30	  x	  10-­‐5	  
-­‐9.26	  x	  10-­‐5	  













Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
















-­‐3.65	  x	  10-­‐1	  





7.97	  x	  10-­‐2	  
8.07	  x	  10-­‐2	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  









2.82	  x	  10-­‐1	  
7.30	  
-­‐34.02	  
-­‐1.07	  x	  102	  
-­‐6.42	  
-­‐2.79	  x	  10-­‐1	  
-­‐2.03	  





























-­‐1.38	  x	  10-­‐1	  
-­‐4.56	  x	  10-­‐1	  
-­‐2.79	  x	  10-­‐2	  









-­‐8.43	  x	  10-­‐3	  
-­‐8.97	  x	  10-­‐1	  
1.03	  
3.53	  x	  10-­‐1	  
1.27	  x	  10-­‐1	  
-­‐5.52	  x	  10-­‐2	  
1.37	  x	  10-­‐1	  












Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
C18:1	  carnitine-­‐to-­‐
oleic	  acid	  ratio	  
6.59	  x	  10-­‐3	   0.493	   2.28	  x	  10-­‐2	   0.081	   1.61	  x	  10-­‐3	   0.058	   -­‐1.73	  x	  10-­‐4	   0.111	  
C3	  and	  C5	  carnitine-­‐
to-­‐BCAA	  ratio	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  







1.67	  x	  10-­‐4	  
	  




-­‐7.86	  x	  10-­‐4	  
	  




-­‐4.88	  x	  10-­‐6	  
	  






-­‐3.55	  x	  10-­‐6	  
	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  

















1.15	  x	  10-­‐2	  
	  










1Data	  were	  adjusted	  for	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	   adjusted	   for	   age,	   sex,	   race,	   group	   of	   subjects	   (non-­‐obese	   or	   obese),	   BMI,	   diabetes	   status	   (yes	   or	   no),	  HOMA-­‐IR	   and	  VO2max	   per	   FFM	   at	  
baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	  





















Table	  A5.8	  Correlations	  of	  targeted	  metabolites	  and	  mtDNA	  profiles	  at	  baseline	  of	  41	  obese	  subjects	  who	  received	  muscle	  biopsy	  at	  both	  baseline	  and	  
after	  CR	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  at	  baseline	  vs.	  mtDNA	  
count	  number	  at	  baseline	  
AAs	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  


























-­‐1.40	  x	  102	  




-­‐1.53	  x	  10-­‐1	  
-­‐146	  x	  102	  
-­‐9.48	  x	  10-­‐1	  





































-­‐2.21	  x	  10-­‐1	  
-­‐65.12	  
-­‐3.50	  x	  10-­‐1	  





































-­‐1.74	  x	  10-­‐2	  
-­‐1.04	  x	  102	  
-­‐2.68	  x	  10-­‐2	  
-­‐2.39	  x	  10-­‐1	  
-­‐8.48	  
-­‐6.56	  x	  10-­‐1	  
-­‐2.04	  
-­‐2.61	  x	  10-­‐1	  
-­‐1.23	  x	  10-­‐1	  





















-­‐4.35	  x	  10-­‐4	  
3.53	  x	  10-­‐1	  
3.07	  x	  10-­‐2	  
-­‐6.06	  x	  10-­‐2	  
1.01	  
-­‐4.15	  x	  10-­‐1	  
-­‐5.15	  x	  10-­‐4	  
	  
-­‐1.05	  x	  10-­‐1	  
-­‐2.81	  x	  10-­‐1	  
-­‐6.62	  x	  10-­‐4	  
3.64	  
-­‐2.36	  x	  10-­‐3	  
7.01	  x	  10-­‐3	  
-­‐2.86	  x	  10-­‐1	  
-­‐9.40	  x	  10-­‐2	  
1.83	  x	  10-­‐2	  
-­‐1.64	  x	  10-­‐2	  
2.51	  x	  10-­‐2	  























Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  


























6.94	  x	  102	  
	  
	  
1.43	  x	  102	  
	  


























-­‐3.78	  x	  10-­‐2	  
-­‐5.40	  x	  10-­‐1	  
	  
	  

















































3.30	  x	  103	  

























-­‐1.53	  x	  10-­‐1	  
	  



















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Oleic	  acid	   4.24	  x	  10-­‐1	   0.908	   3.89	   0.514	   5.86	  x	  10-­‐1	   0.242	   3.97	  x	  10-­‐2	   0.481	  
Acylcarnitines	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  





















2.21	  x	  10-­‐1	  
6.88	  x	  10-­‐2	  
-­‐1.43	  x	  10-­‐3	  
4.30	  x	  10-­‐2	  
-­‐6.28	  x	  10-­‐2	  
-­‐7.58	  x	  10-­‐3	  
5.35	  x	  10-­‐2	  
1.79	  x	  10-­‐2	  
-­‐4.60	  x	  10-­‐4	  
7.95	  x	  10-­‐2	  
-­‐6.57	  x	  10-­‐3	  
5.84	  x	  10-­‐3	  
4.36	  x	  10-­‐2	  
-­‐4.59	  x	  10-­‐3	  
4.88	  x	  10-­‐3	  





















8.91	  x	  10-­‐2	  
5.25	  x	  10-­‐1	  
-­‐5.94	  x	  10-­‐2	  
3.74	  x	  10-­‐2	  
9.74	  x	  10-­‐4	  
1.18	  x	  10-­‐2	  
5.62	  x	  10-­‐2	  
5.41	  x	  10-­‐2	  
1.93	  x	  10-­‐2	  
2.36	  x	  10-­‐1	  
4.60	  x	  10-­‐2	  
3.33	  x	  10-­‐2	  
5.62	  x	  10-­‐1	  
4.81	  x	  10-­‐1	  
1.61	  x	  10-­‐1	  




















-­‐9.80	  x	  10-­‐1	  
-­‐5.90	  x	  10-­‐2	  
1.92	  x	  10-­‐2	  
-­‐9.78	  x	  10-­‐3	  
-­‐5.39	  x	  10-­‐3	  
-­‐2.37	  x	  10-­‐2	  
-­‐8.81	  x	  10-­‐3	  
-­‐6.82	  x	  10-­‐4	  
-­‐9.15	  x	  10-­‐3	  
-­‐2.13	  x	  10-­‐3	  
-­‐1.15	  x	  10-­‐2	  
-­‐1.37	  x	  10-­‐3	  
6.06	  x	  10-­‐4	  
2.22	  x	  10-­‐3	  
4.01	  x	  10-­‐3	  
2.53	  x	  10-­‐3	  



















7.23	  x	  10-­‐1	  
-­‐2.71	  x	  10-­‐1	  
1.81	  x	  10-­‐3	  
-­‐1.03	  x	  10-­‐2	  
-­‐6.22	  x	  10-­‐4	  
-­‐3.67	  x	  10-­‐5	  
-­‐2.67	  x	  10-­‐3	  
-­‐1.14	  x	  10-­‐3	  
1.62	  x	  10-­‐4	  
-­‐3.21	  x	  10-­‐4	  
-­‐2.19	  x	  10-­‐4	  
6.40	  x	  10-­‐4	  
-­‐8.41	  x	  10-­‐5	  
-­‐2.84	  x	  10-­‐5	  
-­‐8.76	  x	  10-­‐4	  
-­‐3.93	  x	  10-­‐4	  
-­‐2.93	  x	  10-­‐5	  































2.72	  x	  10-­‐1	  
1.23	  x	  10-­‐1	  
1.11	  x	  10-­‐2	  
2.79	  x	  10-­‐1	  
7.87	  x	  10-­‐1	  
2.27	  x	  10-­‐1	  
2.21	  x	  10-­‐3	  
2.92	  x	  10-­‐2	  
6.64	  x	  10-­‐3	  
5.30	  x	  10-­‐3	  


















1.24	  x	  10-­‐2	  
1.74	  x	  10-­‐1	  
4.52	  x	  10-­‐2	  
4.04	  x	  10-­‐2	  












3.75	  x	  10-­‐2	  
2.55	  x	  10-­‐2	  
2.77	  x	  10-­‐3	  
5.09	  x	  10-­‐2	  
1.31	  x	  10-­‐1	  
4.71	  x	  10-­‐2	  
4.39	  x	  10-­‐4	  
4.99	  x	  10-­‐3	  
9.11	  x	  10-­‐4	  
8.47	  x	  10-­‐4	  












-­‐7.93	  x	  10-­‐3	  
-­‐2.01	  x	  10-­‐3	  
-­‐6.07	  x	  10-­‐5	  
-­‐5.77	  x	  10-­‐3	  
-­‐2.63	  x	  10-­‐2	  
-­‐6.07	  x	  10-­‐3	  
-­‐2.68	  x	  10-­‐5	  
-­‐4.37	  x	  10-­‐4	  
-­‐1.62	  x	  10-­‐4	  
-­‐1.55	  x	  10-­‐4	  














Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






















1.73	  x	  10-­‐2	  
1.33	  x	  10-­‐1	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  









3.58	  x	  10-­‐1	  
29.41	  
-­‐92.23	  













9.52	  x	  10-­‐1	  
-­‐1.28	  x	  102	  




















-­‐2.77	  x	  10-­‐1	  









4.75	  x	  10-­‐3	  
-­‐1.02	  
-­‐7.51	  x	  10-­‐3	  
5.82	  x	  10-­‐1	  
-­‐2.60	  x	  10-­‐2	  
5.96	  x	  10-­‐2	  
9.82	  x	  10-­‐2	  












Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
C18:1	  carnitine-­‐to-­‐
oleic	  acid	  ratio	  
-­‐1.52	  x	  10-­‐3	   0.927	   5.04	  x	  10-­‐2	   0.069	   -­‐2.87	  x	  10-­‐3	   0.207	   -­‐3.55	  x	  10-­‐4	   0.180	  
C3	  and	  C5	  carnitine-­‐
to-­‐BCAA	  ratio	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	  
 278 






3.13	  x	  10-­‐4	  
	  




6.65	  x	  10-­‐5	  
	  




-­‐3.89	  x	  10-­‐5	  
	  




2.90	  x	  10-­‐6	  
	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  





























1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR	  and	  VO2max	  per	  FFM	  at	  baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	  





















Table	  A5.9	   Correlations	   of	   targeted	  metabolites	   and	  mtDNA	  profiles	   of	   41	   obese	   subjects	   after	   CR	   vs.	   age,	   VO2max	  per	   FFM	  at	   baseline	   and	   [age	   x	  
VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  after	  CR	  vs.	  mtDNA	  count	  number	  after	  CR	  
AAs	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  


























-­‐1.97	  x	  102	  




-­‐1.88	  x	  10-­‐1	  
-­‐6.53	  x	  102	  
































-­‐2.39	  x	  102	  
-­‐7.13	  x	  102	  
1.22	  x	  10-­‐1	  
	  
-­‐26.50	  
-­‐1.09	  x	  102	  
-­‐2.76	  x	  10-­‐1	  
































-­‐2.01	  x	  10-­‐1	  
-­‐8.67	  
-­‐28.87	  




1.52	  x	  10-­‐3	  
-­‐62.48	  
2.47	  x	  10-­‐2	  
-­‐3.05	  x	  10-­‐1	  
-­‐3.86	  
-­‐3.12	  x	  10-­‐1	  
-­‐7.37	  x	  10-­‐1	  
-­‐1.06	  
7.73	  x	  10-­‐2	  






















2.66	  x	  10-­‐1	  
1.04	  x	  10-­‐1	  
-­‐1.66	  x	  10-­‐2	  
2.42	  
1.00	  
-­‐1.89	  x	  10-­‐3	  
	  
-­‐1.12	  x	  10-­‐1	  
1.04	  
-­‐5.91	  x	  10-­‐3	  
-­‐2.67	  
-­‐3.07	  x	  10-­‐2	  
-­‐2.19	  x	  10-­‐2	  
2.38	  x	  10-­‐1	  
-­‐1.85	  x	  10-­‐1	  
1.85	  x	  10-­‐2	  
9.52	  x	  10-­‐2	  
-­‐4.10	  x	  10-­‐2	  























Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  




























1.77	  x	  102	  
7.91	  x	  102	  
	  
	  
2.56	  x	  102	  
	  

































































-­‐1.07	  x	  103	  















6.40	  x	  103	  













6.14	  x	  102	  



























Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Oleic	  acid	   -­‐23.54	   0.342	   20.91	   0.606	   1.88	   0.564	   -­‐4.33	  x	  10-­‐1	   0.224	  
Acylcarnitines	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






















-­‐2.32	  x	  10-­‐2	  
2.60	  x	  10-­‐1	  
-­‐5.19	  x	  10-­‐3	  
5.23	  x	  10-­‐2	  
5.54	  x	  10-­‐1	  
2.11	  x	  10-­‐1	  
2.90	  x	  10-­‐2	  
1.84	  x	  10-­‐1	  
7.29	  x	  10-­‐2	  
1.88	  x	  10-­‐1	  
5.20	  x	  10-­‐2	  
3.06	  x	  10-­‐2	  
2.70	  x	  10-­‐1	  
2.90	  x	  10-­‐1	  
1.08	  x	  10-­‐1	  
9.69	  x	  10-­‐3	  




















-­‐1.42	  x	  102	  
-­‐13.82	  
5.29	  x	  10-­‐3	  
4.62	  x	  10-­‐1	  
-­‐6.23	  x	  10-­‐2	  
2.68	  x	  10-­‐2	  
4.41	  x	  10-­‐1	  
1.54	  x	  10-­‐1	  
3.30	  x	  10-­‐2	  
1.37	  x	  10-­‐1	  
9.50	  x	  10-­‐2	  
1.59	  x	  10-­‐1	  
8.49	  x	  10-­‐2	  
1.53	  x	  10-­‐1	  
1.13	  
7.62	  x	  10-­‐1	  
2.51	  x	  10-­‐1	  























3.40	  x	  10-­‐2	  
1.85	  x	  10-­‐2	  
2.52	  x	  10-­‐3	  
-­‐3.48	  x	  10-­‐3	  
-­‐1.39	  x	  10-­‐2	  
-­‐8.28	  x	  10-­‐4	  
-­‐7.77	  x	  10-­‐3	  
7.62	  x	  10-­‐3	  
4.28	  x	  10-­‐3	  
3.53	  x	  10-­‐2	  
4.38	  x	  10-­‐3	  
1.65	  x	  10-­‐2	  
7.90	  x	  10-­‐2	  
4.55	  x	  10-­‐2	  
1.52	  x	  10-­‐2	  
6.98	  x	  10-­‐3	  





















-­‐0.37	  x	  10-­‐1	  
-­‐1.22	  x	  10-­‐2	  
-­‐3.43	  x	  10-­‐3	  
-­‐8.89	  x	  10-­‐4	  
1.47	  x	  10-­‐4	  
-­‐2.03	  x	  10-­‐3	  
-­‐7.03	  x	  10-­‐4	  
5.07	  x	  10-­‐4	  
-­‐1.49	  x	  10-­‐3	  
-­‐5.48	  x	  10-­‐4	  
-­‐4.73	  x	  10-­‐3	  
-­‐5.86	  x	  10-­‐4	  
-­‐2.05	  x	  10-­‐3	  
-­‐1.10	  x	  10-­‐2	  
-­‐6.27	  x	  10-­‐3	  
-­‐1.90	  x	  10-­‐3	  
-­‐8.17	  x	  10-­‐4	  































7.27	  x	  10-­‐1	  
-­‐3.44	  x	  10-­‐3	  
-­‐4.03	  x	  10-­‐3	  
1.29	  
6.49	  x	  10-­‐1	  
1.02	  x	  10-­‐2	  
1.59	  x	  10-­‐2	  
2.68	  x	  10-­‐3	  
1.42	  x	  10-­‐2	  
















6.09	  x	  10-­‐2	  
3.81	  x	  10-­‐1	  
1.52	  x	  10-­‐1	  
1.38	  x	  10-­‐1	  











2.32	  x	  10-­‐1	  
2.83	  x	  10-­‐2	  
2.93	  x	  10-­‐1	  
9.34	  x	  10-­‐1	  
3.26	  x	  10-­‐1	  
4.18	  x	  10-­‐3	  
2.54	  x	  10-­‐2	  
9.99	  x	  10-­‐3	  
9.65	  x	  10-­‐3	  











-­‐2.68	  x	  10-­‐2	  
-­‐3.68	  x	  10-­‐3	  
-­‐3.81	  x	  10-­‐2	  
-­‐1.18	  x	  10-­‐1	  
-­‐3.70	  x	  10-­‐2	  
-­‐4.93	  x	  10-­‐4	  
-­‐3.42	  x	  10-­‐3	  
-­‐1.44	  x	  10-­‐3	  
-­‐1.29	  x	  10-­‐3	  













Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






















-­‐1.11	  x	  10-­‐1	  
-­‐1.42	  x	  10-­‐2	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  

























-­‐5.93	  x	  10-­‐1	  
28.43	  
-­‐2.37	  x	  102	  
-­‐4.60	  x	  102	  
-­‐12.43	  
-­‐8.58	  x	  10-­‐1	  
3.59	  














-­‐4.42	  x	  10-­‐1	  
-­‐1.80	  x	  10-­‐1	  









-­‐1.90	  x	  10-­‐2	  
3.15	  x	  10-­‐1	  
4.30	  
3.86	  
-­‐1.27	  x	  10-­‐1	  
1.40	  x	  10-­‐2	  
1.17	  x	  10-­‐1	  












Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
C18:1	  carnitine-­‐to-­‐
oleic	  acid	  ratio	  
3.40	  x	  10-­‐2	   0.055	   3.14	  x	  10-­‐2	   0.272	   -­‐2.47	  x	  10-­‐3	   0.275	   1.62	  x	  10-­‐4	   0.525	  
C3	  and	  C5	  carnitine-­‐
to-­‐BCAA	  ratio	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  







1.98	  x	  10-­‐4	  
	  




5.58	  x	  10-­‐4	  
	  




5.77	  x	  10-­‐5	  
	  




-­‐9.77	  x	  10-­‐6	  
	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  











-­‐4.76	  x	  10-­‐2	  
	  
















1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR	  and	  VO2max	  per	  FFM	  at	  baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	  






















Table	  A5.10	   Correlations	  of	  untargeted	  metabolites	  and	  mtDNA	  profiles	  at	  baseline	   (non-­‐obese	  and	  all	   obese	   subjects)	  vs.	   age,	  VO2max	  per	  FFM	  at	  
baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  at	  baseline	  vs.	  mtDNA	  count	  number	  at	  baseline	  
FA	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
3-­‐hydroxypentadeca	  
noic	  acid	  
6.45	  x	  103	   0.847	   -­‐9.30	  x	  104	   0.041$	   3.24	  x	  102	   0.913	   -­‐9.71	  x	  102	   0.010$	  
Phospholipids	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  




















4.26	  x	  102	  
-­‐8.09	  x	  102	  
-­‐5.53	  x	  104	  
-­‐4.33	  x	  102	  
-­‐2.14	  x	  104	  
-­‐1.07	  x	  106	  
-­‐8.14	  x	  104	  
-­‐1.11	  x	  105	  	  
-­‐5.40	  x	  105	  
-­‐3.71	  x	  105	  
-­‐2.46	  x	  105	  
-­‐3.64	  x	  104	  
-­‐9.19	  x	  104	  
-­‐8.04	  x	  104	  
-­‐4.77	  x	  103	  
1.16	  x	  106	  
-­‐2.37	  x	  104	  
-­‐8.01	  x	  104	  




















1.04	  x	  104	  
-­‐4.24	  x	  104	  
-­‐4.29	  x	  104	  
-­‐3.29	  x	  104	  
-­‐8.40	  x	  104	  
-­‐2.01	  x	  106	  
-­‐4.72	  x	  104	  
8.73	  x	  104	  	  	  
-­‐4.68	  x	  105	  
-­‐4.76	  x	  105	  
-­‐4.21	  x	  105	  
-­‐1.97	  x	  105	  
4.16	  x	  105	  
-­‐2.97	  x	  104	  
4.52	  x	  103	  
4.57	  x	  106	  
-­‐4.42	  x	  104	  
-­‐5.61	  x	  104	  




















-­‐2.49	  x	  102	  
-­‐1.24	  x	  102	  
4.04	  x	  103	  
-­‐1.07	  x	  103	  
-­‐1.64	  x	  103	  
-­‐9.70	  x	  103	  
9.74	  x	  103	  
-­‐1.42	  x	  104	  	  
2.40	  x	  104	  
-­‐4.09	  x	  103	  
4.05	  x	  103	  
-­‐6.02	  x	  102	  
1.11	  x	  103	  
2.15	  x	  103	  
1.13	  
2.22	  x	  105	  
3.02	  x	  102	  
1.51	  x	  103	  





















-­‐5.93	  x	  102	  
25.67	  
-­‐1.09	  x	  102	  
-­‐5.29	  x	  102	  
-­‐1.23	  x	  104	  
-­‐2.68	  x	  102	  
-­‐3.47	  x	  102	  
1.44	  x	  103	  
-­‐4.16	  x	  102	  
-­‐2.49	  x	  103	  
-­‐1.75	  x	  103	  
4.36	  x	  102	  
-­‐5.54	  x	  102	  
-­‐43.26	  
2.73	  x	  104	  
1.11	  x	  102	  
9.01	  x	  102	  























Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Stearyl	  citrate	   1.17	  x	  104	   0.102	   -­‐1.23	  x	  103	   0.898	   1.41	  x	  103	   0.024$	   27.30	   0.732	  
Other	  metabolites	   Correlations	  with	  age
1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	  
 284 






-­‐1.29	  x	  104	  
	  
	  
2.38	  x	  104	  






2.08	  x	  103	  
	  
	  
4.93	  x	  104	  






-­‐1.89	  x	  102	  
	  
	  
1.10	  x	  103	  






1.96	  x	  102	  
	  
	  
5.51	  x	  102	  










Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  















4.98	  x	  104	  
	  
-­‐1.93	  x	  103	  
	  
-­‐2.50	  x	  104	  
	  
-­‐1.25	  x	  104	  
	  
-­‐1.78	  x	  104	  
	  
8.38	  x	  104	  
	  















4.51	  x	  104	  
	  
-­‐6.67	  x	  103	  
	  
-­‐3.33	  x	  103	  
	  
4.54	  x	  103	  
	  
4.06	  x	  104	  
	  
-­‐7.29	  x	  104	  
	  



















1.33	  x	  103	  
	  
-­‐2.49	  x	  103	  
	  
3.66	  x	  102	  
	  
2.13	  x	  104	  
	  





















3.12	  x	  102	  
	  
5.36	  x	  102	  
	  
-­‐1.10	  x	  103	  
	  















1Data	  were	  adjusted	  for	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	   adjusted	   for	   age,	   sex,	   race,	   group	   of	   subjects	   (non-­‐obese	   or	   obese),	   BMI,	   diabetes	   status	   (yes	   or	   no),	  HOMA-­‐IR	   and	  VO2max	   per	   FFM	   at	  
baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  group	  of	  subjects	  (non-­‐obese	  or	  obese),	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	  










Table	  A5.11	  Correlations	  of	  untargeted	  metabolites	  and	  mtDNA	  profiles	  at	  baseline	  of	  41	  obese	  subjects	  who	  received	  muscle	  biopsy	  at	  both	  baseline	  
and	  after	  CR	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  [age	  x	  VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  at	  baseline	  vs.	  
mtDNA	  count	  number	  at	  baseline	  
AA	  derivative	  and	  
dipeptide	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  




1.08	  x	  106	  
	  




-­‐6.89	  x	  106	  
	  




-­‐3.89	  x	  105	  
	  




-­‐8.20	  x	  104	  
	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






4.36	  x	  104	  
-­‐2.25	  x	  104	  
1.39	  x	  105	  
4.27	  x	  105	  






1.84	  x	  104	  
-­‐1.12	  x	  104	  
6.70	  x	  104	  
3.44	  x	  105	  






2.26	  x	  103	  
1.52	  x	  103	  
2.07	  x	  103	  








2.99	  x	  102	  
-­‐8.26	  x	  102	  
3.61	  x	  103	  







Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
UDP-­‐n-­‐
acetylglucosamine	  
-­‐9.13	  x	  104	   0.030$	   1.63	  x	  105	   0.017$	   -­‐4.64	  x	  103	   0.403	   1.18	  x	  102	   0.861	  
Other	  metabolites	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
1,25-­‐dihydroxy	  






5.77	  x	  103	  
	  
	  
7.03	  x	  104	  
	  
-­‐3.41	  x	  103	  








6.42	  x	  103	  
	  
	  
1.03	  x	  105	  
	  
2.09	  x	  105	  








1.83	  x	  103	  
	  
	  
1.83	  x	  104	  
	  
-­‐9.68	  x	  103	  











4.43	  x	  102	  
	  
2.19	  x	  103	  











Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	   Regression	   p-­‐value	  
 286 









-­‐3.11	  x	  104	  
	  
4.09	  x	  104	  
	  
-­‐3.40	  x	  104	  
	  









-­‐1.36	  x	  104	  
	  
-­‐2.09	  x	  104	  
	  
8.15	  x	  103	  
	  









-­‐2.24	  x	  103	  
	  
1.27	  x	  104	  
	  
-­‐4.76	  x	  103	  
	  
























1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR	  and	  VO2max	  per	  FFM	  at	  baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	  


























Table	  A5.12	  Correlations	  of	  untargeted	  metabolites	  and	  mtDNA	  profiles	  of	  41	  obese	  subjects	  after	  CR	  vs.	  age,	  VO2max	  per	  FFM	  at	  baseline	  and	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline],	  as	  well	  as	  correlations	  of	  their	  metabolites	  after	  CR	  vs.	  mtDNA	  count	  number	  after	  CR	  
AA	  derivative	  	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Beta-­‐citryl-­‐l-­‐
glutamic	  acid	  
4.44	  x	  105	   0.916	   -­‐1.59	  x	  107	   0.027$	   -­‐5.34	  x	  104	   0.924	   -­‐9.18	  x	  104	   0.160	  
FA	  and	  	  
FA	  derivative	  
Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  






1.62	  x	  105	  
	  
	  





1.22	  x	  105	  
	  
	  





7.22	  x	  103	  
	  
	  














Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  

















-­‐6.50	  x	  104	  
1.85	  x	  103	  
-­‐8.27	  x	  104	  
-­‐1.90	  x	  106	  
-­‐6.67	  x	  104	  
1.94	  x	  105	  
-­‐1.91	  x	  105	  
-­‐1.52	  x	  105	  
4.60	  x	  105	  
-­‐3.15	  x	  105	  
4.73	  x	  105	  
-­‐1.02	  x	  105	  
1.34	  x	  105	  
-­‐8.61	  x	  104	  
-­‐1.15	  x	  105	  

















-­‐2.73	  x	  104	  
4.49	  x	  103	  
-­‐2.90	  x	  104	  
-­‐6.52	  x	  105	  
-­‐3.26	  x	  104	  
3.49	  x	  103	  
-­‐4.24	  x	  104	  
-­‐6.57	  x	  105	  
2.72	  x	  105	  
-­‐9.17	  x	  104	  
8.30	  x	  103	  
-­‐1.14	  x	  105	  
1.15	  x	  105	  
-­‐5.38	  x	  104	  
-­‐8.09	  x	  104	  


















2.68	  x	  103	  
-­‐2.15	  x	  103	  
-­‐1.93	  x	  104	  
-­‐1.70	  x	  103	  
-­‐5.43	  x	  103	  
-­‐1.02	  x	  103	  
6.86	  x	  103	  
-­‐1.03	  x	  104	  
-­‐8.23	  x	  103	  
6.82	  x	  104	  
2.27	  x	  104	  
9.51	  x	  103	  
-­‐2.68	  x	  103	  
-­‐4.08	  x	  103	  

















5.75	  x	  102	  
-­‐94.65	  
8.06	  x	  102	  
7.73	  x	  103	  
4.58	  x	  102	  
-­‐2.01	  x	  102	  
1.51	  x	  103	  
-­‐4.66	  x	  102	  
4.01	  x	  102	  
1.90	  x	  103	  
1.21	  x	  103	  
-­‐1.33	  x	  103	  
-­‐4.35	  x	  102	  
7.67	  x	  102	  
1.09	  x	  103	  

















Nucleotides	   Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  




coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  




3.68	  x	  104	  
	  




7.65	  x	  104	  
	  




-­‐7.28	  x	  103	  
	  




8.08	  x	  102	  
	  





Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  













6.87	  x	  105	  
1.76	  x	  104	  
-­‐9.13	  x	  103	  
	  
	  
-­‐7.84	  x	  104	  
	  
-­‐1.10	  x	  105	  
	  
-­‐8.54	  x	  104	  
-­‐8.03	  x	  104	  













2.85	  x	  105	  
3.54	  x	  103	  
1.49	  x	  104	  
	  
	  
-­‐9.84	  x	  104	  
	  
-­‐7.31	  x	  104	  
	  
-­‐6.37	  x	  104	  
-­‐1.11	  x	  105	  













1.72	  x	  104	  
1.70	  x	  102	  
-­‐1.01	  x	  102	  
	  
	  
-­‐1.42	  x	  104	  
	  
-­‐1.16	  x	  103	  
	  
-­‐3.24	  x	  104	  
1.28	  x	  103	  













1.29	  x	  102	  
76.90	  
1.16	  x	  102	  
	  
	  
1.77	  x	  103	  
	  
1.03	  x	  103	  
	  
4.77	  x	  103	  


















Correlations	  with	  age1	   Correlations	  with	  VO2max	  per	  FFM	  at	  baseline2	  
Correlations	  with	  [age	  x	  
VO2max	  per	  FFM	  at	  baseline]3	  
Correlations	  with	  mtDNA	  
count	  number4	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  
coefficient	   p-­‐value	  
Regression	  















-­‐4.77	  x	  103	  
	  
7.44	  x	  104	  
	  
-­‐9.24	  x	  104	  
	  
-­‐2.83	  x	  105	  
	  
-­‐1.02	  x	  105	  
	  
-­‐2.55	  x	  105	  
	  
















1.83	  x	  104	  
	  
6.00	  x	  104	  
	  
-­‐2.26	  x	  105	  
	  
-­‐8.23	  x	  104	  
	  
-­‐3.61	  x	  104	  
	  
-­‐1.27	  x	  105	  
	  
















7.51	  x	  102	  
	  
-­‐1.18	  x	  104	  
	  
-­‐3.88	  x	  104	  
	  
-­‐6.71	  x	  102	  
	  
-­‐1.87	  x	  103	  
	  
-­‐1.13	  x	  103	  
	  


















6.03	  x	  102	  
	  
5.04	  x	  103	  
	  
1.79	  x	  103	  
	  
7.34	  x	  102	  
	  
2.59	  x	  103	  
	  









































-­‐1.46	  x	  105	  
	  
1.01	  x	  104	  
	  
-­‐5.51	  x	  104	  
	  
7.15	  x	  103	  
	  
-­‐2.62	  x	  105	  
	  
-­‐1.62	  x	  105	  
	  
-­‐1.66	  x	  105	  
	  
-­‐2.14	  x	  104	  
	  
-­‐7.82	  x	  104	  
	  
-­‐3.40	  x	  105	  
	  
-­‐2.57	  x	  104	  
	  

























-­‐6.90	  x	  104	  
	  
-­‐1.64	  x	  103	  
	  
-­‐2.28	  x	  104	  
	  
4.38	  x	  104	  
	  
-­‐1.23	  x	  105	  
	  
-­‐6.52	  x	  104	  
	  
-­‐3.57	  x	  104	  
	  
-­‐2.21	  x	  104	  
	  
-­‐2.12	  x	  104	  
	  
-­‐2.56	  x	  105	  
	  
-­‐1.40	  x	  103	  
	  

























-­‐4.90	  x	  103	  
	  
-­‐5.43	  x	  103	  
	  




-­‐1.08	  x	  104	  
	  
-­‐7.42	  x	  103	  
	  
-­‐8.78	  x	  103	  
	  
-­‐5.29	  x	  103	  
	  
-­‐3.30	  x	  103	  
	  
-­‐2.78	  x	  103	  
	  
-­‐6.59	  x	  103	  
	  

























1.14	  x	  103	  
	  
5.05	  x	  102	  
	  




1.55	  x	  103	  
	  
-­‐2.07	  x	  102	  
	  
9.36	  x	  102	  
	  
4.61	  x	  102	  
	  
4.77	  x	  102	  
	  
-­‐3.61	  x	  102	  
	  
7.57	  x	  102	  
	  

























1Data	  were	  adjusted	  for	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR,	  and	  VO2max	  per	  FFM	  at	  baseline.	  
2Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI	  and	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA	  IR.	  
3Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no),	  HOMA-­‐IR	  and	  VO2max	  per	  FFM	  at	  baseline.	  
4Data	  were	  adjusted	  for	  age,	  sex,	  race,	  BMI,	  diabetes	  status	  (yes	  or	  no)	  and	  HOMA-­‐IR.	  
$	  =	  p-­‐value	  <0.050	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Table	  A6.1	  All	  targeted	  metabolites	  identified	  in	  this	  study	  
Identified	  targeted	  metabolites	  
FFAs	  
	  	  	  Arachidic	  acid	  
	  	  	  Docosanoic	  acid	  
	  	  	  Linoleic	  acid	  
	  	  	  Myristic	  acid	  
	  	  	  Oleic	  acid	  
	  	  	  Palmitic	  acid	  
	  	  	  Palmitoleic	  acid	  
	  	  	  Stearic	  acid	  
AAs	  and	  BCKAs	  
	  	  	  Alanine	  	  
	  	  	  Arginine	  
	  	  	  Asparagine	  	  
	  	  	  Aspartic	  acid	  
	  	  	  Glutamic	  acid	  	  
	  	  	  Glutamine	  	  
	  	  	  Glycine	  
	  	  	  Histidine	  	  
	  	  	  Isoleucine+leucine	  
	  	  	  Ketoisoleucine+ketoleucine	  	  
	  	  	  Lysine	  	  
	  	  	  Methionine	  	  
	  	  	  Ornithine	  
	  	  	  Phenylalanine	  	  
	  	  	  Proline	  	  
	  	  	  Serine	  	  
	  	  	  Threonine	  	  
	  	  	  Tryptophan	  	  
	  	  	  Tyrosine	  	  
	  	  	  Valine	  
Phospholipids	  
	  	  	  LysoPC(16:0)	  
	  	  	  LysoPC(18:0)	  
	  	  	  LysoPC(18:1)	  
	  	  	  LysoPC(18:2)	  
	  	  	  LysoPE(16:0)	  
	  	  	  LysoPE(18:0)	  
	  	  	  LysoPE(18:1)	  
	  	  	  LysoPE(20:0)	  
	  	  	  LysoPE(20:2)	  
	  	  	  LysoPG(18:1)	  	  
	  	  	  LysoPI(18:0)	  
	  	  	  LysoPS(18:0)	  
	  	  	  PA(34:1)	  
	  	  	  PA(36:1)	  
	  	  	  PA(36:2)	  
	  	  	  PC(34:1)	  
	  	  	  PC(34:2)	  
	  	  	  PC(36:1)	  
	  	  	  PC(36:2)	  
	  	  	  PC(36:4)	  
	  	  	  PC(38:6)	  
	  	  	  PE(34:1)	  
	  	  	  PE(36:1)	  
	  	  	  PE(36:2)	  
	  	  	  PE(36:3)	  
	  	  	  PE(38:2)	  
	  	  	  PE(38:4)	  
	  	  	  PE(38:6)	  
	  	  	  PG(34:1)	  
	  	  	  PG(36:1)	  
	  	  	  PG(36:2)	  
	  	  	  PG(38:1)	  
Acylcarnitines	  
	  	  	  L-­‐carnitine	  
	  	  	  C2	  carnitine	  	  
	  	  	  C3	  carnitine	  
	  	  	  C4	  carnitine	  
	  	  	  C5	  carnitine	  
	  	  	  C6	  carnitine	  	  
	  	  	  C8:0	  carnitine	  
	  	  	  C8:1	  carnitine	  
	  	  	  C10:0	  carnitine	  
	  	  	  C10:1	  carnitine	  
	  	  	  C12:0	  carnitine	  
	  	  	  C12:1	  carnitine	  
	  	  	  C14:0	  carnitine	  
	  	  	  C14:1	  carnitine	  
	  	  	  C14:2	  carnitine	  
	  	  	  C16:0	  carnitine	  
	  	  	  C16:1	  carnitine	  
	  	  	  C18:0	  carnitine	  
	  	  	  C18:1	  carnitine	  
	  	  	  C18:2	  carnitine	  
 291 
	  	  	  PI(34:1)	  
	  	  	  PI(36:1)	  
	  	  	  PI(36:2)	  
	  	  	  PI(38:4)	  
	  	  	  PS(36:2)	  
	  	  	  PS(38:4)	  
	  	  	  PS(40:6)	  
Glycerides	  
	  	  	  MG(18:0)	  
	  	  	  DG(34:1)	  
	  	  	  DG(36:1)	  
	  	  	  DG(36:2)	  
	  	  	  TG(48:0)	  
	  	  	  TG(50:1)	  
	  	  	  TG(50:2)	  
	  	  	  TG(52:1)	  
	  	  	  TG(52:2)	  
	  	  	  TG(52:3)	  
	  	  	  TG(52:4)	  
	  	  	  TG(54:1)	  
	  	  	  TG(54:2)	  
	  	  	  TG(54:8)	  
	  
TCA	  cycle	  metabolites	  
	  	  	  Acetyl-­‐CoA	  
	  	  	  Citrate	  
	  	  	  Alpha-­‐ketoglutarate	  
	  	  	  Succinate	  	  
	  	  	  Malate	  
Other	  metabolites	  
	  	  	  2,3-­‐Dihydroxybenzoate	  	  
	  	  	  Acetoacetate	  
	  	  	  Citrulline	  
	  	  	  Creatinine	  
	  	  	  Coenzyme	  A	  
	  	  	  Cytosine	  
	  	  	  FAD	  
	  	  	  Geranyl	  pyrophosphate	  
	  	  	  Glucose	  
	  	  	  Homocysteic	  acid	  
	  	  	  Hypoxanthine	  
	  	  	  Lactate	  
	  	  	  N-­‐Acetylornithine	  
	  	  	  NAD+	  
	  	  	  Para-­‐Aminobenzoate/anthranilate	  
	  	  	  Taurine	  

























Table	  A6.2	   Internal	   standards	   used	   for	   quantitation	   of	   targeted	  metabolites.	   NSK-­‐B	   internal	   standard	  mix	  
was	  purchased	  from	  Cambridge	  Isotope	  (Andover,	  MA).	  All	  other	  carbon-­‐13	  stable	  isotope	  internal	  standards	  
were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  	  
Internal	  Standards	  
Internal	  standard	  concentration	  in	  
extraction	  solvent	  
Algal	  amino	  acid	  mixture_13C	  (Sigma	  426199)	   20	  μg/ml	  
Alpha-­‐ketoglutarate_13C4	   4	  μM	  
Citrate_13C6	   20	  μM	  
Lactate_13C3	   400	  μM	  
Malate_13C4	   8	  μM	  
NSK-­‐B	  acylcarnitine	  internal	  standard	  mix	  
	  	  	  	  	  	  	  	  2H9-­‐Carnitine	  (L-­‐carnitine)	  
	  	  	  	  	  	  	  	  2H3-­‐Acetylcarnitine	  (C2)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Propionylcarnitine	  (C3)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Butyrylcarnitine	  (C4)	  
	  	  	  	  	  	  	  	  2H9-­‐Isovalerylcarnitine	  (C5)	  	  
	  	  	  	  	  	  	  	  2H3-­‐Octanoylcarnitine	  (C8)	  	  
	  	  	  	  	  	  	  	  2H9-­‐Myristoylcarnitine	  (C14)	  	  










Oleic	  acid_13C18	   5	  μM	  
Palmitic	  acid_13C16	   5	  μM	  
Succinate_13C4	   40	  μM	  
	  
	  
	  
